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ABSTRACT OF DISSERTATION 
SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL DRUG CANDIDATES 
TO ADDRESS DRUG RESISTANCE IN TUBERCULOSIS AND FUNGAL 
DISEASES 
Tuberculosis (TB) and fungal infections are two of the most lethal infectious diseases 
worldwide due to the emergence of drug-resistant Mycobacterium tuberculosis (Mtb) and 
fungal strains that can resist the most potent antimicrobial drugs currently employed. Due 
to the rise of these drug resistant strains, effective treatment options for these two 
infections are limited. This dissertation aims at exploring novel drug scaffolds to help 
combat drug resistance in TB and fungal infections. 
TB caused by the pathogenic Mtb is, alongside with human immunodeficiency virus 
acquired immunodeficiency virus (HIV), the deadliest infectious disease worldwide with 
approximately 2-3 billion people infected yearly. The situation has become increasingly 
intensified due to the emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) Mtb strains. Aminoglycoside (AG) antibiotics such as amikacin and 
kanamycin A (KAN) are heavily relied upon for the treatment of MDR- and XDR-Mtb 
strains. However, the success rate for the treatment of these MDR- and XDR-TB cases is 
decreasing as a result of increased KAN resistance. It was reported by the Centers for 
Disease Control and Prevention (CDC) that upregulation of the enhanced intracellular 
survival (eis) gene was the cause of resistance to KAN in a large portion of Mtb clinical 
isolates. Our lab previously demonstrated that Eis is an AG acetyltransferase that can 
inactivate AGs via chemoenzymatic modification of the AG scaffolds. As Eis has been 
shown to acetylate a wide variety of AG scaffolds, the development of novel AGs that 
can completely escape the action of Eis remains highly challenging. Therefore, we 
suggested an alternative therapeutic approach involving inhibiting Eis enzyme and still 
employing the current FDA-approved KAN. As exemplified by the clinically successful 
combination of penicillin and β-lactamase inhibitors, we hypothesized that an Eis 
inhibitor may be used as adjuvant therapy in combination with KAN to treat MDR- and 
XDR-tuberculosis. Using high-throughput screening, we were able to identify several 
small-molecule scaffolds capable of inhibiting Eis. We performed structure activity 
relationship (SAR) studies using purified Eis enzyme and optimized lead compounds. 
Additionally, we also showed that co-administration of Eis lead inhibitors with KAN led 
to recovery of KAN activity against a KAN-resistant Mtb cell line that overexpressed Ei 
Invasive fungal infections are on the rise due to an increased population of critically ill 
patients as a result of HIV infections, chemotherapies, and organ transplantations. Unlike 
antibiotics that are greatly diverse in categories and mechanisms of action, our current 
antifungal drug repertoire is greatly limited and insufficient in addressing the problem of 
drug-resistant fungal infections. Thus, there is a growing need for novel antimycotics that 
are safe and effective. We report a number of lead compounds with potent antifungal 
activitiy. The MIC values of these compounds were as low as 0.02 µg/mL against the 
fungal strains tested. Our compounds are derived from the ebselen core structure, which 
has been shown to be safe in multicenter clinical trials. Notably, fungal cells treated with 
our compounds showed the accumulation of ROS, which may further contribute to the 
growth inhibitory effect against fungi. This study provides new lead compounds for the 
development of antimycotic agents. 
KEYWORDS: Antitubercular Agents, SAR, Eis inhibitors, Aminoglycosides, 
Kanamycin 
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PREFACE 
 
The following dissertation consists of 9 chapters highlighting the most important projects 
of my Ph.D. studies aimed at exploring novel drug scaffolds to address drug resistance in 
tuberculosis and fungal diseases. The first 7 chapters are adapted or partially adapted 
from my previous publications. Chapter 1 focuses on the pathology of tuberculosis (TB), 
the current anti-TB drug options, and the challenges associated with antitubercular drug 
resistance; this chapter was partially adapted from a book chapter. (Green K.D., Holbrook 
S.Y.L., Ngo H.X., and Garneau-Tsodikova S. (2017). Chapter 7: Emerging targets in 
anti-tubercular drug design. Antibiotic drug discovery: new targets and molecular entities. 
141-203. DOI:10.1039/9781782629870-0041.) Chapter 2 describes an SAR study of a 
novel class of pyrrolo[1,5-a]pyrazine-based Eis inhibitors to overcome Eis-mediated 
aminoglycosides (AGs) resistance (Garzan A., Willby M.J, Ngo H.X., Gajadeera C.S., 
Green K.D., Holbrook S.Y.L., Hou C., Posey J.E., Tsodikov O.V., and Garneau-
Tsodikova S. (2017). Combating enhanced intracellular survival (Eis)-mediated 
kanamycin resistance of Mycobacterium tuberculosis by novel pyrrolo[1,5-a]pyrazine-
based Eis inhibitors. ACS Infect. Dis. 3(4): 302-309.). Chapter 3 reports the investigation 
of 1,2,4-triazino[5,6b]indole-3-thioether-based Eis inhibitors, which displays unique 
interactions with Eis AG binding site. (Ngo H.X., Green K.D., Gajadeera C.S., Willby 
M.J., Holbrook S.Y.L., Hou C., Garzan A., Mayhoub A.S., Posey J.E., Tsodikov O.V., 
and Garneau-Tsodikova S. (2017). Potent 1,2,4-triazino[5,6b]indole-3-thioether 
inhibitors of the kanamycin resistance enzyme Eis from Mycobacterium tuberculosis. 
ACS Infect. Dis. 4(6): 1030-1040.). Chapter 4 focuses on synthesis and biological 
 xxix 
evaluation of thieno[2,3-d]pyrimidine-based Eis inhibitors, which uniquely contain their 
own antitubercular activity and are potentially synergistic with a popular antitubercular 
aminoglycoside, kanamycin (KAN) (Unpublished). In chapter 5, we report the synthesis 
ebsulfur-based analogues (originally intended as antitubercular agents) and repurpose of 
these ebsulfur-based compounds as potent agents to treat infections associated with 
methicillin-resistant Staphylococcus aureus (MRSA). (Ngo H.X., Shrestha S.K., Green 
K.D., and Garneau-Tsodikova S. (2016). Development of ebsulfur analogues as potent 
antibacterials against methicillin-resistant Staphylococcus aureus. Bioorg. Med. Chem. 
24(24): 6298-6306.). Chapter 6 presents an introduction of fungal diseases, treatment 
options, and drug resistance problems associated with fungal diseases; this chapter was 
partially adapted from a review paper (Ngo H.X., Garneau-Tsodikova S., and Green K.D. 
(2016) A complex game of hide and seek: the search for new antifungals. 
MedChemComm. 7: 1285-1306.). Chapter 7 explores the application of ebsulfur 
analogues as antifungal agents. (Ngo H.X., Shrestha S.K., and Garneau-Tsodikova S. 
(2016). Identification of ebsulfur analogues with broad-spectrum antifungal activity. 
ChemMedChem. 11(14): 1507-1516.). Chapter 8 discusses ongoing projects that I have 
contributed to. Chapter 9 provides the conclusion and future directions to the projects 
discussed in this dissertation. 
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Chapter 1 
 
Introduction: tuberculosis (TB), current TB drug targets, and resistance associated with 
TB 
 
1.1. INTRODUCTION TO TB 
1.1.1. History of TB  
"Dr. Waksman! You have discovered a new and powerful weapon in the deadly battle against 
one of the oldest foes of mankind, tuberculosis. This battle is as old as medical science and we 
now have a definite impression that at last the enemy is beginning to yield…" 
-Harald Cramér, member of the Royal Swedish Academy of Sciences 
 
Professor Cramér congratulated the Ukrainian-American scientist Selman A. Waksman 
regarding his discovery of streptomycin (STR) at Waksman’s Nobel banquet in 1952.1-2 
Professor Cramér’s optimism resonated with the rest of the scientific world. STR could 
penetrate the highly lipophilic cell envelope of Mycobacterium tuberculosis (Mtb), which was 
previously considered to be an improbable feat.3 Tuberculosis (TB), also known as phthisis, 
consumption, or the white plague, was untreatable for centuries and has devastated humanity 
since the dawn of time.4 To cope with the TB epidemic, during the 19th century, many writers, 
such as John Keats and George Sand, romanticized this disease.5 In fact, TB was considered 
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to be artistic, poetic, and fashionable, which influenced many upper-class young ladies to pale 
their skin to mimic the appearance of the diseased.6 With the discovery of STR, the world 
finally possessed an agent that could treat TB. Like polio and leprosy, it was thought that TB 
would eventually be a banal affliction. Unfortunately, the euphoric feeling about STR 
gradually evaporated, as various clinical studies reported the rapid development of STR 
resistance in Mtb clinical isolates (typically after two months of treatment) as well as the lack 
of clinical efficacy in the landmark trial by the British Medical Research Council.7-8 Today, 
TB still remains a public health threat and is increasingly becoming a global healthcare 
emergency. According to the latest report from the World Health Organization (WHO), in 
2014, about 9.6 million new cases of active TB per year are estimated to occur, leading to 1.5 
million casualties.9 Globally, the prevalence of TB is highest in Southeast Asia with 5.4 
million people currently living with TB. Along with Southeast Asia, Africa and the Western 
Pacific make up more than 85% of the global TB prevalence, whereas the Eastern 
Mediterranean, Europe, and the Americas account for the remaining ~15% (Figure 1.1).9 
 
 
Figure 1.1. Pie chart representing the current global distribution of TB prevalence. 
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Furthermore, Mtb strains continue to evolve to resist the most clinically useful first-line anti-
tubercular agents (isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol 
(EMB)) (Figure 1.2). Multidrug-resistant TB (MDR-TB) is caused by isolates that are 
resistant to at least INH and RIF. The current rate of MDR-TB is estimated to appear in 3.3% 
of all new TB cases and 20% of previously treated TB cases.9 Extensively drug-resistant TB 
(XDR-TB) is a type of MDR-TB, with additional resistance second-line drugs such as any 
fluoroquinolone (FQ) and at least one of three injectable drugs (i.e., the aminoglycosides 
(AGs) kanamycin (KAN) and amikacin (AMK), or the cyclic polypeptide capreomycin 
(CAP)). From the latest estimation, 9.7% of MDR-TB cases eventually become XDR-TB. 
Moreover, the number of TB cases that are unresponsive to the most potent drugs continues to 
rise year after year. As reported by the WHO, the number of RIF-resistant (RR) and MDR-TB 
cases increased by approximately 10-fold from 2005 to 2014 (Figure 1.3). Hence, there is an 
immediate clinical necessity for the discovery and development of anti-tubercular compounds 
with novel drug targets and mechanisms of action. 
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Figure 1.2. Structures of the current anti-tubercular drugs based on their therapeutic 
classification (groups 1-5). 
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Figure 1.3. Bar graph indicating the incidence of global TB of any variety (orange bars), 
RR/MDR-TB (red bars), and XDR-TB (green bars). The data points for incidence of global 
total TB and RR/MDR-TB were extracted from the Global Health Observatory data repository. 
The data points for XDR-TB were calculated from the percentage of XDR-TB related to the 
MDR-TB data reported from 2011 to 2014 in the annual WHO global TB reports. Before 
2010, the percentage of XDR-TB was minimal and not reported. 
 
This story of anti-tubercular drug discovery is mirrored by the PubMed publication log 
(Figure 1.4). For almost a century after the first published report on TB, very few publications 
on this respiratory disease (<100 per year from 1853 to 1943) appeared in the literature. 
Starting from the monumental discovery of STR, there was an explosion of TB-related 
publications ignited by several new and effective anti-tubercular drugs, such as para-
aminosalicylic acid (PAS), INH, PZA, cycloserine (CYS), and KAN, from 1944 to 1952 
(Figure 1.2). The introduction of RIF in the 1960s established the efficacy of the combination 
therapy regimen, including INH, RIF, PZA, and EMB, and eventually shortened the duration 
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of therapy to as low as 6 months. Due to the initial effectiveness of the first-line agents, there 
was a gradual decline in interest in TB research up until 1980 when MDR-Mtb strains began 
to emerge. This observation deeply troubled the public and propelled an immense effort in TB 
research. In fact, the number of publications on TB has exceeded those related to the ESKAPE 
pathogens (Enterococcus faecium, Staphylococcus aureus (Sau), Klebsiella pneumoniae, 
Acinetobacter spp., Pseudomonas aeruginosa, and Enterobacter spp.) in recent years. 
 
 
Figure 1.4. PubMed publication record over the years for Mtb (red circles), E. faecium 
(orange circles), S. aureus (light orange inverted triangles), K. pneumoniae (yellow triangles), 
Acinetobacter spp. (green squares), P. aeruginosa (brown squares), Enterobacter spp. (purple 
diamonds). 
 
Inspired by this renaissance in TB drug discovery, herein, we will first briefly survey the 
pathophysiology of TB, the current targets of clinically approved medications, and the 
resistance mechanisms associated with these drugs. These fundamental topics lay the 
M. tuberculosis
E. faecium
S. aureus
K. pneumoniae
Acinetobacter spp.
P. aeruginosa
Enterobacter spp.
Year
1860 1880 1900 1920 1940 1960 1980 2000 2020
N
um
be
r o
f p
ub
lic
at
io
ns
0
2000
4000
6000
 7 
groundwork and context for our eventual important discussions of novel anti-tubercular agents 
to combat drug-resistant Mtb strains. 
 
1.1.2. Biology and pathology of TB  
The genus Mycobacterium is so named because of the apparent mold-like growth of the 
bacteria on the surface of liquid media. Other characteristics of this genus include slow 
growth, the ability to enter a latent state, a complex cell envelope, and a fairly homogeneous 
genetic content across isolates.10 These bacteria are resistant to most staining techniques and 
are classified as acid-fast bacilli. This resistance to staining is due to the complex and 
lipocentric composition of the mycobacterial cell envelope, which is also responsible for their 
high resistance to environmental stresses, including drying and antiseptics.11 This unique cell 
envelope also precludes mycobacteria from being concretely classified as either Gram-
negative or Gram-positive, since it does not adhere to the strict definition of either class 
(Figure 1.5).12 While the bacteria have a peptidoglycan layer, they only become faintly 
colored by Gram staining. 
 
 8 
 
Figure 1.5. Schematic representation of the Mtb cell envelope showing the major components 
discussed herein. 
 
In Mtb, the inner most layer of the Mtb cell envelope consists of diacylphosphatidylinositol 
dimannoside, a fairly unusual lipid.13 This particular lipid is thought to endow the bacteria 
with poor membrane fluidity and permeability. The peptidoglycan layer is next and linked to a 
layer of arabinogalactan, which is in turn attached to a layer of mycolic acids, and finally 
coated with an outermost layer of phospholipids resulting in a fairly thick overall cell 
envelope.14-15 Amid the cell envelope are found porin proteins that form channels filled with 
water allowing the passage of hydrophilic molecules. Only one porin has been reported for 
Mtb, an OmpA-like porin,16 which plays a role in pH adaptation and does not appear to 
function as a transport channel.16-17 Interestingly, when Mtb expressed the MspA porin from 
Mycobacterium smegmatis (Msm), a non-infectious and fast-growing mycobacterium 
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commonly used as a model for Mtb, it becomes sensitized to β-lactams, INH, EMB, and 
STR.18 The Mtb peptidoglycan layer differs slightly from those of typical Gram-positive and 
Gram-negative bacteria. In Mtb, just like in other bacteria, the peptidoglycan layer consists of 
alternating units of N-acetylglucosamine and N-acetylmuramic acid with peptidic side chains 
of L-alanyl-D-isoglutamyl-meso-diaminopimelyl-D-alanine with further amidation of the 
glutamyl side chain. However, in Mtb, the N-acetylmuramic acid is further acylated with 
glycolic acid and cross-linking occurs not only between meso-diaminopimelyl groups, but 
also between meso-diaminopimelyl and D-alanyl groups (a detailed structure of the 
peptidoglycan layer cross-linkages is depicted in Figure 2.11 where a new target is 
discussed).19 The arabinoglycan layer is composed of the furanose forms of arabinose and 
galactose,19-20 typically arranged in a linear galactan chain bearing several branched arabinose 
chains, each ending in four arabinose dimers, which hold two points of attachment for the 
mycolic acids.21-22 Over 60% of the mycobacterial cell envelope dry-weight consists of 
lipids.12 The three major components of the lipid content are mycolic acids, cord factor (better 
known as trehalose 6,6'-dimycolate, TDM19, 23-24), and wax-D. Mycolic acids are high 
molecular weight branched a-alkyl-b-hydroxy fatty acids that form lipophilic tails of 
glycolipids or are esterified at the end of the arabinogalactans.25 TDM is responsible for the 
serpentine cord into which Mtb cells develop. This lipid is also toxic to mammals and 
abundantly produced in virulent strains of Mtb. Wax-D is the antigen found in Freund’s 
complete adjuvant, which is used in immunopotentiation.12 This unique construction of the 
cell envelope is associated with the bacterium’s characteristic impermeability and resistance 
to antibiotics, acidic and basic compounds, osmotic lysis, and lethal oxidations, and it allows 
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for survival inside the macrophage. Of the ~4,000 encoding genes of Mtb, 525 are involved in 
the synthesis of the cell envelope and 200 are related to fatty acid metabolism. 
 
In addition to the highly specialized cell envelope, Mtb also utilizes some metabolic pathways 
to protect itself from its environment. The fact that Mtb can enter a non-replicating state 
indicates a period of metabolic shutdown.10 During this phase, treatment of TB becomes 
difficult since the etiologic agent is not replicating and, therefore, not utilizing the enzymes 
and pathways targeted by the current anti-tubercular agents, discussed in Section 1.2. While 
the molecular basis for the metabolic shutdown of Mtb is still not completely understood,10 
several recent studies have shed some light on the mechanisms and pathways involved in the 
ability of Mtb to enter this non-replicating and slowed metabolic state. One particular gene 
found to be involved in this process is dosR (rv3133c) that is responsible for mediating the 
hypoxic response26 and aids the rebound of the bacteria back to a normal metabolic state.27 
Changes in glucose phosphorylation have also been documented to be required in the non-
replicating state.28 The genome of Mtb appears to have an abundance of extra metabolic and 
biosynthetic proteins, which is suggestive of its ability to adapt to its environment. Mtb has 
the potential to synthesize all the essential amino acids, vitamins, and cofactors needed for its 
survival.10 It also has the ability to catabolize a wide variety of carbon sources, including, but 
not limited to, carbohydrates, hydrocarbons, and alcohols.10 
 
TB is most commonly acquired by the inhalation of dried particles containing one to three 
Mtb bacilli. When these particles reach the lung, they are phagocytized by macrophages in the 
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alveoli whereupon most bacteria are usually destroyed. In certain instances, whether caused 
by a compromised immune system or another underlying condition, the body’s defenses can 
fail to terminate the inhaled bacilli. In this case, the infection progresses in five distinct steps: 
(i) The tubercle bacilli reach the alveoli of the lung and are ingested by macrophages, however, 
some bacilli survive. At this point, the infection is asymptomatic, indicative of a latent 
infection. (ii) The bacilli replicate in the macrophage, recruiting more macrophages to the area, 
which then become hosts for the mycobacteria. The macrophages form an early tubercle and 
excrete cytokines and other enzymes that cause lung-damaging inflammation. (iii) After a few 
weeks of inflammation, symptoms begin to appear as a result of many macrophages dying and 
releasing their load of bacilli forming a caseous center in the tubercle. The anaerobic 
environment is not ideal for the propagation of bacteria and growth is halted. However, many 
cells survive in dormant or latent states to become activated later. At this point, the lesions can 
become calcified and the disease progression is stalled. (iv) If the growth of the caseous center 
continues, the center can become liquefied and bacilli are able to multiply outside of 
macrophages. (v) The tubercle eventually ruptures from the growth of the bacilli and they are 
released into the bronchiole. From this location, the bacteria can be disseminated to the rest of 
the lungs, the blood stream, and the lymphatic system. 
 
Transcriptional analysis of Mtb cultivated in macrophages reveals that several genes related to 
fatty acid degradation and lipid synthesis are attenuated along with transcriptional regulators, 
proteins involved in the glyoxylate cycle, citrate synthesis, mycobactin synthesis, and α-
crystallin, along with many other genes.29-31 Additionally, several genes with unidentified 
products are also noted. One of the cell envelope components, lipoarabinomannan is essential 
 12 
for the virulence of Mtb. This particular lipoglycan binds the macrophage mannose receptor 
facilitating entry into the macrophage. It is also responsible for modulating the host immune 
response and preventing the phagosome-lysosome fusion. All these factors combined lead to 
intracellular survival and persistence.32 The virulence of Mtb was also found to be reliant on 
lipoamide dehydrogenase, which is a core protein in three separate multi-enzyme complexes 
affecting the biosynthesis of amino acids, acetyl coenzyme A (AcCoA), and reduction of 
reactive nitrogen intermediates.33 
 
1.2. CURRENT TB DRUG TARGETS 
The current drugs targets span three main areas: (i) cell envelope synthesis, (ii) translation, 
and (iii) transcription and DNA replication (Figure 1.6). The structures of these molecules, 
which are classified as first-, second-, and third-line agents are drawn in Figure 1.2. 
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Figure 1.6. A schematic of a Mtb cell showing where the current drug targets affect the cell, 
including the cell envelope, protein/RNA/DNA synthesis, and other areas. 
 
1.2.1. Cell Envelope 
While not among the core treatment regimen of TB, the amino acid-derived CYS and 
terizidone (TRD) display broad-spectrum activity and inhibit the synthesis of the 
peptidoglycan layer.34 These amino acid derivatives target alanine racemase and D-alanine:D-
alanine ligase, both of which are involved in the synthesis of the peptidoglycan layer.35 b-
Lactams (e.g., amoxicillin (AMX)) work in a similar fashion inhibiting transpeptidase and 
preventing the cross-linking of the peptidoglycan layer.36 The penicillin AMX and the 
carbapenem imipenem (IPM) are used as third-line TB treatments in combination with the b-
lactamase inhibitor clavulanate (CLV) and the carbapenemase inhibitor cilastatin (CLN), 
respectively, to prevent the degradation of the anti-tubercular compounds. EMB targets an 
arabinosyltransferase responsible for building the arabinogalactans found in the cell 
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envelope.37-38 Ethionamide (ETH), prothionamide (PRO), and INH all inhibit the enoyl-acyl 
carrier protein (ACP) reductase InhA.39-40 All of these nicotinamide derivatives are prodrugs 
that need to be activated. INH is activated by the catalase-peroxidase hemoprotein KatG. On 
the other hand, ETH is activated by the monooxygenase EthA to an S-oxide metabolite.41 
Thioacetazone (THZ) is also a prodrug that gets transformed by EthA into its active form, 2-
ethyl-4-amidopyridine.42 While THZ is not a nicotinamide analogue, it targets the same 
pathway as PRO, ETH, and INH. These drugs specifically target the cyclopropane synthase 
enzymes, disrupting fatty acid synthesis by forming adducts with NADH and preventing InhA 
from performing its catalytic activity.43 
 
1.2.2. Translation 
The AGs AMK, KAN, and STR function by binding tightly to the 16S rRNA in the 30S 
ribosomal subunit.44-45 When bound to the ribosome, they prevent normal protein translation, 
which inevitably leads to cell death. Clarithromycin (CLA), a macrolide antibiotic, also 
inhibits the ribosome. However, while AGs bind the 30S ribosomal subunit, CLA binds the 
50S ribosomal subunit, which also results in a cessation of protein synthesis.46 CAP and 
viomycin (VIO) are cyclic peptides from the tuberactinomycin family, which are known to 
inhibit protein synthesis by binding the ribosome, hence their usual coupling with AGs. CAP 
also has significant activity against the persistent form of TB and is thought to have a second 
target outside of the ribosome.47 Linezolid (LZD), an oxazolidinone, is responsible for 
inhibiting protein translation in a completely different way than other drugs.48 While most 
compounds bind one of the two large halves (30S and 50S) of the ribosome, preventing 
 15 
translation from proceeding, LZD binds the 23S rRNA, thereby inhibiting translation in the 
early stages by preventing formyl-methionine tRNA from binding the complex.49 
 
1.2.3. Transcription and DNA Replication 
The FQs used to treat TB, including gatifloxacin (GTX), levofloxacin (LEV), moxifloxacin 
(MOX), ciprofloxacin (CFX), and ofloxacin (OFX), all trap the ATP-dependent type II 
topoisomerases (DNA gyrase and topoisomerase IV) in an enzyme-DNA-inhibitor complex. 
When trapped, the enzymes no longer perform DNA uncoiling, freezing that portion of DNA 
and shutting down DNA replication, translation of genes in the region, and DNA repair.50 
Clofazimine (CFZ) binds the guanine bases of bacterial DNA, preventing DNA from being 
used as a template and inhibiting bacterial proliferation.51-52 It also increases activity of 
bacterial phospholipase A2, which causes the release and accumulation of toxic 
lysophospholipids.53-54 PAS was originally proposed to target dihydropteroate synthase, the 
usual target of sulfonamide drugs.55 Several years later, it was discovered that in fact PAS 
inhibits the thymidylate synthase, preventing thymidine from being synthesized and, therefore, 
disrupting DNA replication.56 RIF and its analogues rifabutin, rifalazil, and rifapentine all 
inhibit the b-subunit of DNA-dependent RNA polymerase, halting transcription.57-58 It is 
thought that RIF blocks the transit of the growing RNA chain after the addition of two or three 
nucleotides. In Escherichia coli (Eco), the suicide gene mazEF is triggered, and the same 
system is found in Mtb.59 
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PZA has a poorly understood mechanism of action. As a prodrug, it is activated by the 
pyrazinamidase/nicotinamidase PncA to pyrazinoic acid (POA), which has been shown to 
inhibit many functions in low-pH environments that are often found when Mtb is internalized 
to the macrophage.60-61 POA is pumped out of the cell, and if the extracellular environment is 
acidic enough, POA becomes protonated and reenters the cell at a faster rate than it can be 
egested. This leads to an increase in intracellular acidity, and this change in pH eventually 
affects numerous cellular cycles. 
 
1.3. RESISTANCE RELATED TO TB 
Mtb resists the action of many drugs. The mechanisms of resistance in Mtb comprise (i) 
intrinsic cellular properties and (ii) the presence of efflux pumps and several chromosomally 
encoded resistance genes, as well as mutation of several genes resulting in reduced efficacy of 
the antibiotics.62 It is important to note that Mtb has no reported instances of acquiring 
resistance mechanisms from mobile genetic elements. In addition to the modes of resistance 
employed by Mtb, the mycolic acid-rich cell envelope decreases the permeability of many 
antibiotics and antimicrobial compounds. 
 
1.3.1. Efflux pumps 
One mechanism of resistance shared by many bacteria is the presence of efflux pumps. At 
their basal levels, efflux pumps contribute little to resistance, however, when overexpressed or 
mutated to have higher affinity for a particular substrate, they can greatly affect resistance, 
particularly in mycobacteria considering their low rate of influx. Molecularly, efflux pumps 
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are active transporters and use either an energy source (e.g., ATP) or an ionic gradient to 
shuttle xenobiotics and other toxic compounds out of the cell. An example of a Mtb efflux 
pump includes P55 (Rv1410c). P55, a member of the major facilitator superfamily of efflux 
pumps, acts on tetracycline, STR, gentamicin, and netilmicin. Interestingly, other efflux 
pumps associated with AG resistance are from the resistance-nodulation-cell division (RND) 
superfamily of proteins.63 Additionally, the p55 gene forms an operon with p27, a gene 
encoding an antigenic lipoprotein. The P55 efflux pump is sensitive to inhibition by verapamil 
and reserpine, two known efflux pump inhibitors, and is dependent on the cellular proton 
gradient of the bacteria. In mycobacteria, efflux pumps are also responsible for resistance to 
FQs (in addition to other methods of resistance (See section 1.3.2a)).64-65 
 
1.3.2. Gene mutations 
Genetic mutations occur in two major areas: (i) mutations or modifications of drug targets, 
including methylation of RNA, and (ii) failure to convert prodrugs into active compounds. 
 
1.3.2a. Mutations or modifications of drug targets 
Mutations: Anti-tubercular agents intercept the cellular metabolism preventing requisite 
biomolecules from being made. Most often the interactions of these agents with their protein 
targets is dependent on a few key interactions. A simple and common mechanism for bacteria 
to prevent this from happening is the mutation of the target’s binding site. This can happen 
either naturally during replication error, or through selective pressure. The resulting mutations 
decrease the ability of anti-tubercular drugs from binding to their respective targets allowing 
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the bacteria to survive the therapy. This mechanism is commonly found in Mtb strains 
resistant to RIF, EMB, and FQs by single residue mutations in the b-subunit of RNA 
polymerase,57 a glycosyltransferase,66 and/or type II topoisomerases.67 Slight mutations in the 
16S rRNA (e.g., A1401G) often confer resistance to the injectable drugs AMK, KAN, and 
CAP.68 Two mutations in the rrs gene from Mtb encoding three rRNA residue alterations 
(A1400G, C1401A, and G1483T) were found to cause resistance to KAN.69 
 
Modifications: An alternative mode of resistance in Mtb is the inactivation of rRNA 
methyltransferase enzymes (e.g., TlyA and GibB). TlyA mutations were documented to 
hinder the methylation activity of rRNA 2'-O-methyltransferase at nucleotides C1409 of the 
16S rRNA and C1920 of the 23S rRNA, thereby causing resistance to CAP and VIO.70 
Mutations in GidB were found to confer minor resistance to STR.71-72 
 
1.3.2b. Inability to activate prodrugs 
Among the anti-tubercular agents, some prodrugs are found (e.g., INH, PZA, and ETH). 
These prodrugs are activated by KatG (INH), EthA (ETH), and PncA (PZA). Mutations in the 
katG, ethA, and pncA genes were shown to reduce the ability of the corresponding enzymes to 
activate INH,73-74 ETH,41, 75-76 and PZA,77-78 respectively. Interestingly, mutations in promoter 
regions were additionally found to result in overexpression of drug targets41, 75, 79 and to 
prevent binding of the active form of INH and ETH to their targets.64, 80 
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1.3.3. Enzymatic modifications and inactivation of drugs 
Perhaps the most prevalent and well-studied mechanism of resistance in non-mycobacteria is 
drug modification. Modifications can include degradation of the core structures or alteration 
of the chemical appearance of the antibiotic, to the point where the compound no longer binds 
or inactivates its target. Mtb naturally harbors a chromosomally encoded class A b-lactamase, 
BlaC, which is constitutively expressed to provide intrinsic resistance to penicillins by 
hydrolysis of their b-lactam ring.81 Mtb also contains two genes encoding for AG-modifying 
enzymes in its genome: aac(2')-Ic and eis encoding an AG 2'-N-acetyltransferase45, 82-83 and 
the enhanced intracellular survival (Eis) protein, respectively.84 Both enzymes acetylate AGs, 
reducing the ability of these drugs to bind the ribosome. In the case of Eis, increased 
expression due to mutations in the eis promoter or the 5'-untranslated region of the 
transcriptional activator WhiB7 leads to clinically relevant, low-level resistance to KAN.84 Eis 
has a unique ability to modify AGs at multiple sites and multiple times in vitro, completely 
inactivating these compounds.85 Crystallographic studies recently showed that the AG 
tobramycin (TOB) is able to bind in two distinct modes, allowing for a minimum of two 
acetylations (Figure 1.7).86 Eis was also reported to acetylate CAP at its b-lysine side chain in 
vitro, but a clinical link to CAP resistance still needs to be elucidated.87 This particular 
resistance enzyme has been extensively studied, both for its AG acetylating properties88-90 and 
its other in vivo functions.91-93 Interestingly, Eis enzyme homologues are found in a slew of 
bacteria, both from the genus Mycobacterium as well as other genera.94-97 
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Figure 1.7. Crystal structure of Eis (turquoise) bound to tobramycin (red sticks) (PDB ID: 
4JD6,86 at 3.5 Å) showing a density with two possible orientations of the AG. 
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NOTE: 
This dissertation summarizes the drug discovery projects that I performed under the 
supervision of Professor Sylvie Garneau-Tsodikova. It consists of nine chapters. Chapter one 
and six are the introductions providing relevant background information on the disease states 
(TB and fungal diseases), current treatment options, and resistance mechanisms of current 
FDA approved drugs. Chapter eight describes ongoing work that I have contributed. Chapter 
nine concludes the the findings in these projects and suggests future directions for these 
projects. Chapter two describes an SAR study and lead optimization of a novel class of 
pyrrolo[1,5-a]pyrazine-based Eis inhibitors to overcome Eis-mediated AG resistance. Chapter 
three reports the investigation of 1,2,4-triazino[5,6b]indole-3-thioether-based Eis inhibitors, 
that display unique interactions with Eis AG binding site. Chapter four focuses on synthesis 
and evaluation of thieno[2,3-d]pyrimidine Eis inhibitors, which uniquely contain their own 
antitubercular activity and are potentially synergistic with KAN. Chapter five reports the 
synthesis ebsulfur-based analogues and the repurpose of these compounds as potent 
antibacterials to treat infections associated with methicillin-resistant Staphylococcus aureus 
(MRSA). Chapter seven explores the application of ebsulfur analogues as antifungal agents.  
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Chapter 2 
 
Combating Eis-mediated kanamycin resistance of M. tuberculosis by novel pyrrolo[1,5-
a]pyrazine-based Eis inhibitors 
 
2.1. ABSTRACT 
Tuberculosis (TB) remains one of the leading causes of mortality worldwide. Hence, the 
identification of highly effective antitubercular drugs with novel modes of action is crucial. In 
this manuscript, we report the discovery and development of pyrrolo[1,5-a]pyrazine-based 
analogues as highly potent inhibitors of the Mycobacterium tuberculosis (Mtb) 
acetyltransferase Eis, whose upregulation causes clinically observed resistance to the 
aminoglycoside (AG) antibiotic kanamycin A (KAN). We performed a structure-activity-
relationship (SAR) study to optimize these compounds as potent Eis inhibitors both in 
solution and in mycobacterial cells. A crystal structure of Eis in complex with one of the most 
potent inhibitors reveals that the compound is bound to Eis in the AG-binding pocket, serving 
as the structural basis for the SAR. These Eis inhibitors have no observed cytotoxicity to 
mammalian cells and are promising leads for development of innovative AG adjuvant 
therapies against resistant Mtb strains. 
 
2.2. INTRODUCTION 
Tuberculosis (TB), caused by the pathogenic Mycobacterium tuberculosis (Mtb), is the 
deadliest global bacterial infection. The number of people infected by Mtb is currently 
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estimated to be 2-3 billion worldwide.98 The situation is greatly aggravated by the emergence 
and spread of difficult or impossible to treat multidrug-resistant (MDR) and extensively drug-
resistant (XDR) TB.99 Aminoglycoside (AG) antibiotics such as kanamycin A (KAN) and 
amikacin (AMK) are used for the treatment of MDR and XDR-TB. However, the successful 
outcomes for the treatment of these MDR and XDR-Mtb strains can be impeded as a result of 
KAN resistance.100 It was previously discovered that upregulation of the enhanced 
intracellular survival (eis) gene due to point mutations in its promoter is a cause of resistance 
to KAN in one-third of KAN-resistant Mtb infections in clinic.84, 101 The development of new 
AGs or use of Eis inhibitors are two potential solutions for overcoming the effect of Eis in 
Mtb. We recently demonstrated that Eis is an AG acetyltransferase (AAC) found in a variety 
of bacterial strains that can inactivate AGs via a multiacetylation mechanism.85, 88, 94-97 As Eis 
has been shown to multiacetylate a wide variety of molecules,102-103 including many AG 
scaffolds, the development of new AGs to combat its action is not likely to be successful. 
Some metal salts are inhibitory to Eis, but this strategy alone is not pharmacologically 
relevant.104 A better approach would be to use inhibitors of Eis as adjuvant therapies in 
combination with KAN to combat or forestall the emergence of KAN resistance through Eis 
upregulation. We recently reported discovery and development of Eis inhibitors with 
isothiazole S,S-dioxide heterocyclic core,105 sulfonamide-based,106 methyl 4H-furo[3,2-
b]pyrrole-5-carboxylate,107 and 3-(1,3-dioxolano)-2-indolinone107 scaffolds, which yielded 
compounds that potently inhibited Eis in vitro and abolished KAN-resistance of the Mtb 
mutant strain K204 that was KAN-resistant due to Eis upregulation. We previously reported 
25 hit compounds identified by high-throughput screening (HTS) of a library comprised of 
~23,000 small molecules that displayed Eis inhibitory activities.108 Here, we pursue one of 
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these preliminary hits (compound 1a*, Figure 2.1A) and report the chemical synthesis of this 
compound and that of 47 analogues (Figure 2.1B), along with their biochemical and biological 
studies. Among compounds in this series, we have generated novel and promising Eis 
inhibitors that not only efficiently inhibit the purified enzyme, but also restore KAN 
sensitivity of KAN-resistant Mtb bacteria. We also present a crystal structure of Eis in 
complex with CoA and one potent inhibitor (compound 2k*), which explains the structure-
activity relationship (SAR). 
 
2.3. RESULTS AND DISCUSSION 
2.3.1. Synthesis 
Compound 1a* and 47 additional analogues 1a-3k with different R1 and R2 substituents on 
the two phenyl rings and either a fully aromatized (indicated by an asterisk after the 
compound number) or a non-aromatized pyrrolo[1,5-a]pyrazine core were generated for a 
thorough SAR analysis of Eis inhibition (Figure 2.1B). The synthesis of all compounds started 
with a reaction between the commercially available pyrrole and 2-chloroethylamine, which 
afforded compound 4 in quantitative yield. Compound 4 was reacted with different substituted 
benzoyl chlorides to obtain amides 5-7 in 66-71% yields. The resulting amides were mixed 
with phosphorus(V) oxychloride to generate cyclized products 8-10. Then, compounds 8-10 
were reacted with various substituted 2-bromoacetophenones to obtain the desired non-
aromatized products 1a-k, 2a-k, and 3a,d,h,k. In order to generate the aromatized 
counterparts of these products, compounds 8 and 9 were first aromatized in the presence of 
Pd/C to generate molecules 11 and 12. Conventionally, Pd/C is a hydrogenation catalyst. In 
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the absence of hydrogen gas, Pd/C is known to catalyze an oxidative aromatization instead of 
hydrogenation. More details about this heteroaromatic aromatization were summarized in an 
excellent review.109 Compounds 11 and 12 were further reacted with the different substituted 
2-bromoacetophenones to furnish the desired fully aromatized analogues 1a*-k* and 2a*-k*. 
These compounds were evaluated for Eis inhibition using the clinically relevant KAN as the 
AG substrate (IC50 values in Table 2.1). 
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Figure 2.1. A. Structures of all compounds generated in this study. B. Synthetic scheme used 
to prepare the compounds in panel A. 
 
2.3.2. Biochemical and biological evaluation 
2.3.2.1. Eis inhibition 
We first tested whether the freshly synthesized parent compound 1a* was indeed a potent Eis 
inhibitor. Expectedly, the freshly synthesized compound 1a* was found to display potent 
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inhibition of Eis (IC50 = 0.064 ± 0.008 µM) (Table 2.1), which was ~6-fold better than the 
IC50 value of the commercially available compound 1a* (IC50 = 0.36 ± 0.03 µM) from our 
previous HTS (Note: freshly synthesized powder are often more active than HTS library 
compounds, which may degrade upon storage).108 The hit scaffold 1a* contains a pyrrolo[1,5-
a]pyrazine core, a phenyl ring adjacent to the pyrrolo[1,5-a]pyrazine core(containing R1), and 
an acetophenone moiety (containing R2). A comparison of the chemical structure of 
compound 1a* with those of the previously published isothiazole S,S-dioxide-based Eis 
inhibitors co-crystallized with Eis105 suggested that 1a* binds to Eis at the AG binding 
pocket86 similarly to the isothiazole S,S-dioxides. Examination of the Eis crystal structure 
bound to the AG tobramycin (TOB) (PDB: 4JD686) indicated that the positively-charged 
pyrrolo[1,5-a]pyrazine core is presumably essential for binding to the negatively-charged AG 
binding pocket and thus, should not be modified. Based on our previous survey of the hits of 
this HTS,108 we also determined that the phenyl ring adjacent to the pyrrolo[1,5-a]pyrazine 
core (containing R1) is likely important for Eis inhibition. In fact, replacing the phenyl ring of 
1a* with an ethyl group resulted in a 25-fold reduction in the inhibitory activity (IC50 = 9.25 ± 
1.50 µM).108 Also from the crystal structure of Eis in complex with the isothiazole S,S-
dioxide-based Eis inhibitors, we have rationalized that this phenyl ring is important due to its 
snug fit in a hydrophobic binding pocket in the AG binding cavity. On the other hand, the π-
electron rich acetophenone moiety (containing R2) and the fully aromatic pyrrolo[1,5-
a]pyrazine core were predicted to be crucial for binding due to potential π-π  interactions with 
aromatic residues within the Eis binding pocket. However, it remains unexplored whether and 
which substitutions at R1 and R2 positions would be beneficial. We hypothesized that: (i) 
tailor fitting the Eis binding pocket by introducing subtle modifications at R1 and R2 would 
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lead to the discovery of novel optimized inhibitors from our hit scaffold 1a*, and (ii) 
disruption of the aromaticity of the pyrrolo[1,5-a]pyrazine core would be detrimental to the 
binding affinity of the molecule to the Eis binding pocket. In our biochemical analysis, we 
will first examine the aromatic compounds and then explore their non-aromatic counterparts. 
Both the aromatic and non-aromatic molecules are divided into two series. In series 1, R1 was 
kept constant (R1 = H), and various substituted acetophenones were installed onto the 
pyrrolo[1,5-a]pyrazine core (changing R2). Similarly, in series 2, R1 was kept constant (R1 = 
p-F), and the same various substituted acetophenones were installed onto the pyrrolo[1,5-
a]pyrazine core (changing R2). For the non-aromatic compounds, four additional members 
were added to a third series (series 3) where R1 was m,p-di-F. 
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Table 2.1. Inhibition of Eis-catalyzed KAN acetylation (IC50 values) by the pyrrolo[1,5-a]pyrazine derivatives as 
well as effect of these molecules on KAN MIC values for Mtb H37Rv and KAN-resistant Mtb K204. 
Cpd 
# 
R1 R2 Aroma
tic 
IC50 
(µM)a 
H37Rv 
MICKA
N 
(µg/m
L)b 
K204 
MICKAN 
(µg/mL)
c 
Cpd 
# 
R1 R2 Aroma
tic 
IC50 (µM)a H37Rv 
MICKA
N 
(µg/mL
)b 
K204 
MICKAN 
(µg/mL)
c 
1a H H no 0.9 ± 0.2 -d -d 2a p-F H no 0.47 ± 0.05 -d -d 
1b H o-F no 0.7 ± 0.2 -d -d 2be p-F o-F no 1.4 ± 0.4 -d -d 
1c H m-F no 0.05 ± 
0.01 
≤ 1.25 10, 10 2c p-F m-F no 0.7 ± 0.2 -d -d 
1d H m-Cl no 0.5 ± 0.1 ≤ 1.25 10, 10 2d p-F m-Cl no 0.15 ± 0.04 ≤ 1.25 >10, 
>10 
1e H m-Br no 0.44 ± 
0.16 
≤ 1.25 10, 10 2e p-F m-Br no 0.07 ± 0.02 ≤ 1.25 >10, 
>10 
1fe H m-OH no 4.2 ± 1.7 -d -d 2fe p-F m-OH no 8.7 ± 1.6 -d -d 
1g H m-
OMe 
no 0.15 ± 
0.04 
≤ 1.25 10, 10 2ge p-F m-
OMe 
no 1.3 ± 0.4 -d -d 
1h H p-F no 0.039 ± 
0.007 
≤ 1.25 10, 10 2h p-F p-F no 0.23 ± 0.02 ≤ 1.25 10, 5 
1i H p-Cl no 0.31 ± 
0.09 
≤ 1.25 5, 5 2i p-F p-Cl no 0.5 ± 0.1 -d -d 
1j H p-Br no 0.76 ± 
0.17 
-d -d 2je p-F p-Br no 1.6 ± 0.5 -d -d 
1k H p-Me no 0.64 ± 
0.18 
-d -d 2k p-F p-Me no 0.47 ± 0.08 -d -d 
1a* H H yes 0.064 ± 
0.008 
≤ 1.25 5, 5 2a* p-F H yes 0.35 ± 0.07 ≤ 1.25 5, 5 
1b* H o-F yes 0.21 ± 
0.05 
≤ 1.25 5, 5 2b* p-F o-F yes 0.29 ± 0.07 ≤ 1.25 5, 2.5 
1c* H m-F yes 0.06 ± 
0.01 
≤ 1.25 5, 5 2c* p-F m-F yes 0.22 ± 0.05 ≤ 1.25 2.5, 2.5 
1d* H m-Cl yes 0.025 ± 
0.006 
≤ 1.25 5, 5 2d* p-F m-Cl yes 0.06 ± 0.02 ≤ 1.25 5, 5 
1e* H m-Br yes 0.34 ± 
0.10 
≤ 1.25 2.5, 2.5 2e* p-F m-Br yes 0.06 ± 0.02 ≤ 1.25 5, 5 
1f* H m-OH yes 1.8 ± 0.5 ≤ 1.25 10, 5 2f*e p-F m-OH yes 8.4 ± 2.8 ≤ 1.25 10, 10 
1g* H m-
OMe 
yes 0.21 ± 
0.07 
≤ 1.25 5, 5 2g* p-F m-
OMe 
yes 0.53 ± 0.11 ≤ 1.25 5, 2.5 
1h* H p-F yes 0.029 ± 
0.007 
≤ 1.25 5, 5 2h* p-F p-F yes 0.13 ± 0.04 ≤ 1.25 1.25, 
1.25 
1i* H p-Cl yes 0.56 ± 
0.20 
≤ 1.25 1.25, 
1.25 
2i* p-F p-Cl yes 0.18 ± 0.06 ≤ 1.25 2.5, 5 
1j* H p-Br yes 0.27 ± 
0.01 
≤ 1.25 2.5, 2.5 2j* p-F p-Br yes 0.50 ± 0.13 ≤ 1.25 5, 2.5 
1k* H p-Me yes 0.19 ± 
0.02 
≤ 1.25 2.5, 5 2k* p-F p-Me yes 0.08 ± 0.03 ≤ 1.25 2.5, 5 
       3a m,p-di-
F 
H no 0.15 ± 0.05 ≤ 1.25 10, 10 
       3d m,p-di-
F 
m-Cl no 0.043 ± 
0.006 
≤ 1.25 >10, 
>10 
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       3h m,p-di-
F 
p-F no 0.11 ± 0.03 ≤ 1.25 10, 10 
Control without an Eis inhibitor: 1.25 10 3k m,p-di-
F 
p-Me no 0.11 ± 0.03 ≤ 1.25 10, 10 
a IC50 values against purified Eis_Mtb enzyme. b Anti-tubercular activity of KAN against Mtb H37Rv. c Anti-
tubercular activity of KAN against Mtb K204. d The inhibitor interacted with alamarBlue® resulting in  a color 
change, therefore, it was impossible to determine the MIC using this method. e In MIC assays, the compounds were 
tested at concentrations that were 100-fold higher than IC50. When the IC50 value was >1 mM the compounds were 
tested at 100 µM. The compounds were not toxic to Mtb in the absence of KAN at these concentrations. 
 
We began our analysis of the aromatic compounds by investigating series 1. To probe the 
ortho position of the acetophenone moiety, compound 1b* (R1 = H, R2 = o-F) was generated 
and found to display a ~3-fold reduction in Eis inhibitory activity (IC50 = 0.21 ± 0.05 µM) 
when compared to the freshly synthesized parent 1a* (Note: from here on, when comparing to 
1a*, we refer to the freshly synthesized 1a*), indicating that ortho substitution was not 
beneficial. We then explored substitutions at the meta position with compounds 1c*-1g*. The 
meta-substituted compound 1c* (R1 = H, R2 = m-F) was found to have comparable Eis 
inhibitory activity (IC50 = 0.06 ± 0.01 µM) to the parent compound 1a*. We systematically 
increased the size of the halogen substituents in compounds 1d* (R1 = H, R2 = m-Cl) and 1e* 
(R1 = H, R2 = m-Br). Interestingly, compound 1d* displayed an IC50 value of 0.025 ± 0.006 
µM, which was ~3-fold smaller than that of the parent compound 1a*. On the other hand, 
compound 1e* (IC50 = 0.34 ± 0.10 µM) was not as potent as compound 1d*, suggesting that 
the Br substituent was possibly too sterically hindered and thus, not well tolerated in the Eis 
binding pocket. Compound 1f* (R1 = H, R2 = m-OH) (IC50 = 1.8 ± 0.5 µM) was less potent 
than the parent compound, which suggested that having a highly polar substituent could be 
disfavored. Alternatively, replacing the hydroxyl group by a methoxy (compound 1g* (R1 = H, 
R2 = m-OMe)) yielded a molecule with improved Eis inhibition (IC50 = 0.21 ± 0.07 µM) when 
compared to 1f*. Overall, we found that the Cl was the best substituent at the meta position. 
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We pondered whether this trend would translate to the para position, which prompted us to 
evaluate compounds 1h* (R1 = H, R2 = p-F), 1i* (R1 = H, R2 = p-Cl), and 1j* (R1 = H, R2 = p-
Br). Intriguingly, the smaller F substituent was optimal at the para position with an IC50 value 
of 0.029 ± 0.007 µM contrary to what we observed at the meta position. Intriguingly, inhibitor 
1h* displayed an IC50 of 0.029 ± 0.007 µM, which, similarly to the IC50 values for several 
other inhibitors was smaller than the half of the enzyme concentration used in our assay 
(0.25/2 = 0.125 µM). This effect has at least three potential explanations: (1) If inhibition of 
one monomer per Eis hexamer by one inhibitor molecule leads to the loss of activity of the 
entire hexamer, then the IC50 can, in principle, be as low as 0.125/6 = 0.02 µM; (2) If only a 
fraction of Eis protein is active in acetylating KAN and binding inhibitors (e.g., due to protein 
aggregation), then the concentration of active Eis in the assay is an overestimate of the 
concentration of active enzyme; and (3) If inhibitor binding to Eis causes Eis aggregation and 
inactivates multiple hexamers, then IC50 is also a fraction of the half of the enzyme 
concentration in the assay. Mechanism #3 is unlikely, because we do not observe global 
conformational changes in Eis upon inhibitor binding in crystal structures. Distinguishing 
among these mechanisms of these highly potent analogues is a goal of ongoing work in the 
group. 
 
Subsequently, we investigated the effect of R1 substitutions on the phenyl ring adjacent to the 
pyrrolo[1,5-a]pyrazine core. As the p-F substitution was one of the best in terms of activity 
when we varied R2 in series 1, we first decided to install the p-F substituent at the R1 position 
and generated series 2 analogues. Analogue 2a* (R1 = p-F, R2 = H) displayed weaker Eis 
inhibition (IC50 = 0.35 ± 0.07 µM) than did 1a*. Similarly to 1b* (R1 = H, R2 = o-F), the 
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ortho-substituted analogue 2b* (R1 = p-F, R2 = o-F) was also not optimal. When we increased 
the size of the R2 substituents at the meta position, we observed that the larger halogens led to 
more potent Eis inhibition (Br = Cl > F) and yielded compounds with IC50 values varying 
from 0.06 to 0.22 µM. Unlike compound 1e* (R1 = H, R2 = m-Br; IC50 = 0.34 ± 0.10 µM), the 
m-Br substituted analogue 2e* (R1 = p-F, R2 = m-Br; IC50 = 0.06 ± 0.02 µM) was much more 
potent, which pointed to the possibility that changing R1 from H to p-F could lead to a slight 
variation in the binding orientation of the molecule, especially near the meta position of the 
acetophenone ring. Additionally, the m-hydroxy and m-methoxy substitutions, as in the cases 
of 2f* (R1 = p-F, R2 = m-OH) and 2g* (R1 = p-F, R2 = m-OMe) either completely abolished 
Eis inhibitory activity or resulted in moderate inhibition of the enzyme (IC50 = 8.4 ± 2.8 and 
0.53 ± 0.11 µM, respectively). This was consistent with the observations made with 
compounds 1f* (R1 = H, R2 = m-OH) and 1g* (R1 = H, R2 = m-OMe). For the para-
substituted analogues (2h* (R1 = p-F, R2 = p-F), 2i* (R1 = p-F, R2 = p-Cl) and 2j* (R1 = p-F, 
R2 = p-Br)), similarly to what was observed with series 1, the larger halogen substituents were 
generally less favorable with activities varying in the range of 0.13-0.50 µM. We also 
evaluated the para-methylated analogue 2k* (R1 = p-F, R2 = Me) and found that 2k* 
displayed excellent activity with an IC50 value of 0.08 ± 0.03 µM, which was 2-fold better 
than that of 1k* (IC50 = 0.19 ± 0.02 µM). 
 
Having established the general SAR trends for the aromatic analogues, we next aimed to 
determine whether their non-aromatic counterparts (1a-k and 2a-k) would exhibit decreased 
activity due to potential disruption of the π-π interactions with Eis aromatic amino acid 
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residues. Indeed, we found that most of the non-aromatic analogues generally displayed less 
potent Eis inhibition than their aromatic counterparts did. In four out of 22 cases, the aromatic 
and non-aromatic compounds display nearly equipotent inhibition of Eis. In the case of 
compounds 1c and 1c* (R1 = H, R2 = m-F), the IC50 values were virtually the same (IC50 = 
0.05 ± 0.01 and 0.06 ± 0.01 µM, respectively). Additionally, compounds 2e and 2e* (R1 = p-F, 
R2 = m-Br) were also practically equipotent in terms of Eis inhibitory activities (IC50 = 0.07 ± 
0.02 and 0.06 ± 0.02 µM, respectively). Compounds 1g and 1g* (R1 = H, R2 = m-OMe) (IC50 
= 0.15 ± 0.04 and 0.21 ± 0.07 µM, respectively) were also similar. For the pair 1i and 1i* (R1 
= H, R2 = p-Cl) (IC50 = 0.31 ± 0.09 and 0.56 ± 0.20 µM, respectively), the non-aromatic 
counterpart 1i was marginally better. Regardless of whether the analogue in series 2 was 
aromatic or non-aromatic, it was conclusive that at the meta position of the acetophenone 
moiety, bigger halogen substituents such as Cl and Br were generally better suited, and at the 
para position of the acetophenone, the smaller F substituent was the best. 
 
 
 
2.3.2.2. Activity of Eis inhibitors in Mtb cell culture 
Once our pyrrolo[1,5-a]pyrazine derivatives were optimized for inhibition of the purified Eis 
enzyme in vitro, we set to confirm whether these compounds could display Eis inhibitory 
activity in the Mtb culture, by measuring the effect of the compounds on KAN MIC (MICKAN). 
Compounds were tested in combination with KAN against the KAN-sensitive H37Rv Mtb 
strain as a control and against the KAN-resistant Mtb K204, which is H37Rv Mtb bearing a 
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clinically occurring point mutation in the eis promoter leading to overexpression of Eis.4 Mtb 
H37Rv has an MICKAN of 1.25 mg/mL, whereas KAN-resistant Mtb K204 has an MICKAN of 
≥10 mg/mL. Active compounds were expected to resensitize Mtb K204 to KAN. The 
compounds were generally tested at concentrations that were 100-fold higher than their 
respective IC50 values in the enzymatic assays, to correct for the variation in the potency of 
Eis inhibition. Weakly potent compounds (IC50 >1 mM) were tested at 100 mM in the MIC 
assays. Mtb is notorious for its highly lipophilic and complex cell wall, which provides 
intrinsic resistance to many antibacterial compounds and presents an immense challenge for 
anti-tubercular drug discovery. Indeed, as shown in our previous Eis inhibitors studies,105 
some of the most potent in vitro compounds were not active in Mtb cultures. We also cannot 
exclude low solubility or aggregation of the compounds in the culture media as a reason for 
poor activity. Herein, we determined the MIC values for KAN (MICKAN) against Mtb K204 in 
the absence or presence of our Eis inhibitors and compared them to the MICKAN of the drug-
sensitive Mtb H37Rv strain. As anticipated, most compounds caused a reduction in the 
MICKAN for Mtb K204, overcoming KAN resistance. Poor Eis inhibitors such as compounds 
1f* and 2f* with relatively high IC50 values were unable to resensitize Mtb K204 to the action 
of KAN. These observations, together with the lack of toxicity of these inhibitors when used 
without KAN for either Mtb strains, validate Eis inhibition as the principal mechanism of 
MICKAN reduction by these compounds. Mtb H37Rv, for which MICKAN is virtually 
unaffected by the inhibitors, serves as an important negative control in this regard. Some of 
the good Eis inhibitors such as compounds 1c-1e, 1g, 1h, 2d, 2e, 2h, 3a, 3d, 3h, and 3k did 
not resensitize Mtb K204 to the action of KAN despite their nanomolar IC50 values (MICKAN 
≥10 mg/mL), indicating that these molecules may not go through the cell envelope. 
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Compounds 1a*-1e*, 1g*, 1h*, 1i, 1j*, 1k*, 2a*-2e*, 2g*, 2i*-2k* partially restored activity 
of KAN (MICKAN = 2.5-5 µg/mL). Generally, the analogues in series 1 and 2 displayed better 
potency compared to the analogues in series 3 in Mtb culture. While the charged nature of 
these compounds may contribute adversely to the permeability of the compounds through the 
greasy mycobacterial cell envelope, their better solubility in aqueous solution when compared 
to other uncharged Eis inhibitors may offset this potential issue. Therefore, these compounds 
serve as valuable alternatives to our previously reported uncharged Eis inhibitors of other 
scaffolds in further preclinical development of Eis inhibitors as KAN adjuvants in TB therapy. 
Indeed, two compounds, 1i* and 2h*, are highly promising for future development, as they 
completely restore the potency of KAN, fully overcoming Eis upregulation. 
 
2.3.2.3. Mammalian cytotoxicity 
Cytotoxicity to three different mammalian cell lines was tested for five representative potent 
Eis inhibitors (Figure 2.2) in the absence and presence of KAN at the concentration of 50 
µg/mL (equivalent to 86 µM) greatly exceeding the MICKAN of Mtb. The negative control 
corresponded to no inhibitor treatment and was standardized as 100% cell survival. The 
positive control was a treatment with Triton 100-X®, where we observed most of the cells 
killed. We observed that at sub-IC50 concentrations, our Eis inhibitors induced cell 
proliferation, thereby displaying >100% cell survival. With the exception of compound 1e*, 
which at 50 µM exhibited significant cytotoxicity against one of the three cell lines, none of 
the compounds were cytotoxic against any of the three cell lines up to 50 µM. Three 
compounds (1i*, 2c*, 2h*) had no significant cytotoxicity up to 100 µM, without or with 
KAN. The lack of cytotoxicity indicates the absence of toxic off-target effects in the 
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mammalian cells, strengthening the promise of these compounds as candidates for animal and 
clinical studies. Eis inhibitors appear to be less toxic when co-administering with KAN. Upon 
assessing the cytotoxicity of KAN alone (Figure 2.3) and Eis inhibitors alone (Figure 2.2), one 
can observe that exposure to KAN or to Eis inhibitors alone at sub-IC50 concentrations 
promotes cell growth. This phenomenon of increased growth in the presence of small 
quantities of xenobiotics has been previously observed.110-114 Due to this effect, co-treatment 
with KAN and Eis inhibitors may result in a faster cell growth than that for KAN alone. 
 
 
Figure 2.2. Mammalian cytotoxicity of selected compounds (1e*, 1i*, 2c*, 2h*, and 2i*) 
alone (represented as dark color columns) or in the presence of 50 mg/mL (equivalent to 86 
mM) KAN (represented as light color columns immediately to the right of the dark color 
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column of the corresponding compound in the absence of KAN) against A. A549, B. HEK-
293, and C. J774A.1 cells. Note: The data collected at lower concentrations (0.78, 1.56, 3.13, 
and 6.26 mM) did not indicate any toxicity and are therefore omitted for clarity. 
 
 
 
Figure 2.3. Cytotoxicity of KAN against A549 (pale yellow), HEK-293 (light orange), and 
J774A.1 (red) mammalian cell lines. 
 
2.3.3. Structural biology studies 
To rationalize our SAR study and understand the binding mode of our inhibitors to Eis, we 
determined a crystal structure of Eis in complex with CoA and inhibitor 2k* (one of our best 
inhibitors; IC50 = 0.08 ± 0.03 µM) at the resolution of 2.4 Å (Figure 2.4 and Table 2.2). The 
crystal structure demonstrates that inhibitor 2k* is indeed bound in the AG binding site 
(established by our reported Eis-CoA-TOB crystal structure;86 Figure 2.5) and is stabilized in 
the bound state by numerous hydrophobic interactions with Eis. The pyrazine ring is stacked 
between the side chain of Glu401 of Eis and its C-terminal carboxyl group, with mutually 
orthogonal π-π interactions of the pyrazine ring with the indole ring of Trp36. This 
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observation supports our initial hypothesis that the aromaticity of the pyrrolo[1,5-a]pyrazine 
core is crucial for activity and explains why aromatized compounds resulted in better 
activities during SAR analysis. Attached to the pyrrolo[1,5-a]pyrazine core, the acetophenone 
ring displayed parallel π-π interaction with Phe84 and showed that our prediction about the 
importance of the aromatic acetophenone was correct. Additionally, the R2-substituted 
acetophenone fits in a hydrophobic environment of Leu63, Trp36, and Arg37. Hence, adding 
a polar hydroxyl group at R2, such as in compounds 1f, 1f*, 2f, and 2f*, destabilizes binding 
within the hydrophobic environment and results in weaker Eis inhibitory activity. Furthermore, 
the para position of the acetophenone ring is sterically restrained on all sides, being 
sandwiched between Phe84 and Trp36 and abutting Trp13 and Met65, explaining why the 
larger groups in para position, such as in compounds 1i/i*, 1j/j*, 2i/i*, and 2j/j* resulted in 
decreased Eis inhibitory activities. This R2 binding pocket of Eis accommodates structurally 
similar substitutions of our previously published inhibitors with different core scaffolds 
(Figure 2.5). Otherwise, these previously reported inhibitors are bound in distinct orientations 
in the large AG binding cavity. As shown in Figure 2.4B and in our SAR analysis, near the 
two meta positions of the acetophenone ring, there are spacious pockets allowing 
incorporation of larger substituents at the meta position without compromising activity. Lastly, 
the phenyl ring containing R1 is located in a spacious binding pocket lined by the terminus of 
the phosphopantetheinyl tail of the CoA molecule, Asp26, the C-terminal carboxyl group, 
Ser83, and Phe24, explaining why a phenyl group is preferred over an ethyl group at the R1 
position. In summary, the crystal structure of the EisC204A-CoA-inhibitor 2k* complex 
allowed us to explain our biological data and provides a basis for future additional structure-
based development of Eis inhibitors. 
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Figure 2.4. A. Crystal structure of EisC204A-CoA-inhibitor 2k* complex (PDB ID 5TVJ). 
CoA is colored yellow. Compound 2k* is colored in green. B. A zoom-in view of the binding 
pocket of compound 2k*. Amino acid residues that are interactive with compound 2k* are 
highlighted in red. The strong omit Fo-Fc electron density map contoured at 3σ generated 
without the inhibitor is shown by the mesh, demonstrating that the inhibitor molecule is 
unambiguously defined by the X-ray diffraction data. 
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Figure 2.5. A zoom-in view of the inhibitor/aminoglycoside binding site showing the 
superimposition of Eis inhibitors and TOB from several crystal structures. Inhibitor 2k* (PDB 
ID 5TVJ) from this study is depicted as green sticks. The previously published structure of 
bound TOB (PDB ID 4JD686) is in blue, that of an isothiazole S,S-dioxide heterocyclic core 
(labeled 13g in ref 105, PDB ID 5EC4105) is in red, and that of a sulfonamide-based inhibitor 
(labeled 39 in ref 106, PDB ID 5IV0106) is in orange. Bound CoA from the structure described 
in the current study is depicted as yellow sticks. The chemical structures of inhibitors 2k*, 
13g, and 39, as well as of TOB are shown below the crystal structure. 
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2.4. CONCLUSION 
In conclusion, via a SAR study, we tailor-fitted Eis inhibitors possessing the pyrrolo[1,5-
a]pyrazine core to its Eis binding pocket and identified multiple novel nanomolar potency 
inhibitors. We validated our hypothesis that the aromaticity of the pyrrolo[1,5-a]pyrazine core 
was important for activity and that aromatic analogues were overall better inhibitors than their 
non-aromatic counterparts. For the aromatic analogues, our study indicated that the SAR 
strongly correlates with the size of the halogen substituent(s). At the meta position of the 
acetophenone, bigger halogens such as Cl and Br were generally well tolerated. On the other 
hand, at the para position, substitutions of a smaller F atom and a methyl group produced 
analogues with substantially improved activities. The SAR analysis also revealed that the 
substitution of a polar functional group such as the hydroxyl group greatly perturbed the 
hydrophobic environment leading to decreased activity. These SAR observations were 
explained by the crystal structure analysis, which will greatly facilitate future medicinal 
chemistry studies. Most significantly, by in vitro Mtb culture assays, we confirmed that our 
Eis inhibitors were capable of penetrating the Mtb cell wall and cancelling the KAN-
resistance of Mtb K204, which overexpresses Eis. As exemplified by a clinically used 
combination of a b-lactamase inhibitor, clavulanic acid, and penicillin, these Eis inhibitors 
may become similarly significant as adjuvant molecules in a combination therapy with KAN 
to prevent emergence of and combat KAN resistance in MDR- and XDR-TB. 
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2.5. MATERIALS AND INSTRUMENTATION 
All reagents were purchased from commercial sources and used without any further 
purification. Deuterated solvents were purchased from Cambridge Isotope Laboratories Inc. 
(Tewksbury, MA). TLC analyses were performed on silica gel plates (pre-coated on glass; 
0.25 mm thickness with fluorescent indicator UV254) and were visualized by UV or charring 
in KMnO4 stains. 1H and 13C NMR spectra were recorded on 400 and 500 MHz NMR 
spectrometers (VARIAN INOVA) using CDCl3 or (CD3)2SO. Chemical shifts are reported in 
parts per million (ppm) and are referenced to residual solvent peaks (7.24 ppm for CDCl3 and 
2.50 ppm for (CD3)2SO in 1H NMR; 77.00 ppm for CDCl3 and 39.50 ppm for (CD3)2SO in 
13C NMR). Abbreviations used in NMR spectra: s = singlet, d = doublet, t = triplet, q = quartet, 
m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, tt = 
triplet of triplets, and ddd = doublet of doublet of doublets. All reactions were carried out 
under nitrogen atmosphere and all yields reported represent isolated yields. Known 
compounds were characterized by 1H NMR and are in complete agreement with samples 
reported in the literature. All new compounds were characterized by 1H and 13C NMR as well 
as mass spectrometry. Low-resolution electrospray mass spectra (LRMS) were recorded on a 
liquid chromatography-mass spectrometry using an Agilent 1200 series Quaternary LC 
system equipped with a diode array detector, and Eclipse XDB-C18 column (250 mm x 4.6 
mm, 5 mm), and an Agilent 6120 Quadrupole MSD mass spectrometer. All final molecules 
1a-3k and 1a*-2k* that were tested against purified Eis and in Mtb cells are >95% pure 
according to NMR spectra. Further confirmation of purity for these final molecules was 
obtained by RP-HPLC, which was performed on an Agilent Technologies 1260 Infinity HPLC 
system by using the following general method 1: Flow rate = 1 mL/min; l = 254 nm; column = 
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Vydac 201SPTM C18, 250 × 4.6 mm, 90A 5 mm; Eluents: A = H2O + 0.1% TFA, B = MeCN; 
gradient profile: starting from 5% B, increasing from 5% B to 100% B over 20 min, holding at 
100% B from 20-27 min, decreasing from 100% B to 5% B from 27-30 min. Prior to each 
injection, the HPLC column was equilibrated for 15 min with 5% B. 
 
2.6. METHODS 
2.6.1. Chemical methods 
2.6.1.1. Synthesis of compound 4 
Compound 4 was prepared following a previously published protocol.115 Sodium 
hydroxide (14.41 g, 360.35 mmol) and tetrabutylammonium hydrogen sulfate 
(TBAS) (1.22 g, 3.60 mmol) were added to a solution of pyrrole (5.0 mL, 72.07 mmol) in 
MeCN (220 mL). After stirring for 30 min at rt, 2-chloroethylamine hydrochloride (10.03 g, 
86.48 mmol) was added. The reaction mixture was then refluxed for 24 h. After cooling to rt, 
the solvent was removed under reduced pressure to afford compound 4 (7.9 g, quantitative 
yield) as a yellow oil, which was used without any further purification: 1H NMR (400 MHz, 
CDCl3, Figure A1, which matches lit.115) δ 6.66 (t, J = 2.0 Hz, 2H), 6.14 (t, J = 2.0 Hz, 2H), 
3.92 (t, J = 6.4 Hz, 2H), 3.00 (t, J = 6.4 Hz 2H), 1.36 (br s, 2H). 
 
2.6.1.2. General procedure for benzoylation (e.g., Preparation of compound 5) 
Benzoylation was performed following a previously reported protocol.116 
Pyridine (3.22 mL, 39.94 mmol) and benzoyl chloride (4.22 mL, 36.31 mmol) 
N
NH2
N
HN
O
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were successively added to a solution of compound 4 (4.00 g, 36.31 mmol) in 1,4-dioxane 
(144 mL). The reaction mixture was refluxed for 12 h prior to removing the solvent under 
reduced pressure. The residue was triturated with H2O (100 mL) and extracted with Et2O (2 x 
80 mL). The organic layers were collected, washed with aq. NaHCO3 (100 mL) then with 
H2O (100 mL), dried over MgSO4, and evaporated to dryness to afford compound 5 (5.3 g, 
69%) as a light brown solid, which was used without any further purification: 1H NMR (400 
MHz, CDCl3, Figure A2, which matches lit.117) δ 7.67 (d, J = 6.8 Hz, 2H), 7.59 (t, J = 7.2 Hz, 
1H), 7.59-7.37 (m, 2H), 6.67 (t, J = 2.0 Hz, 2H), 6.20 (br s, 1H), 6.18 (t, J = 2.0 Hz, 2H), 4.12 
(t, J = 6.0 Hz, 2H), 3.73 (q, J = 6.0 Hz, 2H). 
 
Preparation of compound 6. As described for the synthesis of compound 5, 
pyridine (3.14 mL, 35.40 mmol), 4-fluorobenzoyl chloride (4.19 mL, 35.40 
mmol), compound 4 (3.90 g, 35.40 mmol), and 1,4-dioxane (140 mL) were 
used to afford compound 6 (5.4 g, 66%) as a gray solid: 1H NMR (400 MHz, CDCl3, Figure 
A3) δ 7.69-7.65 (m, 2H), 7.14-7.04 (m, 2H), 6.65 (t, J = 2.0 Hz, 2H), 6.17 (t, J = 2.0 Hz, 2H), 
6.15 (br s, 1H), 4.11 (t, J = 5.6 Hz, 2H), 3.71 (q, J = 5.6 Hz, 2H); 13C NMR (100 MHz, CDCl3, 
Figure A4) δ 166.6, 166.1, 163.6, 132.8, 129.3, 129.2, 120.7, 115.8, 115.58, 115.55, 109.0, 
48.8, 41.5; LRMS m/z calcd for C13H13FN2O [M+H]+: 232.1; found 232.8. 
 
Preparation of compound 7. As described for the synthesis of compound 5, 
pyridine (1.61 mL, 19.97 mmol), 3,4-difluorobenzoyl chloride (2.29 mL, 
18.15 mmol), compound 4 (2.0 g, 18.15 mmol), and CH2Cl2 (72 mL) were 
N
HN
O
F
N
HN
O
F
F
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used to afford compound 7 (3.20 g, 71%) as a white solid: 1H NMR (400 MHz, CDCl3, Figure 
A5) δ 7.55 (m, 1H), 7.36 (m, 1H), 7.17 (q, J = 8.4 Hz, 1H), 6.65 (m, 2H), 6.18 (m, 2H), 6.02 
(br s, 1H), 4.12 (t, J = 5.6 Hz, 2H), 3.72 (q, J = 5.6 Hz, 2H); 13C NMR (100 MHz, CDCl3, 
Figure A6) δ 165.4, 123.29, 123.26, 123.23, 123.19, 120.7, 117.6, 117.4, 116.9, 116.73, 
116.72, 109.0, 48.7, 41.6; LRMS m/z calcd for C13H12F2N2O [M+H]+: 250.1; found 250.8. 
 
2.6.1.3. General procedure for cyclization (e.g., Preparation of compound 8) 
Cyclization was performed following a previously reported protocol.116 A 
solution of compound 5 (5.00 g, 23.33 mmol) and phosphorous(V) oxychloride 
(10.9 mL, 116.67 mmol) in toluene (117 mL) was heated under reflux for 12 h. After cooling, 
the precipitate was filtered and dissolved in H2O (200 mL). The solution was then made 
alkaline with NaHCO3 and extracted with CH2Cl2 (200 mL). The organic layer was dried over 
MgSO4 and evaporated to dryness under reduced pressure to give a residue, which was 
purified by flash column chromatography (SiO2, MeOH:CH2Cl2/5:95, Rf 0.23) to yield 
compound 8 (1.10 g, 24%) as a brown solid: 1H NMR (400 MHz, CDCl3, Figure A7, which 
matches lit.118) δ 7.77 (m, 2H), 7.45-7.40 (m, 3H), 6.83 (m, 1H), 6.41 (m, 1H), 6.22 (t, J = 2.8 
Hz, 1H), 4.02 (m, 4H). 
 
Preparation of compound 9. As described for the synthesis of compound 8, 
compound 6 (5.40 g, 23.25 mmol), phosphorous(V) oxychloride (10.9 mL, 
116.25 mmol), and toluene (117 mL) were used to afford compound 9 (1.0 g, 
18%, Rf 0.13 in MeOH:CH2Cl2/5:95) as a brown solid: 1H NMR (400 MHz, CDCl3, Figure 
N N
N N
F
 46 
A8, which matches lit.119) δ 7.77-7.81 (m, 2H), 7.11 (t, J = 8.0 Hz, 2H), 6.88 (m, 1H), 6.43 (d, 
J = 3.2 Hz, 1H), 6.26 (t, J = 3.2 Hz, 1H), 4.08-3.99 (m, 4H). 
 
Preparation of compound 10. As described for the synthesis of compound 8, 
compound 7 (3.20 g, 12.79 mmol), phosphorous(V) oxychloride (5.98 mL, 
63.94 mmol), and toluene (65 mL) were used to afford compound 10 (0.47 g, 
16%, Rf 0.50 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure 
A9) δ 7.61 (ddd, J = 10.8, 7.6, 2.0 Hz, 1H), 7.54-7.51 (m, 1H), 7.19 (q, J = 8.4 Hz 1H), 6.82 
(m, 1H), 6.36 (dd, J = 3.6, 1.6 Hz, 1H), 6.21 (dd, J = 3.6, 1.6 Hz, 1H), 4.02-3.96 (m, 4H); 13C 
NMR (100 MHz, CDCl3, Figure A10) δ 158.3, 152.7, 152.6, 151.3, 151.2, 150.2, 150.1, 148.8, 
148.7, 135.0, 124.69, 124.65, 124.62, 124.59, 123.9, 123.6, 117.6, 117.4, 117.0, 116.8, 112.1, 
108.7, 48.0, 42.0; LRMS m/z calcd for C13H10F2N2 [M+H]+: 232.1; found 232.8. 
 
2.6.1.4. General procedure for N-alkylation (e.g., Preparation of compound 1a) 
A solution of compound 8 (0.10 g, 0.51 mmol) and 2-bromoacetophenone 
(0.10 g, 0.51 mmol) in EtOH (2.5 mL) was heated under reflux for 12 h. 
After cooling to rt, the solvent was removed and the residue was purified by 
column chromatography (SiO2, MeOH:CH2Cl2/5:95, Rf 0.05) to yield compound 1a (0.10 g, 
50%) as a light brown solid: 1H NMR (400 MHz, CDCl3, Figure A11) δ 7.91 (dd, J = 8.4, 1.2 
Hz, 2H), 7.59-7.41 (m, 9H), 6.58 (dd, J = 4.0, 1.6 Hz, 1H), 6.45 (dd, J = 4.0, 2.0 Hz, 1H), 5.90 
(br s, 2H), 4.86 (t, J = 6.0 Hz, 2H), 4.60 (t, J = 6.0 Hz, 2H); 13C NMR (100 MHz, CDCl3, 
Figure A12) δ 192.4, 163.7, 135.22, 135.16, 134.9, 133.3, 132.7, 129.14, 129.07, 128.8, 128.5, 
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128.3, 127.9, 124.7, 115.2, 63.4, 51.5, 43.8; LRMS m/z calcd for C21H19N2O: 315.1; found 
315.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: 
Rt = 9.94 min (98% pure; Figure A13). 
 
Preparation of compound 1b. A solution of compound 8 (0.05 g, 0.28 
mmol) and 2-bromo-2'-fluoroacetophenone (0.06 g, 0.28 mmol) in 
anhydrous THF (1.25 mL) was stirred at rt for 12 h. The product 
precipitated, was filtered and washed with THF (2 x 10 mL) to yield compound 1b (0.05 g, 
40%) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO, Figure A14) δ 7.93-7.89 (m, 2H), 
7.78-7.73 (m, 1H), 7.68 (tt, J = 7.5, 1.0 Hz, 1H), 7.61 (t, J = 7.0 Hz, 2H), 7.51 (d, J = 7.5 Hz, 
2H), 7.39 (t , J = 7.0 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H) 6.70 (dd, J = 4.0, 1.0 Hz, 1H), 6.61 (dd, 
J = 4.5, 2.0 Hz, 1H), 5.31 (d, J = 1.5 Hz, 2H), 4.62 (t, J = 6.0 Hz, 2H), 4.37 (t, J = 6.0 Hz, 2H); 
13C NMR (125 MHz, (CD3)2SO, Figure A15) δ 189.87, 189.83, 162.9, 162.6, 160.5, 136.94, 
136.87, 136.3, 132.5, 130.4, 129.1, 128.6, 128.3, 127.4, 125.3, 125.2, 124.3, 121.9, 121.8, 
117.1, 116.9, 115.1, 64.2, 64.1, 50.8, 42.6; LRMS m/z calcd for C21H18FN2O: 333.1; found 
332.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: 
Rt = 8.75 min (100% pure; Figure A16). 
 
Preparation of compound 1c. As described for the synthesis of compound 
1a, compound 8 (0.05 g, 0.28 mmol), 2-bromo-3'-fluoroacetophenone (0.06 
g, 0.28 mmol), and EtOH (1.25 mL) were used to afford compound 1c 
(0.07 g, 66%, Rf 0.12 in MeOH:CH2Cl2/1:9) as a yellow hydroscopic wax: 1H NMR (400 
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MHz, CDCl3, Figure A17) δ 7.50-7.48 (m, 2H), 7.32 (m, 3H), 7.26-7.14 (m, 5H), 7.04-7.01 
(m, 2H), 6.34 (m, 1H), 6.20 (m, 1H), 5.62 (br s, 2H), 4.65 (t, J = 5.6 Hz, 2H), 4.34 (t, J = 5.6 
Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure A18) δ 191.52, 191.49, 164.0, 163.7, 161.6, 
136.1, 135.4, 135.3, 132.9, 131.13, 131.05, 129.3, 128.8, 128.4, 128.2, 124.79, 124.77, 124.72, 
122.1, 121.9, 115.5, 115.1, 114.8, 63.4, 51.6, 43.8; LRMS m/z calcd for C21H18FN2O: 333.1; 
found 332.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 8.49 min (100% pure; Figure A19). 
 
Preparation of compound 1d. As described for the synthesis of 
compound 1a, compound 8 (0.05 g, 0.28 mmol), 2-bromo-3'-
chloroacetophenone (0.06 g, 0.28 mmol), and EtOH (1.25 mL) were used 
to afford compound 1d (0.01 g, 10%, Rf 0.10 in MeOH:CH2Cl2/1:9) as a yellow hydroscopic 
wax: 1H NMR (400 MHz, CDCl3, Figure A20) δ 7.87-7.85 (m, 2H), 7.60-7.46 (m, 7H), 7.39 (t, 
J = 7.2 Hz, 2H), 6.61 (dd, J = 4.4, 1.2 Hz, 1H), 6.47 (dd, J = 4.4, 2.4 Hz, 1H), 5.90 (br s, 2H), 
4.85 (t, J = 6.4 Hz, 2H), 4.61 (t, J = 6.4 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure A21) δ 
191.8, 164.0, 135.7, 135.5, 135.1, 135.0, 133.1, 130.8, 129.5, 129.0, 128.5, 128.4, 128.3, 
127.3, 125.0, 115.6, 63.6, 51.8, 44.1; LRMS m/z calcd for C21H18ClN2O: 349.1; found 348.8 
[M]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
8.23 min (95% pure; Figure A22). 
 
Preparation of compound 1e. As described for the synthesis of 
compound 1b, compound 8 (0.05 g, 0.28 mmol), 2,3'-
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dibromoacetophenone (0.07 g, 0.28 mmol), and anhydrous THF (1.25 mL) were used to 
afford compound 1e (0.04 g, 35%) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO, Figure 
A23) δ 8.09 (s, 1H), 7.93-7.91 (m, 2H), 7.68 (t, J = 7.5 Hz, 1H), 7.60 (t, J = 7.5 Hz, 2H), 7.53 
(t, J = 8.0 Hz, 1H), 7.49 (d, J = 8.0 Hz, 2H), 6.68 (d, J = 4.0 Hz, 1H), 6.61 (dd, J = 3.5, 2.0 Hz, 
1H), 5.56 (s, 2H), 4.61 (t, J = 6.0 Hz, 2H), 4.35 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, 
(CD3)2SO, Figure A24) δ 191.4, 163.1, 137.1, 136.2, 135.4, 132.3, 131.1, 130.9, 129.0, 128.6, 
128.3, 127.3, 127.2, 124.4, 122.1, 115.0, 61.7, 50.9, 42.5; LRMS m/z calcd for C21H18BrN2O: 
393.1; found 392.7 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 9.66 min (95% pure; Figure A25). 
 
Preparation of compound 1f. As described for the synthesis of 
compound 1b, compound 8 (0.05 g, 0.28 mmol), 2-bromo-3'-
hydroxyacetophenone (0.06 g, 0.28 mmol), and anhydrous THF (1.25 
mL) were used to afford compound 1f (0.05 g, 43%) as a yellow solid: 1H NMR (500 MHz, 
(CD3)2SO, Figure A26) δ 9.93 (s, 1H), 7.91 (m, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 8.0 
Hz, 1H), 7.49 (d, J = 7.5 Hz, 2H), 7.33 (d, J = 4.5 Hz, 2H), 7.26 (br s, 1H), 7.11-7.09 (m, 1H), 
6.67 (dd, J = 4.5, 1.5 Hz, 1H), 6.60 (dd, J = 4.5, 2.0 Hz, 2H), 5.46 (s, 2H), 4.62 (t, J = 6.0 Hz, 
2H), 4.36 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, (CD3)2SO, Figure A27) δ 192.2, 163.2, 
157.9, 136.3, 134.8, 132.5, 130.3, 129.2, 128.7, 128.5, 127.4, 124.6, 122.0, 119.3, 115.2, 
114.4, 61.9, 51.2, 42.8; LRMS m/z calcd for C21H19N2O2: 331.1; found 330.8 [M]+. Purity of 
the compound was further confirmed by RP-HPLC by using method 1: Rt = 9.25 min (97% 
pure; Figure A28). 
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Preparation of compound 1g. As described for the synthesis of 
compound 1b, compound 8 (0.05 g, 0.28 mmol), 2-bromo-3'-
methoxyacetophenone (0.06 g, 0.28 mmol), and anhydrous THF (1.25 
mL) were used to afford compound 1g (0.09 g, 87%) as a yellow solid: 1H NMR (500 MHz, 
(CD3)2SO, Figure A29) δ 7.93 (s, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.5 Hz, 2H), 7.51-
7.49 (m, 3H), 7.46 (t, J = 7.5 Hz, 1H), 7.42 (m, 1H), 7.28 (dd, J = 8.0, 1.5 Hz, 1H), 6.67 (dd, J 
= 4.0, 1.5 Hz, 1H), 6.60 (dd, J = 4.5, 2.0 Hz, 1H), 5.56 (s, 2H), 4.64 (t, J = 6.0 Hz, 2H), 4.39 (t, 
J = 6.0 Hz, 2H). 13C NMR (125 MHz, (CD3)2SO, Figure A30) δ 192.1, 163.0, 159.4, 136.1, 
134.6, 132.3, 130.2, 129.0, 128.5, 128.3, 127.2, 124.4, 120.64, 120.59, 114.9, 112.9, 61.8, 
55.49, 55.47 51.0, 42.6; LRMS m/z calcd for C21H21N2O2: 345.2; found 344.8 [M]+. Purity of 
the compound was further confirmed by RP-HPLC by using method 1: Rt = 8.87 min (98% 
pure; Figure A31). 
 
Preparation of compound 1h. As described for the synthesis of 
compound 1b, compound 8 (0.05 g, 0.28 mmol), 2-bromo-4'-
fluoroacetophenone (0.06 g, 0.28 mmol), and anhydrous THF (1.25 mL) 
were used to afford compound 1h (0.07 g, 60%) as a yellow solid: 1H NMR (500 MHz, 
(CD3)2SO, Figure A32) δ 8.02 (dd, J = 8.0, 5.5 Hz, 2H), 7.93 (m, 1H), 7.67 (t, J = 7.5 Hz, 1H), 
7.59 (t, J = 7.5 Hz, 2H), 7.50 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 8.5 Hz, 2H), 6.67 (d, J = 3.5 Hz, 
1H), 6.61-6.60 (m, 1H), 5.54 (s, 2H), 4.63 (t, J = 6.0 Hz, 2H), 4.38 (t, J = 6.0 Hz, 2H); 13C 
NMR (125 MHz, (CD3)2SO, Figure A33) δ 190.9, 163.0, 136.2, 132.4, 131.6, 131.5, 129.0, 
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128.6, 128.3, 127.3, 124.4, 116.2, 116.0, 115.0, 61.6, 51.0, 42.6; LRMS m/z calcd for 
C21H18FN2O: 333.1; found 332.9 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 8.66 min (96% pure; Figure A34). 
 
Preparation of compound 1i. As described for the synthesis of 
compound 1b, compound 8 (0.05 g, 0.28 mmol), 2-bromo-4'-
chloroacetophenone (0.06 g, 0.28 mmol), and anhydrous THF (1.25 mL) 
were used to afford compound 1i (0.08 g, 89%) as a yellow solid: 1H NMR (500 MHz, 
(CD3)2SO, Figure A35) δ 7.94 (d, J = 8.5 Hz, 2H), 7.91 (s, 1H), 7.67 (t, J = 7.5 Hz, 1H), 7.64 
(d, J = 8.5 Hz, 1H), 7.59 (t, J = 8.0 Hz, 2H), 7.49 (d, J = 7.5 Hz, 2H), 6.69 (d, J = 4.0 Hz, 1H), 
6.61 (dd, J = 4.0, 2.0 Hz, 1H), 5.51 (s, 2H), 4.61 (t, J = 6.5 Hz, 2H), 4.35 (t, J = 6.5 Hz, 2H); 
13C NMR (125 MHz, (CD3)2SO, Figure A36) δ 191.5, 163.1, 139.6, 136.2, 132.4, 132.1, 
130.3, 129.12, 129.06, 128.6, 128.3, 127.3, 124.4, 115.0, 61.7, 51.0, 42.6; LRMS m/z calcd 
for C21H18ClN2O: 349.1; found 348.8 [M]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 8.99 min (96% pure; Figure A37). 
 
Preparation of compound 1j. As described for the synthesis of 
compound 1a, compound 8 (0.05 g, 0.28 mmol), 2,4'-
dibromoacetophenone (0.07 g, 0.28 mmol), and EtOH (1.25 mL) were 
used to afford compound 1j (0.11 g, 79%, Rf 0.12 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H 
NMR (500 MHz, (CD3)2SO, Figure A38) δ 7.90 (s, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.78 (d, J = 
8.5 Hz, 2H), 7.67 (t, J = 8.0 Hz, 1H), 7.59 (t, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 6.68 (d, 
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J = 4.0 Hz, 1H), 6.61-6.60 (m, 1H), 5.50 (s, 2H), 4.60 (t, J = 6.5 Hz, 2H), 4.35 (t, J = 6.5 Hz, 
2H); 13C NMR (100 MHz, CDCl3, Figure A39) δ 191.4, 163.4. 136.1, 132.7, 132.4, 132.3, 
132.0, 130.1, 129.9, 129.3, 129.1, 128.8, 128.7, 128.6, 128.2, 128.0, 124.5, 115.3, 62.9, 51.4, 
43.5; LRMS m/z calcd for C21H18BrN2O: 393.1; found 392.7 [M]+. Purity of the compound 
was further confirmed by RP-HPLC by using method 1: Rt = 8.96 min (95% pure; Figure 
A40). 
 
Preparation of compound 1k. As described for the synthesis of 
compound 1a, compound 8 (0.10 g, 0.51 mmol), 2-bromo-4'-
methylacetophenone (0.11 g, 0.51 mmol), and EtOH (2.5 mL) were used 
to afford compound 1k (0.19 g, 91%, Rf 0.38 in MeOH:CH2Cl2/1:9) as a light brown solid: 1H 
NMR (400 MHz, CDCl3, Figure A41) δ 7.81 (d, J = 8.0 Hz, 2H), 7.59-7.45 (m, 6H), 7.23 (d, J 
= 8.0 Hz, 2H), 6.59 (dd, J = 4.4, 0.8 Hz, 1H), 6.46 (dd, J = 4.4, 2.0 Hz, 1H), 5.85 (br s, 2H), 
4.84 (t, J = 5.6 Hz, 2H), 4.60 (t, J = 5.6 Hz, 2H), 2.37 (s, 3H); 13C NMR (100 MHz, CDCl3, 
Figure A42) δ 191.9, 163.8, 146.3, 134.8, 134.7, 132.7, 130.8, 129.8, 129.2, 128.9, 128.7, 
128.4, 127.9, 124.7, 115.1, 63.4, 51.6, 43.9, 21.8; LRMS m/z calcd for C22H21N2O: 329.2; 
found 329.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 10.52 min (98% pure; Figure A43). 
 
Preparation of compound 2a. As described for the synthesis of compound 
1a, compound 9 (0.10 g, 0.47 mmol), 2-bromoacetophenone (0.08 g, 0.47 
mmol), and EtOH (2.0 mL) were used to afford compound 2a (0.12 g, 71%, 
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Rf 0.30 in MeOH:CH2Cl2/1:9) as a brown solid: 1H NMR (400 MHz, CDCl3, Figure A44) δ 
7.94 (dd, J = 8.4, 1.2 Hz, 2H), 7.65-7.59 (m, 3H), 7.49-7.44 (m, 3H), 7.18 (t, J = 8.8 Hz, 2H), 
6.60 (dd, J = 4.4, 1.2 Hz, 1H), 6.48 (dd, J = 4.0, 2.4 Hz, 1H), 5.89 (br s, 2H), 4.86 (t, J = 6.0 
Hz, 2H), 4.58 (t, J = 6.0 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure A45) δ 192.1, 166.2, 
163.6, 162.5, 135.8, 135.7, 134.9, 133.1, 131.5, 129.0, 128.4, 127.81, 127.76, 127.7, 124.6, 
124.3, 124.2, 116.7, 116.5, 115.34, 115.25, 63.2, 51.6, 43.6; LRMS m/z calcd for 
C21H18FN2O: 333.1; found 333.8 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 9.85 min (97% pure; Figure A46). 
 
Preparation of compound 2b. As described for the synthesis of compound 
1a, compound 9 (0.10 g, 0.47 mmol), 2-bromo-2'-fluoroacetophenone (0.10 
g, 0.47 mmol), and EtOH (2.0 mL) were used to afford compound 2b (0.12 
g, 60%, Rf 0.21 in MeOH:CH2Cl2/1:9) as a brown solid: 1H NMR (400 MHz, CDCl3, Figure 
A47) δ 7.85 (t, J = 7.2 Hz, 1H), 7.68 (m, 1H), 7.56-7.50 (m, 3H), 7.18 (t, J = 7.2 Hz, 1H), 
7.13 (t, J = 7.6 Hz, 2H), 7.03 (dd, J = 10.8, 8.8 Hz, 1H), 6.53 (dt, J = 4.4, 1.6 Hz, 1H), 6.41 (p, 
J = 1.6 Hz, 1H), 5.50 (br s, 2H), 4.84 (t, J = 6.0 Hz, 2H), 4.51 (t, J = 6.0 Hz, 2H); 13C NMR 
(100 MHz, CDCl3, Figure A48) δ 190.1, 190.0, 166.1, 163.5, 163.3, 162.3, 160.8, 136.7, 
136.6, 136.2, 131.4, 131.3, 130.52, 130.50, 127.9, 124.9, 124.8, 124.6, 124.28, 124.25, 121.7, 
121.6, 117.0, 116.7, 116.6, 116.5, 116.4, 115.4, 65.5, 51.6, 43.5; LRMS m/z calcd for 
C21H17F2N2O: 351.1; found 351.8 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 9.22 min (96% pure; Figure A49). 
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Preparation of compound 2c. As described for the synthesis of compound 
1a, compound 9 (0.05 g, 0.23 mmol), 2-bromo-3'-fluoroacetophenone (0.05 
g, 0.23 mmol), and EtOH (1.0 mL) were used to afford compound 2c (0.06 
g, 60%, Rf 0.21 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, (CD3)2SO, 
Figure A50) δ 7.91 (m, 1H), 7.77 (m, 2H), 7.63-7.55 (m, 4H), 7.46 (t, J = 8.4 Hz, 2H), 6.74 
(dd, J = 4.0, 1.2, 1H), 6.61 (dd, J = 4.4, 2.4 Hz, 1H), 5.56 (s, 2H), 4.60 (t, J = 6.8 Hz, 2H), 
4.34 (t, J = 6.8 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure A51) δ 191.54, 191.52, 165.5, 
163.2, 163.0, 162.3, 160.8, 136.3, 135.53, 135.47, 131.7, 131.6, 131.25, 131.16, 127.5, 124.6, 
124.5, 121.6, 121.4, 116.5, 116.3, 115.2, 115.1, 114.9, 61.7, 51.0, 42.6; LRMS m/z calcd for 
C21H17F2N2O: 351.1; found 351.8 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 9.07 min (98% pure; Figure A52). 
 
Preparation of compound 2d. As described for the synthesis of 
compound 1a, compound 9 (0.05 g, 0.23 mmol), 2-bromo-3'-
chloroacetophenone (0.05 g, 0.23 mmol), and EtOH (1.0 mL) were used to 
afford compound 2d (0.07 g, 70%, Rf 0.22 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR 
(400 MHz, (CD3)2SO, Figure A53) δ 7.98 (t, J = 1.6 Hz, 1H), 7.91 (t, J = 1.6 Hz, 1H), 7.89 (d, 
J = 8.0 Hz, 1H), 7.79 (dd, J = 8.4, 1.6 Hz, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.59-7.55 (dd, J = 8.4, 
5.6 Hz, 2H), 7.46 (t, J = 8.4 Hz, 1H), 6.73 (dd, J = 4.0, 1.2, 1H), 6.61 (dd, J = 4.4, 2.4 Hz, 1H), 
5.58 (s, 2H), 4.60 (t, J = 6.8 Hz, 2H), 4.33 (t, J = 6.8 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, 
Figure A54) δ 191.6, 165.5, 163.0, 162.3, 136.3, 135.2, 134.2, 133.7, 131.7, 131.6, 130.9, 
128.2, 127.5, 127.0, 124.70, 124.67, 124.5, 116.5, 116.3, 115.1, 61.7, 50.9, 42.6; LRMS m/z 
calcd for C21H17ClFN2O: 367.1; found 367.8 [M]+. Purity of the compound was further 
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confirmed by RP-HPLC by using method 1: Rt = 8.39 min (95% pure; Figure A55). 
 
Preparation of compound 2e. As described for the synthesis of 
compound 1a, compound 9 (0.05 g, 0.23 mmol), 2-bromo-3'-
bromoacetophenone (0.06 g, 0.23 mmol), and EtOH (1.0 mL) were used to 
afford compound 2e (0.06 g, 55%, Rf 0.31 in MeOH:CH2Cl2/1:9) as an orange solid: 1H NMR 
(400 MHz, (CD3)2SO, Figure A56) δ 8.09 (d, J = 1.2 Hz, 1H), 7.91 (t, J = 8.0 Hz, 3H), 7.57-
7.52 (m, 3H), 7.45 (td, J = 8.0, 1.2 Hz, 2H), 6.74 (d, J = 4.4 Hz, 1H), 6.61-6.60 (m, 1H), 5.56 
(s, 2H), 4.58 (t, J = 6.4 Hz, 2H), 4.31 (t, J = 6.4 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure 
A57) δ 191.2, 166.3, 163.7, 162.7, 137.7, 135.9, 134.8, 131.5, 131.4, 131.0, 130.7, 128.0, 
127.4, 124.7, 124.3, 124.2, 123.3, 116.8, 116.6, 115.4, 63.2, 51.6, 43.7; LRMS m/z calcd for 
C21H17BrFN2O: 411.1; found 411.8 [M]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 9.44 min (98% pure; Figure A58). 
 
Preparation of compound 2f. As described for the synthesis of 
compound 1a, compound 9 (0.05 g, 0.23 mmol), 2-bromo-3'-
hydroxyacetophenone (0.05 g, 0.23 mmol), and EtOH (1.0 mL) were used 
to afford compound 2f (0.05 g, 51%, Rf 0.15 in MeOH:CH2Cl2/1:9) as a white solid: 1H NMR 
(400 MHz, (CD3)2SO, Figure A59) δ 10.04 (s, 1H), 7.86 (t, J = 2.0 Hz, 1H), 7.56-7.53 (m, 
2H), 7.44 (t, J = 8.4 Hz, 2H), 7.35-7.32 (m, 2H), 7.25 (m, 1H), 7.11-7.08 (m, 1H), 6.72 (dd, J 
= 4.4, 1.2 Hz, 1H), 6.60 (dd, J = 4.4, 2.4 Hz, 1H), 5.45 (s, 2H), 4.57 (t, J = 6.0 Hz, 2H), 4.31 (t, 
J = 6.0 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure A60) δ 192.2, 163.1, 162.3, 157.8, 
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136.4, 134.8, 131.8, 131.7, 130.3, 127.6, 124.8, 124.6, 122.0, 119.4, 116.7, 116.5, 115.3, 
114.5, 61.8, 51.2, 42.7; LRMS m/z calcd for C21H18FN2O2: 349.1; found 349.8 [M]+. Purity of 
the compound was further confirmed by RP-HPLC by using method 1: Rt = 8.25 min (99% 
pure; Figure A61). 
 
Preparation of compound 2g. As described for the synthesis of 
compound 1a, compound 9 (0.05 g, 0.23 mmol), 2-bromo-3'-
methoxyacetophenone (0.05 g, 0.23 mmol), and EtOH (1.0 mL) were 
used to afford compound 2g (0.05 g, 50%, Rf 0.20 in MeOH:CH2Cl2/1:9) as an orange solid: 
1H NMR (400 MHz, (CD3)2SO, Figure A62) δ 7.62 (br s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.57 
(d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.40 (m, 1H), 7.29 (t, J = 8.0 Hz, 1H), 7.13 (t, J 
= 8.0 Hz, 2H), 7.07 (dd, J = 8.0, 2.8 Hz, 1H), 6.54 (d, J = 4.4 Hz, 1H), 6.42 (dd, J = 4.4, 2.4 
Hz, 1H), 5.78 (s, 2H), 4.85 (t, J = 6.4 Hz, 2H), 4.51 (t, J = 6.4 Hz, 2H), 3.78 (s, 3H); 13C NMR 
(100 MHz, CDCl3, Figure A63) δ 192.1, 166.2, 163.7, 162.6, 159.9, 135.7, 134.5, 131.5, 
131.4, 130.1, 127.7, 124.7, 124.34, 124.30, 121.6, 121.1, 116.7, 116.5, 115.3, 112.2, 63.3, 
55.6, 51.6, 43.6; LRMS m/z calcd for C22H20FN2O2: 363.1; found 363.8 [M]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 8.89 min (99% pure; 
Figure A64). 
 
Preparation of compound 2h. As described for the synthesis of 
compound 1a, compound 9 (0.10 g, 0.47 mmol), 2-bromo-4'-
fluoroacetophenone (0.10 g, 0.47 mmol), and EtOH (2.0 mL) were used 
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to afford compound 2h (0.08 g, 40%, Rf 0.21 in MeOH:CH2Cl2/1:9) as a green solid: 1H NMR 
(400 MHz, CDCl3, Figure A65) δ 8.03 (dd, J = 8.4, 4.8 Hz, 2H), 7.63 (m, 2H), 7.44 (m, 1H), 
7.20 (t, J = 8.4 Hz, 2H), 7.14 (t, J = 8.4 Hz, 2H), 6.62 (d, J = 2.4, 1H), 6.50 (dd, J = 4.4, 2.4 
Hz, 1H), 5.92 (br s, 2H), 4.82 (m, 2H), 4.59 (m, 2H); 13C NMR (100 MHz, CDCl3, Figure 
A66) δ 190.9, 168.1, 166.4, 165.5, 163.9, 162.9, 135.4, 131.64, 131.57, 131.5, 129.74, 129.71, 
128.0, 124.8, 124.30, 124.27, 116.9, 116.7, 116.6, 116.4, 115.4, 63.4, 51.6, 43.9; LRMS m/z 
calcd for C21H17F2N2O: 351.1; found 351.8 [M]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 8.97 min (100% pure; Figure A67). 
 
Preparation of compound 2i. As described for the synthesis of 
compound 1a, compound 9 (0.10 g, 0.47 mmol), 2-bromo-4'-
chloroacetophenone (0.11 g, 0.47 mmol), and EtOH (2.0 mL) were used 
to afford compound 2i (0.11 g, 52%, Rf 0.34 in MeOH:CH2Cl2/1:9) as a brown solid: 1H NMR 
(400 MHz, (CD3)2SO, Figure A68) δ 7.94 (d, J = 8.4, 2H), 7.90 (m, 1H), 7.65 (dd, J = 8.4, 1.2, 
2H), 7.56 (app. t, J = 7.2, 2H), 7.45 (app. t, J = 8.4 Hz, 2H), 6.74 (m, 1H), 6.61 (m, 1H), 5.53 
(s, 2H), 4.59 (t, J = 6.0, 2H), 4.33 (t, J = 6.0, 2H); 13C NMR (100 MHz, CDCl3, Figure A69) δ 
191.1, 166.1, 163.6, 162.5, 141.3, 135.9, 131.5, 131.42, 131.37, 129.9, 129.3, 127.8, 124.6, 
124.2, 124.1, 116.7, 116.4, 115.3, 63.0, 51.5, 43.5; LRMS m/z calcd for C21H17ClFN2O: 
367.1; found 367.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 9.52 min (95% pure; Figure A70). 
 
Preparation of compound 2j. As described for the synthesis of 
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compound 1a, compound 9 (0.10 g, 0.47 mmol), 2-bromo-4'-bromoacetophenone (0.13 g, 
0.47 mmol), and EtOH (2.0 mL) were used to afford compound 2j (0.11 g, 48%, Rf 0.32 in 
MeOH:CH2Cl2/1:9) as a brown solid: 1H NMR (400 MHz, (CD3)2SO, Figure A71) δ 7.90-
7.85 (m, 3H), 7.79 (d, J = 8.4, 2H), 7.57-7.54 (m, 2H), 7.45 (t, J = 8.4 Hz, 2H), 6.74 (dd, J = 
4.0, 1.2 Hz, 1H), 6.61 (dd, J = 4.4, 2.4 Hz, 1H), 5.52 (s, 2H), 4.58 (t, J = 5.6, 2H), 4.32 (t, J = 
5.6, 2H); 13C NMR (100 MHz, CDCl3, Figure A72) δ 191.3, 166.1, 163.6, 162.5, 135.9, 132.2, 
131.8, 131.4, 131.3, 131.2, 130.2, 129.9, 127.8, 124.5, 124.14, 124.11, 116.7, 116.6, 116.4, 
115.3, 63.0, 51.5, 43.5; LRMS m/z calcd for C21H17BrFN2O: 411.1; found 411.8 [M]+. Purity 
of the compound was further confirmed by RP-HPLC by using method 1: Rt = 9.53 min (99% 
pure; Figure A73). 
 
 
Preparation of compound 2k. As described for the synthesis of 
compound 1a, compound 9 (0.10 g, 0.47 mmol), 2-bromo-4'-
methylacetophenone (0.09 g, 0.47 mmol), and EtOH (2.0 mL) were used 
to afford compound 2k (0.10 g, 57%, Rf 0.33 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H 
NMR (400 MHz, CDCl3, Figure A74) δ 7.82 (d, J = 8.4 Hz, 2H), 7.63 (dd, J = 8.0, 4.4 Hz, 
2H), 7.45 (t, J = 1.6 Hz, 1H), 7.25 (d, J = 7.2 Hz, 2H), 7.17 (t, J = 8.4 Hz, 2H), 6.59 (dd, J = 
4.8, 1.6 Hz, 1H), 6.47 (dd, J = 4.4, 2.4 Hz, 1H), 5.82 (br s, 2H), 4.84 (t, J = 6.0 Hz, 2H), 4.58 
(t, J = 6.0 Hz, 2H), 2.38 (s, 3H); 13C NMR (100 MHz, CDCl3, Figure A75) δ 191.8, 166.4, 
163.8, 162.9, 146.5, 134.9, 131.6, 130.7, 129.9, 128.7, 127.8, 124.8, 124.3, 116.8, 116.6, 
115.3, 63.5, 51.7, 43.9, 21.9; LRMS m/z calcd for C22H20FN2O: 347.2; found 347.8 [M]+. 
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Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 9.98 min 
(95% pure; Figure A76). 
 
Preparation of compound 3a. As described for the synthesis of compound 
1a, compound 10 (0.05 g, 0.22 mmol), 2-bromoacetophenone (0.04 g, 0.22 
mmol), and EtOH (1 mL) were used to afford compound 3a (0.07 g, 78%, 
Rf 0.23 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A77) δ 
7.92 (dd, J = 8.8, 1.2 Hz, 2H), 7.63 (dd, J = 2.0, 1.2 Hz, 1H), 7.57 (tt, J = 7.2, 1.2 Hz, 1H), 
7.53-7.40 (m, 4H), 7.27 (m, 1H), 6.57 (dd, J = 4.4, 1.2 Hz, 1H), 6.45 (dd, J = 4.4, 2.4 Hz, 1H), 
5.76 (q, J = 18.0 Hz, 2H), 4.86 (t, J = 6.4 Hz, 2H), 4.59-4.45 (m, 2H); 13C NMR (100 MHz, 
CDCl3, Figure A78) δ 192.0, 161.2, 136.1, 135.0, 133.1, 129.1, 128.5, 127.8, 126.2, 124.6, 
119.0, 118.8, 118.7, 118.6, 115.6, 63.3, 51.8, 43.6; LRMS m/z calcd for C21H17F2N2O: 351.1; 
found 351.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 8.79 min (98% pure; Figure A79). 
 
Preparation of compound 3d. As described for the synthesis of 
compound 1a, compound 10 (0.06 g, 0.26 mmol), 2-bromo-3'-
chloroacetophenone (0.06 g, 0.26 mmol), and EtOH (2 mL) were used to 
afford compound 3d (0.08 g, 67%, Rf 0.26 in MeOH:CH2Cl2/1:9) as a brown solid: 1H NMR 
(400 MHz, CDCl3, Figure A80) δ 7.81-7.79 (m, 2H), 7.73 (m, 1H), 7.49-7.45 (m, 2H), 7.40-
7.37 (m, 1H), 7.34 (t, J = 7.2 Hz, 1H), 7.28-7.21 (m, 1H), 6.55 (dd, J = 4.4, 1.6 Hz, 1H), 6.42 
(dd, J = 4.4, 2.0 Hz, 1H), 5.75 (q, J = 7.6 Hz, 2H), 4.86 (t, J = 6.4 Hz, 2H), 4.56-4.45 (m, 2H); 
N N
OBr
FF
N N
OBr
Cl
FF
 60 
13C NMR (100 MHz, CDCl3, Figure A81) δ 190.9, 160.9, 136.6, 135.2, 134.7, 134.4, 130.4, 
128.0, 127.9, 126.8, 126.0, 124.4, 118.9, 118.7, 118.5, 115.7, 63.1, 51.6, 43.5; LRMS m/z 
calcd for C21H16ClF2N2O: 385.1; found 385.8 [M]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 9.94 min (95% pure; Figure A82). 
 
Preparation of compound 3h. As described for the synthesis of 
compound 1a, compound 10 (0.05 g, 0.22 mmol), 2-bromo-4'-
fluoroacetophenone (0.05 g, 0.22 mmol), and EtOH (1 mL) were used to 
afford compound 3h (0.08 g, 82%, Rf 0.20 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR 
(400 MHz, CDCl3, Figure A83) δ 7.99 (m, 2H), 7.65 (m, 1H), 7.50-7.42 (m, 2H), 7.29 (q, J = 
8.4 Hz, 1H), 7.09 (t, J = 8.4 Hz, 2H), 6.58 (dd, J = 4.8, 1.6 Hz, 1H), 6.46 (dd, J = 4.8, 2.4 Hz, 
1H), 5.79 (q, J = 18.0 Hz, 2H), 4.86 (t, J = 6.4 Hz, 2H), 4.59-4.47 (m, 2H); 13C NMR (100 
MHz, CDCl3, Figure A84) δ 190.5, 168.0, 165.4, 161.2, 151.6, 151.5, 148.9, 148.8, 136.2, 
131.6, 131.5, 129.62, 129.59, 127.9, 126.2, 124.8, 124.5, 119.0, 118.8, 118.6, 116.5, 116.3, 
115.7, 63.2, 51.7, 43.6; LRMS m/z calcd for C21H16F3N2O: 369.1; found 369.8 [M]+. Purity of 
the compound was further confirmed by RP-HPLC by using method 1: Rt = 9.02 min (95% 
pure; Figure A85). 
 
Preparation of compound 3k. As described for the synthesis of 
compound 1a, compound 10 (0.05 g, 0.22 mmol), 2-bromo-4'-
methylacetophenone (0.05 g, 0.22 mmol), and EtOH (1 mL) were used to 
afford compound 3k (0.05 g, 51%, Rf 0.26 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR 
N N
OBr F
FF
N N
OBr
FF
 61 
(400 MHz, CDCl3, Figure A86) δ 7.81 (d, J = 8.0, 1.2 Hz, 2H), 7.60 (m, 1H), 7.49 (q, J = 8.0 
Hz, 2H), 7.27 (q, J = 8.4 Hz, 1H), 7.22 (m, 2H), 6.58 (dd, J = 4.0, 1.2 Hz, 1H), 6.47-6.45 (m, 
1H), 5.72 (q, J = 18.0 Hz, 2H), 4.86 (t, J = 6.4 Hz, 2H), 4.59-4.44 (m, 2H); 13C NMR (100 
MHz, CDCl3, Figure A87) δ 191.4, 161.2, 151.5, 146.4, 135.9, 130.6, 129.8, 128.7, 127.7, 
126.2, 124.6, 119.0, 118.8, 118.7, 118.6, 115.6, 63.3, 51.8, 43.7, 21.8; LRMS m/z calcd for 
C22H19F2N2O: 365.1; found 365.8 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 9.58 min (95% pure; Figure A88). 
 
2.6.1.5. General procedure for aromatization (e.g., Preparation of compound 11) 
Aromatization was prepared following a previously published protocol.120 10% 
Palladium on activated carbon (0.51 g) was added to a solution of compound 8 
(0.75 g, 3.82 mmol) in xylenes (10 mL). The mixture was refluxed for 20 h, then cooled and 
filtered through Celite® and washed with CH2Cl2. The solution was concentrated under 
reduced pressure to yield compound 11 (0.44 g, 60%) as a brown liquid, which was used 
without further purification: 1H NMR (400 MHz, CDCl3, Figure A89, which matches lit.121) δ 
7.97-9.94 (m, 2H), 7.78 (dd, J = 4.8, 1.2 Hz, 1H), 7.61 (d, J = 4.8 Hz, 1H), 7.50-7.46 (m, 4H), 
6.93 (dt, J = 4.4, 1.2 Hz, 1H), 6.88 (dd, J = 4.4, 2.4 Hz, 1H). 
 
Preparation of compound 12. As described for the synthesis of compound 11, 
compound 9 (0.65 g, 3.03 mmol), 10% Pd/C (0.40 g), and xylenes (8 mL) were 
used to afford compound 12 (0.30 g, 48%) as a brown solid: 1H NMR (400 MHz, 
CDCl3, Figure A90, which matches lit.121) δ 7.94-7.72 (m, 2H), 7.78 (d, J = 4.4, 1.2 Hz, 1H), 
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7.61 (dd, J = 6.8, 4.8 Hz, 1H), 7.47 (t, J = 2.0 Hz, 1H), 7.18 (t, J = 8.8 Hz, 2H), 6.89 (d, J = 
2.4 Hz, 2H). 
 
Preparation of compound 1a*. As described for the synthesis of 
compound 1a, compound 11 (0.10 g, 0.51 mmol), 2-bromoacetophenone 
(0.10 g, 0.51 mmol), and EtOH (2.0 mL) were used to afford compound 1a* 
(0.07 g, 35%, Rf 0.20 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, 
Figure A91) δ 9.00 (d, J = 5.6 Hz, 1H), 8.54 (dd, J = 2.4, 1.2 Hz, 1H), 7.98 (d, J = 6.0 Hz, 1H), 
7.65 (dd, J = 6.8, 1.2 Hz, 2H), 7.30-7.23 (m, 6H), 7.14 (t, J = 8.0 Hz, 2H), 6.93 (dd, J = 4.8, 
2.4 Hz, 1H), 6.66 (d, J = 4.8 Hz, 1H), 6.12 (br s, 2H); 13C NMR (100 MHz, CDCl3, Figure 
A92) δ 191.3, 151.5, 134.6, 133.2, 132.1, 129.4, 128.9, 128.5, 128.4, 128.3, 127.6, 127.0, 
126.2, 121.7, 121.0, 117.5, 62.3; LRMS m/z calcd for C21H17N2O: 313.1; found 313.8 [M]+. 
Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 8.99 min 
(98% pure; Figure A93). 
 
Preparation of compound 1b*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-2'-
fluoroacetophenone (0.011 g, 0.051 mmol), and EtOH (0.5 mL) were used 
to afford compound 1b* (0.006 g, 28%, Rf 0.19 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H 
NMR (400 MHz, CDCl3, Figure A94) δ 9.12 (d, J = 5.6 Hz, 1H), 8.66 (m, 1H), 8.38 (d, J = 
5.2 Hz, 1H), 7.90 (t, J = 7.6 Hz, 1H), 7.60 (d, J = 6.8 Hz, 1H), 7.54 (t, J = 7.6 Hz, 3H), 7.49 (t, 
J = 8.0 Hz, 2H), 7.23-7.20 (m, 2H), 7.08 (dd, J = 10.8, 8.4 Hz 1H), 6.95 (d, J = 4.8 Hz, 1H), 
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6.09 (br s, 2H); 13C NMR (100 MHz, CDCl3, Figure A95) δ 189.31, 189.26, 163.4, 160.9, 
151.3, 136.5, 136.4, 132.3, 130.89, 130.87, 129.5, 128.5, 128.4, 127.7, 127.0, 126.2, 125.0, 
124.9, 122.3, 121.8, 121.1, 117.7, 117.0, 116.8, 64.6, 64.5; LRMS m/z calcd for C21H16FN2O: 
331.1; found 331.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 8.69 min (97% pure; Figure A96). 
 
Preparation of compound 1c*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-3'-
fluoroacetophenone (0.011 g, 0.051 mmol), and EtOH (0.5 mL) were used 
to afford compound 1c* (0.004 g, 20%, Rf 0.17 in MeOH:CH2Cl2/1:9) as a brown solid: 1H 
NMR (400 MHz, CDCl3, Figure A97) δ 9.05 (d, J = 6.0 Hz, 1H), 8.60 (m, 1H), 8.31 (d, J = 
6.0 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.60-7.49 (m, 6H), 7.45-7.40 (m, 1H), 7.27-7.21 (m, 
2H), 6.96 (d, J = 4.4 Hz, 1H), 6.41 (br s, 2H); 13C NMR (100 MHz, CDCl3, Figure A98) δ 
190.5, 164.0, 161.5, 151.7, 135.23, 135.16, 132.3, 131.05, 130.97, 129.5, 128.5, 127.6, 127.1, 
125.9, 124.85, 124.82, 122.0, 121.9, 121.8, 121.7, 120.9, 117.8, 115.0, 114.8, 62.4; LRMS 
m/z calcd for C21H16FN2O: 331.1; found 331.8 [M]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 9.14 min (95% pure; Figure A99). 
 
Preparation of compound 1d*. As described for the synthesis of 
compound 1a, compound 11 (0.020 g, 0.103 mmol), 2-bromo-3'-
chloroacetophenone (0.024 g, 0.103 mmol), and EtOH (1.0 mL) were used 
to afford compound 1d* (0.023 g, 52%, Rf 0.17 in MeOH:CH2Cl2/1:9) as a brown solid: 1H 
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NMR (400 MHz, CDCl3, Figure A100) δ 9.23 (d, J = 6.0 Hz, 1H), 8.74 (m, 1H), 8.32 (d, J = 
6.0 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.81 (s, 1H), 7.59-7.48 (m, 6H), 7.36 (t, J = 7.6 Hz, 1H), 
7.20-7.19 (m, 1H), 6.93 (d, J = 4.8 Hz, 1H), 6.39 (br s, 2H); 13C NMR (100 MHz, CDCl3, 
Figure A101) δ 190.5, 151.5, 135.2, 134.7, 134.5, 132.2, 130.5, 129.5, 128.5, 128.0, 127.6, 
127.1, 127.0, 126.3, 121.8, 121.7, 121.1, 117.7, 62.3; LRMS m/z calcd for C21H16ClN2O: 
347.1; found 347.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 8.95 min (100% pure; Figure A102). 
 
Preparation of compound 1e*. As described for the synthesis of 
compound 1a, compound 11 (0.020 g, 0.103 mmol), 2-bromo-3'-
bromoacetophenone (0.029 g, 0.103 mmol), and EtOH (1.0 mL) were used 
to afford compound 1e* (10:1 mixture of product and hydrated product) (0.023 g, 48%, Rf 
0.17 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A103) for 
product δ 9.00 (d, J = 6.0 Hz, 1H), 8.57 (m, 1H), 8.30 (d, J = 6.0 Hz, 1H), 7.98 (m, 1H), 7.67 
(m, 1H), 7.59 (dt, J = 6.8, 2.4 Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.50 (t, J = 6.8 Hz, 3H), 7.32 
(t, J = 7.6 Hz, 1H), 7.22 (dd, J = 4.4, 2.4 Hz, 1H), 6.96 (d, J = 4.4 Hz, 1H), 6.40 (br s, 2H); 1H 
NMR (400 MHz, CDCl3, Figure A103) for hydrated product δ 8.96 (d, J = 6.0 Hz, 1H), 8.53 
(m, 1H), 8.25 (d, J = 6.0 Hz, 1H), 7.96 (m, 1H), 7.71-7.69 (m, 1H), 7.62 (m, 1H), 7.46-7.44 
(m, 5H), 7.26 (m, 1H), 7.18 (dd, J = 4.8, 2.4 Hz, 1H), 6.92 (d, J = 4.4 Hz, 1H), 6.35 (br s, 2H), 
1.59 (br s, 3H, 1.5xH2O); 13C NMR (100 MHz, CDCl3, Figure A104) for the mixture of 
product and hydrated product δ 190.5, 151.7, 137.5, 134.9, 132.3, 131.0, 130.8, 130.7, 129.5, 
128.52, 128.48, 127.6, 127.1, 125.9, 123.3, 122.0, 121.8, 120.9, 117.81, 117.78, 62.2; LRMS 
m/z calcd for C21H16BrN2O: 391.1; found 391.8 [M]+. Purity of the compound was further 
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confirmed by RP-HPLC by using method 1: Rt = 9.24 min (99% pure; Figure A105). 
 
Preparation of compound 1f*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-3'-
hydroxycetophenone (0.011 g, 0.051 mmol), and EtOH (0.5 mL) were 
used to afford compound 1f* (0.007 g, 34%, Rf 0.11 in MeOH:CH2Cl2/1:9) as a yellow solid: 
1H NMR (400 MHz, CDCl3, Figure A106) δ 9.40 (br s, 1H), 8.80 (d, J = 6.0 Hz, 1H), 8.48 (m, 
1H), 8.01 (d, J = 6.0 Hz, 1H), 7.58 (m, 1H), 7.53 (m, 1H), 7.48 (t, J = 7.6 Hz, 2H), 7.43 (m, 
2H), 7.20-7.17 (m, 2H), 7.07 (d, J = 8.8 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 4.8 Hz, 
1H), 6.02 (br s, 2H); 13C NMR (100 MHz, CDCl3, Figure A107) δ 191.2, 157.7, 151.6, 134.1, 
132.3, 129.9, 129.8, 129.5, 128.5, 127.4, 127.0, 125.8, 122.5, 121.7, 120.9, 119.0, 117.7, 
115.6, 62.1; LRMS m/z calcd for C21H17N2O2: 329.1; found 329.8 [M]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 8.00 min (97% pure; 
Figure A108). 
 
Preparation of compound 1g*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-3'-
methoxyacetophenone (0.012 g, 0.051 mmol), and EtOH (0.5 mL) were 
used to afford compound 1g* (0.007 g, 32%, Rf 0.23 in MeOH:CH2Cl2/1:9) as a yellow solid: 
1H NMR (400 MHz, CDCl3, Figure A109) δ 9.02 (d, J = 6.0 Hz, 1H), 8.58 (m, 1H), 8.22 (d, J 
= 6.0, 1H), 7.57-7.45 (m, 7H), 7.31 (t, J = 7.6 Hz, 1H), 7.20 (dd, J = 4.8, 2.4 Hz, 1H), 7.08 (d, 
J = 8.4, 1H), 6.94 (d, J = 4.0, 1H), 6.36 (s, 2H) 3.82 (s, 3H); 13C NMR (100 MHz, CDCl3, 
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Figure A110) δ 191.4, 159.9, 151.8, 134.6, 132.2, 130.1, 129.4, 129.2, 128.6, 127.7, 127.1, 
125.8, 122.1, 121.7, 121.2, 121.0, 117.6, 112.3, 62.3, 55.7; LRMS m/z calcd for C22H19N2O2: 
343.1; found 343.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 8.86 min (99% pure; Figure A111). 
 
Preparation of compound 1h*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-4'-
fluoroacetophenone (0.011 g, 0.051 mmol), and EtOH (0.5 mL) were 
used to afford compound 1h* (2:1 mixture of product and hydrated product) (0.008 g, 38%, Rf 
0.17 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A112) for 
product δ 9.10 (d, J = 6.0 Hz, 1H), 8.63 (m, 1H), 8.25 (d, J = 6.0 Hz, 1H), 8.03-7.99 (m, 2H), 
7.58-7.56 (m, 1H), 7.53-7.50 (m, 4H), 7.22-7.20 (m, 1H), 7.11-7.05 (m, 2H), 6.94 (d, J = 4.0 
Hz, 1H), 6.39 (br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A112) for hydrated product δ 
9.04 (d, J = 6.0 Hz, 1H), 8.59 (m, 1H), 8.27 (d, J = 6.0 Hz, 1H), 8.03-7.99 (m, 2H), 7.58-7.56 
(m, 1H), 7.53-7.50 (m, 4H), 7.22-7.20 (m, 1H), 7.11-7.05 (m, 2H), 6.95 (d, J = 4.0 Hz, 1H), 
6.41 (br s, 2H), 1.58 (br s, 1H, 0.5xH2O); 13C NMR (100 MHz, CDCl3, Figure A113) for the 
mixture of product and hydrated product δ 190.0, 167.9, 165.3, 151.7, 132.2, 131.6, 131.5, 
129.8, 129.7, 129.4, 128.5, 127.6, 127.1, 125.9, 121.9, 121.7, 121.0, 117.7, 116.4, 116.2, 62.1; 
LRMS m/z calcd for C21H16FN2O: 331.1; found 331.8 [M]+. Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 8.67 min (99% pure; Figure A114). 
 
Preparation of compound 1i*. As described for the synthesis of 
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compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-4'-chloroacetophenone (0.012 g, 
0.051 mmol), and EtOH (0.5 mL) were used to afford compound 1i* (8:2 mixture of product 
and hydrated product) (0.011 g, 50%, Rf 0.23 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H 
NMR (400 MHz, CDCl3, Figure A115) for product δ 9.14 (d, J = 6.0 Hz, 1H), 8.66 (m, 1H), 
8.28 (d, J = 6.0 Hz, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.58-7.55 (m, 1H), 7.52-7.47 (m, 4H), 7.36 
(d, J = 8.4 Hz, 2H), 7.20 (dd, J = 4.4, 2.4 Hz, 1H), 6.94 (d, J = 4.4 Hz, 1H), 6.40 (br s, 2H); 
1H NMR (400 MHz, CDCl3, Figure A115) for hydrated product δ 9.18 (d, J = 5.6 Hz, 1H), 
8.71 (m, 1H), 8.32 (d, J = 5.6 Hz, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.61-7.59 (m, 1H), 7.52-7.47 
(m, 4H), 7.40 (d, J = 8.4 Hz, 2H), 7.28 (m, 1H), 6.98 (d, J = 4.4 Hz, 1H), 6.44 (br s, 2H), 1.58 
(br s, 1H, 0.5xH2O); 13C NMR (100 MHz, CDCl3, Figure A116) for the mixture of product 
and hydrated product δ 190.4, 151.7, 141.3, 132.3, 131.6, 130.1, 129.45, 129.36, 128.5, 127.6, 
127.1, 126.1, 121.82, 121.77, 121.0, 117.7, 62.2; LRMS m/z calcd for C21H16ClN2O: 347.1; 
found 347.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 9.25 min (99% pure; Figure A117). 
 
Preparation of compound 1j*. As described for the synthesis of 
compound 1a, compound 11 (0.010 g, 0.051 mmol), 2-bromo-4'-
bromoacetophenone (0.014 g, 0.051 mmol), and EtOH (0.5 mL) were 
used to afford compound 1j* (0.011 g, 46%, Rf 0.23 in MeOH:CH2Cl2/1:9) as a yellow solid: 
1H NMR (400 MHz, CDCl3, Figure A118) δ 9.15 (d, J = 6.0 Hz, 1H), 8.68 (m, 1H), 8.28 (d, J 
= 4.8 Hz, 1H), 7.82 (d, J = 6.8 Hz, 2H), 7.57-7.49 (m, 7H), 7.21 (dd, J = 4.0, 1.6 Hz, 1H), 
6.94 (d, J = 4.0 Hz, 1H), 6.39 (br s, 2H); 13C NMR (100 MHz, CDCl3, Figure A119) δ 190.6, 
151.7, 132.4, 132.3, 132.0, 130.2, 129.5, 128.5, 127.6, 127.1, 126.1, 121.83, 121.79, 121.0, 
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117.7, 62.2; LRMS m/z calcd for C21H16BrN2O: 391.1; found 391.8 [M]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 9.25 min (99% pure; 
Figure A120). 
 
Preparation of compound 1k*. As described for the synthesis of 
compound 1a, compound 11 (0.10 g, 0.51 mmol), 2-bromo-4'-
methylacetophenone (0.11 g, 0.51 mmol), and EtOH (2.0 mL) were used 
to afford compound 1k* (0.05 g, 25%, Rf 0.24 in MeOH:CH2Cl2/1:9) as a dark green solid: 1H 
NMR (400 MHz, CDCl3, Figure A121) δ 9.15 (dd, J = 6.0, 0.8 Hz, 1H), 8.70 (dd, J = 2.4, 1.2 
Hz, 1H), 8.21 (d, J = 6.0 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.56-7.46 (m, 5H), 7.21-7.18 (m, 
3H), 6.92 (d, J = 4.8 Hz, 1H), 6.35 (br s, 2H), 2.34 (s, 3H); 13C NMR (100 MHz, CDCl3, 
Figure A122) δ 190.7, 145.9, 132.1, 130.8, 129.7, 129.4, 128.7, 128.6, 128.45, 128.37, 127.7, 
127.1, 125.9, 122.0, 121.6, 120.9, 117.5, 62.4, 21.8; LRMS m/z calcd for C22H19N2O: 327.1; 
found 327.8 [M]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 9.25 min (95% pure; Figure A123). 
 
Preparation of compound 2a*. As described for the synthesis of 
compound 1a, compound 12 (0.10 g, 0.47 mmol), 2-bromoacetophenone 
(0.09 g, 0.47 mmol), and EtOH (2.0 mL) were used to afford compound 2a* 
(3:2 mixture of product and hydrated product) (0.09 g, 47%, Rf 0.25 in MeOH:CH2Cl2/1:9) as 
a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A124) for product δ 8.99 (d, J = 6.0 Hz, 
1H), 8.57 (dd, J = 2.4, 1.2 Hz, 1H), 8.23 (d, J = 6.0 Hz, 1H), 7.98-7.95 (m, 2H), 7.62-7.43 (m, 
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7H), 7.24-7.20 (m, 1H), 6.95 (t, J = 4.8 Hz, 1H), 6.43 (br s, 2H); 1H NMR (400 MHz, CDCl3, 
Figure A124) for hydrated product δ 8.95 (d, J = 5.2 Hz, 1H), 8.54 (dd, J = 1.6, 0.8 Hz, 1H), 
8.30 (d, J = 6.0 Hz, 1H), 7.98-7.95 (m, 2H), 7.62-7.43 (m, 7H), 7.24-7.20 (m, 1H), 6.95 (t, J = 
4.8 Hz, 1H), 6.44 (br s, 2H), 1.64 (br s, 4H, 2xH2O); 13C NMR (100 MHz, CDCl3, Figure 
A125) for the mixture of product and hydrated product δ 191.2, 191.1, 165.7, 163.2, 151.4, 
150.5, 134.7, 134.5, 133.1, 133.0, 132.1, 131.3, 131.2, 129.3, 129.0, 128.94, 128.89, 128.5, 
128.4, 127.5, 127.1, 126.9, 126.2, 126.1, 123.6, 123.5, 121.8, 121.7, 121.6, 121.1, 121.0, 
117.5, 117.3, 116.9, 116.7, 62.5, 62.3; LRMS m/z calcd for C21H16FN2O: 331.1; found 331.8 
[M]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
9.43 min (99% pure; Figure A126). 
 
Preparation of compound 2b*. As described for the synthesis of 
compound 1a, compound 12 (0.100 g, 0.051 mmol), 2-bromo-2'-
fluoroacetophenone (0.011 g, 0.051 mmol), and EtOH (0.5 mL) were used 
to afford compound 2b* (3:2 mixture of product and hydrated product) (0.103g, 51%, Rf 0.27 
in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A127) for 
product δ 9.28 (d, J = 6.0 Hz, 1H), 8.80 (m, 1H), 8.39 (d, J = 6.0 Hz, 1H), 7.90 (t, J = 7.2 Hz, 
1H), 7.60-7.48 (m, 4H), 7.25-7.19 (m, 3H), 7.10 (t, J = 8.0 Hz, 1H), 6.93 (d, J = 4.8 Hz, 1H), 
6.13 (s, 2H); 1H NMR (400 MHz, CDCl3, Figure A127) for hydrated product δ 9.25 (d, J = 
5.2 Hz, 1H), 8.78 (m, 1H), 8.45 (d, J = 6.0 Hz, 1H), 7.90 (t, J = 7.2 Hz, 1H), 7.60-7.48 (m, 
4H), 7.25-7.19 (m, 3H), 7.07 (t, J = 8.0 Hz, 1H), 6.94 (d, J = 5.2 Hz, 1H), 6.13 (s, 2H), 1.84 
(br s, 2H, 1xH2O); 13C NMR (100 MHz, CDCl3, Figure A128) for the mixture of product and 
hydrated product δ 189.5, 189.4, 166.2, 163.64, 163.62, 161.1, 151.5, 150.6, 136.85, 136.75, 
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136.6, 132.5, 131.5, 131.4, 131.09, 131.07, 129.7, 128.7, 127.9, 127.4, 127.3, 126.7, 126.5, 
125.23, 125.20, 125.14, 123.97, 123.93, 122.4, 122.2, 122.13, 122.05, 122.0, 121.4, 121.3, 
117.9, 117.7, 117.35, 117.33, 117.27, 117.13, 117.1, 117.0, 77.4, 65.1, 64.9, 64.8; LRMS m/z 
calcd for C21H15F2N2O: 349.1; found 349.1 [M]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 8.48 min (99% pure; Figure A129). 
 
Preparation of compound 2c*. As described for the synthesis of 
compound 1a, compound 12 (0.107 g, 0.506 mmol), 2-bromo-3'-
fluoroacetophenone (0.1023 g, 0.471 mmol), and EtOH (5.0 mL) were 
used to afford compound 2c* (1.3:1 mixture of product and hydrated product) (0.123 g, 61%, 
Rf 0.13 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A130) 
for product δ 8.97 (d, J = 5.6 Hz, 1H), 8.55 (dd, J = 2.4, 1.2 Hz, 1H), 8.37 (d, J = 6.0 Hz, 1H), 
7.86 (t, J = 7.6 Hz, 1H), 7.62-7.41 (m, 6H), 7.31-7.22 (m, 2H), 6.97 (d, J = 4.8 Hz, 1H), 6.49 
(br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A130) for hydrated product δ 8.93 (d, J = 5.2 
Hz, 1H), 8.52 (dd, J = 2.4, 1.2 Hz, 1H), 8.43 (d, J = 5.2 Hz, 1H), 7.86 (t, J = 7.6 Hz, 1H), 
7.62-7.41 (m, 6H), 7.31-7.22 (m, 2H), 6.98 (d, J = 4.8 Hz, 1H), 6.49 (br s, 2H), 1.65 (br s, 4H, 
2xH2O); 13C NMR (100 MHz, (CD3)2SO, Figure A131) for the mixture of product and 
hydrated product δ 190.99, 190.97, 190.92, 190.89, 165.2, 163.27, 163.26, 162.7, 160.8, 151.5, 
150.7, 135.24, 135.18, 135.1, 132.1, 131.7, 131.6, 131.39, 131.35, 131.31, 131.27, 129.3, 
128.7, 127.5, 126.7, 126.6, 126.1, 124.61, 124.58, 124.51, 124.49, 123.87, 123.84, 122.1, 
122.0, 121.9, 121.8, 121.64, 121.62, 121.3, 121.03, 120.98, 117.70, 117.66, 116.8, 116.5, 
115.1, 115.0, 114.9, 114.8, 61.7; LRMS m/z calcd for C21H15F2N2O: 349.1; found 349.1 [M]+. 
Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 8.59 min 
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(100% pure; Figure A132). 
 
Preparation of compound 2d*. As described for the synthesis of 
compound 1a, compound 12 (0.108 g, 0.509 mmol), 2-bromo-3'-
chloroacetophenone (0.110 g, 0.471 mmol), and EtOH (5.0 mL) were used 
to afford compound 2d* (1.1:1 mixture of product and hydrated product) (0.087 g, 42%, Rf 
0.30 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A133) for 
product δ 9.07 (d, J = 5.2 Hz, 1H), 8.61 (m, 1H), 8.31 (d, J = 6.0 Hz, 1H), 7.95 (t, J = 7.2 Hz, 
1H), 7.86 (t, J = 1.2 Hz, 1H), 7.62-7.48 (m, 5H), 7.40 (td, J = 7.6, 5.2 Hz, 1H), 7.25-7.21 (m, 
1H), 6.95 (d, J = 5.2 Hz, 1H), 6.43 (br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A133) for 
hydrated product δ 9.04 (d, J = 6.0 Hz, 1H), 8.59 (m, 1H), 8.36 (d, J = 6.0 Hz, 1H), 7.95 (t, J 
= 7.2 Hz, 1H), 7.85 (t, J = 1.6 Hz, 1H), 7.62-7.48 (m, 5H), 7.40 (td, J = 7.6, 5.2 Hz, 1H), 7.25-
7.21 (m, 1H), 6.95 (d, J = 4.8 Hz, 1H), 6.43 (br s, 2H), 1.76 (br s, 4H, 2xH2O); 13C NMR (100 
MHz, (CD3)2SO, Figure A134) for the mixture of product and hydrated product δ 191.5, 191.4, 
165.6, 163.2, 152.0, 151.2, 135.41, 135.35, 134.91, 134.89, 134.32, 134.27, 132.5, 132.2, 
132.1, 131.49, 131.45, 129.7, 129.2, 128.7, 128.5, 127.9, 127.4, 127.3, 127.2, 127.1, 126.5, 
124.32, 124.29, 122.53, 122.49, 121.7, 121.51, 121.46, 118.2, 118.1, 117.2, 117.0, 62.1; 
LRMS m/z calcd for C21H15ClFN2O: 365.1; found 365.1 [M]+. Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 9.26 min (100% pure; Figure A135). 
 
Preparation of compound 2e*. As described for the synthesis of 
compound 1a, compound 12 (0.107 g, 0.504 mmol), 2-bromo-3'-
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bromoacetophenone (0.138 g, 0.497 mmol), and EtOH (5.0 mL) were used to afford 
compound 2e* (1:1.1 mixture of product and hydrated product) (0.051 g, 22%, Rf 0.31 in 
MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A136) for product 
δ 8.72 (d, J = 5.6 Hz, 1H), 8.44 (d, J = 5.6 Hz, 1H), 8.40-8.36 (m, 1H), 8.06-8.01 (m, 2H), 
7.73-7.69 (m, 1H), 7.64-7.50 (m, 4H), 7.36 (t, J = 8.0 Hz, 1H), 7.29-7.24 (m, 1H), 7.00 (d, J = 
4.4 Hz, 1H), 6.51 (br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A136) for hydrated product 
δ 8.75 (d, J = 5.2 Hz, 1H), 8.40-8.36 (m, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.06-8.01 (m, 2H), 
7.73-7.69 (m, 1H), 7.64-7.50 (m, 4H), 7.35 (t, J = 8.0 Hz, 1H), 7.29-7.24 (m, 1H), 6.99 (d, J = 
4.0 Hz, 1H), 6.51 (br s, 2H), 1.58 (br s, 7H, 3.5xH2O); 13C NMR (100 MHz, (CD3)2SO, Figure 
A137) for the mixture of product and hydrated product δ 190.94, 190.86, 165.2, 162.7, 151.5, 
150.8, 137.32, 137.30, 135.2, 135.1, 132.0, 131.7, 131.6, 131.22, 131.18, 131.0, 130.9, 129.3, 
128.7, 127.5, 127.3, 127.2, 126.7, 126.6, 126.1, 125.9, 123.9, 123.8, 122.3, 122.2, 122.1, 
122.0, 121.2, 117.72, 117.67, 116.7, 116.5, 61.7, 61.6; LRMS m/z calcd for C21H15BrFN2O: 
409.0 found 409.0 [M]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 8.89 min (100% pure; Figure A138). 
 
Preparation of compound 2f*. As described for the synthesis of 
compound 1a, compound 12 (0.101 g, 0.476 mmol), 2-bromo-3'-
hydroxycetophenone (0.108 g, 0.501 mmol), and EtOH (0.5 mL) were 
used to afford compound 2f* (1.3:1 mixture of product and hydrated product) (0.146 g, 73%, 
Rf 0.13 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A139) 
for product δ 9.24 (br s, 1H), 8.84 (d, J = 6.4 Hz, 1H), 8.51 (m, 1H), 8.08 (t, J = 5.2 Hz, 1H), 
7.63 (br t, 1H), 7.57-7.43 (m, 4H), 7.21-7.09 (m, 2H), 6.99 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 
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4.4 Hz, 2H), 6.05 (br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A139) for hydrated product 
δ 9.24 (br s, 1H), 8.83 (d, J = 6.4 Hz, 1H), 8.52 (m, 1H), 8.08 (t, J = 5.2 Hz, 1H), 7.60 (br t 
1H), 7.57-7.43 (m, 4H), 7.21-7.09 (m, 2H), 6.97 (d, J = 8.0 Hz, 2H), 6.91 (d, J = 4.8 Hz, 2H), 
6.03 (br s, 2H), 1.85 (br s, 3H, 1.5xH2O); 13C NMR (100 MHz, (CD3)2SO, Figure A140) for 
the mixture of product and hydrated product δ 191.5, 191.4, 165.1, 162.6, 157.8, 151.4, 150.6, 
134.4, 134.3, 132.0, 131.7, 131.6, 130.2, 131.1, 129.2, 128.7, 127.5, 126.7, 126.6, 125.95, 
125.93, 123.90, 123.87, 122.04, 121.98, 121.93, 121.4, 121.0, 120.9, 119.2, 119.1, 117.6, 
117.5, 116.7, 116.5, 114.3, 114.2, 61.6; LRMS m/z calcd for C21H17FN2O2: 347.1; found 
347.1 [M]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: 
Rt = 7.66 min (99% pure; Figure A141). 
 
Preparation of compound 2g*. As described for the synthesis of 
compound 1a, compound 12 (0.1071 g, 0.505 mmol), 2-bromo-3'-
methoxyacetophenone (0.1089 g, 0.475 mmol), and EtOH (5.0 mL) were 
used to afford compound 2g* (1.7:1 mixture of product and hydrated product) (0.136 g, 66%, 
Rf 0.37 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A142) 
for product δ 9.09 (d, J = 6.0 Hz, 1H), 8.65 (m, 1H), 8.24 (d, J = 6.0 Hz, 1H), 7.61-7.47 (m, 
5H), 7.34 (t, J = 8,0 Hz, 2H), 7.24-7.20 (m, 2H), 7.13-7.09 (m, 1H), 6.94 (d, J = 4.0 Hz, 1H), 
6.41 (s, 2H), 3.84 (s, 3H); 1H NMR (400 MHz, CDCl3, Figure A142) for hydrated product δ 
9.05 (d, J = 5.6 Hz, 1H), 8.62 (m, 1H), 8.30 (d, J = 5.6 Hz, 1H), 7.61-7.47 (m, 5H), 7.32 (t, J 
= 5.2 Hz, 2H), 7.24-7.22 (m, 2H), 7.13-7.09 (m, 1H), 6.95 (d, J = 4.8 Hz, 1H), 6.43 (s, 2H), 
3.84 (s, 3H), 1.71 (br s, 2H, 1xH2O); 13C NMR (100 MHz, CDCl3, Figure A143) for the 
mixture of product and hydrated product δ 191.5, 191.4, 166.2, 163.6, 160.3, 160.2, 152.1, 
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151.2, 134.8, 134.7, 132.5, 131.5, 131.4, 130.43, 130.37, 129.7, 128.8, 127.9, 127.5, 127.4, 
126.2, 126.0, 123.88, 123.85, 122.33, 122.30, 122.13, 122.10, 122.0, 121.9, 121.50, 121.48, 
121.2, 121.0, 117.9, 117.8, 117.3, 117.1, 112.60, 112.56, 77.4, 63.0, 62.8, 56.0; LRMS m/z 
calcd for C22H18FN2O2: 361.1; found 361.1 [M]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 9.45 min (100% pure; Figure A144). 
 
Preparation of compound 2h*. As described for the synthesis of 
compound 1a, compound 12 (0.1064 g, 0.501 mmol), 2-bromo-4'-
fluoroacetophenone (0.1065 g, 0.491 mmol), and EtOH (5.0 mL) were 
used to afford compound 2h* (3:2 mixture of product and hydrated product) (0.078 g, 39%, Rf 
0.29 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A145) for 
product δ 8.83 (d, J = 5.6 Hz, 1H), 8.45 (m, 1H), 8.32 (d, J = 6.0 Hz, 1H), 8.09-8.04 (m, 2H), 
7.61-7.51 (m, 3H), 7.26-7.22 (m, 2H), 7.13 (t, J = 8.8 Hz, 2H), 6.98 (d, J = 4.8 Hz, 1H), 6.49 
(br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A145) for hydrated product δ 8.79 (d, J = 5.6 
Hz, 1H), 8.42 (m, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.09-8.04 (m, 2H), 7.61-7.51 (m, 3H), 7.26-
7.22 (m, 2H), 7.11 (t, J = 8.4 Hz, 2H), 6.99 (d, J = 3.6 Hz, 1H), 6.49 (br s, 2H), 1.58 (br s, 4H, 
2xH2O); 13C NMR (100 MHz, CDCl3, Figure A146) for the mixture of product and hydrated 
product δ 190.1, 190.0, 169.1, 168.3, 168.2, 166.2, 165.7, 165.6, 163.7, 152.2, 151.3, 132.6, 
131.99, 131.94, 131.9, 131.5, 131.4, 129.99, 129.97, 129.86, 129.83, 129.7, 128.8, 127.8, 
127.5, 127.4, 126.1, 125.9, 123.82, 123.78, 122.37, 122.36, 122.2, 122.0, 121.1, 121.0, 118.0, 
117.9, 117.4, 117.2, 116.8, 116.7, 116.6, 116.5, 77.4, 62.8, 62.6; LRMS m/z calcd for 
C21H15F2N2O: 349.1; found 349.1 [M]+. Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 8.31 min (100% pure; Figure A147). 
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Preparation of compound 2i*. As described for the synthesis of 
compound 1a, compound 12 (0.1065 g, 0.502 mmol), 2-bromo-4'-
chloroacetophenone (0.114 g, 0.510 mmol), and EtOH (5.0 mL) were 
used to afford compound 2i* (5:4 mixture of product and hydrated product) (0.128 g, 61%, Rf 
0.24 in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A148) for 
product δ 9.12 (d, J = 5.6 Hz, 1H), 8.65 (dd, J = 2.4, 0.8 Hz, 1H), 8.32 (d, J = 5.6 Hz, 1H), 
7.96-7.92 (m, 2H), 7.60-7.48 (m, 4H), 7.41-7.38 (m, 2H), 7.25-7.20 (m, 1H), 6.95 (d, J = 4.8 
Hz, 1H), 6.46 (br s, 2H); 1H NMR (400 MHz, CDCl3, Figure A148) for hydrated product δ 
9.08 (d, J = 6.0 Hz, 1H), 8.63 (dd, J = 2.4, 0.8 Hz, 1H), 8.36 (d, J = 6.0 Hz, 1H), 7.96-7.92 (m, 
2H), 7.59-7.48 (m, 4H), 7.41-7.38 (m, 2H), 7.25-7.2 (m, 1H), 6.96 (d, J = 5.2 Hz, 1H), 6.46 
(br s, 2H), 1.78 (br s, 2H, 1xH2O); 13C NMR (100 MHz, CDCl3, Figure A149) for the mixture 
of product and hydrated product δ 190.6, 190.5, 166.2, 163.7, 152.1, 151.1, 141.8, 141.6, 
132.6, 131.8, 131.7, 131.5, 131.4, 130.40, 130.36, 129.72, 129.65, 128.8, 127.8, 127.46, 
127.36, 126.3, 126.1, 123.81, 123.77, 122.2, 122.0, 121.2, 121.1, 118.0, 117.8, 117.4, 117.2, 
77.4, 62.7, 62.6; LRMS m/z calcd for C21H15ClFN2O: 365.1; found 365.1 [M]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 9.13 min (100% pure; 
Figure A150). 
 
Preparation of compound 2j*. As described for the synthesis of 
compound 1b, compound 12 (0.052 g, 0.245 mmol), 2-bromo-4'-
bromoacetophenone (0.062 g, 0.224 mmol), and THF (1.25 mL) were 
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used to afford compound 2j* (0.052 g, 46%, Rf 0.10 in MeOH:CH2Cl2/1:9) as a white solid: 
1H NMR (400 MHz, CDCl3, Figure A151) δ 9.06 (d, J = 6.0 Hz, 1H), 8.61-8.60 (m, 1H), 8.32 
(d, J = 5.2 Hz, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.59-7.56 (m, 4H), 7.25-7.21 (m, 3H), 6.96 (d, J 
= 4.4 Hz, 1H), 6.46 (s, 2H); 13C NMR (100 MHz, CDCl3, Figure A152) δ 190.7, 166.2, 163.7, 
151.2, 132.7, 132.1, 131.5, 131.4, 130.8, 130.4, 127.5, 126.2, 123.8, 123.7, 122.3, 121.1, 
117.9, 117.4, 117.2, 77.4, 62.8; LRMS m/z calcd for C21H15BrFN2O: 409.0; found 409.0 [M]+. 
Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 9.30 min 
(100% pure; Figure A153). 
 
Preparation of compound 2k*. As described for the synthesis of 
compound 1a, compound 12 (0.10 g, 0.47 mmol), 2-bromo-4'-
methylacetophenone (0.10 g, 0.47 mmol), and EtOH (2.0 mL) were used 
to afford compound 2k* (3:2 mixture of product and hydrated product) (0.10 g, 50%, Rf 0.26 
in MeOH:CH2Cl2/1:9) as a yellow solid: 1H NMR (400 MHz, CDCl3, Figure A154) for 
product δ 8.91 (m, 1H), 8.51 (m, 1H), 8.17 (m, 1H), 7.85 (m, 2H), 7.60-7.52 (m, 4H), 7.25-
7.23 (m, 3H), 6.95 (d, J = 3.6 Hz, 1H), 6.36 (br s, 2H), 2.37 (s, 3H); 1H NMR (400 MHz, 
CDCl3, Figure A154) for hydrated product δ 8.88 (m, 1H), 8.49 (m, 1H), 8.25 (m, 1H), 7.85 
(m, 2H), 7.60-7.52 (m, 4H), 7.25-7.23 (m, 3H), 6.95 (d, J = 3.6 Hz, 1H), 6.38 (br s, 2H), 2.37 
(s, 3H), 1.63 (br s, 4H, 2xH2O); 13C NMR (100 MHz, CDCl3, Figure A155) for the mixture of 
product and hydrated product δ 190.6, 190.2, 165.7, 163.2, 151.5, 150.6, 146.0, 145.8, 132.0, 
131.3, 131.2, 130.6, 130.5, 129.64, 129.59, 129.3, 128.61, 128.58, 128.5, 127.6, 127.1, 127.0, 
126.1, 126.0, 123.63, 123.59, 121.7, 121.6, 121.1, 121.0, 117.4, 117.3, 116.9, 116.6, 62.4, 
62.2, 21.7; LRMS m/z calcd for C22H18FN2O: 345.1; found 345.8 [M]+. Purity of the 
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compound was further confirmed by RP-HPLC by using method 1: Rt = 9.62 min (99% pure; 
Figure A156). 
 
2.6.2. Biochemical and biological methods 
2.6.2.1. Protein, reagents, and small-molecule libraries 
The Eis protein from Mycobacterium tuberculosis (Eis_Mtb) was expressed and purified as 
reported previously.85 All chemicals for biochemical/biological assays, including 5',5-
dithiobis-(2-nitrobenzoic acid) (DTNB), Tween® 80, neomycin B (NEO), kanamycin A 
(KAN), acetyl-CoA (AcCoA), and chlorhexidine were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Albumin-dextrose-catalase (ADC) was from BD Biosciences (San Jose, 
CA, USA). The high-throughput screening (HTS) that identified compound 1a* as capable of 
inhibiting the acetyltransferase activity of purified Eis_Mtb was performed at the Center for 
Chemical Genomics (CCG, University of Michigan) against 23,000 compounds from three 
different libraries: (i) a ChemDiv library (20,000), (ii) the BioFocus NCC library, and (iii) the 
MicroSource MS2000 library. The immediate follow-up hit validation assay to confirm the 
inhibition of Eis_Mtb by compound 1a* was performed by using fresh powder purchased 
from ChemDiv (San Diego, CA, USA). Compound 1a* was freshly synthesized for all 
biochemical and structural studies described in sections 2.4-3.2 below. All small molecules 
synthesized (1a-3k and 1a*-2k*) in this study were dissolved in DMSO (10 mM stock) prior 
to testing. Note: All concentrations noted below are the final concentrations in the assays. The 
pH of all buffers was adjusted at rt. 
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2.6.2.2. Eis chemical library screening 
For HTS, as previously described,108 the absorbance signal from the reaction of the 
enzymatically released CoASH with Ellman’s reagent (DTNB) at 412 nm (e412 = 14150 M-
1cm-1) was used to monitor the acetylation by Eis_Mtb. The reactions (40 mL) contained Tris-
HCl (50 mM, pH 8.0), Eis (0.25 mM), NEO (100 mM), AcCoA (40 mM), DTNB (0.5 mM), 
and library compounds (20 mM). Chlorhexidine (5 mM) and DMSO (0.5%) served as positive 
and negative controls, respectively. Plates were incubated at room temperature and read on a 
PHERAstar plate reader 5 min after initiation of the reaction. The average Z' score for the 
HTS assay was 0.60. 
 
2.6.2.3. Hit validation 
The hit compound 1a* was defined as displaying ≥ 3-fold inhibition than the standard 
deviation (calculated for the inert compounds) in the HTS. This compound (purchased from 
ChemDiv) was tested in triplicate. As it exhibited reproducible inhibitory activity in all three 
trials, we then tested it in dose-response assays in the concentration range from 20 mM to 78 
nM (generated by 2-fold dilutions of the compound stock). As this lead compound 1a* 
showed promise, we synthesized it along with 47 of its analogues and determined their IC50 
values. 
 
2.6.2.4. Inhibition kinetics 
For compounds 1a-3k and 1a*-2k* freshly synthesized in this study, the absorbance at 412 
nm was measured on a SpectraMax M5 plate reader for the reaction mixtures in 96-well plates 
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(Thermo Fisher Scientific). Measurements were taken every 30 s for 10 min. Compounds 1a-
3k and 1a*-2k* were first serially dissolved in Tris-HCl (50 mM, pH 8.0, containing 10% v/v 
DMSO). A mixture (50 mL) of Eis (1 mM), KAN (400 mM), and Tris-HCl (50 mM, pH 8.0) 
was added to compounds 1a-3k and 1a*-2k* (100 mL) and incubated for 10 min. Reactions 
were initiated by the addition of a mixture (50 mL) of DTNB (8 mM), AcCoA (2 mM), and 
Tris-HCl (50 mM, pH 8.0). All assays were performed in triplicate. IC50 values were 
calculated by curved fitting to a Hill plot with KaleidaGraph 3.6 software (Table 2.1 and 
Figure 2.6). 
 
 
Figure 2.6. Representative IC50 curves. 
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2.6.2.5. Mycobacterial MIC determination by alamarBlue® assay 
Mtb strains H37Rv and K204 were inoculated from frozen stocks into Middlebrook 7H9 broth 
supplemented with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%), and incubated at 
37 °C until turbidity appeared. The cultures were diluted with fresh 7H9 medium to OD600 of 
0.2, further diluted 1:25 in fresh 7H9 medium in 50 mL polypropylene tubes containing glass 
beads and vortexed for 30 s. The cultures were kept still for 10 min, and then 90 mL aliquots 
were distributed into the wells of a clear 96-well culture plate. Compounds 1a-3k and 1a*-
2k* were initially tested at concentrations that were either 100-fold higher than their IC50 
values or at 100 mM if their IC50 values was >1 mM, while keeping the DMSO concentration 
≤ 1% in test wells. Working stocks for each compound were prepared at concentrations twice 
that of the desired final concentration in fresh 7H9 medium, and 100 mL of each of these 
working stocks was added to the 90 mL of bacterial cultures in the wells. The plates were 
incubated at 37 °C for 24 h in a humid environment before the addition of KAN (10 mL). 
Growth of H37Rv was evaluated at 2.5, and 1.25 mg/mL KAN while growth of K204 was 
evaluated at 10, 5, 2.5, and 1.25 mg/mL KAN. The plates were incubated at 37 °C for 6 days 
after the addition of KAN. Then, 40 mL of alamarBlue® diluted 1:2 in 10% Tween® 80 was 
added to each well and the plates continued to be incubated 37 °C. The color of each well was 
preliminarily evaluated 24 h after the addition of alamarBlue®, with a final evaluation after 
48 h. AlamarBlue® changes from indigo blue to pink as a result of bacterial growth. The 
lowest concentration of KAN that resulted in no change in color was defined as the MIC for 
each concentration of an inhibitory compound. Compound screening was carried out on 
biological replicates in duplicate. Several controls were included with every compound: 
uninoculated 7H9, compound and inoculated 7H9 only, inoculated 7H9 + DMSO only, and 
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inoculated 7H9 only. For each plate, 200 mL of sterile water was added to all perimeter wells 
to minimize evaporation. 
 
2.6.2.6. Mammalian cytotoxicity assays  
Mammalian cytotoxicity assays were performed as previously described with minor 
modifications.122-123 The human embryonic kidney cells HEK-293 (ATCC CRL-1573) were 
purchased from ATCC (Manassas, VA). The human lung carcinoma epithelial cells A549 
(ATCC CCL-185) and the murine macrophage cells J774A.1 (ATCC TIB-67) were generous 
gifts from Dr. David K. Orren and Dr. David J. Feola (University of Kentucky, Lexington, 
KY), respectively. The A549 and HEK-293 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (catalog # 11965-092, ThermoFisher Scientific, Waltham, MA) 
supplemented with 10% fetal bovine serum (FBS, ATCC, Manassas, VA) and 1% 
penicillin/streptomycin (ATCC, Manassas, VA) at 37 °C with 5% CO2. J774A.1 cells were 
cultured in a different DMEM (catalog # 30-2002, ATCC, Manassas, VA) with the same 
supplements under the same conditions as those described for the A549 and HEK-293 cells. 
A549 and HEK-293 cells were dislodged from culturing dish by treating with 0.05% trypsin-
0.53 mM EDTA (ATCC, Manassas, VA) when sub-culturing, whereas J774A.1 cells were 
dislodged from culturing dish by mechanical scraping. For the assessment of the toxicity of 
the selected compounds (1e*, 1i*, 2c*, 2h*, and 2i*) (Figure 2.2) or KAN alone (Figure 2.6), 
assays were performed in 96-well tissue culture plates in quadruplicate where HEK-293 and 
J774A.1 cells were plated at 10,000 cells/well density in 100 mL of the appropriate media and 
A549 cells were plated at 3,000 cells/well density in the same amount of DMEM. After 
overnight incubation at 37 °C with 5% CO2, the old medium was replaced with fresh medium 
 82 
containing serially diluted compounds (concentration ranging from 0.78-200 mM with 0.5% 
DMSO) or KAN (concentration ranging from 2-500 mM). Cells for negative and positive 
controls were treated with the appropriate medium containing 0.5% DMSO (no DMSO for 
KAN treated cells) or 0.5% DMSO and 1% v/v triton-X 100® (no DMSO for KAN treated 
cells), respectively. After 24 h of incubation at 37 °C with 5% CO2, rezasurin (10 mL of 2 
mM solution, Sigma Aldrich, Milwaukee, WI) was added to each well and incubated for 6 h 
in order to assess the amount of cells viable, as rezasurin can be converted to resorufin, which 
has excitation and emission wavelengths at λ560 and λ590 nm, respectively. Fluorescence was 
measured with a SpectraMax M5 plate reader. The percent cell survival in the presence of 
each compound alone or KAN alone is summarized in Figure 2.2 and 2.3, respectively. The 
cytotoxicity assays for these compounds in the presence of 50 mg/mL KAN were performed 
with the same protocol as described above, except that the DMEM was further supplemented 
with 50 mg/mL (equivalent to 86 mM) KAN in order to assess the combined toxicity of these 
compounds in the presence of KAN (Figure 2.2). 
 
2.6.3. Structural biological methods 
2.6.3.1. Purification of EisC204A  
The active point mutant EisC204A that is less prone to oxidation than the wild-type Eis_Mtb 
was overexpressed in E. coli BL21 (DE3) and purified as previously reported,86 with only 
minor modifications, as follows. The EisC204A-pET28a plasmid was transformed into E. coli 
BL21 (DE3) chemically competent cells and plated onto LB agar containing KAN (50 
mg/mL). After overnight incubation, a single colony from the plate was inoculated into LB 
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broth (5 mL) containing KAN (50 mg/mL) (LB/KAN). This culture was grown at 37 °C until 
an OD600 of 0.5, then the culture was inoculated into 4 L of LB/KAN and grown at 37 °C. At 
an OD600 of ~0.1, the culture was transferred to 16 °C for 1.5 h, and then IPTG was added at 
the final concentration of 0.5 mM. The induced culture was grown for an additional 16-18 h at 
16 °C with shaking (200 rpm). All following purification steps were done at 4 °C. The cells 
were pelleted by centrifugation at 5,000 rpm for 10 min. The cell pellets were resuspended in 
chilled lysis buffer (NaCl (300 mM), Tris-HCl pH 8.0 (40 mM), glycerol (10% v/v), and b-
mercaptoethanol (2 mM)). The cells were then disrupted by sonication and the insoluble 
material was removed by centrifugation at 35,000×g for 45 min at 4 °C. The supernatant was 
passed through a 0.45 mm Millex-HV PVDF filter (Millipore, Billerica, MA, USA) and then 
loaded onto a 5 mL Ni-IMAC HisTrap FF column (GE Healthcare) pre-equilibrated in the 
lysis buffer. The column was washed with 100 mL of lysis buffer containing 20 mM 
imidazole and then the protein was eluted in 10 mL of lysis buffer containing 200 mM 
imidazole. The eluate was concentrated using an Amicon Ultra-15 (10,000 MWCO) 
centrifugal filter device (Millipore) to the volume of 5 mL. The protein was then purified on a 
size-exclusion S-200 column (GE Healthcare) equilibrated in gel filtration buffer (Tris-HCl 
pH 8.0 (40 mM), NaCl (100 mM), and b-mercaptoethanol (2 mM)). The EisC204A-
containing fractions were pooled and concentrated using an Amicon Ultra (10,000 MWCO) 
centrifugal filter device (Millipore) to 4 mg/mL. The pure EisC204A protein was stored on ice 
at 4 °C. 
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2.6.3.2. Crystallization, diffraction data collection, and structure determination and 
refinement of EisC204A-CoA-inhibitor 2k* complex 
Crystals of EisC204A-CoA complex were grown by vapor diffusion in hanging drops. The 
drops were set by mixing 1 mL of concentrated (4 mg/mL) EisC204A protein containing 
KAN (10 mM), and CoA (8 mM) with 1 µL of the reservoir solution (100 mM Tris-HCl pH 
8.5 adjusted at room temperature, 10-15% w/v PEG 8,000, and 0.4 M (NH4)2SO4). The drops 
were incubated against 1 mL of the reservoir solution at 22 °C. Crystals were grown in 2-3 
weeks. The crystals were first transferred into the reservoir solution. Then the (NH4)2SO4 and 
KAN were exchanged out by a gradual transfer into the reservoir solution lacking (NH4)2SO4: 
(100 mM Tris-HCl pH 8.5 and 15% w/v PEG 8,000) and incubated for 30 min. Then the 
crystals were transferred into the cryoprotectant solution (100 mM Tris-HCl pH 8.5, 15% w/v 
PEG 8,000, and 20% v/v glycerol) and incubated in this solution for 10 min. After the 
incubation, the crystals were transferred into the cryoprotectant solution containing 0.5 mM 
2k*, incubated for 30 min, and then frozen in liquid nitrogen by quick immersion. All crystal 
transfer and incubation steps were carried out at 22 °C. 
 
The X-ray diffraction data were collected at synchrotron beamline 22-ID of the Advanced 
Photon Source at the Argonne National Laboratory (Argonne, IL) at 100 K. The data were 
processed with HKL2000.124 The crystal form in space group R32 was the same as that of 
wild-type Eis-CoA-acetamide complex determined previously by our group (PDB code 
3R1K85). The crystals contained one Eis monomer per asymmetric unit, with the Eis hexamer 
generated by crystal symmetry operations. For this structure, we performed rigid body 
refinement by Refmac,125 with the entire Eis monomer as a single rigid-body domain. After 
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the rigid body refinement, strong difference Fo-Fc electron density for a bound inhibitor 2k* 
and a CoA molecule was observed. The conformations of the inhibitor and the CoA were 
clearly defined by the difference density. We built these molecules into this difference 
electron density by using Coot.126 The structure of EisC204A-CoA-inhibitor 2k* complex was 
then adjusted and refined iteratively using programs Coot and Refmac, respectively. The data 
collection and structure refinement statistics are given in Table 2.2. The crystal structure 
coordinates and structure factor amplitudes for EisC204A-CoA-2k* complex were deposited 
in the Protein Data Bank with the PDB accession number 5TVJ. 
 
 
Table 2.2. X-ray diffraction data collection and refinement 
statistics for the EisC204A-CoA-inhibitor 2k* ternary complex 
structure. 
Data collection  
Space group R32 
Number of monomers per asymmetric 
unit 
1 
Unit cell dimensions  
     a, b, c (Å) 175.5, 175.5, 120.7 
     a, b, g (°) 90, 90, 120 
cResolution (Å) 50.0-2.3 (2.34-2.30)a 
I/s 24 (2.1) 
Completeness (%) 99.7 (96.5) 
Redundancy 7.3 (6.9) 
Rmerge 0.13 (0.69) 
Number of unique reflections 30,515 
  
Structure refinement statistics  
Resolution (Å) 40.0-2.3 
R (%) 19.3 
Rfree (%) 22.4 
Bond length deviation (rmsd) from ideal 
(Å) 
0.007 
Bond angle deviation (rmsd) from ideal 
(°) 
1.42 
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Ramachandran plot statisticsb  
     % of residues in most allowed regions 93.5 
     % of residues in additional allowed 
regions 
6.5 
     % of residues in generously allowed 
regions 
0.0 (0 residues) 
     % of residues in disallowed regions 0.0 (0 residues) 
a Numbers in parentheses indicate the values in the highest-
resolution shell. b Indicates Procheck statistics.127 
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Chapter 3 
Potent 1,2,4-triazino[5,6b]indole-3-thioether inhibitors of the kanamycin resistance 
enzyme Eis from Mycobacterium tuberculosis 
3.1. ABSTRACT 
A common cause of resistance to kanamycin (KAN) in tuberculosis is overexpression of the 
enhanced intracellular survival (Eis) protein. Eis is an acetyltransferase that multiacetylates 
KAN and other aminoglycosides, rendering them unable to bind the bacterial ribosome. By 
high-throughput screening, a series of substituted 1,2,4-triazino[5,6b]indole-3-thioether 
molecules were identified as effective Eis inhibitors. Herein, we purchased 18 and synthesized 
22 new compounds, evaluated their potency, and characterized their steady-state kinetics. 
Four inhibitors were found not only to inhibit Eis in vitro, but also to act as adjuvants of KAN 
and partially restore KAN sensitivity in a Mycobacterium tuberculosis KAN-resistant strain in 
which Eis is upregulated. A crystal structure of Eis in complex with a potent inhibitor and 
CoA shows that the inhibitors bind in the aminoglycoside binding site snugly inserted into a 
hydrophobic cavity. These inhibitors will undergo preclinical development as novel KAN 
adjuvant therapies to treat KAN-resistant tuberculosis. 
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3.2. INTRODUCTION 
Mycobacterium tuberculosis (Mtb), the etiological agent of tuberculosis (TB), is a dominant 
worldwide threat to human health.128-129 The evolution of resistance of this bacterium to 
conventional anti-tubercular drugs has exacerbated the problem.130-131 This is particularly 
concerning as in the last 50 years only two new anti-tubercular agents, bedaquiline (Food and 
Drug Administration (FDA), USA) and delamanid (European Medicines Agency, EU) were 
approved by these agencies for treatment of multidrug-resistant tuberculosis (MDR-TB) and 
extensively drug-resistant tuberculosis (XDR-TB), respectively.132 The need to combat drug-
resistant TB remains a pressing issue, and work towards developing new anti-tubercular 
agents continues to be at the forefront of TB research. Several directions are being pursued in 
TB drug development: (i) investigation of chemical modifications of current TB treatments 
(e.g., isoniazid and rifampin), (ii) development of agents inhibiting already exploited targets, 
but capable of avoiding the resistance mechanisms (e.g., KatG and topoisomerase mutations), 
(iii) development of inhibitors of novel pathways or enzymes that are specific to Mtb or 
bacteria in general (e.g., mycolic acid pathway, amino acid biosynthesis, PanK, and 
dihydrofolate reductase), and (iv) development of inhibitors of resistance enzymes (e.g., BlaC 
and Eis) as adjuvants of currently approved anti-tubercular drugs.62, 133 
 
Aminoglycosides (AGs) have been used extensively to treat a broad spectrum of bacterial 
infections since the discovery of streptomycin in the 1950s. The injectable AGs, kanamycin 
(KAN) and amikacin (AMK), have been efficacious therapeutic agents against Mtb strains for 
decades. However, KAN- and AMK-resistant Mtb strains have emerged. Mtb has three main 
mechanisms to overcome the action of KAN and AMK: (i) increased expression of the 
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enhanced intracellular survival (eis) gene as a result of a mutation in its promoter,84 (ii) 
increased expression of Eis and the efflux pump, Tap, due to upregulation of transcriptional 
activator WhiB7,134 and (iii) ribosome mutations that interfere with AG binding.101 
Upregulation of the eis gene by either mechanism (i) or (ii) confers resistance to KAN in one-
third of KAN-resistant clinical isolates.84, 134 Eis is a unique AG acetyltransferase (AAC) due 
to its distinct structure and ability to multi-acetylate AGs at several different positions 
including the 3"-amine of 4,6-disubstituted 2-deoxystreptamine AGs and 4"'-amine of AGs 
containing an (S)-4-amino-2-hydroxybutyryl group that are not modified by other AACs.85-86 
It is also of note that one AG modification may not completely abolish the antibacterial 
activity of an AG, whereas two or more modifications fully eliminate this activity.135 Eis has a 
larger and more complex active site than that of other AACs, which results in its broader 
substrate profile and multi-acetylating activity.85-86, 90 The kinetics of AG acetylation by Eis 
have been studied and this bisubstrate enzyme was found to operate by a random sequential 
mechanism.88	  
 
Two potential strategies that may be envisioned to overcome the resistance caused by Eis are: 
(i) identification of new AGs that are not susceptible to inactivation by Eis, and (ii) discovery 
of structurally unrelated inhibitors of Eis, which would sensitize the KAN-resistant bacteria to 
KAN when administered as a combination therapy. Because Eis can acetylate multiple amines 
on clinically relevant AGs of different structures, the first strategy is not likely to be 
productive. We recently demonstrated that the second strategy is a useful approach by 
discovering several structural classes of potent Eis inhibitors and demonstrating that they 
indeed target Eis in Mtb cells.105-106, 108, 136-137 Diversifying a drug pipeline with different 
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structural classes early on in the drug development process increases the chances of one of the 
compounds progressing to clinical applications. Development of drugs that need to act in the 
Mtb cytoplasm is especially complicated by the requirement for these molecules to cross the 
extremely waxy Mtb envelope as well as the membrane of the macrophage, which harbors 
persistent Mtb infections. Therefore, we sought a structural class of Eis inhibitors that would 
be distinct from those that we discovered previously. 
 
In this study, we present novel 1,2,4-triazino[5,6b]indole-3-thioether-based Eis inhibitors. The 
structures of these inhibitors are unique as they contain a tricyclic core and a long flexible 
linker, which allows access to novel binding surfaces of Eis that were unexplored in our 
previous Eis inhibitor studies. We also introduce a simple and easily scalable synthetic route 
to derivatize the 1,2,4-triazino[5,6b]indole-3-thioether scaffold. We present kinetic and 
crystallographic analysis of these inhibitors as well as describe their biological activity as 
KAN adjuvants. We also perform a thorough comparison of the interactions of this scaffold 
with those of four previously published divergent Eis inhibitor classes. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Identification of lead compounds and synthetic optimization 
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Figure 3.1. Stepwise cone diagram showing the winnowing of 23,000 compounds to the four 
Eis inhibitors that restored KAN activity in Mtb K204. 
 
Inhibitors of Eis were sought by a high-throughput screening (HTS) assay against a collection 
of ~23,000 compounds from three different libraries: the BioFocus NCC library (~1,000 
compounds), the ChemDiv library (~20,000 compounds), and the MicroSource MS2000 
library (~2,000 compounds).108 The average Z' score for the HTS was 0.65, indicating assay 
robustness. Forty-six compounds with a 1,2,4-triazino[5,6b]indole-3-thioether core substituted 
at three different positions were present in the HTS campaign (Figure 3.1 and 3.2). Out of 
these 46 compounds, seven molecules (14a, 23a, 23c, 37b, 37d, 39b, and 40b; Figure 3.2), 
some of which displayed Eis inhibition, were selected for additional investigation (Table 3.1). 
Step 1: HTS of ~23,000 molecules against pure Eis enzyme
Step 2: 46 molecules from HTS with the following core:
Step 3: Validation of 7 of the 46 cpds above
+ 17 purchased analogues
Step 4: Validation 22 synthesized analogues
 + 2 re-synthesized of the 46 cpds above
Step 5: Determination of IC50 values for
 46 Eis inhibitors from steps 3-4
Step 6: Determination of MICs of
KAN with 28 Eis inhibitors with
IC50 values < 28 μM
N
N
NN
X SR2
R1
Step 7: 4 Eis inhibitors with
MICKAN ≤ 2.5 - 5 μg/mL
against Mtb K204
 93 
Four (14a, 37b, 37d, and 39b) of these seven molecules were confirmed to be Eis inhibitors 
by dose-response assays. Seventeen additional compounds were purchased to further explore 
the utility of this scaffold. Based on IC50 data obtained for the commercially available 
compounds against purified Eis (Table 3.1), 22 new derivatives (Figure 3.3) were synthesized. 
As neomycin B (NEO) was found to be the one of the best substrates for Eis in a previous 
study,85, 108 the HTS was performed with NEO as a substrate for optimal signal-to-noise ratio 
relative to the background hydrolysis of acetyl coenzyme A (AcCoA). However, as KAN is 
the clinically relevant substrate for inactivation by Eis in Mtb, we determined IC50 using KAN 
(IC50,KAN) for all of our synthesized compounds to validate their potential clinical use. 
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Figure 3.2. Structures of all molecules used in this study along with their origin. Note: At the 
bottom of the figure, the compound numbers listed in orange indicate that the compounds 
were tested in the HTS only. Those listed in pink were tested in the HTS and repurchased for 
validation. Those listed in gray were compounds that were not present in the HTS, but were 
purchased to expand the preliminary SAR study. Those in green were new derivatives 
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COMPOUNDS STUDIED: 1b, 2c, 2e, 3e, 4a, 5a, 
5b, 5c, 6a, 7a, 8a, 9a, 10k, 11a, 11b, 11c, 11d, 
11e, 12d, 12e, 12j, 13b, 14a, 15a, 16a, 17b, 17c, 
17e, 18a, 19a, 20a, 20b, 20i, 20j, 21d, 21e, 22a, 
22b, 22c, 23a, 23c, 24a, 25a, 26a, 27a, 28a, 29a, 
30b, 31a, 32b, 33b, 34b, 35b, 36b, 37b, 37c, 37d, 
37g, 37h, 37i, 38b, 39b, 39c, 39i, 40b, 40c, 40d, 
41d, 42b, 43b, 43d, 44b, 45b, 46b, 47b, 48b, 48c, 
48d, 48f, 48h, 49b, 50d, 51d, 52, 53
Series I: Series II: Series III:
Series IV:
3
5
8
ORIGIN OF COMPOUNDS:
HTS only: 1b, 2c, 2e, 3e, 4a, 5a, 5b, 5c, 6a, 7a, 8a, 11a, 12d, 12e, 12j, 13b, 15a, 17b, 17c, 17e, 18a, 19a, 20a, 20b, 20i, 20j, 21d, 21e, 
22a, 22b, 22c, 26a, 27a, 28a, 29a, 37c, 40c, 40d, 51d
HTS & repurchased: 14a, 23a, 23c, 37d, 40b
Not in HTS, only purchased: 9a, 10k, 11b, 11c, 11d, 11e, 16a, 24a, 25a, 30b, 31a, 37g, 37i, 39c, 39i, 41d, 50d
Synthesized: 32b, 33b, 34b, 35b, 36b, 37h, 38b, 42b, 43b, 43d, 44b, 45b, 46b, 47b, 48b, 48c, 48d, 48f, 48h, 49b, 52, 53
HTS, repurchased, & re-synthesized: 37b
HTS, repurchased, re-synthesized, & crystallized: 39b
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synthesized to further expand our SAR study. Compound 37b is in purple as it was present in 
the HTS, repurchased, and re-synthesized to confirm the values obtained for purchased 
material. Compound 39b is in blue as, not only was it present in the HTS, repurchased, and re-
synthesized, but was additionally crystallized with Eis. All compounds (except those listed 
with orange numbers) had an IC50 or/and an MICKAN value determined as presented in Table 
3.2. 
 
The synthesis of all compounds started with N-alkylation of the commercially available 
compounds 54 and 55 with alkyl halides, to afford compounds 56 and 57, respectively, in 
quantitative yields. The resulting products were mixed with thiosemicarbazide in the presence 
of potassium carbonate or cesium carbonate, followed by acidification with concentrated 
hydrochloric acid to generate the cyclized or uncyclized products 58-59 in 22-52% yields. 
Subsequently, intermediates 58-59 were reacted with various organo halides to obtain the 
desired S-substituted products (32 and 34-49) with fluoro or methyl substituents at the C8-
position (indicated as X in Figure 3.3) in 14-82% yields. The free hydroxyl group of 32b was 
methylated in the presence of iodomethane and sodium hydride to generate 33b in 47% yield. 
Compound 58b was reacted with bromoacetonitrile to afford the desired molecule 47b in 63% 
yield. Compounds 52-53 were prepared in three steps from 58b. S-Methylation of compound 
58b with iodomethane afforded 60b (91% yield), which was oxidized with m-CPBA to give 
sulfone 61b (45% yield). Compound 61b was reacted with different N,N-
dialkylaminoalkylamines to generate the desired compounds 52 and 53. 
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Figure 3.3. Synthetic schemes used for the synthesis of 24 compounds generated in this study. 
 
3.3.2. Structure-activity-relationship (SAR) study 
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Table 3.1. IC50 values of synthetic Eis inhibitors and compounds purchased and/or from 
HTS with activity under 28 µM and MICKAN values for Mtb H37Rv and Mtb K204 when 
treated in combination with the inhibitor at the listed concentration. 
Cpd IC50,KAN 
(µM) 
IC50,NEO 
(µM) 
H37Rv MICKAN 
(µg/mL) 
K204 MICKAN 
(µg/mL) 
Concentration 
tested (µM) 
-   ≤1.25 >10  
9a  5.8 ± 0.8 ≤1.25 5 100 
10k  28 ± 4 ≤1.25 10 100 
11b 0.23 ± 
0.02 
0.64 ± 0.15 ≤1.25 5 23 
11c 0.27 ± 
0.05 
1.1 ± 0.2 ≤1.25 5-10 27 
11d  2.4 ± 0.5 ≤1.25 10 100 
11e  4.4 ± 0.4 ≤1.25 5-10 100 
14a 1.5 ± 0.1 5.3 ± 1.0 ≤1.25 5 100 
16a  3.9 ± 0.9 ≤1.25 10 100 
23a  >200    
23c  >200    
24a  >200    
25a  13 ± 2 ≤1.25, ≤1.25 10 100 
30b  >200    
31a  >200    
32b >200     
33b >200     
34b 0.056 ± 
0.006 
-- ≤1.25 5 
5 
100 
5.6 
35b >200     
36b 0.43 ± 
0.04 
0.26 ± 0.07 ≤1.25 2.5-5 43 
37b 0.17 ± 
0.04 
0.39 ± 0.14 ≤1.25 2.5 17 
37d 0.8 ± 0.1 0.21 ± 0.03 ≤1.25 5 80 
37g 0.43 ± 
0.06 
0.5 ± 0.1 ≤1.25 5-10 43 
37h 1.3 ± 0.1     
37i 0.56 ± 
0.03 
1.7 ± 0.5 ≤1.25 10 56 
38b 0.07 ± 
0.01 
0.13 ± 0.04 ≤1.25-2.5 5-10 7 
39b 0.030 ± 
0.005 
0.15 ± 0.02 ≤1.25 2.5-5 13 
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39c 0.14 ± 
0.01 
0.18 ± 0.02 ≤1.25 5 14 
39i 0.05 ± 
0.02 
0.30 ± 0.14 ≤1.25 ≥10 5 
40b  >200    
41d  >200    
42b >200     
43b 0.10 ± 
0.02 
0.25 ± 0.03   Insoluble 
43d 1.1 ± 0.2  ≤1.25 2.5-5 
10 
100 
10 
44b 3.3 ± 0.7  ≤1.25 >10 100 
45b 0.17 ± 
0.03 
 ≤1.25-2.5 5-10 17 
46b 0.14 ± 
0.04 
   Insoluble 
47b >200     
48b 0.17 ± 
0.04 
0.51 ± 0.03   Insoluble 
48c 0.6 ± 0.1    -- 
48d 0.15 ± 
0.02 
 2.5 5-10 15 
48f 1.2 ± 0.2  1.25 10 100 
48h 0.54 ± 
0.13 
    
49b 1.0 ± 0.1  ≤1.25 5 100 
50d 0.08 ± 
0.02 
0.19 ± 0.07 ≤1.25 10 8 
52 0.23 ± 
0.03 
0.30 ± 0.04 ≤1.25 5 
10 
100 
23 
53 0.71 ± 
0.08 
2.27 ± 0.03 ≤1.25 5-10 71 
 
Inhibitor potency (IC50) against purified Eis (Tables 3.1 and 3.2, Figure 3.4-3.10) was 
determined for a total of 46 compounds. Examination of the activity of this series of 
derivatives of the 1,2,4-triazino[5,6b]indole-3-thioether scaffold (Tables 3.1 and 3.2, Figure 
3.2), revealed several SAR insights. Overall, our chemical library can be divided into four 
chemical series (I, II, III, and IV; Figure 3.2). Series I contains the 1,2,4-triazino[5,6b]indole-
3-thioether core with a hydrogen atom at the C8-position, while series II and III contain a 
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fluoro and a methyl substituent at this position, respectively. In series IV, we replaced the 
thioether at the C3-position of the core by secondary amines in an effort to understand the 
biological importance of a sulfur atom at this position. 
 
Table 3.2. IC50 values and MIC values of tested compounds. 
Cp
d 
Stat
us 
IC50,KAN 
(µM) 
IC50,NEO 
(µM) 
H37Rv 
MICKAN 
(µg/mL) 
K204 
MICKAN 
(µg/mL) 
Concentr
ation 
tested 
(µM) 
-    ≤1.25 >10  
1b x      
2c x      
2e x      
3e x      
4a x      
5a x      
5b x      
5c x      
6a x      
7a x      
8a x      
9a  √√
x 
 5.8 ± 0.8 ≤1.25 5 100 
10k √√x  28 ± 4 ≤1.25 10 100 
11a x      
11b √√x 0.23 ± 
0.02 
0.64 ± 
0.15 
≤1.25 5 23 
11c √√x 0.27 ± 
0.05 
1.1 ± 0.2 ≤1.25 5-10 27 
11d √√x  2.4 ± 0.5 ≤1.25 10 100 
11e √√x  4.4 ± 0.4 ≤1.25 5-10 100 
12d x      
12e x      
12j x      
13b x      
14a √√x 1.5 ± 0.1 5.3 ± 1.0 ≤1.25 5 100 
15a x      
16a √√x  3.9 ± 0.9 ≤1.25 10 100 
17b x      
17c x      
17e x      
 100 
18a x      
19a x      
20a x      
20b x      
20i x      
20j x      
21d x      
21e x      
22a x      
22b x      
22c x      
23a xx--  >200    
23c xx--  >200    
24a --x--  >200    
25a √√x  13 ± 2 ≤1.25 10 100 
26a x      
27a x      
28a x      
29a x      
30b --x--  >200    
31a --x--  >200    
32b Sx-- >200     
33b Sx-- >200     
34b S√√  0.056 ± 
0.006 
-- ≤1.25 5 
5 
100 
5.6 
35b Sxx >200     
36b S√√  0.43 ± 
0.04 
0.26 ± 
0.07 
≤1.25 5-2.5 43 
37b √√√  
S√√  
0.13 ± 
0.03 
0.17 ± 
0.04 
0.047 ± 
0.003 
0.39 ± 
0.14 
≤1.25 2.5 
2.5 
13 
17 
37c x      
37d √√x 0.8 ± 0.1 0.21 ± 
0.03 
≤1.25 5 80 
37g √√x 0.43 ± 
0.06 
0.5 ± 0.1 ≤1.25 5-10 43 
37h S√-- 1.3 ± 0.1     
37i √√x 0.56 ± 
0.03 
1.7 ± 0.5 ≤1.25 10 56 
38b S√x 0.07 ± 
0.01 
0.13 ± 
0.04 
≤1.25-2.5 5-10 7 
39b √√√  
S√√  
0.13 ± 
0.03 
0.030 ± 
0.005 
0.6 ± 0.1 
0.15  ± 
0.02 
≤1.25 2.5-5 
 
13 
Ins 
 101 
39c √√x 0.14 ± 
0.01 
0.18 ± 
0.02 
≤1.25 5 14 
39i √√x 0.05 ± 
0.02 
0.30 ± 
0.14 
≤1.25 ≥10 5 
40b √x--  >200    
40c x      
40d x      
41d --x--  >200    
42b Sxx >200     
43b S√-- 0.10 ± 
0.02 
0.25 ± 
0.03 
  Ins 
43d S√x 1.1 ± 0.2  ≤1.25 2.5-5 
10 
100 
10 
44b S√x 3.3 ± 0.7  ≤1.25 >10 100 
45b S√x 0.17 ± 
0.03 
 ≤1.25-2.5 5-10 17 
46b S√-- 0.14 ± 
0.04 
   Ins 
47b Sx-- >200     
48b S√-- 0.17 ± 
0.04 
0.51 ± 
0.03 
  Ins 
48c S√-- 0.6 ± 0.1    -- 
48d S√x 0.15 ± 
0.02 
 ≤1.25-2.5 5-10 15 
48f S√-- 1.2 ± 0.2  1.25 10 100 
48h S√-- 0.54 ± 
0.13 
    
49b S√x 1.0 ± 0.1  ≤1.25 5 100 
50d √√x 0.08 ± 
0.02 
0.19 ± 
0.07 
≤1.25 10 8 
51d x      
52 S√x 0.23 ± 
0.03 
0.30 ± 
0.04 
≤1.25 5 
10 
100 
23 
53 S√x 0.71 ± 
0.08 
2.27 ± 
0.03 
≤1.25 5-10 71 
Symbol legend: 
x Indicates that the compound did not inhibit purified Eis enzyme in 
the initial HTS. 
xx-
- 
Indicates that the compound did not inhibit purified Eis enzyme in 
the initial HTS, but the compound was purchased as a control and 
displayed an IC50 value >200 µM and was not further pursued for 
determination of MIC values in Mtb H37Rv and Mtb K204. 
--x-
- 
Indicates that we purchased this compound, not initially in the HTS, 
which displayed an IC50 value >200 µM and was not further pursued 
for determination of MIC values in Mtb H37Rv and Mtb K204. 
√√ Indicates that we purchased this compound, which was found to be a 
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x good inhibitor of the purified Eis enzyme, but when tested in Mtb 
K204 was found to not restore the activity of KAN. 
Sx-- Indicates that we synthesized this compound, which displayed 
an IC50 value >200 µM and was not further pursued for determination 
of MIC values in Mtb H37Rv and Mtb K204. 
S√
x 
Indicates that we synthesized this compound, which was found to be 
a good inhibitor of the purified Eis enzyme, but when tested in Mtb 
K204 was found to not restore the activity of KAN. 
√√
√  
Indicates that we purchased this compound, which was found to be a 
good inhibitor of the purified Eis enzyme, and when tested in Mtb 
K204 was found to restore the activity of KAN. 
S√
√  
Indicates that we synthesized this compound, which was found to be 
a good inhibitor of the purified Eis enzyme, and when tested in Mtb 
K204 was found to restore the activity of KAN. 
 
 
 
Figure 3.4. IC50 curves for purchased compounds A. 9a, B. 10k, C. 11b, D. 11c, E. 11d, F. 
11e, G. 14a, H. 16a, and I. 25a against Eis by using NEO as the substrate. 
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Figure 3.5. IC50 curves for purchased compounds A. 37b, B. 37d, C. 37g, D. 37i, E. 39b, and 
F. 39c against Eis by using NEO as the substrate. 
 
 
Figure 3.6. IC50 curves for purchased compounds A. 39i and B. 50d, against Eis by using 
NEO as the substrate. Insets show the double reciprocal plots for the fitted Ki values. 
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Figure 3.7. IC50 curves for purchased compounds that displayed an IC50 value ≥1 µM with 
NEO. A. 11b, B. 11c, C. 14a, D. 37b, E. 37d, F. 37g, G. 37i, H. 39b, I. 39c, J. 39i, and K. 
50d against Eis by using KAN as the substrate. 
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Figure 3.8. IC50 curves for synthesized compounds A. 36b, B. 37b, C. 38b, D. 39b, E. 43b, F. 
48b, G. 52, and H. 53 against Eis by using NEO as the substrate. 
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Figure 3.9. IC50 curves for synthesized compounds A. 34b, B. 36b, C. 37b, D. 37h, E. 38b, F. 
39b, G. 43b, H. 43d, and I. 45b against Eis by using KAN as the substrate. 
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Figure 3.10. IC50 curves for synthesized compounds J. 46b, K. 48b, L. 48c, M. 48d, N. 48f, 
O. 48h, P. 49b, Q. 52, and R. 53 against Eis by using KAN as the substrate. 
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(piperidin-1-yl)ethyl; IC50,KAN = 0.27 ± 0.05 µM) and its C8-fluorinated counterpart 39c from 
series II (IC50,KAN = 0.14 ± 0.01 µM) displayed a similar trend, with the fluoro-substituted 
compound 39c being about twice as potent. These observations suggested that adding a 
fluorine atom at the C8-position increased the potency of Eis inhibition. We concluded that 
the strong electronegativity of the fluorine atom may play a critical role in inhibition. Next, 
we explored the effect of replacing the C8-hydrogen of series I or the C8-fluoro of series II by 
a methyl group (series III). Compounds 48d (series III, X = methyl, R1 = n-propyl, and R2 = 
2-(N,N-diethylamino)ethyl; IC50,KAN = 0.15 ± 0.02 µM) and its R1 = N5-i-pentyl counterpart 
48h (IC50,KAN = 0.54 ± 0.13 µM) both with a methyl at their C8-position, were slightly more 
potent than their direct respective counterparts with a fluorine at the C8-position, 37d 
(IC50,KAN = 0.8 ± 0.1 µM) and 37h (IC50,KAN = 1.3 ± 0.1 µM). On the other hand, in the case of 
compounds 37b (series II, X = F, R1 = methyl, R2 = 2-(N,N-diethylamino)ethyl; IC50,KAN = 
0.13 ± 0.03 µM) and its C8-methylated counterpart 48b (IC50,KAN = 0.17 ± 0.04 µM) from 
series III, the IC50,KAN values were virtually the same. Overall, we observed that compounds 
with a methyl substituent at their C8-position displayed the same or more potent activity when 
compared to those with a fluoro substituent, which in turn were more potent than the C8-
unsubstituted compounds. 
 
Having analyzed the effect of three substituents at the C8-position of the 1,2,4-
triazino[5,6b]indole-3-thioether scaffold, we next explored the effect of modifying the N5-
position with eleven different chemical moieties (indicated by the letters a-k following the 
compound numbers in Figure 3.2). We varied the diversity at N5 by not substituting the amine 
(a) or by introducing various linear alkyl chains (b-e and g), branched alkyl chains (f and h), 
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alkylaryl groups (i and j), and an amido group (k). To establish the favorable N5-substituents, 
as we did during our analysis of the C8-substituent, we compared pairs of compounds that 
only differed in their N5-substitutent. We first looked at the N5-unsubstituted compound 11a 
(Table 3.2, series I, X = H, R1 = H, and R2 = 2-(piperidin-1-yl)ethyl), which was found to not 
be an inhibitor in our HTS. We next investigated the effect of adding linear alkyl chains at the 
N5-position. For compounds 11b-d, systematically increasing the size of the R1 substituent 
from methyl (b) to ethyl (c) and n-propyl (d) led to 2-fold incremental decrease in Eis 
inhibitory activity (IC50,NEO = 0.64 ± 0.15 µM, 1.1 ± 0.2 µM, and 2.4 ± 0.5 µM, respectively). 
This relationship between the size of R1 and Eis inhibitory activity did not perfectly translate 
to compounds 37b-d (X = F, R2 = 2-(N,N-diethylamino)ethyl), 39b-c (X = F, R2 = 2-
(piperidin-1-yl)ethyl), or 48b-d (X = Me, R2 = 2-(N,N-diethylamino)ethyl). However, we 
noticed by looking at IC50,KAN values that, generally, a methyl group (R1 = b) at the N5-
position of most compounds resulted in the best inhibitors as demonstrated with compounds 
11b, 37b, 39b, 43b, and 48b. When examining the effect of branched alkyl chains (f and h) at 
the N5-position, we observed that these moieties typically decreased or abolished inhibition of 
Eis. For the alkylaryl (i and j) and amido (k) functionalities, a concrete conclusion could not 
be drawn from our data due to a small sample size. Overall, we found that the methyl 
substituent (R1 = b) was the most favored out of all N5-modifications tested. 
 
Next, we studied the effect of modifications at the C3-position of the 1,2,4-
triazino[5,6b]indole-3-thioether scaffold. Compared to the substituents at the C8- and N5-
positions, the groups added at the C3-position contained the highest diversity as a result of 
various heteroatoms in their structures. Examination of compounds 1-6, 41d, and 42b led us 
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to conclude that any C3-side chain containing only carbon and hydrogen atoms (e.g., aromatic, 
unsaturated, or aliphatic chains) resulted in compounds with no Eis inhibitory activity. 
Likewise, substituents at the C3-position containing oxygen atoms (e.g., carbonyl (compounds 
13 and 17-30), hydroxyl (compound 32b), ether (compounds 8a and 33b), morpholine 
(compounds 12d, 12e, 12j, 15a, 40b, 40c, 40d, and 51d)) or a cyano group (compounds 31a 
and 47b) were not tolerated. However, we observed that, with the exception of the morpholino 
and cyano groups, C3-side chains containing a tertiary non-aromatic nitrogen atom located 2-
3 carbons away from the sulfur atom yielded potent Eis inhibitors (Figure 3.2). We then 
closely examined the (i) spatial and (ii) steric effects of these tertiary amines on Eis inhibition. 
For spatial effects, through comparisons of pairs of compounds that differ by a 2- versus 3-
carbon linker, such as compounds 11a and 14a, 36b and 43b, as well as 39b and 45b, we 
found that, with the exception of 11a, the length of the linker did not greatly influence the IC50 
values against purified Eis. To evaluate the steric effects on Eis inhibition, compounds 36b 
(R2 = 2-(N,N-dimethylamino)ethyl; IC50,KAN = 0.43 ± 0.04 µM), 37b (R2 = 2-(N,N-
diethylamino)ethyl; IC50,KAN = 0.17 ± 0.04 µM), 38b (R2 = 2-(pyrrol-1-yl)ethyl; IC50,KAN = 
0.07 ± 0.01 µM), and 39b (R2 = 2-(piperidin-1-yl)ethyl; IC50,KAN = 0.030 ± 0.005 µM) were 
assessed. In these instances, we recognized that increasing the number of carbons attached to 
the nitrogen atom from the dimethyl- to the diethylamino functionality correlated with 
increased Eis inhibitory activity as evidenced by comparison of 36b and 37b. Further 
cyclization of the diethylamino to the pyrrolyl moiety led to more potent Eis inhibitors as seen 
when comparing 37b and 38b. Expectedly, this observation was also consistent when 
comparing the diethylamino-containing analogue 48d (IC50,KAN = 0.15 ± 0.02 µM) with the 
piperidinyl-containing inhibitor 50d (IC50,KAN = 0.08 ± 0.02 µM). Size expansion of the 
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pyrrolyl ring in 38b (IC50,KAN = 0.07 ± 0.01 µM) to the piperidinyl ring in 39b (IC50,KAN = 
0.030 ± 0.005 µM) additionally suggested that the larger six-membered heterocycle occupied 
the chemical space more efficiently, which resulted in an improved inhibitor (2-fold 
improvement). Comparison of compounds 43b (IC50,KAN = 0.10 ± 0.02 µM) and 44b (IC50,KAN 
= 3.3 ± 0.7 µM) showed that the chemical space around the tertiary amino group has a limit, 
and the addition of the phenyl group was not well-tolerated. The rigidity of the tertiary amine 
was explored by assessing compounds 34b (IC50,KAN = 0.056 ± 0.006 µM), 43b (IC50,KAN = 
0.10 ± 0.02 µM), and 45b (IC50,KAN = 0.17 ± 0.03 µM). We observed that additional rigidity in 
the side chain as in 43b led to improved Eis inhibitory activity compared to 43b and 45b. 
Further substitution of the piperidinyl group of 45b (IC50,KAN = 0.17 ± 0.03 µM), as in 46b 
(IC50,KAN = 0.14 ± 0.04 µM), was well tolerated. Overall, our study of the R2 side chains 
demonstrated that side chains containing tertiary amino groups were favorable for Eis 
inhibition. We suspected that this phenomenon was the result of these tertiary amino groups 
possessing positive charges, which mimicked the positively charged nature of the AG 
substrates. Additionally, we found that tertiary amines with higher degree of bulkiness and 
rigidity were typically more potent Eis inhibitors. 
 
Finally, we explored the importance of the thioether at C3 (series II) by replacing it with an 
amine (series IV). When comparing series IV compounds 52 (IC50,KAN = 0.23 ± 0.03 µM) and 
53 (IC50,KAN = 0.71 ± 0.08 µM) to their counterparts from series II 37b (IC50,KAN = 0.17 ± 0.04 
µM) and 43b (IC50,KAN = 0.10 ± 0.02 µM), respectively, we found that the thioether afforded 
compounds with slightly better (1.4 to 7.1-fold) Eis inhibitory activity. 
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3.3.3. Inhibition kinetics 
Once we completed the analysis of the IC50 measurements, we aimed to understand the 
mechanism by which these Eis inhibitors function. For this analysis, we selected seven 
inhibitors, all with an IC50 <1 µM when using NEO as the substrate. Data analysis of kinetics 
as a function of the concentrations of the inhibitors and the substrate indicated that the 
inhibitors are competitive with NEO and yielded the inhibition constants (Ki, Table 3.3) for 
compounds 36b, 37b, 37d, 37g, 39b, 39c, 39i, and 50d. Representative plots for 39i and 50d 
as insets in the IC50 curves are presented in Figure 3.7. All compounds, with the exception of 
39i, showed a Ki <1 µM. From this data, the best inhibitor is 37b, followed by 39b, 39c, 37g, 
36b, 37d = 50d, and 39i. Interestingly, based on the IC50 values 39i is the best followed by 
50d, 39b, 37b = 36b, 39c, 37g, and 37d. These observations indicate that the most effective 
Eis inhibitors (lowest IC50 values) may not bind the tightest to the enzyme (lowest Ki values). 
 
Table 3.3. Ki values determined using regression 
analysis for Eis inhibitors displaying an IC50 value <1 
mM using NEO as the substrate. 
Compound Ki (µM) 
36b 0.6 ± 0.2 
37b 0.08 ± 0.01 
37d 0.82 ± 0.48 
37g 0.45 ± 0.05 
39b 0.16 ± 0.03 
39c 0.32 ± 0.13 
39i 1.4 ± 0.3 
50d 0.89 ± 0.23 
 
3.3.4. Selectivity of inhibitors towards Eis over other AACs 
Mtb contains another AAC chromosomally encoded in its genome, AAC(2')-Ic.83 To 
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determine the selectivity of the 1,2,4-triazino[5,6b]indole-3-thioether-based Eis inhibitors 
towards Eis, we also tested the potential ability of these compounds to inhibit other AACs. 
Previously, only one Eis inhibitor, from a completely unrelated scaffold, displayed inhibitory 
activity against AAC(2')-Ic.108 Compounds 36b and 37b were tested for inhibitory activity 
with AAC(2')-Ic, AAC(3)-IV from E. coli,138-139 and AAC(6')-Ie from S. aureus.140 No 
inhibition of these three AACs was observed with these two compounds at concentrations up 
to 200 µM, indicating that the compounds presented here are highly selective to Eis. 
 
3.3.5. Effect of inhibitors on KAN MIC for M. tuberculosis 
To determine if the identified Eis inhibitors could restore the activity of KAN in KAN-
resistant Mtb, the MIC of KAN (MICKAN) was determined in KAN-sensitive Mtb H37Rv and 
KAN-resistant Mtb strain K204 for all compounds displaying Eis inhibition (<28 µM). Mtb 
K204 is genetically identical to H37Rv with the exception of one clinically important eis 
promoter mutation upregulating Eis expression resulting in resistance to KAN;84 therefore, 
Mtb K204 is also an excellent tool for validation of Eis inhibition as a mode of action of these 
compounds. Inhibitors were tested at concentrations of 100-fold of their respective IC50,KAN or 
at 100 µM when 100× IC50 was unknown or unachievably high. As expected, the Eis 
inhibitors did not affect the MICKAN in the KAN-sensitive Mtb H37Rv strain. Four 
compounds (36b, 37b, 39b, and 43d) lowered the MICKAN value for K204 from >10 µg/mL in 
the absence of inhibitors to 2.5-5 µg/mL. Interestingly, compound 43d, while not the most 
potent Eis inhibitor when tested against the purified Eis, reduced the MICKAN for Mtb K204 to 
2.5-5 µg/mL. Conversely, two of the most potent inhibitors, 38b and 39i, did not efficiently 
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restore the activity of KAN in Mtb K204. Thus, while many Eis compounds aid in the 
restoration of KAN activity, there is not always a direct correlation between Eis inhibition and 
MICKAN. There may be off-target proteins that bind the compounds and possibly a portion 
gets caught up in the complex cell wall of Mtb, accounting for the large excess required to 
restore MICKAN. 
 
Several factors validate Eis inhibition as the likely mechanism of action of these molecules. 
Compounds increased the sensitivity of Mtb K204, but not H37Rv to KAN while not affecting 
Mtb viability in general. Furthermore, we performed MICKAN dose-dependence experiments 
with compounds 36b and 39b using a double-dilution protocol and a concentration range of 
Eis inhibitors of 0-32 µM (Table 3.4). We observed an inversely proportional relationship 
between the MICKAN for Mtb K204 and the concentration of compound implying increasing 
Eis inhibition as the concentration of compound increased. 
 
Table 3.4. MICKAN values for Mtb H37Rv and K204 
with varying concentrations of cpds 36b and 39b. 
 36b  39b  
Concentr
ation 
tested 
(µM) 
H37Rv 
MICKAN 
(µg/mL) 
K204 
MICKAN 
(µg/mL) 
H37Rv 
MICKAN 
(µg/mL) 
K204 
MICKAN 
(µg/mL) 
0 1.25, 2.5 20, 20 1.25, 2.5 20, 20 
0.5 1.25, 1.25 10, 20 1.25, 1.25 10, 20 
1 1.25, 1.25 10, 20 1.25, 1.25 10, 20 
2 1.25, 1.25 10, 20 0.625, 
1.25 
10, 10 
4 0.625, 
1.25 
10, 10 0.625, 
1.25 
5, 10 
8 0.625, 
1.25 
5, 5 0.625, 
1.25 
5, 5 
 115 
16 0.625, 
1.25 
5, 5 0.625, 
1.25 
5, 5 
32 0.625, 
1.25 
5, 5 0.625, 
1.25 
2.5, 2.5 
 
3.3.6. A crystal structure of Eis-CoA-inhibitor 39b complex confirms mechanism of 
inhibition 
To establish the structural basis for Eis inhibition by compounds with a 1,2,4-
triazino[5,6b]indole-3-thioether core, we determined the crystal structure of the enzyme in 
complex with CoA and one of the potent inhibitors, 39b (Figure 3.11). Compound 39b 
(Figure 3.11A,B) binds at a site that partially overlaps the site occupied by the AG tobramycin 
(TOB) as well as other Eis inhibitors in the literature (Figure 3.11C).86, 105-106, 141 This binding 
site supports the mode of action of inhibitor 39b as an AG competitive inhibitor. The crystal 
structure shows that the aromatic 1,2,4-triazino[5,6b]indole core of compound 39b is 
stabilized by interactions with two neighboring aromatic residues, Trp36 and Phe84 
(highlighted in orange) via sandwich π−π stacking interactions (Figure 3.11B). We have 
previously observed similar π−π interactions with Trp36 and Phe84 during studies with Eis 
inhibitors of other structural classes (inhibitors a, b, and c; Figure 3.11B,D-F). Additionally, 
the fluorine atom at the C8-position of the 1,2,4-triazino[5,6b]indole-3-thioether core projects 
towards a hydrophobic pocket and interacts with the Cγ of Arg37 (~3.3 Å away from the 
fluorine atom) and the Cδ atoms of Leu63 (~3.6 Å away from the fluorine atom) by 
hydrophobic interactions (Figure 3.11B). Hydrophobic interactions with Arg37 and Leu63 
were also seen with other Eis inhibitors (Figure 3.11B,D-F). 
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While sharing some interactions with other Eis inhibitor classes, this structural scaffold 
enabled us to explore a novel inhibitor-Eis interface. The unique tricyclic core of 39b allows 
the flexible C3-linker to extend towards a large opening in the AG-binding pocket, such that 
the piperidinyl group on the end of the linker comes into a hydrophobic contact with the 
aliphatic stem of Glu401. In this conformation, the linker and the piperidinyl group at the end 
are juxtaposed against the Asp26-Ser32 loop (Figure 3.11B,C). Interactions with Asp26-Ser32 
loop appear to be essential for Eis binding of this inhibitor class, because analogues 1b, 32b 
and 33b, which all have shorter C3 substituents, do not inhibit Eis. A water molecule located 
2.8 Å away from the N2-nitrogen of the tricyclic core could form a hydrogen bond with either 
the hydroxyl of Ser32 or the backbone carbonyl oxygen of Gly29. Furthermore, the sulfur 
atom of 39b is in a hydrophobic contact with the Cε of Ile28, and the linker makes extensive 
van der Waals contacts with the backbone of residues 26-28. Two carbons away from the 
sulfur, the nitrogen atom of the piperidinyl moiety bearing a positive charge at the 
physiological pH forms a salt bridge with the negatively charged carboxylate of Asp26 
(located 3.4 Å away). Even though none of the previous Eis inhibitor classes exploit 
interactions with the Asp26-Ser32 as extensively as this class, among the previously 
discovered inhibitor classes, inhibitor b interacts with this region by forming hydrogen bonds 
with the carboxyl group of Asp26 and the backbone N of Ile28 (Figure 3.11E). 
 
This crystal structure and the SAR will guide future rational fine-tuning of the inhibitors with 
this new scaffold. First, other C3 substitutions bearing a positive charge could favorably 
interact with another negatively charged residue (e.g., Glu401 or the terminal carboxyl group). 
These electrostatic interactions support our previous SAR observations that positively charged 
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tertiary amine functionalities such as those in compounds 37b or 36b are more tolerated 
compared to the neutral or partially negatively charged C3 substituents. In the R1 substitution 
of the tricyclic core, the carbon of the N5-methyl is in close proximity to the terminal 
carboxyl group of Eis (located 3.4 Å away) and the hydroxyl group of Ser83 (located 3.1 Å 
away), which explains why N5 alkylation with bulkier groups is not well tolerated. For 
instance, the IC50,NEO values for compounds 11b, 11c, and 11d increase almost 2 folds for 
every carbon atom added to the N5-alkyl chain. Additionally, there are a variety of ways to 
install different hydrogen bond donors at the N5 to take advantage of the polar protein C-
terminus and side chain of Ser83. In summary, the crystal structure of the Eis-CoA-inhibitor 
39b complex allowed us to compare and contrast the current class of inhibitors with previous 
inhibitors in the literature, explain some of the observed SAR trends, and gain insight into 
further optimization of this class of inhibitors. Even though these 1,2,4-triazino[5,6b]indole-3-
thioether-based inhibitors are competitive KAN inhibitors as are the other previously 
published Eis inhibitors, the new inhibitors interact extensively with an underexplored surface 
of the substrate binding cavity of Eis. This property may help combat resistance to other Eis 
inhibitor classes that could arise due to point mutations in other inhibitor interacting surfaces. 
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Figure 3.11. A. Crystal structure of one of the six monomers of the EisC204A-CoA-inhibitor 
39b (shown as yellow sticks in a box) complex. Note: For the sake of simplicity, the CoA is 
omitted in this figure, but is shown in panel C. B. Zoom-in view of the binding pocket of 
compound 39b. The strong omit Fo-Fc electron density map contoured at 3σ generated 
without compound 39b is shown by a magenta mesh. The amino acid residues interacting with 
compound 39b are depicted in dark turquoise. The conserved residues that interact with 39b 
and previously published Eis inhibitors are depicted as orange sticks. The Asp26-Ser32 loop 
is shown as dark turquoise sticks. The C-terminus is labeled as C-ter. A water molecule is 
shown as a green sphere. The distances between atoms of the inhibitor 39b and those of amino 
acid residues of the Eis protein are shown by a dark blue dashed line and are in Å. For 
compound 39b, the carbon, oxygen, nitrogen, fluorine, and sulfur atoms are colored pale 
green, red, blue, dark green, and orange, respectively. C. Compound 39b is overlapped with 
previously published Eis inhibitors. The previously published structure of bound tobramycin 
(TOB) (PDB ID 4JD686) is in blue. Bound CoA is depicted as red sticks. D. Inhibitor “a”, a 
pyrrolo[1,5-a]pyrazine-based Eis inhibitor (labeled 2k* in ref 141, PDB ID 5TVJ), is depicted 
as green sticks. E. Inhibitor “b”, a sulfonamide-based inhibitor (labeled 39 in ref 106, PDB ID 
5IV0), is depicted as gray sticks. F. Inhibitor “c”, an isothiazole S,S-dioxide heterocyclic core 
(labeled 11c in ref 105, PDB ID 5EBV) is depicted as purple sticks. Note: In panels D-F, amino 
acid residues that interact specifically with the inhibitors presented are depicted in lilac. G. 
The chemical structures of TOB as well as inhibitors 39b and “a-c”. 
 
 
 
 120 
3.3.7. Mammalian cytotoxicity of Eis inhibitors 
The ability of some molecules bearing the 1,2,4-triazino[5,6b]indole-3-thioether scaffold to 
restore the activity of KAN in Mtb K204 is highly encouraging. However, to understand the 
utility of these compounds as potential therapeutic agents, the mammalian cell cytotoxicity 
needed to be examined. Four of the best compounds (34b, 37b, 39b, and 43d) were tested 
against three mammalian cell lines (A549 (lung), HEK-293 (kidney), and J774A.1 
(macrophage)) alone and in the presence of KAN (50 µg/mL = 86 µM). Compounds were 
evaluated for mammalian cytotoxicity at concentrations ranging from 0 to 100 µM. Cells 
displayed 100% survival rate from 0 to 12.5 µM; therefore, we showed the cytotoxicity data 
only in the range from 12.5 to 100 µM (Figure 3.12). The negative and positive controls used 
for these experiments were 0.5% DMSO (100% cell survival) and 1% v/v Triton-X 100® in 
0.5% DMSO (>5% cell survival), respectively. Overall, we found that the compounds did not 
display significant toxicity until concentrations of 50 µM with and without KAN (Figure 
3.13). Because compounds 34b, 37b and 39b sensitize KAN-resistant Mtb cells to KAN when 
used at concentrations between 5.6 to 17 µM, where they are not cytotoxic, these molecules 
are good candidates for further development into therapeutically useful KAN adjuvants for 
treatment of KAN-resistant Mtb. 
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Figure 3.12. Mammalian cytotoxicity of selected compounds (34b, 37b, 39b, and 43d) alone 
(depicted as dark color columns) or in the presence of 50 µg/mL (86 µM) KAN (depicted as 
light color column directly to the right of the dark color column for the compound alone) 
against A. A549, B. HEK-293, and C. J774A.1 cells. Note: No cytotoxicity was observed 
from 0-12.5 µM. 
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Figure 3.13. Mammalian cell cytotoxicity of KAN in a concentration range of 2.0-500 µM 
against A. A549, B. HEK-293, and C. J774A.1 cell lines showing that KAN is not toxic at 
least up to 500 µM. 
 
3.4. CONCLUSION 
In summary, by chemical, biochemical, biological, and structural studies, we discovered, 
optimized, and extensively characterized Eis inhibitors with the 1,2,4-triazinyl-indole scaffold. 
This scaffold enables inhibitor interactions with a previously underexploited region of the Eis 
active site. These compounds act as KAN adjuvants against KAN-resistant Mtb. This study 
lays the groundwork for the further optimization of these compounds for clinical applications. 
 
3.5. MATERIALS AND INSTRUMENTATION 
3.5.1. Materials and instrumentation for chemistry experiments 
All chemicals were bought from Sigma-Aldrich (St. Louis, MO, USA) and AK Scientific 
(Union City, CA, USA) and used without further purification. Deuterated solvents were 
obtained from Cambridge Isotope Laboratories Inc. (Tewksbury, MA, USA). TLC (Merck, 
Silica gel 60 F250) was used to monitor reaction progress. Silica gel (SiO2, Dynamic 
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Adsorbents Inc. Flash silica gel 32-63u) was used to perform flash column chromatography. 
Visualization of reaction progress was achieved using one or more of the following methods: 
UV absorption and a cerium-molybdate stain ((NH4)2Ce(NO3)6 (5 g), (NH4)6Mo7O24•4H4O 
(120 g), H2SO4 (80 mL), and H2O (720 mL)). NMR spectra were measured in δ (ppm) using 
the 1H NMR CDCl3 (δ 7.24 ppm), 13C NMR CDCl3 (δ 77.23 ppm), 1H NMR (CD3)2SO (δ 
2.50 ppm), and 13C NMR (CD3)2SO (δ 39.51 ppm) as internal standards. Abbreviations used: 
J = coupling constants in Hz, app. = apparent, br = broad, d = doublet, dd = doublet of 
doublets, dt = doublet of triplets, m = multiplet, p = pentet, q = quartet, s = singlet, t = triplet, 
td = triplet of doublets. 1H NMR and 13C NMR spectra were recorded on a Varian 400 MHz 
instrument (Palo Alto, CA, USA). Low-resolution electrospray mass spectra (LRMS) were 
recorded on a liquid chromatography-mass spectrometry using an Agilent 1200 series 
Quaternary LC system (Santa Clara, CA, USA) equipped with a diode array detector, and 
Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 µm), and an Agilent 6120 Quadrupole MSD 
mass spectrometer. Further confirmation of purity for these final molecules was obtained by 
reversed-phase high-performance liquid chromatography (HPLC), which was performed on 
an Agilent Technologies 1260 Infinity HPLC system (Santa Clara, CA, USA), by using the 
following general method 1: Flow rate = 1 mL/min; λ = 254 nm; column = Vydac 201SPTM 
C18, 250 × 4.6 mm, 90A 5 µm; Eluents: A = H2O + 0.1% TFA, B = MeCN; gradient profile: 
starting from 5% B, increasing from 5% B to 100% B over 20 min, holding at 100% B from 
20-27 min, decreasing from 100% B to 5% B from 27-30 min. Prior to each injection, the 
HPLC column was equilibrated for 15 min with 5% B. All compounds were ≥95% pure. All 
reactions were conducted under nitrogen atmosphere, unless otherwise specified. All yields 
reported refer to isolated yields. 
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3.5.2. Materials and instrumentation for biochemistry and biology experiments 
UV-Vis assays were performed using a multimode SpectraMax M5 plate reader from 
Molecular Devices (Sunnyvale, CA) and 96-well plates from Fisher Scientific (Hampton, NH, 
USA). Reagents for Eis inhibition assays such as 5',5-dithiobis-(2-nitrobenzoic acid) DTNB, 
Tween® 80, neomycin B (NEO), kanamycin A (KAN), acetyl-CoA (AcCoA), and 
chlorhexidine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Albumin-dextrose-
catalase (ADC) was purchased from BD Biosciences (San Jose, CA, USA). Eis was screened 
at the Center for Chemical Genomics (CCG, University of Michigan) against ~23,000 
compounds from a ChemDiv library (~20,000), a BioFocus NCC library (~1,000 compounds), 
and a MicroSource MS2000 library(~2,000 compounds). Stock compounds for HTS were 
dissolved in DMSO. The human embryonic kidney cell line HEK-293 (ATCC CRL-1573) 
was purchased from ATCC (Manassas, VA, USA). The human lung carcinoma epithelial cell 
line A549 (ATCC CCL-185) and the murine macrophage cell line J774A.1 (ATCC TIB-67) 
were kindly provided by Dr. David K. Orren and Dr. David J. Feola (University of Kentucky, 
Lexington, KY, USA), respectively. The A549 and HEK-293 cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (ATCC, Manassas, VA, USA) with 10% fetal bovine 
serum (FBS) (ATCC, Manassas, VA, USA) and 1% penicillin/streptomycin (ATCC, 
Manassas, VA, USA) at 37 °C with 5% CO2. The J774A.1 cell line was grown under the same 
conditions, except that the medium used was a different type of DMEM (catalog # 30-2002, 
ATCC, Manassas, VA, USA). The A549 and HEK-293 cell lines were dislodged from the 
tissue culture Petri dish by trypsinization with 0.05%-trypsin-0.53 mM EDTA (ATCC, 
Manassas, VA, USA) for subculturing. The J774A.1 cell line was dislodged from the tissue 
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culture Petri dish by mechanical scraping for subculturing. The cells’ confluence was 
observed by using a Nikon Eclipse TS100 microscope (Minato, Tokyo, Japan). Resazurin was 
purchased from Sigma Aldrich (Milwaukee, WI, USA). Fluorescence of the resazurin product, 
resorufin, was detected with a SpectraMax M5 plate reader. 
 
3.6. METHODS 
3.6.1. Chemical methods 
3.6.1.1. General procedure A for the preparation of the N-alkylisatin compounds 56b, 
56d, 56h, 57b, 57c, 57d, 57f, and 57h 
5-Fluoroisatin (54) (2.5 g, 15.2 mmol) or 5-methylisatin (55) (2.45 g, 15.2 mmol), and cesium 
carbonate (5 g, 15.5 mmol) were added to MeCN (100 mL). The reaction mixture was stirred 
at 30 min at rt, and then an alkyl halide (30 mmol) was added dropwise over a period of 1-2 h. 
After complete addition of the alkyl halide, the reaction mixture was stirred at rt for an 
additional 5-24 h. Upon completion of the reaction (as determined by monitoring by TLC) the 
solvent was removed under reduced pressure and the solid residue was dissolved in EtOAc 
(100 mL) and washed with H2O (100 mL). The organic layer was washed with 1 M NH4Cl 
(10 mL,), dried over anhydrous MgSO4, and evaporated to afford the desired products. The 
syntheses of 5-fluoro-N-methylisatin (56b),142 5-fluoro-N-propylisatin (56d),143 5-methyl-N-
ethylisatin (57c),144 5-methyl-N-n-propylisatin (57d),145 5-methyl-N-isopropylisatin (57f)146 
have been previously reported. Compounds from groups 56 and 57 were used directly in the 
next step of the synthesis without any further purification. Confirmation of the identity of 
these intermediates (56b, 56d, 56h, 57b, 57c, 57d, 57f, and 57h) was accomplished by 1H 
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NMR spectroscopy for known compounds and by 1H NMR and 13C NMR, as well as mass 
spectrometry for compounds 56h, 57b, and 57h. 
 
Preparation of 5-fluoro-N-methylisatin (56b). The known compound 56b 
was prepared by using general procedure A with methyl iodide (4.3 g, 30 
mmol). Red solid (2.7 g, quantitative); Rf 0.10 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, 
CDCl3, which matches the lit.142) δ 7.34-7.26 (m, 2H), 6.84 (dd, J1 = 8.0 Hz, J2 = 3.2 Hz, 1H), 
3.23 (s, 3H). 
 
Preparation of 5-fluoro-N-propylisatin (56d). The known compound 56d was 
prepared by using general procedure A with propyl bromide (3.7 g, 30 mmol). 
Red solid (3.1 g, quantitative); Rf 0.20 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, CDCl3, 
which matches the lit.143) δ 7.30-7.26 (m, 2H), 6.84 (dd, J1 = 7.6 Hz, J2 = 3.2 Hz, 1H), 3.67 (t, 
J = 7.2 Hz, 2H), 1.71 (sextet, J = 7.2 Hz, 2H), 0.98 (t, J = 7.2 Hz, 3H). 
 
Preparation of 5-fluoro-N-isopentylisatin (56h). Compound 56h was 
prepared by using general procedure A with 1-bromo-3-methyl butane (4.5 g, 
30 mmol). Red solid (3.6 g, quantitative); Rf 0.41 (Hexanes:EtOAc/4:1); 1H 
NMR (400 MHz, CDCl3) δ 7.31-7.4 (m, 2H), 6.83 (dd, J1 = 8.0 Hz, J2 = 3.6 Hz, 1H), 3.69 (t, J 
= 7.6 Hz, 2H), 1.63 (nonet, J = 6.4 Hz, 1H), 1.53 (q, J = 7.2 Hz, 2H), 0.95 (d, J = 6.8 Hz, 6H); 
13C NMR (100 MHz, CDCl3) δ 183.3, 160.6, 158.2, 158.0, 147.2, 124.9, 124.7, 118.5, 118.4, 
N
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112.8, 112.6, 111.5, 111.4, 38.9, 35.9, 26.2, 22.6; LRMS m/z calcd for C13H14FNO2: 235.1; 
found 236.1 [M+H]+. 
 
Preparation of 5-methyl-N-methylisatin (57b). Compound 57b was prepared 
by using general procedure A with methyl iodide (4.3 g, 30 mmol). Red solid 
(2.7 g, quantitative); Rf 0.10 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 
1H), 7.38 (d, J = 6.8 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 3.21 (s, 3H), 2.32 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 183.6, 158.3, 149.3, 138.7, 133.6, 125.6, 117.5, 109.7, 26.2, 20.6; 
LRMS m/z calcd for C10H9NO2: 175.1; found 176.0 [M+H]+. 
 
Preparation of 5-methyl-N-ethylisatin (57c). The known compound 57c was 
prepared by using general procedure A with ethyl bromide (3.3 g, 30 mmol). 
Red solid (2.9 g, quantitative); Rf 0.16 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, CDCl3, 
which matches the lit.144) δ 7.39 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 8.0 Hz, 1H), 
3.74 (q, J = 7.2 Hz, 2H), 2.31 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H). 
 
Preparation of 5-methyl-N-propylisatin (57d). The known compound 57d 
was prepared by using general procedure A with propyl bromide (3.7 g, 30 
mmol). Red solid (3.1 g, quantitative); Rf 0.28 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, 
CDCl3, which matches the lit.145) δ 7.38 (s, 1H), 7.36 (d, J = 7.6 Hz, 1H), 6.77 (d, J = 7.6 Hz, 
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1H), 3.64 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.70 (sextet, J = 7.6 Hz, 2H), 0.96 (t, J = 7.6 Hz, 
3H). 
 
Preparation of 5-methyl-N-isopropylisatin (57f). Compound 57f was 
prepared by using general procedure A with isopropyl bromide (3.7 g, 30 mmol). 
Red solid (3.1 g, quantitative); Rf 0.25 (Hexanes:EtOAc/4:1); 1H NMR (400 MHz, CDCl3, 
which matches the lit.146) δ 7.40 (s, 1H), 7.33 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 
4.50 (septet, J = 6.8 Hz, 1H), 2.30 (s, 3H), 1.48 (d, J = 6.8 Hz, 6H). 
 
Preparation of 5-methyl-N-isopentylisatin (57h). Compound 57h was 
prepared by using general procedure A with 1-bromo-3-methyl butane (4.5 g, 
30 mmol). Red solid (3.5 g, quantitative); Rf 0.38 (Hexanes:EtOAc/4:1); 1H 
NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 7.6 Hz, 1H), 
3.68 (t, J = 7.6 Hz, 2H), 2.31 (s, 3H), 1.64 (nonet, J = 6.8 Hz, 1H), 1.55 (q, J = 6.8 Hz, 2H), 
0.96 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 184.1, 158.3, 148.9, 138.8, 133.6, 
125.9, 117.8, 110.1, 38.8, 36.0, 26.1, 22.6, 20.8; LRMS m/z calcd for C14H17NO2: 231.1; 
found 232.1 [M+H]+. 
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3.6.1.2. General procedure B for the preparation of compounds 58b, 58d, 58h, 59b, 59c, 
59d, 59f, and 59h 
N-Alkylisatin (1 eq.), thiosemicarbazide (1.2 eq.), and K2CO3 (1.2 eq.) were added to dH2O 
(50-250 mL) for compounds 58b, 58d, 58h, and 59b. The same protocol was used for 
compounds 59c, 59d, 59f, and 59h, but the base was changed to Cs2CO3 (1.2 eq.) and the 
solvent was changed to 30% aq. 1,4-dioxane (5-10 mL) to assist in solubilizing the isatin 
starting materials. The reaction mixture was stirred at 100 °C for 12-24 h. After cooling to rt, 
the solid by-products were filtered-off and the filtrate was acidified with conc. HCl to a pH of 
1.5-2.5. The precipitated solid was collected by filtration, washed with copious amount of 
dH2O and dried under vacuum. If no purification methods specified, it indicates that the dried 
solid was used directly in the next step of the synthesis without any further purification. Note: 
In some instances (e.g., compounds 58b, 58d, 58h, 59b, and 59f) the cyclized version of the 
product was obtained, whereas in others, the uncyclized version of the product (e.g., 59c, 59d, 
and 59h) was obtained. It is important to note that both the cyclized and uncyclized versions 
for the products can be used in the next synthetic step to generate the desired products. 
 
Preparation of 8-fluoro-2,5-dihydro-5-methyl-3H-1,2,4-triazino[5,6-
b]indole-3-thione (58b). Compound 58b was prepared by using general 
procedure B with compound 56b (2.0 g, 11.2 mmol), thiosemicarbazide (1.22 g, 13.4 mmol), 
and K2CO3 (3.09 g, 22.4 mmol). Yellow solid (2.20 g, 42%); 1H NMR (400 MHz, (CD3)2SO) 
δ 7.92 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1H), 7.68 (dd, J1 = 9.2 Hz, J2 = 4.0 Hz, 1H), 7.57 (app. td, 
J1 = 9.2 Hz, J2 = 2.4 Hz, 1H), 3.65 (s, 3H); 13C NMR (100 MHz, (CD3)2SO) δ 179.1, 160.0, 
N
F
N
NN
SH
 130 
157.6, 148.6, 140.6, 134.9, 118.9, 118.7, 118.5, 118.4, 113.0, 112.9, 108.5, 108.3, 27.6; 
LRMS m/z calcd for C10H7FN4S: 234.0; found 235.0 [M+H]+. 
 
Preparation of 8-fluoro-2,5-dihydro-5-propyl-3H-1,2,4-triazino[5,6-
b]indole-3-thione (58d). Compound 58d was prepared by using general 
procedure B with compound 56d (60 mg, 0.48 mmol), thiosemicarbazide (32 mg, 0.35 mmol), 
and K2CO3 (80 mg, 0.58 mmol). Yellow solid (53 mg, 42%); 1H NMR (400 MHz, (CD3)2SO) 
δ 7.85 (d, J = 6.4 Hz, 1H), 7.70 (dd, J1 = 8.4 Hz, J2 = 3.6 Hz, 1H), 7.54-7.47 (m, 1H), 4.12 (t, 
J = 7.2 Hz, 2H), 1.75 (sextet, J = 7.6 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, 
(CD3)2SO) δ 179.2, 159.9, 157.5, 148.5, 140.0, 134.9, 119.0, 118.8, 118.7, 118.6, 113.3, 113.2, 
108.6, 108.4, 42.6, 20.9, 11.2; LRMS m/z calcd for C12H11FN4S: 262.1; found 262.9 [M+H]+. 
 
Preparation of 8-fluoro-2,5-dihydro-5-isopentyl-3H-1,2,4-triazino[5,6-
b]indole-3-thione (58h). Compound 58h was prepared by using general 
procedure B with compound 56h (100 mg, 0.43 mmol), thiosemicarbazide 
(48 mg, 0.52 mmol), and K2CO3 (48 mg, 0.86 mmol). Yellow solid (35 mg, 28%): 1H NMR 
(400 MHz, (CD3)2SO) δ 7.89 (d, J = 7.6 Hz, 1H), 7.66 (dd, J1 = 8.8 Hz, J2 = 3.6 Hz, 1H), 
7.57-7.52 (m, 1H), 4.14 (t, J = 6.8 Hz, 2H), 1.63-1.60 (m, 3H), 0.95 (d, J = 5.2 Hz, 6H); 13C 
NMR (100 MHz, (CD3)2SO) δ 179.5, 160.3, 157.9, 148.7, 140.1, 135.3, 119.4, 119.2, 119.0, 
113.5, 109.1, 108.8, 36.4, 25.8, 27.7, 21.9; LRMS m/z calcd for C14H15FN4S: 290.1; found 
291.0 [M+H]+. 
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Preparation of 8-methyl-2,5-dihydro-5-methyl-3H-1,2,4-triazino[5,6-
b]indole-3-thione (59b). Compound 59b was prepared by using general 
procedure B with compound 57b (108 mg, 0.62 mmol), thiosemicarbazide (68 mg, 0.74 
mmol), and K2CO3 (171 mg, 1.24 mmol). Red solid (104 mg, 45%); 1H NMR (400 MHz, 
(CD3)2SO) δ 7.40-7.70 (m, 1H), 7.49-7.46 (m, 2H), 3.60 (s, 3H), 2.41 (s, 3H); 13C NMR (100 
MHz, (CD3)2SO) δ 178.8, 148.0, 142.3, 135.2, 133.0, 132.6, 121.6, 117.3, 111.2, 27.4, 20.7; 
LRMS m/z calcd for C11H10N4S: 230.1; found 231.0 [M+H]+. 
 
Preparation of 2-(1-ethyl-1,2-dihydro-5-methyl-2-oxo-3H-indol-3-
ylidene)-hydrazinecarbothiamide (59c). Compound 59c was prepared by 
using general procedure B with compound 57c (65 mg, 0.34 mmol), 
thiosemicarbazide (38 mg, 0.41 mmol), and Cs2CO3 (113 mg, 0.82 mmol) in 30% aq. 1,4-
dioxane (5 mL). The crude product was purified via flash column chromatography (SiO2, 100% 
CH2Cl2) to afford compound 59c as an orange solid (22 mg, 25%; Rf 0.39 
(CH2Cl2:MeOH/49:1); 1H NMR (400 MHz, (CD3)2SO) δ 12.37 (s, 1H), 9.00 (s, 1H), 8.65 (s, 
1H), 7.51 (s, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 3.72 (q, J = 7.2 Hz, 2H), 
2.28 (s, 3H), 1.15 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO) δ 178.7, 160.4, 140.4, 
131.9, 131.5, 131.3, 121.3, 119.4, 109.6, 34.0, 20.6, 12.6; LRMS m/z calcd for C13H6N4OS: 
262.1; found 263.1 [M+H]+. 
 
Preparation of 2-(1-propyl-1,2-dihydro-5-methyl-2-oxo-3H-indol-3-
ylidene)-hydrazinecarbothiamide (59d). Compound 59d was prepared by 
N
N
NN
SH
N
NHN
2
O
NHHS
N
NHN
O
NHHS
 132 
using general procedure B with compound 57d (200 mg, 0.98 mmol), thiosemicarbazide (108 
mg, 1.18 mmol), and Cs2CO3 (637 mg, 1.96 mmol) in 30% aq. 1,4-dioxane (10 mL). The 
crude product was purified via recrystallization from EtOH/DMF and then flash column 
chromatography (SiO2, 100% CH2Cl2, CH2Cl2:MeOH/49:1, CH2Cl2:MeOH/19:1) to afford 
compound 59d as an orange solid (169 mg, 52%; Rf 0.39 in CH2Cl2:MeOH/49:1); 1H NMR 
(400 MHz, CDCl3) δ 12.89 (s, 1H), 7.49 (br s, 1H), 7.38 (s, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.76 
(d, J = 8.0 Hz, 1H), 6.52 (br s, 1H), 3.67 (t, J = 6.8 Hz, 2H), 2.34 (s, 3H), 1.70 (sextet, J = 6.8 
Hz, 2H), 0.94 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 180.2, 141.5, 133.0, 132.8, 
132.2, 124.6, 121.7, 119.5, 109.5, 41.6, 21.2, 21.1, 11.6; LRMS m/z calcd for C13H6N4OS: 
276.1; found 277.0 [M+H]+. 
 
Preparation of 8-methyl-2,5-dihydro-5-isopropyl-3H-1,2,4-triazino[5,6-
b]indole-3-thione (59f). Compound 59f was prepared by using general 
procedure B with compound 57f (80 mg, 0.393 mmol), thiosemicarbazide (43 mg, 0.471 
mmol), and Cs2CO3 (255 mg, 0.786 mmol) in 30% aq. 1,4-dioxane (10 mL). The crude 
product was purified via recrystallization from EtOH/DMF and then flash column 
chromatography (SiO2, 100% CH2Cl2, CH2Cl2:MeOH/49:1, CH2Cl2:MeOH/19:1) to afford 
compound 59f as a yellow solid (22 mg, 22%; Rf 0.35 in CH2Cl2:MeOH/49:1); 1H NMR (400 
MHz, CDCl3) δ 7.85 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 5.03 (septet, J 
= 6.8 Hz, 1H), 2.43 (s, 3H), 1.56 (d, J = 6.8 Hz, 6H); 13C NMR (100 MHz, (CD3)2SO) δ 178.4, 
147.5, 140.6, 135.2, 132.7, 132.5, 121.8, 118.0, 112.7, 45.7, 20.6, 19.5; LRMS m/z calcd for 
C13H14N4S: 258.1; found 259.0 [M+H]+. 
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Preparation of 2-(1-isopentyl-1,2-dihydro-5-methyl-2-oxo-3H-indol-3-
ylidene)-hydrazinecarbothiamide (59h). Compound 59h was prepared by 
using general procedure B with compound 57h (110 mg, 0.48 mmol), 
thiosemicarbazide (52 mg, 0.57 mmol), and Cs2CO3 (313 mg, 0.96 mmol) in 30% aq. 1,4-
dioxane (10 mL). The crude product was further purified via recrystallization from 
EtOH/DMF to afford compound 59h as an orange solid (40 mg, 29%; Rf 0.42 in 
CH2Cl2:MeOH/49:1); 1H NMR (400 MHz, CDCl3) δ 12.91 (s, 1H), 7.49 (br s, 1H), 7.38 (s, 
1H), 7.16 (dd, J1 = 8.0 Hz, J2 = 2.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 6.43 (br s, 1H), 3.72 (t, 
J = 7.6 Hz, 2H), 2.34 (s, 3H), 1.65-1.52 (m, 3H), 0.96 (d, J = 6.4 Hz, 6H); 13C NMR (100 
MHz, CDCl3) δ 180.2, 161.2, 141.4, 133.0, 132.8, 132.3, 121.7, 119.6, 109.4, 38.4, 36.3, 26.1, 
22.6, 21.2; LRMS m/z calcd for C15H20N4OS: 304.1; found 305.0 [M+H]+. 
 
3.6.1.3 General procedure C for the preparation of compounds 32b, 34b, 35b, 36b, 37b, 
37h, 38b, 39b, 42b, 43b, 43d, 44b, 45b, 46b, 48b, 48c, 48d, 48f, 48h, and 49b 
Compound 58 or 59 (1 eq.), an organo halide (1.1 eq.), KI (3 eq.), and K2CO3 (1.2 eq.) were 
added to DMF (5-25 mL). The reaction mixture was stirred at 100 °C for 6-12 h, and then 
allowed to cool to rt prior to quenching by addition of H2O. The precipitate formed during 
quenching of the reaction was filtered and purified by column chromatography (SiO2, 
CH2Cl2:MeOH/95:5 or 97:3) to afford the desired products. 
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Preparation of 3-{(8-fluoro-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio} 
ethan-1-ol (32b). Compound 32b was prepared by using general procedure C with compound 
58b (300 g, 1.28 mmol), 2-bromoethanol (176 mg, 1.41 mmol), KI (640 mg, 3.84 mmol), and 
K2CO3 (210 mg, 1.54 mmol). Yellow solid (130 mg, 36%); Rf 0.38 (CH2Cl2:MeOH/9:1); 1H 
NMR (400 MHz, (CD3)2SO, Figure B1) δ 7.78 (d, J = 8.0 Hz, 1H), 7.54 (dd, J1 = 8.8 Hz, J2 = 
4.0 Hz, 1H), 7.46 (t, J = 8.8 Hz, 1H), 3.73 (t, J = 7.2 Hz, 2H), 3.56 (br s, 1H), 3.54 (s, 3H), 
3.20 (t, J = 7.2 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure B2) δ 1557.3, 154.6, 154.4, 
140.78, 140.77, 118.9, 118.8, 117.6, 117.3, 112.2, 112.1, 107.8, 107.5, 34.4, 31.5, 27.1; 
LRMS m/z calcd for C12H11FN4OS: 278.1; found 279.1 [M+H]+. Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 5.02 min (97% pure; Figure B3). 
 
Preparation of 8-fluoro-5-methyl-3-{[(1-methylpiperidin-3-
yl)methyl]thio}-5H-[1,2,4]triazino[5,6-b]indole (34b). Compound 
34b was prepared by using general procedure C with compound 58b (40 mg, 0.17 mmol), 2-
(chloromethyl)-1-methylpiperidine hydrochloride (35 mg, 0.19 mmol), KI (85 mg, 0.51 
mmol), and K2CO3 (28 mg, 0.20 mmol). Dark yellow solid (23 mg, 39%); Rf 0.55 
(CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, Figure B4) δ 8.03 (d, J = 8.0 Hz, 1H), 
7.45-7.30 (m, 2H), 3.80 (s, 3H), 3.36 (dd, J1 = 13.6 Hz, 6.4 Hz, 1H), 3.23 (dd, J1 = 13.6 Hz, 
7.6 Hz, 1H), 3.03 (d, J = 10.8 Hz, 1H), 2.75 (d, J = 11.2 Hz, 1H), 2.27 (s, 3H), 2.15-2.05 (m, 
1H), 2.00-1.80 (m, 3H), 1.75-1.55 (m, 2H), 1.18-1.05 (m, 1H); 13C NMR (400 MHz, CDCl3, 
Figure B5) δ 169.0, 160.5, 158.0, 147.1, 140.8, 137.8, 119.3, 118.4, 118.2, 111.0, 110.9, 108.7, 
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108.4, 61.4, 56.2, 46.8, 36.2, 35.1, 30.1, 27.5, 25.2; LRMS m/z calcd for C17H20FN5S: 345.1; 
found 346.0 [M+H]+. Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 7.90 min (99% pure; Figure B6). 
 
Preparation of 8-fluoro-5-methyl-3-[(pyridin-3-ylmethyl)thio]-
5H-[1,2,4]triazino[5,6-b]indole (35b). Compound 35b was prepared 
by using general procedure C with compound 58b (49 mg, 0.21 mmol), 3-
(chloromethyl)pyridine hydrochloride (38 mg, 0.23 mmol), KI (104 mg, 0.63 mmol), and 
K2CO3 (34 mg, 0.24 mmol). Brownish solid (46 mg, 68%); Rf 0.55 (CH2Cl2:MeOH/97:3); 1H 
NMR (400 MHz, CDCl3, Figure B7) δ 8.67 (s, 1H), 8.35 (d, J = 3.6 Hz, 1H), 7.88 (d, J = 7.2 
Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.28-7.20 (m, 2H), 7.16-7.12 (m, 1H), 4.44 (s, 2H), 3.67 (s, 
3H); 13C NMR (100 MHz, CDCl3, Figure B8) δ 167.6, 160.5, 158.1, 150.4, 148.6, 147.0, 
141.2, 141.1, 137.7, 136.9, 133.8, 123.6, 119.1, 119.0, 118.7, 118.5, 111.1, 111.0, 108.7, 
108.5, 32.5, 27.6; LRMS m/z calcd for C16H12FN5S: 325.1; found 326.0 [M+H]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 7.38 min (99% pure; 
Figure B9). 
 
Preparation of 2-[(8-fluoro-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio]-N,N-dimethylethan-amine (36b). Compound 36b 
was prepared by using general procedure C with compound 58b (23 mg, 0.10 mmol), 2-
chloro-N,N-dimethylethylamine hydrochloride (16 mg, 0.11 mmol), KI (49 mg, 0.30 mmol), 
and K2CO3 (16 mg, 0.12 mmol). Yellow solid (12 mg, 40%); Rf 0.60 (CH2Cl2:MeOH/97:3); 
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1H NMR (400 MHz, CDCl3, Figure B10) δ 8.07-8.03 (m, 1H), 7.43-7.35 (m, 2H), 3.80 (s, 3H), 
3.49 (t, J = 7.2 Hz, 2H), 2.79 (t, J = 7.2 Hz, 2H), 2.35 (s, 6H); 13C NMR (100 MHz, CDCl3, 
Figure B11) δ 169.2, 160.8, 158.4, 147.6, 138.2, 119.6, 118.9, 118.6, 111.4, 111.3, 109.2, 
108.9, 58.9, 45.8, 29.0, 27.9; LRMS m/z calcd for C14H16FN5S: 305.1; found 306.0 [M+H]+. 
Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 7.02 min 
(98% pure; Figure B12). 
 
Preparation of N,N-diethyl-2-{(8-fluoro-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio ethanamine (37b). Compound 
37b was prepared by using general procedure C with compound 58b (25 mg, 0.10 mmol), 2-
chloro-N,N-diethylethylamine hydrochloride (20 mg, 0.11 mmol), KI (49 mg, 0.30 mmol), 
and K2CO3 (16 mg, 0.12 mmol). Yellow solid (15 mg, 43%); Rf 0.39 (CH2Cl2:MeOH/97:3); 
1H NMR (400 MHz, CDCl3, Figure B13) δ 8.02 (dd, J1 = 7.2 Hz, J2 = 2.0 Hz, 1H), 7.42-7.34 
(m, 2H), 3.80 (s, 3H), 3.49 (t, J = 7.6 Hz, 2H), 3.01 (t, J = 7.6 Hz, 2H), 2.77 (q, J = 7.6 Hz, 
4H), 1.16 (t, J = 7.6 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure B14) δ 168.6, 160.5, 158.1, 
147.3, 141.13, 141.08, 137.9, 119.3, 119.2, 118.6, 118.4, 111.1, 111.0, 108.8, 108.6, 52.1, 
47.3, 27.8, 27.6, 11.6; LRMS m/z calcd for C16H20FN5S: 333.1; found 334.0 [M+H]+. Purity 
of the compound was further confirmed by RP-HPLC by using method 1: Rt = 7.71 min (97% 
pure; Figure B15). 
 
Preparation of N,N-diethyl-2-{(8-fluoro-5-isopentyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio}ethan-amine (37h). Compound 
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37h was prepared by using general procedure C with compound 58h (29 mg, 0.10 mmol), 2-
chloro-N,N-diethylethylamine hydrochloride (20 mg, 0.11 mmol), KI (49 mg, 0.30 mmol), 
and K2CO3 (16 mg, 0.12 mmol). Yellow solid (12 mg, 31%); Rf 0.35 (CH2Cl2:MeOH/9:1); 1 
HNMR (400 MHz, CDCl3, Figure B16) δ 8.06 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 6.4 Hz, 2H), 
4.31 (t, J = 7.2 Hz, 2H), 3.47 (t, J = 7.6 Hz, 2H), 3.01 (t, J = 7.6 Hz, 2H), 2.75 (q, J = 7.2 Hz, 
4H), 1.72 (q, J = 7.2 Hz, 2H), 1.60 (nonet, J = 6.4 Hz, 1H), 1.14 (t, J = 7.2, 6H), 0.99 (d, J = 
6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure B17) δ 168.5, 160.2, 157.8, 146.8, 136.9, 
119.4, 119.3, 118.2, 118.0, 111.1, 111.0, 110.0, 108.7, 108.4, 52.0, 47.0, 39.9, 36.9, 27.8, 25.9, 
22.4, 11.5; LRMS m/z calcd for C20H28FN5S: 389.2; found 390.2 [M+H]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 9.49 min (98% pure; 
Figure B18). 
 
Preparation of 8-fluoro-5-methyl-3-{(2-(pyrrolidin-1-yl)ethyl)thio-
5H-[1,2,4]triazino[5,6-b]indole (38b). Compound 38b was prepared 
by using general procedure C with compound 58b (25 mg, 0.11 mmol), 1-(2-
chloroethyl)pyrrolidine hydrochloride (20 mg, 0.12 mmol), KI (52 mg, 0.33 mmol), and 
K2CO3 (17 mg, 0.13 mmol). Yellow solid (16 mg, 18%); Rf 0.41 (CH2Cl2:MeOH/97:3); 1H 
NMR (400 MHz, CDCl3, Figure B19) δ 8.00 (dd, J1 = 7.6 Hz, J2 = 2.0 Hz, 1H), 7.42-7.34 (m, 
2H), 3.80 (s, 3H), 3.57 (t, J = 7.6 Hz, 2H), 3.09 (t, J = 7.6 Hz, 2H), 2.86 (br t, 4H), 1.90 (p, J = 
3.2 Hz, 4H); 13C NMR (100 MHz, CDCl3, Figure B20) δ 168.4, 160.5, 158.1, 147.2, 141.14, 
141.10, 137.9, 119.3, 119.2, 118.7, 118.4, 111.1, 111.0, 108.8, 108.5, 55.3, 54.2, 28.8, 27.6, 
23.7; LRMS m/z calcd for C16H18FN5S: 331.1; found 332.0 [M+H]+. Purity of the compound 
N
F
N
NN
S
N
 138 
was further confirmed by RP-HPLC by using method 1: Rt = 7.73 min (100% pure; Figure 
B21). 
 
Preparation of 8-fluoro-5-methyl-3-{[2-(piperidin-1-
yl)ethyl]thio}-5H-[1,2,4]triazino[5,6-b]indole (39b). Compound 
39b was prepared by using general procedure C with compound 58b (23 mg, 0.10 mmol), 1-
(2-chloroethyl)piperidine hydrochloride (20 mg, 0.11 mmol), KI (50 mg, 0.30 mmol), and 
K2CO3 (17 mg, 0.12 mmol). Yellow solid (22 mg, 64%); Rf 0.32 (CH2Cl2:MeOH/97:3); 1H 
NMR (400 MHz, CDCl3, Figure B22) δ 8.06 (d, J = 7.6 Hz, 1H), 7.44-7.36 (m, 2H), 3.82 (s, 
3H), 3.54 (t, J = 7.2 Hz, 2H), 2.88 (t, J = 7.2 Hz, 2H), 2.70-2.60 (m, 4H), 1.67 (p, J = 5.6 Hz, 
4H), 1.45 (m, 2H); 13C NMR (100 MHz, CDCl3, Figure B23) δ 169.0, 160.6, 158.1, 147.3, 
140.7, 137.8, 119.4, 118.5, 118.3, 111.1, 111.0, 108.9, 108.6, 58.3, 54.6, 28.0, 27.6, 26.0, 24.4; 
LRMS m/z calcd for C17H20FN5S: 345.1; found 346.0 [M+H]+. Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 8.18 min (99% pure; Figure B24). 
 
Preparation of 8-fluoro-5-methyl-3-[(3-phenylpropyl)thio]-5H-
[1,2,4]triazino[5,6-b]indole (42b). Compound 42b was prepared 
by using general procedure C with compound 58b (118 mg, 0.50 mmol), 1-chloro-3-
phenylpropane (85 mg, 0.55 mmol), KI (250 mg, 1.50 mmol), and K2CO3 (83 mg, 0.60 mmol). 
Pale yellow solid (92 mg, 52%); Rf 0.83 (CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, 
Figure B25) δ 8.06 (dd, J1 = 7.6 Hz, J2 = 2.0 Hz, 1H), 7.44-7.34 (m, 2H), 7.32-7.16 (m, 5H), 
3.78 (s, 3H), 3.38 (t, J = 7.6 Hz, 2H), 2.85 (t, J = 7.6 Hz, 2H), 2.17 (p, J = 7.6 Hz, 2H); 13C 
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NMR (100 MHz, CDCl3, Figure B26) δ 169.1, 160.5, 158.1, 147.3, 141.5, 140.93, 140.88, 
137.8, 128.8, 128.7, 128.6, 126.2, 119.4, 119.3, 118.5, 118.2, 111.0, 110.9, 108.8, 108.5, 35.1, 
31.0, 30.6, 27.5; LRMS m/z calcd for C19H17FN4S: 352.1; found 353.1 [M+H]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 10.36 min (98% pure; 
Figure B27). 
 
Preparation of 3-{(8-fluoro-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio}-N,N-dimethylpropan-1-amine (43b). Compound 
43b was prepared by using general procedure C with compound 58b (30 mg, 0.13 mmol), 3-
dimethylamino-1-propylchloride hydrochloride (22 mg, 0.14 mmol), KI (64 mg, 0.39 mmol), 
and K2CO3 (21 mg, 0.16 mmol). Dark yellow solid (21 mg, 51%); Rf 0.11 
(CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, Figure B28) δ 8.06 (d, J = 7.2 Hz, 1H), 
7.42-7.36 (m, 2H), 3.81 (s, 3H), 3.38 (t, J = 7.2 Hz, 2H), 2.47 (t, J = 7.2 Hz, 2H), 2.26 (s, 6H), 
2.01 (p, J = 7.2 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure B29) δ 168.7, 160.3, 157.9, 
140.8, 137.6, 118.3, 118.1, 110.8, 110.7, 108.6, 108.4, 58.3, 45.2, 28.8, 27.4, 26.9; LRMS m/z 
calcd for C15H18FN5S: 319.1; found 320.0 [M+H]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 7.41 min (100% pure; Figure B30). 
 
Preparation of 3-[(8-fluoro-5-propyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio]-N,N-dimethylpropan-1-amine (43d). Compound 
43d was prepared by using general procedure C with compound 58d (25 mg, 0.09 mmol), 3-
dimethylamino-1-propylchloride hydrochloride (16 mg, 0.10 mmol), KI (47 mg, 0.27 mmol), 
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and K2CO3 (16 mg, 0.11 mmol). Yellow solid (13 mg, 40%); Rf 0.58 (CH2Cl2:MeOH/97:3); 
1H NMR (400 MHz, CDCl3, Figure B31) δ 8.24 (d, J = 8.0 Hz, 1H), 7.60-7.54 (m, 2H), 4.46 
(t, J = 7.2 Hz, 2H), 3.56 (t, J = 7.2 Hz, 2H), 2.68 (t, J = 7.2 Hz, 2H), 2.46 (s, 6H), 2.22 (p, J = 
7.2 Hz, 2H), 2.09 (sextet, J = 7.2 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, 
CDCl3, Figure B32) δ 169.0, 160.4, 157.9, 147.2, 140.8, 140.7, 137.2, 119.6, 119.5, 118.4, 
118.1, 111.4, 111.3, 108.8, 108.6, 58.7, 45.6, 43.2, 29.1, 27.5, 21.9, 11.7; LRMS m/z calcd for 
C17H22FN5S: 347.2; found 348.0 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 6.29 min (99% pure; Figure B33). 
 
Preparation of N-{3-[(8-fluoro-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl}-N-methyl-aniline 
(44b). Compound 44b was prepared by using general procedure C with compound 58b (109 
mg, 0.46 mmol), N-methyl-N-(3-chloropropyl)aniline (93 mg, 0.51 mmol) (Note: this reagent 
was prepared by reacting N-methylaniline (1 eq.) with 1-bromo-3-chloropropane (5 eq.) in 
DMF at 70 °C for 24 h), KI (231 mg, 1.38 mmol), and K2CO3 (77 mg, 0.55 mmol). Beige 
solid (74 mg, 39%); Rf 0.77 (CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, Figure B34) 
δ 8.04 (dd, J1 = 8.0 Hz, J2 = 2.0 Hz, 1H), 7.41-7.34 (m, 2H), 7.19 (t, J = 7.2 Hz, 2H), 6.73 (d, 
J = 8.0 Hz, 2H), 6.66 (t, J = 7.2 Hz, 1H), 3.75 (s, 3H), 3.53 (t, J = 7.2 Hz, 2H), 3.37 (t, J = 7.2 
Hz, 2H), 2.96 (s, 3H), 2.13 (p, J = 7.2 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure B35) δ 
168.6, 160.3, 157.9, 147.0, 140.8, 140.7, 137.6, 129.2, 119.1, 119.0, 118.3, 118.1, 116.2, 
112.2, 110.8, 110.7, 108.6, 108.4, 51.6, 38.6, 28.5, 27.3, 26.6; LRMS m/z calcd for 
C20H20FN5S: 381.1; found 382.1 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 8.58 min (95% pure; Figure B36). 
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Preparation of 8-fluoro-5-methyl-3-{[3-(piperidin-1-
yl)propyl]thio}-5H-[1,2,4]triazino[5,6-b]indole (45b). 
Compound 45b was prepared by using general procedure C with compound 58b (94 mg, 0.40 
mmol), 1-(3-chloropropyl)piperidine hydrochloride (88 mg, 0.44 mmol), KI (201 mg, 1.20 
mmol), and K2CO3 (67 mg, 0.48 mmol). Yellow solid (42 mg, 29%); Rf 0.51 
(CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, Figure B37) δ 8.02 (dd, J1 = 7.6 Hz, J2 = 
1.6 Hz, 1H), 7.40-7.34 (m, 2H), 3.81 (s, 3H), 3.37 (t, J = 7.2 Hz, 2H), 2.74 (t, J = 7.2 Hz, 2H), 
2.54-2.52 (m, 4H), 2.19 (p, J = 7.2 Hz, 2H), 1.73 (p, J = 5.2 Hz, 4H), 1.48 (br p, 2H); 13C 
NMR (100 MHz, CDCl3, Figure B38) δ 168.9, 160.4, 158.0, 147.1, 140.7, 137.6, 131.0, 118.4, 
118.1, 111.0, 110.9, 108.5, 108.2, 58.0, 54.5, 29.1, 27.5, 26.1, 25.5, 24.1; LRMS m/z calcd for 
C18H22FN5S: 359.2; found 360.0 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 8.11 min (95% pure; Figure B39). 
 
Preparation of 3-{[3-(3,5-dimethylpiperidin-1-yl)propyl]thio-
8-fluoro-5-methyl-5H-[1,2,4]triazino [5,6-b]indole (46b). 
Compound 46b was prepared by using general procedure C with compound 58b (52 mg, 0.22 
mmol), 1-(3-chloropropyl)-3,5-dimethylpiperidine hydrochloride (47 mg, 0.24 mmol), KI 
(111 mg, 0.66 mmol), and K2CO3 (37 mg, 0.26 mmol). Yellow solid (32 mg, 37%); Rf 0.49 
(CH2Cl2:MeOH/97:3); 1H NMR (400 MHz, CDCl3, Figure B40) δ 7.98 (dd, J1 = 8.4 Hz, J2 = 
2.0 Hz, 1H), 7.38-7.28 (m, 2H), 3.77 (s, 3H), 3.32 (t, J = 7.2 Hz, 2H), 2.85-2.79 (m, 2H), 2.48 
(t, J = 7.2 Hz, 2H), 2.02 (p, J = 7.2 Hz, 2H), 1.67-1.61 (m, 2H), 1.41 (t, J = 10.8 Hz, 2H), 0.91 
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(m, 1H), 0.81 (d, J = 6.8 Hz, 6H), 0.55-0.40 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure 
B41) δ 169.1, 160.4, 158.0, 147.2, 140.74, 140.69, 137.7, 119.3, 119.2, 118.4, 118.1, 111.0, 
110.9, 108.6, 108.4, 61.8, 57.9, 53.9, 42.3, 32.3, 31.2, 29.4, 27.5, 26.7, 19.8, 19.7; LRMS m/z 
calcd for C20H26FN5S: 387.2; found 388.1 [M+H]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 8.84 min (98% pure; Figure B42). 
 
Preparation of 2-{(5,8-dimethyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio}-N,N-diethylethanamine (48b). Compound 48b was 
prepared by using general procedure C with compound 59b (50 mg, 0.22 mmol), 2-chloro-
N,N-diethylethylamine hydrochloride (41 mg, 0.24 mmol), KI (111 mg, 0.66 mmol), and 
K2CO3 (37 mg, 0.26 mmol). Orange solid (31 mg, 43%); Rf 0.40 (CH2Cl2:MeOH/9:1); 1H 
NMR (400 MHz, CDCl3, Figure B43) δ 8.16 (s, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.30 (d, J = 8.4 
Hz, 1H), 3.78 (s, 3H), 3.55 (m, 2H), 3.12 (m, 2H), 2.87 (q, J = 7.2 Hz, 4H), 2.52 (s, 3H), 1.23 
(t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure B44) δ 146.9, 141.6, 140.0, 133.0, 
132.2, 122.4, 118.4, 109.8, 52.0, 47.3, 27.5, 27.2, 21.6, 11.1; LRMS m/z calcd for C17H23N5S: 
329.2; found 330.1 [M+H]+. Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 8.26 min (98% pure; Figure B45). 
 
Preparation of N,N-diethyl-2-{(5-ethyl-8-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio}ethan-amine (48c). Compound 
48c was prepared by using general procedure C with compound 59c (21 mg, 0.09 mmol), 2-
chloro-N,N-diethylethylamine hydrochloride (17 mg, 0.10 mmol), KI (44 mg, 0.27 mmol), 
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and K2CO3 (14 mg, 0.11 mmol). Yellow solid (12 mg, 40%; Rf 0.40 in CH2Cl2:MeOH/9:1); 
1H NMR (400 MHz, CDCl3, Figure B46) δ 8.19 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 
8.4 Hz, 1H), 4.36 (q, J = 7.2 Hz, 2H), 3.67 (t, J = 7.2 Hz, 2H), 3.40-3.20 (m, 2H), 3.10-3.00 
(m, 4H), 2.53 (s, 3H), 1.44 (t, J = 6.8 Hz, 3H), 1.36 (t, J = 6.8 Hz, 6H); 13C NMR (100 MHz, 
CDCl3, Figure B47) δ 166.8, 146.1, 141.5, 138.9, 132.7, 131.9, 122.4, 118.3, 109.7, 51.7, 
47.14, 47.07, 36.2, 21.3, 13.6, 12.8, 10.7, 10.5; LRMS m/z calcd for C18H25N5S: 343.2; found 
344.1 [M+H]+. Purity of the compound was further confirmed by RP-HPLC by using method 
1: Rt = 8.55 min (95% pure; Figure B48). 
 
Preparation of N,N-diethyl-2-{(5-propyl-8-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio}ethan-amine (48d). Compound 
48d was prepared by using general procedure C with compound 59d (26 mg, 0.10 mmol), 2-
chloro-N,N-diethylethylamine hydrochloride (19 mg, 0.11 mmol), KI (51 mg, 0.30 mmol), 
and K2CO3 (17 mg, 0.12 mmol). Yellow solid (16 mg, 44%); Rf 0.42 (CH2Cl2:MeOH/9:1); 1H 
NMR (400 MHz, CDCl3, Figure B49) δ 8.18 (s, 1H), 7.47 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 
7.33 (d, J = 8.8 Hz,1H), 4.25 (t, J = 7.6 Hz, 2H), 3.63 (t, J = 7.6 Hz, 2H), 3.23 (br t, 2H), 3.10-
2.90 (m, 4H), 2.52 (s, 3H), 2.20 (sextet, J = 7.6 Hz, 2H), 1.32 (t, J = 7.2 Hz, 6H), 0.94 (t, J = 
7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure B50) δ 166.5, 146.5, 141.5, 139.4, 132.7, 
132.0, 122.3, 118.2, 110.0, 51.6, 47.0, 43.0, 26.0, 21.7, 21.3, 11.4, 10.0; LRMS m/z calcd for 
C19H27N5S: 357.2; found 358.1 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 8.96 min (100% pure; Figure B51). 
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Preparation of N,N-diethyl-2-{(5-isopropyl-8-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio}ethanamine (48f). Compound 
48f was prepared by using general procedure C with compound 59f (41 mg, 0.16 mmol), 2-
chloro-N,N-diethylethylamine hydrochloride (30 mg, 0.18 mmol), KI (80 mg, 0.48 mmol), 
and K2CO3 (27 mg, 0.19 mmol). Yellow solid (8 mg, 14%); Rf 0.43 (CH2Cl2:MeOH/97:3); 1H 
NMR (400 MHz, CDCl3, Figure B52) δ 8.18 (s, 1H), 7.41 (m, 2H), 5.12 (septet, J = 6.8 Hz, 
1H), 3.46 (t, J = 6.8 Hz, 2H), 2.99 (t, J = 7.2 Hz, 2H), 2.74 (q, J = 7.2 Hz, 4H), 2.50 (s, 3H), 
1.65 (d, J = 7.2 Hz, 6H), 1.13 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure B53) δ 
167.3, 146.3, 141.3, 138.4, 132.4, 131.7, 122.5, 119.0, 111.4, 52.3, 47.3, 46.3, 27.9, 21.4, 20.6, 
11.7; LRMS m/z calcd for C19H27N5S: 357.2; found 358.1 [M+H]+. Purity of the compound 
was further confirmed by RP-HPLC by using method 1: Rt = 9.13 min (95% pure; Figure 
B54). 
 
Preparation of N,N-diethyl-2-{(8-methyl-5-isopentyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio}ethan-amine (48h). Compound 
48h was prepared by using general procedure C with compound 59h 
(34 mg, 0.12 mmol), 2-chloro-N,N-diethylethylamine hydrochloride (22 mg, 0.13 mmol), KI 
(59 mg, 0.36 mmol), and K2CO3 (20 mg, 0.14 mmol). Yellow solid (10 mg, 22%); Rf 0.39 
(CH2Cl2:MeOH/9:1); 1H NMR (400 MHz, CDCl3, Figure B55) δ 8.18 (s, 1H), 7.48 (dd, J1 = 
8.4 Hz, J2 = 2.4 Hz, 1H) (m, 4H), 7.32 (d, J = 8.4 Hz, 1H), 4.29 (t, J = 7.6 Hz, 2H), 3.68 (t, J 
= 7.6 Hz, 2H), 3.33 (br t, 2H), 3.11-3.00 (m, 4H), 2.53 (s, 3H), 1.71 (q, J = 7.2 Hz, 2H), 1.60 
(nonet, J = 6.8 Hz, 1H), 1.36 (t, J = 7.2 Hz, 6H), 0.98 (d, J = 6.8 Hz, 6H); 13C NMR (100 
MHz, CDCl3, Figure B56) δ 166.6, 146.3, 141.5, 139.2, 132.7, 132.0, 122.3, 118.3, 109.9, 
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51.6, 47.0 (2 carbons), 39.8, 36.9, 25.9, 22.4 (2 carbons), 21.3; LRMS m/z calcd for 
C21H31N5S: 385.2; found 386.1 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 9.35 min (95% pure; Figure B57). 
 
Preparation of 5,8-dimethyl-3-[(2-(pyrrolidin-1-yl)ethyl)thio]-5H-
[1,2,4]triazino[5,6-b]indole (49b). Compound 49b was prepared by 
using general procedure C with compound 59b (26 mg, 0.11 mmol), 1-(2-
chloroethyl)pyrrolidine hydrochloride (21 mg, 0.12 mmol), KI (56 mg, 0.33 mmol), and 
K2CO3 (19 mg, 0.13 mmol). Pale yellow solid (30 mg, 82%); Rf 0.40 (CH2Cl2:MeOH/9:1); 1H 
NMR (400 MHz, CDCl3, Figure B58) δ 8.15 (s, 1H), 7.48 (d, J = 8.4 Hz, 1H), 7.31 (d, J = 8.0 
Hz, 1H), 3.78 (s, 3H), 3.65 (t, J = 7.6 Hz, 2H), 3.26 (t, J = 7.2 Hz, 2H), 3.12-3.02 (m, 4H), 
2.55 (s, 3H), 2.04-1.94 (m, 4H); 13C NMR (100 MHz, CDCl3, Figure B59) δ 166.9, 146.8, 
141.6, 140.1, 133.1, 132.3, 122.4, 118.2, 109.8, 55.2, 54.1, 27.8, 27.5, 23.7, 21.5; LRMS m/z 
calcd for C17H21N5S: 327.2; found 328.0 [M+H]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 8.13 min (96% pure; Figure B60). 
 
Preparation of 8-fluoro-3-[(3-methoxyethyl)thio]-5-methyl-5H-
[1,2,4]triazino[5,6-b]indole (33b). Compound 32b (110 mg, 0.40 
mmol) was dissolved in anhydrous CH2Cl2 (12 mL), under nitrogen gas, at 0 °C and NaH (64 
mg, 60%, 1.60 mmol) was added. The reaction mixture was stirred at 0 °C for 15 min at 
which point methyl iodide (0.25 mL, 4.00 mmol) was added dropwise. After complete 
addition of the methyl iodide the reaction mixture was stirred for an additional 1 h at 0 °C and 
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allowed to warm up to rt prior to quenching with H2O (10 mL). CH2Cl2 (10 mL) was then 
added and the organic layer was separated, dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The brown solid obtained was purified using column chromatography 
(SiO2, CH2Cl2:MeOH/99:1) to afford compound 33b (55 mg, 47%) as a white solid. Rf 0.45 
(CH2Cl2:MeOH/99:1); 1H NMR (400 MHz, CDCl3, Figure B61) δ 8.04 (app. dt, J1 = 7.6 Hz, 
J2 = 1.2 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 6.4 Hz, 1H), 4.81 (t, J = 6.8 Hz, 2H), 
3.80 (s, 3H), 3.01 (t, J = 6.8 Hz, 2H), 2.23 (s, 3H); 13C NMR (100 MHz, CDCl3, Figure B62) 
δ 162.9, 160.4, 158.0, 140.8, 138.3, 119.3, 117.8, 117.5, 110.8, 110.7, 108.5, 108.3, 67.2, 32.6, 
27.4, 15.9; LRMS m/z calcd for C13H13FN4OS: 292.1; found 293.0 [M+H]+. Purity of the 
compound was further confirmed by RP-HPLC by using method 1: Rt = 8.05 min (95% pure; 
Figure B63). 
 
Preparation of 2-[(8-fluoro-5-methyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio]acetonitrile (47b). Compound 58b (300 mg, 1.28 mmol) and 
K2CO3 (190 mg, 1.41 mmol) were added to a stirred solution of 2-bromoacetonitrile (0.45 mL, 
6.4 mmol) in DMF (13 mL). The reaction mixture was heated to reflux and stirred for 12 h. 
After cooling to rt, the reaction mixture was quenched with H2O (20 mL). The flocculant solid 
was collected by filtration, washed 3 times with MeOH (5 mL), and recrystallized from an 
EtOAc:DMF mixture (1:6) to afford the desired compound 47b (220 mg, 63%) a beige solid. 
Rf 0.63 (CH2Cl2:MeOH/95:5); 1H NMR (400 MHz, (CD3)2SO, Figure B64) δ 8.19 (dd, J = 8.8, 
2.8 Hz, 1H), 7.84 (dd, J1 = 8.8 Hz, J2 = 4.0 Hz, 1H), 7.68 (td, J1 = 8.8 Hz, J2 = 2.8 Hz, 1H), 
4.46 (s, 2H), 3.85 (s, 3H); 13C NMR (100 MHz, (CD3)2SO, Figure B65) δ 164.6, 159.7, 157.4, 
146.5, 141.42, 141.38, 138.3, 118.9, 118.6, 118.1, 117.9, 112.94, 112.85, 107.9, 107.7, 27.6, 
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16.3; LRMS m/z calcd for C12H8FN5S: 273.1; found 274.0 [M+H]+. Purity of the compound 
was further confirmed by RP-HPLC by using method 1: Rt = 7.92 min (100% pure; Figure 
B66). 
 
Preparation of 8-fluoro-5-methyl-3-(methylthio)-5H-
[1,2,4]triazino[5,6-b]indole (60b). Compound 58b (235 mg, 1.0 mmol) 
was dissolved in MeCN (20 mL). Cs2CO3 (350 mg, 1.1 mmol) was added and the reaction 
mixture was allowed to stir for 30 min at rt. Methyl iodide (0.2 mL, 3.1 mmol) was added 
dropwise over 1 h. After complete addition of the methyl iodide, the reaction mixture was 
stirred for an addition 1 h more prior to filtration. The organic compounds were concentrated 
and purified by column chromatography (SiO2, CH2Cl2:MeOH/97:3, Rf 0.6) to yield 
compound 60b (225 mg, 91%) as a brown solid. 1H NMR (400 MHz, CDCl3, Figure B67) δ 
8.07 (dd, J1 = 8.0 Hz, J2 = 2.8 Hz, 1H), 7.44-7.36 (m, 2H), 3.80 (s, 3H), 2.75 (s, 3H); 13C 
NMR (100 MHz, CDCl3, Figure B68) δ 169.4, 160.6, 158.2, 137.9, 119.5, 118.6, 118.3, 
111.05, 110.96, 108.9, 108.7, 27.6, 14.4; LRMS m/z calcd for C11H9FN4S: 248.1; found 249.0 
[M+H]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
7.92 min (100% pure; Figure B69). 
 
Preparation of 8-fluoro-5-methyl-3-(methylsulfonyl)-5H-
[1,2,4]triazino[5,6-b]indole (61b). Compound 61b (250 mg, 1.0 mmol) 
was suspended in anhydrous CH2Cl2 (10 mL) under nitrogen. m-Chloroperbenzoic acid (430 
mg, 2.5 mmol) was carefully added and the reaction mixture was stirred at rt for 24 h. The 
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reaction mixture was partitioned between a sodium thiosulfate solution (5% in H2O, 50 mL) 
and EtOAc (50 mL). The organic layer was separated, washed with brine (20 mL), dried over 
anhydrous MgSO4, and evaporated under reduced pressure. The brown solid obtained was 
purified by column chromatography (SiO2, CH2Cl2:MeOH/97:3, Rf 0.34) to yield compound 
61b (126 mg, 45%) as a brown solid. 1H NMR (400 MHz, CDCl3, Figure B70) δ 8.25 (dd, J1 
= 8.0 Hz, J2 = 2.4 Hz, 1H), 7.64-7.54 (m, 2H), 4.01 (s, 3H), 3.59 (s, 3H); 13C NMR (100 MHz, 
CDCl3, Figure B71) δ 162.3, 161.0, 158.5, 147.0, 145.2, 139.8, 121.4, 121.2, 118.4, 118.3, 
112.1, 112.0, 110.1, 109.9, 40.4, 28.5; LRMS m/z calcd for C11H9FN4O2S: 280.0; found 280.9 
[M+H]+. Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
5.99 min (100% pure; Figure B72). 
 
Preparation of N1,N1-diethyl-N2-(8-fluoro-5-methyl-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)ethane-1,2-diamine (52). N1,N1-
Diethylethane-1,3-diamine (15 mg, 0.13 mmol) was added to a solution of compound 62b (30 
mg, 1.0 mmol) in anhydrous THF (5 mL). The reaction mixture was stirred under reflux for 6 
h. After cooling the reaction mixture to rt, the solvent was evaporated under reduced pressure. 
The residual material was purified by column chromatography (SiO2, CH2Cl2:MeOH/97:3, Rf 
0.35) to yield compound 52 (13 mg, 42%) as a yellow solid. 1H NMR (400 MHz, CDCl3, 
Figure B73) δ 7.87 (d, J = 8.0 Hz, 1H), 7.22-7.18 (m, 2H), 6.10 (br s, 1H), 3.67 (s, 3H), 3.60 
(q, J = 5.2 Hz, 2H), 2.72 (t, J = 6.4 Hz, 2H), 2.60 (q, J = 7.2 Hz, 4H), 1.04 (t, J = 7.2 Hz, 6H); 
13C NMR (100 MHz, CDCl3, Figure B74) δ 160.4, 160.0, 149.4, 137.1, 120.7, 120.6, 115.7, 
115.5, 110.2, 110.1, 107.4, 107.2, 51.7, 46.9, 39.2, 27.0, 11.9; LRMS m/z calcd for 
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C16H21FN6S: 316.4; found 317.1 [M+H]+. Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 3.30 min (98% pure; Figure B75). 
 
Preparation of N1-(8-fluoro-5-methyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)-N3,N3-dimethylpropane-1,3-diamine (53). N1,N1-
Dimethylpropane-1,3-diamine (110 mg, 1.1 mmol) was added to a solution of compound 62b 
(280 mg, 1.0 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred under reflux 
for 2 h. After cooling the reaction mixture to rt, the solvent was evaporated under reduced 
pressure. The residual material was purified by column chromatography (SiO2, 
CH2Cl2:MeOH/97:3, Rf 0.27) to yield compound 53 (24 mg, 8%) as a yellow solid. 1H NMR 
(400 MHz, CDCl3, Figure B76) δ 7.87 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1H), 7.20-7.16 (m, 2H), 
6.39 (br s, 1H), 3.66 (s, 3H), 3.61 (q, J = 6.0 Hz, 2H), 2.45 (t, J = 6.8 Hz, 2H), 2.26 (s, 6H), 
1.85 (p, J = 6.8 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure B77) δ 160.3, 157.9, 149.4, 
137.1, 120.7, 120.6, 115.6, 115.4, 110.14, 110.05, 107.3, 107.1, 58.2, 45.7, 40.7, 27.0; LRMS 
m/z calcd for C15H19FN6: 302.2; found 303.1 [M+H]+. Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 4.97 min 98% pure; Figure B78). 
 
3.6.2. Biochemical, biological, and biophysical methods 
3.6.2.1. Eis chemical library screening 
Eis activity suppression was determined by monitoring the increase in absorbance at 412 nm 
resulting from a secondary reaction of DTNB with the CoA-SH released upon acetylation of 
NEO. Reactions (40 µL) contained a mixture of Eis (0.25 µM), NEO (100 µM), Tris-HCl (50 
N
F
N
NN
NH
N
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mM, pH 8.0 adjusted at rt), AcCoA (40 µM), DTNB (0.5 mM), and the potential inhibitors 
(20 µM). Control experiments were performed using a known inhibitor, chlorhexidine (5 µM) 
(positive) and DMSO (0.5% v/v, negative), instead of the potential inhibitors. Briefly, a 
solution (30 µL) of Eis (0.33 µM) and NEO (133.33 µM) in Tris-HCl (50 mM, pH 8.0 
adjusted at rt) was added to 384-well non-binding-surface plates (Thermo Fisher Scientific, 
Waltham, MA) using a Multidrop dispenser (Thermo Fisher Scientific). The potential 
inhibitors (0.2 µL of a 4 mM stock), chlorhexidine (0.2 µL of a 1 mM stock), or DMSO (0.2 
µL) were then added to each well by Biomek HDR (Beckman, Fullerton, CA). After 
incubation at rt (10 min), reactions were initiated by adding a mixture (10 µL) containing 
AcCoA (160 µM), DTNB (2 mM), and Tris-HCl (50 mM, pH 8.0 adjusted at rt). After an 
additional 5 min of reaction at rt, the absorbance was measured at 412 nm using a PHERAstar 
plate reader (BMG Labtech, Cary, NC). The average Z' score for the entire high-throughput 
screening assay was 0.65. 
 
3.6.2.2. Hit validation 
With the aforementioned conditions, all compounds with > 3σ, as a statistical hit threshold 
from the mean negative control, were characterized as an inhibitory compound and tested in 
triplicate. Compounds that displayed inhibition at least 2 of the 3 independent assays were 
then tested for a dose-response using 2-fold dilutions from 20 µM to 78 nM. IC50 values were 
determined for all select compounds displaying a dose-dependent activity. 
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3.6.2.3. Inhibition kinetics 
IC50 values were determined on a multimode SpectraMax M5 plate reader using 96-well 
plates (Thermo Fisher Scientific) by using the UV-Vis assay as above taking measurements 
every 30 s for 20 min. Compounds were dissolved in Tris (50 mM, pH 8.0 adjusted at rt 
containing 10% v/v DMSO) (100 µL) and a 5-fold dilution was performed. To the solution of 
inhibitors, a mixture (50 µL) of Eis (1 mM), NEO or KAN (400 µM), and Tris (50 mM, pH 
8.0 adjusted at rt) was added and incubated for 10 min, to allow for competitive binding. 
Reactions were initiated by addition of a mixture (50 µL) containing AcCoA (2 mM), DTNB 
(2 mM), and Tris-HCl (50 mM, pH 8.0 adjusted at rt). All assays were performed at least in 
triplicate. Initial rates were calculated from the first 2-5 min of reaction, where linear product 
accumulation is observed, to ensure the steady-state regime. Data was fit to a Hill-plot fit 
using KaleidaGraph 4.1 software and IC50 values were calculated. All IC50 values are listed in 
Tables 3.1 and 3.4 and IC50 curves are presented in Figures 3.5-3.11. 
 
3.6.2.4. Mode of inhibition 
By using the conditions described for inhibition kinetics with varying concentrations of NEO 
(50, 75, 100, 125, 150, and 200 µM) and inhibitory compounds that displayed an IC50 value 
<1 µM using NEO as the substrate (compounds 36b, 37b, 37d, 37g, 39b, 39c, 39i, and 50d) 
(0, 0.13, 0.25, 0.50 and 1.0 µM), inhibitory constants (Ki) were determined (Table 3.3). 
Resulting reaction rates (𝑣), substrate concentrations ([S]) and inhibitor concentrations ([I]) 
were analyzed by nonlinear regression with SigmaPlot (SysStat) using Equation 1 to 
determine the Ki values. Representative IC50 curves and Lineweaver-Burk double reciprocal 
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plots (insets; to simplify visualization of the competitive mode of inhibition) are presented in 
Figure 3.7. 
 
Equation 1: 𝑣 = !!"# !! !!! !! !!!  
 
3.6.2.5. Selectivity of inhibitors towards Eis over other AACs 
To determine if the inhibitors were Eis specific or pan-AAC, we verified the specificity of two 
of our inhibitors (36b and 37b) with three regiospecific AACs: AAC(6')-Ie from the 
bifunctional AAC(6')-Ie/APH(2")-Ia,139 AAC(3)-IV,139 and AAC(2')-Ic.85 Similar conditions 
to those described above were used. AAC(6')-Ie (0.5 µM) and AAC(3)-IV (0.125 µM) were 
tested in MES buffer (50 mM, pH 6.6), and AAC(2')-Ic (0.125 µM) was tested in phosphate 
buffer (50 mM, pH 7.0) using neomycin B (100 µM) as the substrate. AcCoA (150 µM) was 
used to initiate the reactions. Both AAC(2')-Ic and AAC(3)-IV were incubated at 25 °C, while 
AAC(6')-Ie was incubated at 37 °C. 
 
3.6.2.6. Mycobacterium tuberculosis MIC values determination 
Compounds were tested at 100-fold IC50,KAN or 100 µM (if IC50,KAN was unknown or could not 
be achieved while keeping the DMSO concentration ≤1% in test wells). Experiments were 
conducted in 96-well dishes as previously reported.141 Briefly, Mtb strains were grown in 
Middlebrook 7H9 supplemented with ADC (10%), Tween® 80 (0.05%), and glycerol (0.4%) 
at 37 °C until slightly turbid, diluted in fresh 7H9 to attenuance at 600 nM of 0.2, diluted 
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again 1:25 in fresh 7H9 in a 50 mL polypropylene tube containing glass beads, vortexed for 
30 s, and allowed to rest for 10 min. Compounds were diluted to 2× the desired final 
concentrations in 7H9 and 100 µL was added to test wells along with 90 µL of prepared 
bacteria cultures. Plates were incubated at 37 °C in a humid environment for 24 h. KAN was 
diluted to 20× the desired final concentration in H2O and 10 µL was added to test wells. 
H37Rv was evaluated at 2.5 and 1.25 µg/mL KAN and K204 was evaluated at 10, 5, 2.5, and 
1.25 µg/mL KAN. The plates were then incubated for 6 days at 37 °C. To assess growth 
inhibition, AlamarBlue® was diluted 1:1 in 10% Tween® 80 and (40 µL) added to each test 
well, plates were further incubated at 37 °C and the color of the wells was observed at 24 h 
and 48 h. AlamarBlue® is converted from indigo blue to pink in the presence of bacterial 
growth. The MIC was defined as the lowest concentration of KAN which resulted in no 
change in color. Compounds were tested at least twice in duplicate. Controls for this study 
included: uninoculated 7H9, inoculated 7H9 only, inoculated 7H9 + DMSO only, and 
compound and inoculated 7H9 only. To prevent drying out of the plates, 200 µL of sterile 
H2O was added to all perimeter wells. Dose-dependent MICKAN values were determined 
similarly for compounds 36b and 39b with Eis inhibitor concentrations of 0, 0.5, 1, 2, 4, 8, 16, 
32 µM. 
 
3.6.2.7. Crystallization, diffraction data collection, and structure determination and 
refinement of EisC204A-CoA-inhibitor 39b complex 
Crystals were grown, soaked in the inhibitor solution, and frozen using a previously published 
protocol with the exception that the inhibitor used was compound 39b from the current 
 154 
study.105 The diffraction data was collected at the synchrotron beamline 22-ID of the 
Advanced Photon Source at the Argonne National Laboratory (Argonne, IL) and processed as 
previously reported.105 The X-ray diffraction data collection and refinement statistics are 
summarized in Table 3.5. The EisC204A-CoA-inhibitor 39b structure was deposited in the 
Protein Data Bank (PDB) with accession number 6B3T. Note: An overlay of inhibitor 39b, 
TOB, and three other Eis inhibitors of different scaffolds is presented in Figure 3.12. 
 
Table 3.5. X-ray diffraction data collection and refinement 
statistics for the EisC204A-CoA-inhibitor 39b ternary complex 
structure. 
Data collection  
Space group R32 
Number of monomers per asymmetric 
unit 
1 
Unit cell dimensions  
     a, b, c (Å) 175.5, 175.5, 120.7 
     a, b, g (°) 90, 90, 120 
Resolution (Å) 50.0-2.4 (2.44-2.40)a 
I/s 29 (4.6) 
Completeness (%) 99.9 (100.0) 
Redundancy 7.5 (7.6) 
Rmerge 0.10 (0.61) 
Number of unique reflections 27,954 
  
Structure refinement statistics  
Resolution (Å) 34.0-2.4 
R (%) 21.7 
Rfree (%) 23.1 
Bond length deviation (rmsd) from ideal 
(Å) 
0.006 
Bond angle deviation (rmsd) from ideal 
(°) 
1.41 
Ramachandran plot statisticsb  
     % of residues in most allowed regions 98.5 
     % of residues in additional allowed 
regions 
1.5 
     % of residues in disallowed regions 0.0 (0 residues) 
a Numbers in parentheses indicate the values in the highest-
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resolution shell. b Indicates Rampage statistics.147 
 
3.6.2.8. Mammalian cytotoxicity assays 
In order to assess the potential cytotoxicity of our inhibitors to mammalian cells, we selected 
our best Eis inhibitors and tested their cytotoxicity alone or in the presence of KAN against 
A549, HEK-293, and J774A.1 cells. Experiments were performed as previously described 
with slight modifications.122, 148 HEK-293 and J774A.1 cells were plated at 10,000 cells/well 
density in 100 µL/well of the appropriate media in 96-well tissue culture plates (see Materials 
and instrumentations section). A549 cells were plated at 3,000 cells/well density in the same 
amount of medium overnight. For the cytotoxicity of Eis inhibitors alone, after overnight 
culturing at 37 °C with 5% CO2, the old medium was replaced with 200 µL of fresh medium 
supplemented with serially diluted Eis inhibitors with final concentrations ranging from 0.34 
to 100 µM and 0.5% DMSO. Cells for negative control were treated with the appropriate 
DMEM medium supplemented with 0.5% DMSO. Cells for positive control were treated with 
the appropriate medium with 0.5% DMSO and 1% v/v Triton-X 100®. The cells were then 
incubated at 37 °C with 5% CO2 for 24 h. Resazurin (10 µL of 2 mM sterile solution in 1× 
PBS) was then added to each well in order to detect the amount of live cells, which convert 
resazurin into highly fluorescent resorufin. After incubation at 37 °C with 5% CO2 for 6 h, 
fluorescence was measured with plate reader with an excitation wavelength of λ560 nm and an 
emission wavelength of λ590 nm. The percent cell survival was summarized and presented in 
Figure 3.12. Experiments were done in quadruplicate. 
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By using the same protocol, the toxicity of KAN alone against the above three cell lines was 
determined with the final concentration of KAN ranging from 2 to 500 µM (without DMSO 
since KAN is water soluble). After seeing that KAN displayed no toxicity up to 500 µM 
(Figure 3.13), we decided to perform the above toxicity experiments with Eis inhibitors in the 
presence of 50 µg/mL KAN (equivalent of 86 µM), which is 10-40× MIC of KAN against 
Mtb H37Rv in order to better assess the combined toxicity of Eis inhibitors and KAN (Figure 
3.13). Experiments were done in quadruplicate. 
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Chapter 4 
 
Eis inhibitors with potential synergistic bactericidal activity with Kanamycin against 
Mycobacterium tuberculosis 
 
4.1. INTRODUCTION 
Since the discovery of the penicillin, antibiotics have arguably been the most successful 
technological advancement in healthcare as they are responsible for the rapid reduction of 
mortality and morbidity associated with a large number of previously fatal diseases.149 
Unfortunately, in the last few decades, resistance to antibiotics has emerged to be a global 
crisis. Unlike other classes of drugs, there is a constant need for discovery of new molecules 
and strategies to combat antibiotic resistance.150 The antibiotic crisis has been attributed to the 
lack of new drug development by the pharmaceutical industry as well as inappropriate usage 
of these drugs in the clinical setting.151 Unlike anticancer or cardiovascular drugs, typical 
antibiotic courses normally only last 7 to 10 days, which severely limits the potential for 
antibiotics as blockbuster drugs.101 The lack of potential significant profit return, hence, 
discourages investment by major pharmaceutical companies.  
 
Amongst the most common bacterial infections, tuberculosis (TB) has become a major health 
problem, which was responsible for approximately 710,000 deaths in 2015.9 To make matters 
worse, ineffective TB treatment potentially led to over 200,000 cases of drug-resistant TB 
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(DR-TB) in 2015. Treating DR-TB can cost as much as $5000 per case. More importantly, 
among communicable diseases, TB is the most deadly disease from the age of 15 to 49, which 
is considered to be the most productive time in a human lifespan. Thus, there is a clear need 
for new anti-tubercular drugs. Many new promising anti-tubercular drug scaffolds currently 
being developed in the literature include: the selective 1,3,5-triazaspiro[5.5]undeca-2,4-diene-
based inhibitors of dihydrofolate reductase,152 a β-lactone inhibitor that can knock out Pks13 
and Ag85, which halts mycolic acid synthesis,153 and the natural products Kuwanon G and H, 
which are inhibitors of PtpA and PtpB of Mycobacterium tuberculosis (Mtb).154 
 
Previously, we proposed Eis inhibitors as adjuvants to reactivate the anti-tubercular activity of 
kanamycin (KAN) in KAN-resistant Mtb strains. These inhibitors were found to specifically 
inhibit Eis and thus, did not kill Mtb strains by themselves. However, during our search for 
Eis inhibitors, we were able to identify a novel class of thieno[2,3-d]pyrimidine-based 
inhibitors that do not only inhibit Eis to restore the activity of KAN, but also possessed their 
own anti-tubercular activity. Basal-level expression of Eis is hypothesized to decrease the 
efficacy of KAN and limit the MIC of KAN to 1.25 µg/mL. Thus, compounds that can inhibit 
Eis and display their own activities may be synergistic with KAN against Mtb cells. To 
validate this hypothesis, we will perform synergy checkerboard assays with these compounds. 
Additionally, we accessed the therapeutic indices of these analogues via mammalian 
cytotoxicity.  
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4.2. RESULTS AND DISCUSSION 
4.2.1. High-throughput screen 
To identify potential Eis inhibitors, we performed a high-throughput screen (HTS) against 
purified Eis enzyme using ~23,000 compounds from three commercially available chemical 
libraries: the BioFocus NCC library (~1,000 compounds), the ChemDiv library (~20,000 
compounds), and the MicroSource MS2000 library (~2,000 compounds).108 We achieved high 
robustness in our HTS with a Z’ score of 0.65. Sixty-six compounds with thieno[2,3-
d]pyrimidine core structure were identified as potential inhibitors and compound 2i was 
validated as an Eis inhibitor. We then re-synthesized 2i and 71 other analogues and 
determined the IC50 values for these inhibitors. More interestingly, we found that some of 
these inhibitors are also active against Mtb cells on their own. Thus, we determined the MIC 
values for all of our compounds and found 11 analogues with MIC of 4 µM against Mtb 
MC26020, a fast-growing attenuated double lysine and pantothenate auxotroph of Mtb.  
 
4.2.2. Chemistry 
The library is composed of 72 molecules shown in Figure 4.1. Overall, the library can be 
divided in to 7 series of compounds where various modifications are introduced in the 
aliphatic ring that is annulated and adjacent to the thiophene ring. For instance, the annulated 
ring can be a cyclopentane ring (series 1), cyclohexane (series 2), cycloheptane (series 8). 
Additionally, we also introduced substitutions at the R2 and R3 positions. These substitutions 
could be unsubsituted (H) (series 2) or substituted with methyl (series 3), ethyl (series 5), 
tert-butyl (series 6), or phenyl groups (series 7). Furthermore, within these 7 major series, we 
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also installed aliphatic tertiary amino side chains at the R1 position (Figure 4.1). These 
aliphatic tertiary amino side chains were selected based on our previous observations that 
inhibitors with a tertiary amino groups tend to have superior IC50 compared to the ones that do 
not. This phenomenon can perhaps be explained by the fact that these tertiary amino 
compounds are positively charged at physiology pH allowing them to better mimic the 
positively charged natural AG substrates. To access the thieno[2,3-d]pyrimidine core, we 
initially prepared a series of 2-aminothiophenes (17-24) as building blocks via the classic 
Gewald reaction starting from the commercially available malononitrile, ethyl cyanoacetate, 
elemental sulfur, and various cyclic ketones (9-15). The building blocks 17-24 were reacted 
with benzoyl isothiocyanate in 1,2-dioxane to afford the thioureas (25-32). The intermediates 
25-32 were condensed in 2N NaOH and EtOH to afford the thieno[2,3-d]pyrimide core 
scaffolds (33-40). Compounds 33-40 precipitated after neutralization with 10% acetic acid. 
Side chains were introduced to compounds 33-40 via thiol alkylations to afford the final 
products 1-8(a-i). Cesium carbonate was found to be superior to potassium carbonate in terms 
of reaction times and yields. Please note that the alkyl halides 41-44 were not commercially 
available and were prepared by reacting commercially primary amines with bromoacetyl 
chloride. The alkyl halides 41-44 were used in alkylation reactions with intermediates 33-40 
to afford final products with side chains: g, h, and i. 
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Figure 4.1. Structures of the synthesized thieno[2,3-d]pyrimidine compounds 
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Figure 4.2. Synthetic scheme to generate the thieno[2,3-d]pyrimidine library. A. Reactions to 
prepare the thieno[2,3-d]pyrimidine. B. Reactions to prepare the amido side chains. 
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(Table 4.1). From the hit 2i, we started to derivitize and synthesize a library of 72 analogues. 
Our library contains analogues that are modified at 2 sites: (1) the annulated ring at the 
western side of the thieno[2,3-d]pyrimidine core and (2) the side chain R1 (Figure 4.1 and 
Table 4.1). By comparing the IC50 values of analogues with the same side chains (R1), we 
realized that some annulated rings that are more likely to generate potent Eis inhibitors. In 7 
out of the 9 side chains, the cyclohexane (series 2) was most tolerated with IC50 values 
ranging from 0.154 ±  0.022 to 1.61 ± 0.16 µM. Other than the cyclohexane ring, the next two 
annulated rings that most likely yield potent compounds were the cyclopentane (series 1) and 
the 4-methyl cyclohexane (series 4) rings. On the other hand, all of the bulkier annulated rings 
such as 4-tertbutyl cyclohexane (series 6), 4-phenyl cyclohexane (series 7), and cycloheptane 
(series 8) tend to lead to analogues with diminished or no Eis inhibitory activity. This 
observation indicates that the Eis active site likely has spatial limitation in the area 
surrounding the western side of the thieno[2,3-d]pyrimidine core.  
 
To assess the side chain (R1), we compared compounds with the same annulated rings and 
varying R1 side chains. The R1 side chains are greatly diverse in terms of chemical structures. 
Despite the diversity, they all share the same characteristics, which is that they all contain 
tertiary aliphatic nitrogen-containing rings. In terms of the connection to the core, the linker 
may be methylene, ethylene, or propylene. Because the hit compound 2i contains an amide 
bond, we initially tried to replicate this feature in our study. Side chains g, h, and i generated a 
few potent inhibitors such as compounds 2g (IC50 = 0.249 ± 0.019 µM), 4g (0.197 ± 0.032 
µM), 2h (0.460 ± 0.061 µM), 5h (0.676 ± 0.0896 µM), and 4i (0.466 ± 0.080 µM). However, 
overall, adding amide bonds to these molecules typically decreased inhibitory activity. 
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Table 4.1. IC50 and MIC values of 
compounds. 
Cpd IC50 (µM) MC26020 MIC 
(µM) 
1a 2.19 ± 0.30 8  
2a 0.986 ± 
0.055 
4   
3a 6.68 ± 0.69 4   
4a 2.37 ± 0.16 4   
5a >200    
6a 22.6 ± 5.4 4   
7a 4.02 ± 1.12 4   
8a 6.64 ± 0.58 4   
1b 1.86 ± 0.16 64   
2b 1.14 ± 0.08 32   
3b 13.8 ± 1.3 32   
4b 1.97 ± 0.30 8   
5b 5.42 ± 0.52 4   
6b 15.8 ± 1.8 4   
7b 15.5 ± 2.1 16   
8b 7.55 ± 1.06 32   
1c 0.748 ± 
0.064 
32-64   
2c 0.172 ± 
0.037 
64   
3c 3.76 ± 0.47 16   
4c 0.612 ± 
0.079 
16   
5c 0.912 ± 
0.134 
16   
6c 6.62 ± 1.19    
7c 0.230 ± 
0.078 
4   
8c 1.22 ± 0.12 16   
1d 1.81 ± 0.12 16   
2d 0.450 ± 
0.029 
16   
3d 3.58 ± 0.16 16   
4d 0.810 ± 
0.132 
8   
5d >200 >100   
6d 6.33 ± 1.46 4   
7d 0.533 ± 
0.038 
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8d 2.25 ± 0.18 16   
1e 0.796 ± 
0.101 
128   
2e 0.154 ± 
0.022 
64   
3e 1.98 ± 0.11 64   
4e 0.358 ± 
0.053 
8   
5e 6.95 ± 0.72 >100   
6e 4.64 ± 0.63 4   
7e 0.463 ± 
0.174 
8   
8e 2.52 ± 0.07 32   
1f 11.4 ± 0.8 >100   
2f 1.48 ± 0.10 >100   
3f 51.6 ± 6.5 >100   
4f 3.56 ± 0.35    
5f 1.05 ± 0.07    
6f ~200    
7f 2.96 ± 0.58 16   
8f 8.74 ± 1.23 >100   
1g 1.86 ± 0.59    
2g 0.249 ± 
0.019 
>100   
3g ~2.4    
4g 0.197 ± 
0.032 
64   
5g 1.07 ± 0.24  16   
6g >200    
7g 0.484 ± 
0.058 
   
8g 3.10 ± 0.31 8   
1h 2.46 ± 0.37    
2h 0.460 ± 
0.061 
>100   
3h 6.79 ± 0.59 128   
4h 3.74 ± 0.650  64   
5h 0.676 ± 
0.896 
32   
6h 10.0 ± 4.1 16   
7h 0.925 ± 
0.291 
8   
8h 0.297 ± 
0.061 
   
1i 17.4 ± 1.3 >100   
2i 1.61 ± 0.16 >100 
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3i 55.6 ± 5.5  
4i 0.466 ± 
0.080 
>100 
5i 18.5 ± 3.4 128 
6i >200 32 
7i 15.7 ± 3.3 32 
8i 8.53 ± 1.31  
 
Subsequently, we analyzed the IC50 values for each series of compounds separately and 
recognized that side chain e (Figure 4.1) tends to be associated with the most potent Eis 
inhibitors. For instance, within the compound series 2a-e, compound 2e (IC50 = 0.154 ± 0.022) 
was the most potent inhibitor. Additionally, except in the case of compounds 5e (IC50 = 6.95 ± 
0.72), all molecules with side chain e, such as compounds 1e (IC50 = 0.796 ± 0.101), 3e (IC50 
= 1.98 ± 0.11), 4e (IC50 = 0.358 ± 0.053), and 6e (IC50 = 4.64 ± 0.63), were always part of the 
top 2 inhibitors in their respective compound series.  
 
Other than fragment e, we found that fragment c is also well representative within the best 
inhibitors. Compounds 1c (IC50 = 0.748 ± 0.064), 2c (IC50 = 0.172 ± 0.037), 4c (IC50 = 0.612 
± 0.079), 5c (IC50 = 0.912 ± 0.134), 7c (IC50 = 0.230 ± 0.078), and 8c (IC50 = 1.22 ± 0.12) 
were amongst the top two inhibitors in their respective series.  
 
While fragments e and c are highly associated with the most inhibitors, fragment i 
significantly diminished the activity of inhibitors. In the cases of compounds 1i, 2i, 4i, 5i, 6i, 
7i, and 8i, we observed that they were the worst inhibitors in their respective compound series. 
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4.2.4. Activity of thieno[2,3-d]pyrimidine Eis inhibitors against Mtb K204 cells  
With the help of our collaborators at the CDC, we were also able to co-administer some of 
these Eis inhibitors along with KAN against Mtb K204 cells to verify whether these inhibitors 
could restore the activity of KAN (Table 4.2). We observed that the most potent Eis inhibitors 
(1c, 2c, and 2e) were able to restore the activity of KAN at 2.5 µg/mL. On the other hand, the 
bad Eis inhibitors (3i and 8f) were not able to restore the activity of KAN. More interestingly, 
we also found that some compounds such as compounds 5g and 7g were displayed toxicity 
effects against Mtb K204 cells independently of KAN. This finding was intriguing and 
prompted us to evaluate all of our inhibitors against Mtb MC26020, an engineered fast-
growing Mtb strain. Since Mtb MC26020 is also a BSL 2 cell line, we were able to 
conveniently perform these MIC assays in the laboratory. 
 
Table 4.2. Activity of compounds on Mtb K204 cells. 
Cpd IC50 (µM) MICKAN (K204) treated with 
100 µM inhibitor (µg/mL) 
1c 0.748 ± 0.064 2.5 
2c 0.172 ± 0.037 2.5  
2e 0.154 ± 0.022 2.5 
3i 55.6 ± 5.5  10 
8f 8.74 ± 1.23 10 
5g 1.07 ± 0.24 Toxic without KAN 
7g 0.484 ± 0.058 Toxic without KAN 
 
4.2.5. Antitubercular activity against Mtb MC26020 
The best compounds displayed MIC as low as 4 µM (Table 4.1). Comparing IC50 with MIC 
values revealed that there is definitely no correlation between Eis inhibition and toxicity 
against Mtb cells. This finding suggested the mechanism of toxicity of these thieno[2,3-
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d]pyrimidine compounds is likely independent of Eis inhibition. We found that a large 
numbers of the compounds with potent MIC of 4 µM contain the side chain a (2a, 3a, 4a, 6a, 
7a, and 8a). Additionally, many molecules with the tert-butyl moiety (series 6) (6a, 6b, and 
6d) also have potent activity against Mtb cells. Compounds 2a and 7c are interesting because 
in addition to low MIC values, they are also low micromolar Eis inhibitors making them 
interesting molecules to evaluate for synergism with aminoglycosides. Efforts to elucidate the 
mechanism of action and synergism with aminoglycosides are ongoing. 
  
4.3. CONCLUSION 
From HTS, we were able to identify a novel class of Eis inhibitors. We also discovered that 
this class of compounds also displays cytotoxicity to Mtb cells, which is most likely unrelated 
to their abilities to inhibit Eis enzyme. However, this finding presents an intriguing 
application for these molecules. While capable of restoring the activity of KAN, these 
thieno[2,3-d]pyrimidine compounds are also likely to complement the bactericidal effect of 
KAN with their own mechanism of action. Future studies are ongoing to elucidate the 
unknown mechanism of action and explore the potential synergism between thieno[2,3-
d]pyrimidine compounds and aminoglycosides. 
 
4.4. MATERIALS AND INSTRUMENTATION 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and AK Scientific 
(Union City, CA, USA) and used without further purification. Deuterated solvents ((CD3)2SO, 
CDCl3, and CD3OD) were bought from Cambridge Isotope Laboratories Inc. (Tewksbury, 
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MA, USA). TLC (Merck, Silica gel 60 F250) was used to monitor reaction progress. 
Visualization of reaction progress was achieved using one or more of the following methods: 
UV absorption and a cerium-molybdate stain ((NH4)2Ce(NO3)6 (5 g), (NH4)6Mo7O24•4H4O 
(120 g), H2SO4 (80 mL), and H2O (720 mL)). Silica gel (SiO2, Dynamic Adsorbents Inc. 
Flash silica gel 32-63u) was used to perform flash column chromatography. NMR spectra 
were measured in δ (ppm) using the 1H NMR CDCl3 (δ 7.24 ppm), 13C NMR CDCl3 (δ 77.23 
ppm), 1H NMR (CD3)2SO (δ 2.50 ppm), 13C NMR (CD3)2SO (δ 39.51 ppm), 1H NMR 
CD3OD (δ 3.31 ppm), and 13C NMR CD3OD (δ 49.15 ppm) as internal standards. 
Abbreviations used: J = coupling constants in Hz, app. = apparent, br = broad, d = doublet, dd 
= doublet of doublets, dt = doublet of triplets, m = multiplet, p = pentet, q = quartet, s = 
singlet, t = triplet, qd = quartet of doublets, qt = quartet of triplets, td = triplet of doublets, tt = 
triplet of triplets; ddd = doublet of doublets of doublets, ddt = doublet of doublets of triplets, 
tdd = triplet of doublets of doublets. 1H NMR and 13C NMR spectra were recorded on a 
Varian 400 MHz instrument (Palo Alto, CA, USA). Low-resolution electrospray mass spectra 
(LRMS) were recorded on a liquid chromatography-mass spectrometry using an Agilent 1200 
series Quaternary LC system (Santa Clara, CA, USA) equipped with a diode array detector, 
and Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 µm), and an Agilent 6120 Quadrupole 
MSD mass spectrometer. Further confirmation of purity for these final molecules was 
performed on an Agilent Technologies 1260 Infinity HPLC system (Santa Clara, CA, USA), 
by using the following general method 1 and 2. Method 1: Flow rate = 0.5 mL/min; λ = 254 
nm; column = Apollo C18 column, 250 × 4.6 mm, 100 Å, 5 µm; Eluents: A = H2O + 0.1% 
formic acid, B = MeCN + 0.1% formic acid; gradient profile: starting from 5% B, increasing 
from 5% B to 95% B over 16 min, hold 100% B from 16-20 min, decreasing from 100% B to 
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5% B from 20-30 min. Method 2: Flow rate = 0.5 mL/min; λ = 254 nm; column = Vydac 
DENALI C18 column, 150 x 4.6 mm, 120 Å, 5 µm; Eluents: A = H2O + 0.1% TFA, B = 
MeCN; gradient profile: starting from 5% B to 100% B over 20 min, hold 100% B from 20-25 
min, decreasing from 100% B to 5% B from 25-27 min. Prior to each injection, the HPLC 
column was equilibrated for 15 min with 5% B. All compounds were ≥95% pure. All 
reactions were conducted under nitrogen atmosphere, unless otherwise specified. All yields 
reported refer to isolated yields. 
 
4.5. METHODS 
4.5.1. Chemical methods 
4.5.1.1. General procedure A for the preparation of compounds 17-24 
Synthesis of compounds 17-24 was done following a modified published protocol.155 
Malononitrile (1 eq) and sulfur (1 eq) were added to a solution of a cycloalkyl ketone (1 eq) in 
EtOH (30 mL). Morpholine (5 mL) was added to the mixture. After stirring at rt for 1-15 h, 
the reaction was quenched by the addition of ddH2O. The product was filtered, washed with 
ddH2O, and dried to afford the desired product. Note: Although we did not purify these 
compounds via SiO2 column chromatography, we report Rf values as an additional mean to 
verify that the correct compound is obtained. 
 
Preparation of compound 17. The known compound 17 was prepared by using 
the general procedure A. Malononitrile (3.97 g, 60.0 mmol), sulfur (1.91 g, 59.5 
mmol), cyclopentanone (9) (5.3 mL, 59.9 mmol), and morpholine (5 mL) in EtOH (30 mL) 
S
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were used to afford compound 17 (9.18 g, 94%; Rf 0.39 in 5:1/Hexanes:EtOAc) as a yellow 
solid after reacting for 15 h. This product was without any further purification: 1H NMR (400 
MHz, (CD3)2SO) δ 7.03 (s, 2H), 2.65 (m, 2H), 2.56 (m, 2H), 2.26 (m, 2H); 13C NMR (100 
MHz, (CD3)2SO) δ 168.6, 141.0, 121.3, 116.5, 78.8, 28.9, 28.0, 26.8; LRMS m/z calcd for 
C8H8N2S: 164.0; found 165.0 [M+H]+. 
 
Preparation of compound 18. The known compound 18 was prepared by using 
the general procedure A. Malononitrile (3.40 g, 50.1 mmol), sulfur (1.64 g, 50.1 
mmol), cyclohexanone (10) (4.7 mL, 50.1 mmol), and morpholine (5 mL) in EtOH (30 mL) 
were used to afford compound 18 (7.60 g, 84%) as a yellow solid after reacting for 5 h and 
purification using flash column chromatography (SiO2, 5:1/Hexanes:EtOAc, Rf 0.59): 1H 
NMR (400 MHz, CDCl3, which matches lit.155) δ 4.55 (s, 2H), 2.49-2.46 (m, 4H), 1.80-1.74 
(m, 4H). 
 
Preparation of compound 19. Compound 19 was prepared by using the 
general procedure A. Malononitrile (2.94 g, 44.58 mmol), sulfur (1.47 g, 51.40 
mmol), 2-methylcyclohexanone (11) (5.40 mL, 44.58 mmol), and morpholine (5 mL) in EtOH 
(30 mL) were used to afford compound 19 (1.43 g, 17%; Rf 0.25 in 4:1/Hexanes:EtOAc) as a 
brown crystal after reacting for 5 h: 1H NMR (400 MHz, CDCl3) δ 4.16 (br s, 2H), 2.80-2.75 
(m, 1H), 2.50-2.39 (m, 2H), 1.84-1.70 (m, 3H), 1.58-1.50 (m, 1H), 1.25 (d, J = 6.8 Hz, 3H); 
13C NMR (100 MHz, (CD3)2SO) δ 163.2, 135.9, 116.8, 116.5, 82.7, 29.7, 28.6, 23.8, 20.4, 
19.3; LRMS m/z calcd for C10H12N2S: 192.1; found 193.1 [M+H]+. 
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Preparation of compound 20. Compound 20 was prepared by using the 
general procedure A. Malononitrile (2.95 g, 44.60 mmol), sulfur (1.43 g, 44.60 
mmol), 4-methylcyclohexanone (12) (5.47 mL, 44.60 mmol), and morpholine (5 mL) in EtOH 
(30 mL) were used to afford compound 20 (6.29 g, 73%; Rf 0.88 in 9:1/CH2Cl2:MeOH) as a 
yellow solid after reacting for 5 h: 1H NMR (400 MHz, (CD3)2SO) δ 6.93 (s, 2H), 2.46 (d, J = 
5.2 Hz, 1H), 2.41-2.29 (m, 2H), 2.02 (ddt, J = 16.0, 9.6, 2.8 Hz, 1H), 1.86-1.75 (m, 2H), 1.35-
1.25 (m, 1H), 0.99 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO) δ 162.9, 130.8, 116.4, 
116.3, 83.0, 31.6, 30.0, 29.3, 23.9, 21.2; LRMS m/z calcd for C10H12N2S: 192.1; found 193.1 
[M+H]+. 
 
Preparation of compound 21. Compound 21 was prepared by using the 
general procedure A. Malononitrile (2.65 g, 39.62 mmol), sulfur (1.26 g, 
39.62 mmol), 4-ethylcyclohexanone (13) (5.6 mL, 39.62 mmol), and morpholine (5 mL) in 
EtOH (30 mL) were used to afford compound 21 (2.1 g, 26%; Rf 0.52 in 4:1/Hexanes:EtOAc) 
as a yellow solid after reacting for 5 h: 1H NMR (400 MHz, CDCl3, which matches the lit.156) 
δ 4.66 (br s, 2H), 2.56 (m, 2H), 2.42 (m, 1H), 2.14-2.07 (m, 1H), 1.92-1.86 (m, 1H), 1.67-1.59 
(m, 1H), 1.43-1.29 (m, 3H), 0.92 (t, J = 7.6 Hz, 3H). 
 
Preparation of compound 22. Compound 22 was prepared by using the 
general procedure A. Malononitrile (2.16 g, 32.41 mmol), sulfur (1.06 g, 
32.41 mmol), 4-tert-butylcyclohexanone (5.07, 32.41 mmol), and morpholine (5 mL) in EtOH 
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(30 mL) were used to afford compound 22 (7.32 g, 97%; Rf 0.42 in 4:1/Hexanes:EtOAc) as a 
yellow solid after reacting for 5 h: 1H NMR (400 MHz, CDCl3, which matches the lit.156) δ 
2.65-2.60 (m, 1H), 2.54-2.49 (m, 1H), 2.44-2.35 (m, 1H), 2.31-2.22 (m, 1H), 2.00-1.95 (m, 
1H), 1.48 (tdd, J = 12.0, 5.2, 2.0 Hz, 1H), 1.29 (qd, J = 12.0, 5.2 Hz, 1H), 0.92 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 163.0, 131.1, 117.3, 116.3, 82.8, 44.9, 32.2, 27.1, 25.1, 25.0, 23.4. 
 
Preparation of compound 23. Compound 23 was prepared by using the 
general procedure A. Malononitrile (1.18 g, 17.21 mmol), sulfur (0.58 g, 
17.21 mmol), 4-phenylcyclohexanone (3.06, 17.21 mmol), and morpholine (3 mL) in EtOH 
(20 mL) were used to afford compound 23 (3.22 g, 74%; Rf 0.22 in 4:1/Hexanes:EtOAc) as a 
yellow solid after reacting for 5 h: 1H NMR (400 MHz, CDCl3, which matches the lit.157) δ 
7.35-7.31 (m, 2H), 7.26-7.22 (m, 3H), 4.27 (br s, 2H), 3.06-2.98 (m, 1H), 2.82-2.77 (m, 1H), 
2.73-2.58 (m, 3H), 2.15-2.10 (m, 1H), 2.00-1.89 (m, 1H); 13C NMR (100 MHz, (CD3)2SO) δ 
163.1, 145.7, 130.9, 128.4, 126.9, 126.3, 116.4, 116.2, 83.0, 40.4, 31.4, 29.1, 24.4. 
 
Preparation of compound 24. Compound 24 was prepared by using the 
general procedure A. Malononitrile (2.95 g, 44.60 mmol), sulfur (1.43 g, 44.60 
mmol), cycloheptanone (5.26 mL, 44.60 mmol), and morpholine (5 mL) in EtOH (30 mL) to 
afford compound 24 (5.36 g, 63%; Rf 0.37 in 4:1/Hexanes:EtOAc) as a dark red solid after 
reacting for 5 h: 1H NMR (400 MHz, CDCl3) δ 4.18 (br s, 2H), 2.62-2.55 (m, 4H), 1.85-1.75 
(m, 2H), 1.68-1.58 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 158.2, 136.8, 123.6, 116.0, 91.6, 
31.8, 29.4, 29.1, 28.0, 27.2; LRMS m/z calcd for C10H12N2S: 192.1; found 193.1 [M+H]+. 
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4.5.1.2. General procedure B for the preparation of compounds 25-32 
Synthesis of compounds 25-32 was done following a published protocol.155 Benzoyl 
isothiocyanate (1 eq) was added to a solution of a thiophene derivative (1 eq) in anhydrous 
1,4-dioxane (20 mL). After stirring at rt for 1-3 h, the product was filtered and washed with a 
4:1/Hexanes:EtOAc mixture to afford the desired product, which was used without any further 
purification. Note: Although we did not purify these compounds via SiO2 column 
chromatography, we report Rf values as an additional mean to verify that the correct 
compound is obtained. 
 
Preparation of compound 25. The known compound 25 was prepared 
by using general procedure B. Benzoyl isothiocyanate (7.15 mL, 53.2 
mmol) and compound 17 (8.73 g, 53.2 mmol) in anhydrous 1,4-dioxane (20 mL) were used to 
afford compound 25 (12.54 g, 72%; Rf 0.66 in 10:1/Hexanes:EtOAc) as a yellow solid after 
reacting for 2 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.23 (s, 1H), 8.01 (app. d, J = 7.6 Hz, 2H), 
7.69 (app. t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 2.89 (t, J = 7.2 Hz, 2H), 2.80 (t, J = 7.2 
Hz, 2H), 2.39 (p, J = 7.2 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO) δ 175.1, 169.4, 151.6, 
140.9, 135.6, 133.5, 131.5, 128.9, 128.5, 113.9, 109.5, 29.1, 27.6, 27.5; LRMS m/z calcd for 
C16H13N3OS2: 327.1; found 328.0 [M+H]+. 
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Preparation of compound 26. The known compound 26 was prepared 
using general procedure B. Benzoyl isothiocyanate (1.45 mL, 10.78 
mmol) and compound 18 (2.01 g, 10.78 mmol) in anhydrous 1,4-dioxane (25 mL) were used 
to afford compound 26 (3.36 g, 90%; Rf 0.76 in 49:1/CH2Cl2:MeOH) as a yellow solid after 
reacting for 1 h: 1H NMR (400 MHz, (CD3)2SO, which matches lit.155) δ 12.26 (s, 1H), 8.01 
(d, J = 7.6 Hz, 2H), 7.69 (t, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 2H), 2.66 (m, 2H), 2.57 (m, 
2H), 1.78 (m, 4H); LRMS m/z calcd for C17H15N3OS2: 341.1; found 342.7 [M+H]+. 
 
Preparation of compound 27. Compound 27 was prepared using 
general procedure B. Benzoyl isothiocyanate (3.90 mL, 29.01 mmol) 
and compound 19 (5.54 g, 28.83 mmol) in anhydrous 1,4-dioxane (67 mL) were used to 
afford compound 27 (5.39 g, 53%; Rf 0.50 in 1:2/Hexanes:EtOAc) as a yellow solid after 
reacting for 1 h: 1H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 7.91 (dd, J = 8.8, 1.2 Hz, 2H), 
7.64 (tt, J = 6.8, 1.2 Hz, 1H), 7.53 (t, J = 8.0 Hz, 2H), 2.98-2.95 (m, 1H), 2.69-2.55 (m, 2H), 
2.14-1.75 (m, 3H), 1.63-1.54 (m, 1H), 1.31 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 174.3, 167.3, 147.7, 136.9, 134.3, 131.0, 129.8, 129.5, 128.0, 114.4, 98.4, 30.3, 29.0, 24.7, 
21.2, 19.8; LRMS m/z calcd for C18H17N3OS2: 355.1; found 356.1 [M+H]+. 
 
Preparation of compound 28. Compound 28 was prepared using 
general procedure B. Benzoyl isothiocyanate (4.40 mL, 32.7 mmol) 
and compound 20 (6.29 g, 32.7 mmol) in anhydrous 1,4-dioxane (60 mL) were used to afford 
compound 28 (9.00 g, 78%; Rf 0.55 in 1:2/Hexanes:EtOAc) as a yellow solid after reacting for 
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1 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.25 (s, 1H), 8.01 (dd, J = 8.4, 1.6 Hz, 2H), 7.69 (tt, J 
= 7.6, 1.2 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 2.77 (dd, J = 16.8, 4.8 Hz, 1H), 2.67-2.57 (m, 2H), 
2.28-2.21 (m, 1H), 1.89-1.86 (m, 2H), 1.44-1.34 (m, 1H), 1.04 (d, J = 6.0 Hz, 3H); 13C NMR 
(100 MHz, (CD3)2SO) δ 175.3, 169.4, 147.0, 133.5, 131.5, 130.7, 129.0, 128.6, 128.5, 113.6, 
96.8, 31.3, 29.7, 29.0, 23.1, 21.1; LRMS m/z calcd for C18H17N3OS2: 355.1; found 356.1 
[M+H]+. 
 
Preparation of compound 29. Compound 29 was prepared using 
general procedure B. Benzoyl isothiocyanate (2.70 mL, 20.36 
mmol) and compound 21 (4.20 g, 20.36 mmol) in anhydrous 1,4-dioxane (30 mL) were used 
to afford compound 29 (6.04 g, 80%, Rf 0.62 in 1:2/Hexanes:EtOAc) as a yellow solid after 
reacting for 1 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.24 (s, 1H), 8.01 (app. d, J = 8.0 Hz, 2H), 
7.69 (app. t, J = 7.2 Hz, 1H), 7.56 (t, J = 8.0 Hz, 2H), 2.79 (dd, J = 16.9, 4.8 Hz, 1H), 2.67-
2.62 (m, 1H), 2.57-2.54 (m, 1H), 2.25 (dd, J = 15.6, 10.4 Hz, 1H), 1.94-1.91 (m, 1H), 1.64 (m, 
1H), 1.44-1.30 (m, 3H), 0.93 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO) δ 175.3, 
169.4, 147.0, 133.5, 131.5, 130.9, 128.9, 128.6, 128.5, 113.6, 96.8, 35.7, 29.3, 28.0, 27.6, 23.1, 
11.3; LRMS m/z calcd for C19H19N3OS2: 369.1; found 370.1 [M+H]+. 
 
Preparation of compound 30. Compound 30 was prepared using 
general procedure B. Benzoyl isothiocyanate (4.40 mL, 32.7 mmol) 
and compound 22 (3.04 g, 13.0 mmol) in anhydrous 1,4-dioxane (30 mL) were used to afford 
compound 30 (5.09 g, 100%; Rf 0.49 in 4:1/Hexanes:EtOAc) as a yellow solid after reacting 
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for 3 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.23 (s, 1H), 8.03-8.00 (dd, J = 8.8, 1.2 Hz, 2H), 
7.69 (tt, J = 7.6, 1.2 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 2.71 (td, J = 16.4, 4.4 Hz, 2H), 2.53-
2.46 (m, 2H), 2.38 (m, 1H), 2.03-2.00 (m, 1H), 1.51-1.44 (m, 1H), 1.28 (qd, J = 12.4, 5.2 Hz, 
1H), 0.92 (s, 9H); 13C NMR (100 MHz, (CD3)2SO) δ 175.7, 169.9, 147.5, 133.9, 131.9, 131.4, 
130.0, 129.4, 128.9, 114.1, 97.0, 45.0, 32.7, 27.5, 25.5, 24.8, 23.8; LRMS m/z calcd for 
C21H23N3OS2: 397.1; found 398.1 [M+H]+. 
 
Preparation of compound 31. Compound 31 was prepared using 
general procedure B. Benzoyl isothiocyanate (1.58 mL, 11.8 
mmol) and compound 23 (3.03 g, 11.8 mmol) in anhydrous 1,4-dioxane (30 mL) were used to 
afford compound 31 (3.64 g, 74%; Rf 0.50 in 4:1/Hexanes:EtOAc) as a yellow solid after 
reacting for 1 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.22 (s, 1H), 8.02 (d, J = 7.2 Hz, 2H), 
7.69 (t, J = 7.2 Hz, 1H), 7.55 (t, J = 7.2 Hz, 2H), 7.33-7.30 (m, 4H), 7.23-7.20 (m, 1H), 2.99-
2.90 (m, 2H), 2.76-2.70 (m, 3H), 2.04-1.87 (m, 2H); 13C NMR (100 MHz, (CD3)2SO) δ 175.2, 
169.4, 147.2, 145.3, 133.5, 131.5, 130.7, 128.9, 128.5, 128.4, 126.9, 126.4, 113.6, 96.6, 66.3, 
40.0, 31.1, 28.9, 23.8; LRMS m/z calcd for C23H19N3OS2: 417.1; found 418.0 [M+H]+. 
 
Preparation of compound 32. Compound 32 was prepared using 
general procedure B. Benzoyl isothiocyanate (3.80 mL, 27.8 mmol) 
and compound 24 (5.36 g, 27.8 mmol) in anhydrous 1,4-dioxane (50 mL) were used to afford 
compound 32 (8.06 g, 82%; Rf 0.35 in 4:1/Hexanes:EtOAc) as a yellow solid after reacting for 
1 h: 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 7.93 (s, 1H), 7.91 (app. d, J = 1.1 Hz, 1H), 
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7.65 (app. t, J = 7.9 Hz, 1H), 7.53 (t, J = 8.1 Hz, 2H), 2.80-2.72 (m, 4H), 1.90-1.83 (m, 2H), 
1.73-1.63 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 173.8, 167.1, 144.6, 136.7, 134.1, 133.3, 
130.8, 129.2, 127.7, 114.2, 101.0, 32.0, 29.4, 29.1, 27.9, 27.3; LRMS m/z calcd for 
C18H17N3OS2: 355.1; found 356.1 [M+H]+. 
 
4.5.1.3. General procedure C for the preparation of compounds 33-40 
Synthesis of compounds 33-40 was done following a published protocol.155 2 N NaOH (50 
mL) was added to a mixture of benzamides (38.3 mmol) in EtOH (70 mL). After refluxing at 
100 °C for 30 min to 2 h, the solution was cooled to rt and then neutralized in an ice bath by 
adding 10% AcOH until the pH reached 7. The resultant precipitate was filtered and washed 
with a 4:1/H2O:EtOH mixture to afford the desired product, which was used without any 
further purification. Note: Although we did not purify these compounds via SiO2 column 
chromatography, we report Rf values as an additional mean to verify that the correct 
compound is obtained. 
 
Preparation of compound 33. Compound 33 was prepared using general 
procedure C. 2 N NaOH (50 mL) and compound 25 (12.54 g, 38.3 mmol) in 
EtOH (70 mL) were used to afford compound 33 (7.55 g, 88%; Rf 0.16 in 9:1/CH2Cl2:MeOH) 
as a brown solid after refluxing for 2 h: 1H NMR (400 MHz, (CD3)2SO) δ 12.58 (br s, 1H), 
7.42 (br s, 2H), 2.91 (app. t, J = 7.2 Hz, 2H), 2.82 (app. t, J = 7.2 Hz, 2H), 2.37 (app. p, J = 
7.2 Hz, 2H); LRMS m/z calcd for C9H9N3S2: 223.0; found 224.0 [M+H]+. 
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Preparation of compound 34. Compound 34 was prepared using general 
procedure C. 2 N NaOH (30 mL) and compound 26 (8.39 g, 24.6 mmol) in 
EtOH (45 mL) were used to afford compound 34 (5.80 g, 98%; Rf 0.22 in 49:1/ 
CH2Cl2:MeOH) as a yellow solid after refluxing for 30 min: 1H NMR (400 MHz, (CD3)2SO, 
which matches lit.155) δ 12.73 (br s, 1H), 7.23 (br s, 2H), 2.76 (m, 2H), 2.64 (m, 2H), 1.77 (m, 
4H); LRMS m/z calcd for C10H11N3S2: 237.0; found 238.8 [M+H]+. 
 
Preparation of compound 35. Compound 35 was prepared using general 
procedure C. 2 N NaOH (19 mL) and compound 27 (5.34 g, 15.0 mmol) in 
EtOH (28 mL) were used to afford compound 35 (2.88 g, 76%; Rf 0.27 in 
49:1/CH2Cl2:MeOH) as a yellow solid after refluxing for 45 min: 1H NMR (400 MHz, 
(CD3)2SO) δ 12.60 (br s, 1H), 7.34 (br s, 1H), 2.70-2.50 (m, 2H), 1.90-1.70 (m, 3H), 1.54-
1.50 (m, 1H), 1.08 (d, J = 4.4 Hz, 3H); LRMS m/z calcd for C11H13N3S2: 251.1; found 252.0 
[M+H]+. 
 
Preparation of compound 36. Compound 36 was prepared using general 
procedure C. 2 N NaOH (38 mL) and compound 28 (8.91 g, 25.3 mmol) in 
EtOH (50 mL) were used to afford compound 36 (6.10 g, 96%; Rf 0.26 in 
1:2/Hexanes:EtOAc) as a yellow solid after refluxing for 30 min: 1H NMR (400 MHz, 
(CD3)2SO) δ 13.04 (br s, 1H), 7.18 (br s, 2H), 2.90-2.60 (m, 1H), 2.73 (dd, J = 16.4, 5.1 Hz, 
1H), 2.25 (ddt, J = 16.5, 9.6, 2.5 Hz, 1H), 1.88-1.83 (m, 2H), 1.44-1.34 (m, 1H), 1.03 (d, J = 
6.5 Hz, 3H); LRMS m/z calcd for C11H13N3S2: 251.1; found 252.0 [M+H]+. 
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Preparation of compound 37. Compound 37 was prepared using general 
procedure C. 2 N NaOH (4 mL) and compound 29 (1.09 g, 5.24 mmol) in 
EtOH (4 mL) were used to afford compound 37 (0.79 g, 57%; Rf 0.32 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after refluxing for 30 min: 1H NMR (400 MHz, 
(CD3)2SO) δ 12.53 (very br s, 1H), 7.50 (very br s, 2H), 2.88-2.84 (m, 1H), 2.77 (dd, J = 16.4, 
4.8 Hz, 1H), 2.74-2.64 (m, 1H), 2.27 (dd, J = 16.4, 9.6 Hz, 1H), 1.91 (m, 1H), 1.64 (m, 1H), 
1.37 (m, 3H), 0.93 (t, J = 7.6 Hz, 3H); LRMS m/z calcd for C12H15N3S2: 265.1; found 266.1 
[M+H]+. 
 
Preparation of compound 38. Compound 38 was prepared using general 
procedure C. 2 N NaOH (38 mL) and compound 30 (8.91 g, 25.3 mmol) in 
EtOH (50 mL) were used to afford compound 38 (6.10 g, 96%; Rf 0.26 in 
1:2/Hexanes:EtOAc) as a white solid after refluxing for 30 min: 1H NMR (400 MHz, 
(CD3)2SO) δ 12.70 (very br s, 1H), 7.42 (very br s, 2H), 2.91-2.88 (m, 1H), 2.67-2.63 (m, 2H), 
2.37 (t, J = 13.2 Hz, 1H), 1.96-1.93 (m, 1H), 1.44 (td, J = 12.8, 4.4 Hz, 1H), 1.26 (qd, J = 12.8, 
4.8 Hz, 1H), 0.88 (s, 9H); 13C NMR (100 MHz, (CD3)2SO) δ 168.2, 131.8, 129.2, 128.3, 128.1, 
127.1, 43.9, 32.1, 27.0, 25.93, 25.87, 23.4; LRMS m/z calcd for C14H19N3S2: 293.1; found 
294.1 [M+H]+. 
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Preparation of compound 39. Compound 39 was prepared using general 
procedure C. 2 N NaOH (13.2 mL) and compound 31 (4.50 g, 10.8 
mmol) in EtOH (20 mL) were used to afford compound 39 (3.30 g, 98%; 
Rf 0.25 in 9:1/CH2Cl2:MeOH) as a yellow solid after refluxing for 30 min: 1H NMR (400 
MHz, (CD3)2SO) δ 12.64 (br s, 1H), 7.29 (m, 4H), 7.19 (m, 1H), 3.28 (br s, 2H), 3.03-2.94 (m, 
1H), 2.88 (m, 3H), 2.76 (m, 1H), 2.02-1.86 (m, 2H); LRMS m/z calcd for C16H15N3S2: 313.1; 
found 314.1 [M+H]+. 
 
Preparation of compound 40. Compound 40 was prepared using general 
procedure C. 2 N NaOH (26 mL) and compound 32 (8.06 g, 22.6 mmol) in 
EtOH (45 mL) were used to afford compound 40 (4.64 g, 82%; Rf 0.19 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after reacting for 30 min: 1H NMR (400 MHz, 
(CD3)2SO) δ 12.82 (br s 1H), 7.42 (br s, 2H), 2.83 (m, 2H), 2.71 (m, 2H), 1.79-1.73 (m, 2H), 
1.64-1.56 (m, 4H); LRMS m/z calcd for C11H13N3S2: 251.1; found 252.0 [M+H]+. 
 
4.5.1.4. General procedure for S-alkylation of compounds 33-40 
4.5.1.4.1. General procedure D for the preparation of compounds 1a, 2a, 7a, 8a, 1b, 2b, 
4b, 5b, 6b, 7b, 8b, 1c, 2c, 3c, 4c, 7c, 8c, 1d, 2d, 4d, 7d, 8d, 1e, 2e, 4e, 5e, 6e, 7e, 8e, 2f, 4f, 
5f, 6f, 7f, 8f, 1g, 2g, 4g, 7g, 8g, 1h, 2h, 4h, 7h, 8h, 1i,  2i, 3i, 4i, 7i, and 8i 
K2CO3 (2 eq) was added to a solution of thieno[2,3-d]pyrimidin-4amines (1 eq) in anhydrous 
DMF and stirred at 80 °C for about 20 min. Alkyl halide (1 eq) was added to the mixture, 
which was stirred for an additional 3-4 h at 80 °C. The reaction mixture was cooled to rt and 
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quenched by the addition of aq. NaHCO3 or ddH2O. The product was either extracted with 
EtOAc or CH2Cl2 three times and then washed with brine three times or filtered. The organic 
layer was then dried over MgSO4 and evaporated to dryness under reduced pressure to give a 
residue, which was purified by column chromatography to afford the desire product. 
 
4.5.1.4.2. General procedure E for the preparation of compounds 3a, 4a, 5a, 6a, 3b, 5c, 
6c, 3d, 5d, 6d, 3e, 1f, 3f, 3g, 5g, 6g, 3h, 5h, 6h, 3i, 5i, and 6i. 
The synthesis of these compounds was done following a published thiol alkylation protocol.158 
Cs2CO3 (1.1 eq) and TBAI (1 eq) were added to a solution of thieno[2,3-d]pyrimidin-4amines 
(1 eq) in anhydrous DMF and stirred at 80 °C for 30 min. Alkyl halide (1.5 eq) was added, 
and the mixture was heated at 80 °C for an additional 1-4 h. The reaction was cooled to rt and 
quenched by addition of aq. NaHCO3, extracted with EtOAc three times, and washed with 
brine three times. The organic layer was then dried over MgSO4 and evaporated to dryness 
under reduced pressure to give a residue, which was purified by column chromatography to 
afford the desire product. 
 
Preparation of compound 1a. Compound 1a was synthesized using 
general procedure D. Compound 33 (0.20 g, 0.91 mmol), K2CO3 (0.28 g, 
2.00 mmol), and 1-(2-chloroethyl)pyrrolidine hydrochloride (0.15 g, 0.91 
mmol) in anhydrous DMF (7.4 mL) were used to afford compound 1a (103 mg, 35%, Rf 0.22 
in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, 
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CD3OD, Figure C7) δ 3.38 (t, J = 6.8 Hz, 2H), 3.20 (t, J = 6.4 Hz, 2H), 3.08 (br t, J = 6.0 Hz, 
4H), 3.02 (t, J = 7.2 Hz, 2H), 2.94 (t, J = 7.2 Hz, 2H), 2.50 (p, J = 7.2 Hz, 2H), 1.98 (p, J = 
3.2 Hz, 4H); 13C NMR (100 MHz, (CD3)2SO, Figure C8) δ 171.5, 163.3, 157.3, 135.9, 134.3, 
109.3, 54.2, 53.2, 29.0, 28.7, 27.2, 27.0, 22.9; LRMS m/z calcd for C15H20N4S2: 320.1; found 
321.1 [M+H]+ (Figure C1A); Purity of the compound was further confirmed by RP-HPLC by 
using method 2: Rt = 19.29 min (96% pure, Figure C9). 
 
Preparation of compound 2a HXN-1-98. Compound 2a was 
synthesized using general procedure D. Compound 34 (0.24 g, 0.78 
mmol), K2CO3 (0.24 g, 1.72 mmol), and 1-(2-chloroethyl)pyrrolidine 
hydrochloride (0.13 g, 0.78 mmol) in anhydrous DMF (4 mL) were used to afford compound 
2a (145 mg, 56%, Rf 0.36 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 
1H NMR (400 MHz, (CD3)2SO, Figure C10) δ 6.86 (br s, 2H), 3.21 (t, J = 7.4 Hz, 2H), 2.84 
(m, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.69 (m, 2H), 2.64-2.55 (m, 4H), 1.79-1.77 (m, 4H), 1.73-
1.64 (m, 4H); 13C NMR (100 MHz, (CD3)2SO, Figure C11) δ 166.6, 164.4, 158.0, 129.4, 
127.2, 112.6, 55.4, 53.8, 28.8, 25.8, 25.1, 23.5, 22.7, 22.4; LRMS m/z calcd for C16H22N4S2: 
334.1; found 335.1 [M+H]+ (Figure C1B); Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 19.96 min (96% pure, Figure C12). 
 
Preparation of compound 3a. Compound 3a was synthesized using 
general procedure E. Compound 35 (0.20 g, 0.78 mmol), Cs2CO3 (0.29 g, 
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0.88 mmol), TBAI (0.30 g, 0.80 mmol), and (1-(2-chloroethyl)pyrrolidine hydrochloride (0.16 
g, 1.21 mmol) in anhydrous DMF (4 mL) were used to afford compound 3a (144 mg, 54%, Rf 
0.39 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 
MHz, CD3OD, Figure C13) δ 3.30-3.26 (m, 2H), 3.24-3.19 (m, 1H), 2.84-2.79 (m, 2H), 2.78-
2.70 (m, 2H), 2.66 (br t, J = 5.6 Hz, 4H), 2.02-1.94 (m, 2H), 1.94-1.78 (m, 2H), 1.84 (app. p, J 
= 3.6 Hz, 4H), 1.30 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C14) δ 168.1, 
164.3, 156.5, 131.1, 130.9, 112.3, 55.9, 54.0, 29.7, 29.5, 29.1, 25.3, 23.4, 21.7, 17.7; LRMS 
m/z calcd for C17H24N4S2: 348.1; found 349.0 [M+H]+ (Figure C1C); Purity of the compound 
was further confirmed by RP-HPLC by using method 2: Rt = 20.82 min (95% pure, Figure 
C15). 
 
Preparation of compound 4a. Compound 4a was synthesized using 
general procedure E. Compound 36 (0.31 g, 1.00 mmol), Cs2CO3 (0.14 
g, 0.42 mmol), TBAI (0.16 g, 0.42 mmol), and 1-(2-chloroethyl)-
pyrrolidine hydrochloride (0.10 g, 0.60 mmol) in anhydrous DMF (2 mL) at 90 °C were used 
to afford compound 4a (28 mg, 20%, Rf 0.35in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as 
a white solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C16) δ 3.26 (m, 2H), 3.02-2.93 (m, 
1H), 2.90-2.84 (m, 1H), 2.83-2.76 (m, 3H), 2.64 (br t, J = 5.6 Hz, 4H), 2.38-2.30 (m, 1H), 
2.02-1.88 (m, 2H), 1.83 (p, J = 3.6 Hz, 4H), 1.54-1.44 (m, 1H), 1.11 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CD3OD, Figure C17) δ 168.4, 165.8, 159.5, 131.6, 127.6, 113.9, 57.5, 55.1, 
34.3, 31.9, 30.5, 29.9, 26.7, 24.4, 21.7; LRMS m/z calcd for C17H24N4S2: 348.1; found 349.0 
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[M+H]+ (Figure C1D); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 11.72 min (96% pure, Figure C18). 
 
Preparation of compound 5a. Compound 5a was synthesized using 
general procedure E. Compound 37 (0.20 g, 0.75 mmol), Cs2CO3 
(0.24 g, 0.75 mmol), TBAI (0.28 g, 0.75 mmol), and 1-(2-
chloroethyl)-pyrrolidine hydrochloride (0.14 g, 0.83 mmol) in anhydrous DMF (4 mL) were 
used to afford compound 5a (30 mg, 11%, Rf 0.43 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a white solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C19) δ 
3.36-3.26 (m, 2H), 3.10 (t, J = 8.0 Hz, 2H), 3.00 (m, 4H), 2.91 (m, 1H), 2.79 (dd, J = 16.0, 4.0 
Hz, 2H), 2.34-2.26 (m, 1H), 2.04-1.96 (m, 1H), 1.93 (m, 4H), 1.70-1.60 (m, 1H), 1.48-1.34 (m, 
3H), 0.97 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO, Figure C20) δ 166.3, 164.3, 
157.5, 128.6, 126.7, 111.9, 35.2, 31.2, 30.6, 29.4, 28.0, 27.9, 25.1, 21.4, 13.6, 11.3; LRMS 
m/z calcd for C18H26N4S2: 362.2; found 363.0 [M+H]+ (Figure C1E); Purity of the compound 
was further confirmed by RP-HPLC by using method 2: Rt = 22.41 min (98% pure, Figure 
C21). 
 
Preparation of compound 6a. Compound 6a was synthesized using 
general procedure E. Compound 38 (0.31 g, 1.00 mmol) Cs2CO3 
(0.33 g, 1.00 mmol), TBAI (0.37 g, 1.00 mmol), and 1-(2-
chloroethyl)-pyrrolidine hydrochloride (0.19 g, 1.10 mmol) in anhydrous DMF (2 mL) were 
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used to afford compound 6a (15 mg, 10%, Rf 0.40 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a white solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CDCl3, Figure C22) δ 5.33 
(br s, 2H), 3.31 (t, J = 7.6 Hz, 2H), 2.81 (dd, J = 15.2, 5.2 Hz, 1H), 2.84 (t, J = 7.2 Hz, 2H), 
2.81-2.76 (m, 2H), 2.67 (br t, 4H), 2.55-2.45 (m, 1H), 2.09 (dd, J = 11.6, 5.2 Hz, 1H), 1.89 
(app. p, J = 3.2 Hz, 4H), 1.70-1.62 (m, 1H), 1.54 (td, J = 11.6, 3.2 Hz, 2H), 1.48-1.38 (m, 1H), 
0.94 (s, 9H); 13C NMR (100 MHz, CDCl3, Figure C23) δ 168.1, 164.7, 157.4, 132.5, 125.6, 
112.8, 56.2, 54.3, 44.9, 32.7, 29.4, 27.5, 27.3, 27.1, 24.3, 23.7; LRMS m/z calcd for 
C20H30N4S2: 390.2; found 391.1 [M+H]+ (Figure C1F); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 15.69 min (96% pure, Figure C24). 
 
Preparation of compound 7a. Compound 7a was synthesized 
using general procedure D. Compound 39 (0.2 g, 0.65 mmol), 
K2CO3 (0.19 g, 1.41 mmol), and 1-(2-chloroethyl)-pyrrolidine 
hydrochloride (0.11 g, 0.64 mmol) in anhydrous DMF (4 mL) were used to afford compound 
7a (124 mg, 47%, Rf 0.26 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, 
CDCl3, Figure C25) δ 7.35-7.30 (m, 2H), 7.26-7.20 (m, 3H), 5.38 (br s, 2H), 3.32 (m, 2H), 
3.13-2.88 (m, 5H), 2.85 (m, 2H), 2.67 (br p, 4H), 2.30-2.18 (m, 1H), 2.10-2.00 (m, 1H), 1.82 
(p, J = 3.2 Hz, 4H); 13C NMR (100 MHz, CDCl3, Figure C26) δ 167.8, 164.1, 157.4, 144.9, 
130.9, 128.6, 126.8, 126.6, 125.3, 112.6, 55.6, 53.9, 40.1, 32.9, 29.7, 28.4, 26.2, 23.4; LRMS 
m/z calcd for C22H26N4S2: 410.2; found 411.0 [M+H]+ (Figure C1G); Purity of the compound 
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was further confirmed by RP-HPLC by using method 1: Rt = 14.85 min (97% pure, Figure 
C27). 
 
Preparation of compound 8a. Compound 8a was synthesized using 
general procedure D. Compound 40 (0.21 g, 0.82 mmol), K2CO3 (0.21 g, 
1.47 mmol), and 1-(2-chloroethyl)-pyrrolidine hydrochloride (0.14 g, 
0.81 mmol) in anhydrous DMF (4 mL) were used to afford compound 8a (117 mg, 41%, Rf 
0.35 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, (CD3)2SO, Figure C28) δ 
6.92 (s, 2H), 3.14 (t, J = 7.2 Hz, 2H), 2.93-2.91 (m, 2H), 2.77-2.74 (m, 2H), 2.62 (t, J = 7.2 
Hz, 2H), 2.45-2.41 (m, 4H), 1.80-1.75 (m, 2H), 1.67-1.57 (m, 8H); 13C NMR (100 MHz, 
CDCl3, Figure C29) δ 166.4, 163.9, 157.3, 135.2, 130.3, 114.2, 56.0, 54.0, 30.6, 29.9, 29.3, 
28.9, 27.1, 26.4, 23.5; LRMS m/z calcd for C17H24N4S2: 348.1; found 349.1 [M+H]+ (Figure 
C1H); Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
13.24 min (97% pure, Figure C30). 
 
Preparation of compound 1b. Compound 1b was synthesized using 
general procedure D. Compound 33 (0.11 g, 0.50 mmol), K2CO3 (0.15 g, 
1.11 mmol), and 1-(2-chloroethyl)piperidine hydrochloride (0.10 g, 0.53 
mmol) in anhydrous DMF (4 mL) were used to afford compound 1b (65 mg, 55%, Rf 0.16 in 
CH2Cl2:MeOH/9:1 with NH4OH (7mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CDCl3, Figure C31) δ 5.13 
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(s, 2H), 3.29 (t, J = 7.6 Hz, 2H), 2.96 (m, 4H), 2.70 (t, J = 7.6 Hz, 2H), 2.50 (m, 6H), 1.61 (p, 
J = 5.6 Hz, 4H), 1.44 (p, J = 4.8 Hz, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure C32) δ 
171.5, 163.9, 157.2, 135.9, 134.2, 109.3, 57.7, 53.5, 29.0, 28.7, 27.2, 26.7, 25.0, 23.6; LRMS 
m/z calcd for C16H22N4S2: 334.1; found 335.1 [M+H]+ (Figure C1I); Purity of the compound 
was further confirmed by RP-HPLC by using method 2: Rt = 20.59 min (95% pure, Figure 
C33). 
 
Preparation of compound 2b. Compound 2b was synthesized using 
general procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.24 g, 
1.72 mmol), and 1-(2-chloroethyl)piperidine hydrochloride (0.15 g, 0.78 
mmol) in anhydrous DMF (4 mL) were used to afford compound 2b (145 mg, 53%, Rf 0.25 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a light yellow solid after purification by 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 
MHz, CDCl3, Figure C34) δ 5.33 (br s, 2H), 3.31 (m, 2H), 2.84 (m, 2H), 2.74 (m, 4H), 2.58 
(br s, 4H), 1.89-1.85 (m, 4H), 1.67 (br s, 4H), 1.46 (br s, 2H); 13C NMR (100 MHz, (CD3)2SO, 
Figure C35) δ 166.1, 163.9, 157.6, 129.0, 126.8, 112.1, 57.8, 53.6, 26.7, 25.3, 25.1, 24.7, 23.7, 
22.2, 21.9; LRMS m/z calcd for C17H24N4S2: 348.1; found 349.1 [M+H]+ (Figure C1J); Purity 
of the compound was further confirmed by RP-HPLC by using method 2: Rt = 20.21 min 
(97% pure, Figure C36). 
 
Preparation of compound 3b. Compound 3b was synthesized using 
general procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.29 g, 
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0.88 mmol), TBAI (0.29 g, 0.80 mmol), and 1-(2-chloroethyl)piperidine hydrochloride (0.18 g, 
1.20 mmol) in anhydrous DMF (4 mL) were used to afford compound 3b (141 mg, 49%, Rf 
0.42 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 
MHz, CD3OD, Figure C37) δ 3.28-3.18 (m, 2H), 3.10-3.00 (m, 2H), 2.82-2.66 (m, 2H), 2.34 
(s, 3H), 2.32-2.22 (m, 2H), 2.18-2.08 (m, 2H), 2.22-1.56 (m, 8H), 1.29 (d, J = 7.2 Hz, 3H); 
13C NMR (100 MHz, CDCl3, Figure C38) δ 168.1, 164.5, 146.4, 131.0, 130.9, 112.2, 58.8, 
54.4, 29.7, 29.5, 27.6, 25.9, 25.31, 24.3, 21.7, 17.7; LRMS m/z calcd for C18H26N4S2: 362.2; 
found 363.0 [M+H]+ (Figure C1K); Purity of the compound was further confirmed by RP-
HPLC by using method 1: Rt = 13.68 min (96% pure, Figure C39). 
 
Preparation of compound 4b. Compound 4b was synthesized using 
general procedure D. Compound 36 (0.10 g, 0.39 mmol), K2CO3 (0.07 
g, 0.43 mmol), and 1-(2-chloroethyl)piperidine hydrochloride (0.07 g, 
0.39 mmol) in anhydrous DMF (4 mL) were used to afford compound 4b (78 mg, 55%, Rf 
0.44 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a light yellow solid after purification by 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 
MHz, (CD3)2SO, Figure C40) δ 6.84 (br s, 2H), 3.17 (t, J = 6.8 Hz, 2H), 2.96-2.76 (m, 4H), 
2.55 (m, 1H), 2.41 (m, 3H), 2.35-2.28 (m, 2H), 1.90-1.86 (m, 2H), 1.51-1.37 (m, 7H), 1.05 (d, 
J = 6.5 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO, Figure C41) δ 166.3, 164.1, 157.6, 128.5, 
126.4, 112.0, 58.1, 53.7, 32.7, 30.0, 28.5, 27.1, 25.4, 25.0, 23.9, 21.1; LRMS m/z calcd for 
C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure C1L); Purity of the compound was further 
confirmed by RP-HPLC by using method 2: Rt = 20.74 min (96% pure, Figure C42). 
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Preparation of compound 5b. Compound 5b was synthesized using 
general procedure D. Compound 37 (0.10 g, 0.42 mmol), Cs2CO3 
(0.14 g, 0.42 mmol), TBAI (0.16 g, 0.42 mmol), and 1-(2-
chloroethyl)piperidine hydrochloride (0.11 g, 0.62 mmol) in anhydrous DMF were used to 
afford compound 5b (56 mg, 35%, Rf 0.52 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a 
white solid after purification by recrystallization from Hexanes:EtOAc: 1H NMR (400 MHz, 
CD3OD, Figure C43) δ 3.28-3.24 (m, 2H), 3.02-2.96 (m, 1H), 2.90-2.80 (m, 2H), 2.69-2.65 
(m, 2H), 2.55 (br t, 4H), 2.42-2.33 (m, 1H), 2.11-2.03 (m, 1H), 1.89-1.68 (m, 1H), 1.64 (p, J = 
5.2 Hz, 4H), 1.55-1.43 (m, 5H), 1.02 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure 
C44) δ 168.0, 164.9, 157.4, 131.6, 125.5, 112.9, 59.0, 54.6, 36.0, 31.4, 28.74, 28.67, 27.9, 
26.10, 26.06, 24.5, 11.7; LRMS m/z calcd for C19H28N4S2: 376.2; found 377.0 [M+H]+ 
(Figure C2A); Purity of the compound was further confirmed by RP-HPLC by using method 
1: Rt = 14.82 min (95% pure, Figure C45). 
 
Preparation of compound 6b. Compound 6b was synthesized using 
general procedure D. Compound 38 (0.31 g, 1.02 mmol), K2CO3 
(0.225, 1.63 mmol), and 1-(2-chloroethyl)piperidine hydrochloride 
(0.21 g, 1.14 mmol) in anhydrous DMF (6 mL) were used to afford compound 6b (10 mg, 3%, 
Rf 0.42 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by 
recrystallization from CH2Cl2:Hexanes: 1H NMR (400 MHz, CDCl3, Figure C46) δ 5.30 (s, 
2H), 3.28 (t, J = 7.2 Hz, 2H), 2.95 (dd, J = 14.8, 4.8 Hz, 1H), 2.78 (dd, J = 16.0, 4.0 Hz, 2H), 
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2.69 (t, J = 7.6 Hz, 2H), 2.58-2.44 (m, 5H), 2.10-2.08 (m, 1H), 1.61 (p, J = 5.2 Hz, 4H), 1.53 
(dd, J = 15.2, 4.0 Hz, 2H), 1.44 (p, J = 5.2 Hz, 2H), 0.94 (s, 9H); 13C NMR (100 MHz, CDCl3, 
Figure C47) δ 167.8, 164.6, 157.1, 132.2, 125.3, 112.6, 58.7, 54.3, 44.6, 32.5, 27.6, 27.2, 27.1, 
26.8, 25.7, 24.2, 24.1; LRMS m/z calcd for C21H32N4S2: 404.2; found 405.0 [M+H]+ (Figure 
C2B); Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
16.03 min (96% pure, Figure C48). 
 
Preparation of compound 7b. Compound 7b was synthesized 
using general procedure D. Compound 38 (0.20 g, 0.65 mmol), 
K2CO3 (0.20 g, 1.42 mmol), and 1-(2-chloroethyl)piperidine 
hydrochloride (0.12 g, 0.64 mmol) in anhydrous DMF (4 mL) were used to afford compound 
7b (34 mg, 12%, Rf 0.34 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 
1H NMR (400 MHz, CDCl3, Figure C49) δ 7.35-7.30 (m, 2H), 7.28-7.20 (m, 3H), 5.47 (s, 2H), 
3.31 (m, 2H), 3.13-2.85 (m, 5H), 2.75 (m, 2H), 2.57 (br p, 4H), 2.25-2.15 (m, 1H), 2.10-1.98 
(m, 1H), 1.65 (p, J = 5.6 Hz, 4H), 1.45 (p, J = 5.6 Hz, 2H); 13C NMR (100 MHz, CDCl3, 
Figure C50) δ 167.8, 164.6, 157.3, 145.0, 130.9, 128.6, 126.8, 126.6, 125.3, 112.6, 58.5, 54.2, 
40.1, 32.9, 29.7, 27.4, 26.2, 25.4, 24.0; LRMS m/z calcd for C23H28N4S2: 424.2; found 425.0 
[M+H]+ (Figure C2C); Purity of the compound was further confirmed by RP-HPLC by using 
method 2: Rt = 22.54 min (96% pure, Figure C51). 
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Preparation of compound 8b. Compound 8b was synthesized using 
general procedure D. Compound 39 (0.10 g, 0.39 mmol), K2CO3 (0.12 
g, 0.86 mmol), and 1-(2-chloroethyl)piperidine hydrochloride (0.07 g, 
0.39 mmol) in anhydrous DMF (4 mL) were used to afford compound 8b (80 mg, 57%, Rf 
0.45 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a brown solid after purification by 
column chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CDCl3, Figure 
C52) δ 5.28 (s, 2H), 3.28-3.24 (m, 2H), 2.95-2.92 (m, 2H), 2.83-2.81 (m, 2H), 2.68-2.64 (m, 
2H), 2.48 (t, J = 5.4 Hz, 4H), 1.90-1.84 (m, 2H), 1.81-1.74 (m, 4H), 1.59 (p, J = 5.4 Hz, 4Hz), 
1.42 (p, J = 5.4 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure C53) δ 166.4, 157.4, 135.2, 
130.4, 114.2, 58.2, 54.1, 30.6, 29.9, 29.2, 28.9, 27.1, 26.9, 26.4, 24.9, 23.8; LRMS m/z calcd 
for C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure C2D); Purity of the compound was 
further confirmed by RP-HPLC by using method 2: Rt = 23.15 min (100% pure, Figure C54). 
 
Preparation of compound 1c. Compound 1c was synthesized using 
general procedure D. Compound 33 (0.20 g, 0.90 mmol), K2CO3 
(0.28 g, 2.00 mmol), and 1-(3-chloropropyl)piperidine 
monohydrochloride (0.18 g, 0.91 mmol) in anhydrous DMF (4 mL) were used to afford 
compound 1c (120 mg, 39%, Rf 0.16 in 9:1/CH2Cl2:MeOH with NH4OH (7mL/L)) as a brown 
solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)): 1H NMR (400 MHz, (CD3)2SO, Figure C55) δ 6.90 (br s, 2H), 3.03 (t, J = 8.0 Hz, 
2H), 2.94 (t, J = 8.0 Hz, 2H), 2.83 (t, J = 8.0 Hz, 2H), 2.34 (p, J = 8.0 Hz, 2H), 1.82 (p, J = 
8.0 Hz, 2H), 1.51 (p, J = 4.0 Hz, 4H), 1.36 (p, J = 4.0 Hz, 2H); 13C NMR (100 MHz, 
(CD3)2SO, Figure C56) δ 171.5, 164.1, 157.1, 135.9, 134.1, 109.2, 60.1, 55.2, 45.7, 35.5, 33.6, 
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29.0, 28.8, 28.7, 27.2, 24.0; LRMS m/z calcd for C17H24N4S2: 348.1; found 349.1 [M+H]+ 
(Figure C2E); Purity of the compound was further confirmed by RP-HPLC by using method 
2: Rt = 24.10 min (99% pure, Figure C57). 
 
Preparation of compound 2c. Compound 2c was synthesized using 
general procedure D. Compound 34 (0.21 g, 0.78 mmol), K2CO3 
(0.15 g, 0.78 mmol), and 1-(3-chloropropyl)piperidine 
monohydrochloride (0.15 g, 0.78 mmol) in anhydrous DMF (4 mL) were used to afford 
compound 2c (120 mg, 42%, Rf 0.32 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a light 
yellow solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C58) δ 3.21 (t, J = 7.2 Hz, 2H), 
3.24-3.06 (m, 6H), 2.94-2.86 (m, 2H), 2.80-2.74 (m, 2H), 2.18 (m, 2H), 1.91 (m, 4H), 1.83 (br 
p, 4H), 1.72-1.60 (m, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure C59) δ 166.1, 163.7, 157.6, 
129.1, 126.8, 112.2, 54.9, 51.9, 27.1, 25.3, 24.7, 23.8, 22.4, 22.2, 21.9, 21.4; LRMS m/z calcd 
for C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure C2F); Purity of the compound was 
further confirmed by RP-HPLC by using method 2: Rt = 18.58 min (99% pure, Figure C60). 
 
Preparation of compound 3c. Compound 3c was synthesized using 
general procedure D. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 
(0.30 g, 0.90 mmol), TBAI (0.29 g, 0.78 mmol), and 1-(3-
chloropropyl)piperidine monohydrochloride (0.19 g, 1.19 mmol) in anhydrous DMF (4 mL) 
were used to afford compound 3c (183 mg, 60%, Rf 0.26 in 9:1/CH2Cl2:MeOH with NH4OH 
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(7 mL/L)) as a white solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C61) δ 
3.28-3.18 (m, 1H), 3.15 (t, J = 6.8 Hz, 2H), 2.84-2.64 (m, 2H), 2.58-2.40 (m, 6H), 1.97 (t, J = 
6.8 Hz, 2H), 2.02-1.92 (m, 2H), 1.92-1.74 (m, 2H), 1.62 (p, J = 5.2 Hz, 4H), 1.48 (m, 2H), 
1.29 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C62) δ 168.0 164.8, 156.7, 
131.2, 130.9, 112.3, 58.3, 54.6, 29.7, 29.5, 29.0, 26.9, 26.0, 25.4, 24.5, 21.8, 17.8; LRMS m/z 
calcd for C19H28N4S2: 376.2; found 377.0 [M+H]+ (Figure C2G); Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 11.81 min (97% pure, Figure C63). 
 
Preparation of compound 4c. Compound 4c was synthesized 
using general procedure D. Compound 36 (0.21 g, 0.78 mmol), 
K2CO3 (0.21 g, 0.78 mmol), and 1-(3-chloropropyl)piperidine 
monohydrochloride (0.15 g, 0.78 mmol) in anhydrous DMF (4 mL) were used to afford 
compound 4c (215 mg, 79%, Rf 0.29 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white 
solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)): 1H NMR (400 MHz, CD3OD, Figure C64) δ 3.11 (t, J = 7.2 Hz, 2H), 3.01-2.92 (m, 
1H), 2.90-2.83 (m, 1H), 2.81 (dd, J = 17.2 Hz, 4.0 Hz, 1H), 2.46 (t, J = 7.6 Hz, 2H), 2.46-2.37 
(m, 4H), 2.36-2.30 (m, 1H), 2.00 (m, 2H), 1.93 (p, J = 7.2 Hz, 2H), 1.57 (p, J = 5.6 Hz, 4H), 
1.54-1.48 (m, 1H), 1.44 (p, J = 5.2 Hz, 2H), 1.10 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3, Figure C65) δ 167.7, 164.8, 157.1, 131.1, 125.0, 112.7, 57.9, 54.3, 33.3, 30.5, 29.0, 
28.9, 26.4, 25.8, 25.3, 24.0, 21.2; LRMS m/z calcd for C19H28N4S2: 376.2; found 377.1 
[M+H]+ (Figure C2H); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 13.58 min (97% pure, Figure C66). 
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Preparation of compound 5c. Compound 5c was synthesized 
using general procedure E. Compound 37 (0.10 g, 0.42 mmol), 
Cs2CO3 (0.14 g, 0.42 mmol), TBAI (0.16 g, 0.42 mmol), and 1-
(3-chloropropyl)piperidine monohydrochloride (0.12 g, 0.62 mmol) in anhydrous DMF (8 
mL) were used to afford compound 5c (44 mg, 27%, Rf 0.33 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by recrystallization from Hexanes:EtOAc 
and washed with cold 1:8/Hexanes:EtOAc: 1H NMR (400 MHz, CD3OD, Figure C67) δ 3.13 
(t, J = 7.2 Hz, 2H), 3.02-2.94 (m, 1H), 2.90-2.78 (m, 2H), 2.48 (t, J = 7.2 Hz, 2H), 2.52-2.42 
(m, 4H), 2.42-2.32 (m, 1H), 2.10-2.02 (m, 1H), 1.95 (p, J = 7.6 Hz, 2H), 1.78-1.68 (m, 1H), 
1.61 (p, J = 5.6 Hz, 4H), 1.54-1.40 (m, 5H), 1.01 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, 
CD3OD, Figure C68) δ 168.4, 166.3, 159.4, 131.7, 127.9, 113.8, 59.5, 55.7, 37.3, 32.3, 29.83, 
29.79, 29.7, 27.9, 26.7, 26.6, 25.4, 11.9; LRMS m/z calcd for C20H30N4S2: 390.2; found 391.0 
[M+H]+ (Figure C2I); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 14.47 min (96% pure, Figure C69). 
 
Preparation of compound 6c. Compound 6c was synthesized 
using general procedure E. Compound 38 (0.10 g, 0.42 mmol), 
Cs2CO3 (0.14 g, 0.42 mmol), TBAI (0.16 g, 0.42 mmol), and 1-
(3-chloropropyl)piperidine monohydrochloride (0.12 g, 0.62 mmol) in anhydrous DMF (8 
mL) were used to afford compound 6c (80 mg, 45%, Rf 0.33 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by column chromatography (SiO2, 
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CH2Cl2, 49:1/CH2Cl2:MeOH, 19:1/CH2Cl2:MeOH, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH, 
then 7:3/CH2Cl2:MeOH with 7 mL/L NH4OH): 1H NMR (400 MHz, CD3OD, Figure C70) δ 
3.14 (t, J = 7.2 Hz, 2H), 3.09-3.02 (m, 1H), 2.85-2.75 (m, 2H), 2.54 (t, J = 7.2 Hz, 2H), 2.59-
2.45 (m, 5H), 2.20-2.12 (m, 1H), 1.97 (p, J = 7.2 Hz, 2H), 1.63 (p, J = 5.6 Hz, 4H), 1.59-1.54 
(m, 1H), 1.48 (p, J = 5.6 Hz, 2H), 1.52-1.39 (m, 1H), 0.99 (s, 9H); 13C NMR (100 MHz, 
CDCl3, Figure C71) δ 168.0, 165.2, 157.3, 132.4, 125.6, 112.8, 58.3, 54.6, 44.8, 32.7, 29.2, 
27.5, 27.3, 27.1, 26.8, 25.8, 24.4, 24.3; LRMS m/z calcd for C22H34N4S2: 418.2; found 419.1 
[M+H]+ (Figure C2J); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 15.83 min (97% pure, Figure C72). 
 
Preparation of compound 7c. Compound 7c was synthesized 
using general procedure D. Compound 39 (0.20 g, 0.65 mmol), 
K2CO3 (0.20 g, 1.41 mmol), and 1-(2-chloroethyl)piperidine 
hydrochloride (0.11 g, 0.66 mmol) in anhydrous DMF (4 mL) were used to afford compound 
7c (84 mg, 30%, Rf 0.26 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 
1H NMR (400 MHz, CD3OD, Figure C73) δ 7.32-7.28 (m, 4H), 7.23-7.19 (m, 1H), 3.15 (t, J = 
7.2 Hz, 2H), 3.11-2.94 (m, 4H), 2.89 (m, 1H), 2.62 (t, J = 7.2 Hz, 2H), 2.65-2.54 (m, 4H), 
2.20-2.14 (m, 1H), 2.10-1.96 (m, 3H), 1.65 (p, J = 5.6 Hz, 4H), 1.05 (app. p, J = 5.6 Hz, 2H); 
13C NMR (100 MHz, CDCl3, Figure C74) δ 167.7, 165.1, 157.3, 145.0, 130.7, 128.6, 126.8, 
126.6, 125.3, 112.5, 58.0, 54.4, 40.1, 32.9, 29.6, 28.9, 26.6, 26.2, 25.6, 24.2; LRMS m/z calcd 
for C24H30N4S2: 438.2; found 439.2 [M+H]+ (Figure C2K); Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 15.61 min (97% pure, Figure C75). 
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Preparation of compound 8c. Compound 8c was synthesized using 
general procedure D. Compound 40 (0.21 g, 0.82 mmol), K2CO3 
(0.21 g, 1.47 mmol), and 1-(3-chloropropyl)-piperidine 
hydrochloride (0.13 g, 0.80 mmol) in anhydrous DMF (4 mL) were used to afford compound 
8c (158 mg, 52%, Rf 0.39 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid 
after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, 
CDCl3, Figure C76) δ 5.43 (s, 2H), 3.12 (t, J = 7.3 Hz, 2H), 2.93-2.90 (m, 2H), 2.81-2.79 (m, 
2H), 2.48 (t, J = 7.2 Hz, 2H), 2.43 (br t, J = 5.5 Hz, 4H), 1.96 (p, J = 7.3 Hz, 2H), 1.88-1.82 
(m, 2H), 1.79-1.72 (m, 4H), 1.59 (p, J = 5.7 Hz, 4H), 1.44-1.38 (p, J = 5.7 Hz, 2H); 13C NMR 
(100 MHz, CDCl3, Figure C77) δ 166.4, 164.4, 157.2, 135.1, 130.3, 114.1, 58.2, 54.4, 30.6, 
29.9, 28.92, 28.89, 27.1, 26.7, 26.4, 25.7, 24.3; LRMS m/z calcd for C19H28N4S2: 376.2; found 
377.1 [M+H]+ (Figure C2L); Purity of the compound was further confirmed by RP-HPLC by 
using method 2: Rt = 20.59 min (100% pure, Figure C78). 
 
Preparation of compound 1d. Compound 1d was synthesized using 
general procedure D. Compound 33 (0.21 g, 0.92 mmol), K2CO3 (0.27 g, 
1.98 mmol), and 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride 
(0.17 g, 0.90 mmol) in DMF (4 mL) were used to afford compound 1d (89 mg, 30%, Rf 0.11 
in CH2Cl2:MeOH/9:1 with NH4OH (7mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, 
CD3OD, Figure C79) δ 3.25 (ddd, J = 14.8, 8.6, 5.2 Hz, 2H), 3.15-3.09 (m, 1H), 3.08-3.06 (m, 
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1H), 3.02 (t, J = 7.6 Hz, 2H), 2.94 (t, J = 7.2 Hz, 2H), 2.50 (p, J = 7.2 Hz, 2H), 2.46-2.39 (m, 
1H), 2.41 (s, 3H), 2.36 (q, J = 8.8 Hz, 1H), 2.22-2.13 (m, 2H), 1.83 (p, J = 8.0 Hz, 2H), 1.77-
1.60 (m, 2H); 13C NMR (100 MHz, (CD3)2SO, Figure C80) δ 171.5, 164.2, 157.2, 135.9, 
134.0, 109.2, 64.9, 56.5, 39.3, 32.5, 29.6, 29.0, 28.7, 27.2, 26.5, 21.6; LRMS m/z calcd for 
C16H22N4S2: 334.1; found 335.1 [M+H]+ (Figure C3A); Purity of the compound was further 
confirmed by RP-HPLC by using method 2: Rt = 23.38 min (97% pure, Figure C81). 
 
Preparation of compound 2d. Compound 2d was synthesized using 
general procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.23 
g, 1.72 mmol), and 2-(2-chloroethyl)-1-methylpyrrolidine 
hydrochloride (0.14 g, 0.78 mmol) in anhydrous DMF (4 mL) were used to afford compound 
2d (103 mg, 38%, Rf 0.26 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 
1H NMR (400 MHz, CD3OD, Figure C82) δ 3.21 (ddd, J = 11.6, 9.2, 5.2 Hz, 2H), 3.04 (ddd, J 
= 13.6, 9.2, 6.8 Hz, 1H), 2.84-2.78 (m, 2H), 2.72-2.66 (m, 2H), 2.62 (qd, J = 8.8, 3.6 Hz, 1H), 
2.50 (q, J = 8.8 Hz, 1H), 2.49 (s, 3H), 2.23-2.14 (m, 2H), 1.90-1.82 (m, 6H), 1.81-1.73 (m, 
1H), 1.73-1.63 (m, 1H); 13C NMR (100 MHz, CD3OD, Figure C83) δ 168.1, 165.8, 159.2, 
132.0, 127.8, 114.0, 67.8, 57.8, 40.5, 34.0, 31.2, 28.7, 26.9, 26.2, 23.9, 23.7, 22.7; LRMS m/z 
calcd for C17H24N4S2: 348.1; found 349.1 [M+H]+ (Figure C3B); Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 12.45 min (97% pure, Figure C84). 
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Preparation of compound 3d. Compound 3d was synthesized using 
general procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.30 
g, 0.91 mmol), TBAI (0.29 g, 0.77 mmol), and 2-(2-chloroethyl)-1-
methylpyrrolidine hydrochloride (0.18 g, 1.20 mmol) in DMF (4 mL) were used to afford 
compound 3d (157 mg, 54%, Rf 0.23 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white 
solid: 1H NMR (400 MHz, CD3OD, Figure C85) δ 3.28-3.18 (m, 2H), 2.10-2.99 (m, 2H), 
2.82-2.66 (m, 2H), 2.35 (s, 3H), 2.33-2.10 (m, 2H), 2.18-2.08 (m, 2H), 2.03-1.56 (m, 8H), 
1.29 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C86) δ 168.1, 164.8, 156.7, 
131.1, 131.0, 112.3, 65.6, 57.3, 40.51, 33.5, 30.5, 29.7, 29.6, 27.8, 25.4, 22.0, 21.9, 17.8; 
LRMS m/z calcd for C18H26N4S2: 362.2; found 363.2 [M+H]+ (Figure C3C); Purity of the 
compound was further confirmed by RP-HPLC by using method 2: Rt = 20.18 min (98% pure, 
Figure C87). 
 
Preparation of compound 4d. Compound 4d was prepared using 
procedure D. Compound 36 (0.10 g, 0.39 mmol), K2CO3 (0.06 g, 0.43 
mmol), and 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride 
(0.07 g, 0.39 mmol) in anhydrous DMF (4 mL) were used to afford compound 4d (92 mg, 
65%, Rf 0.20 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid after purification 
by column chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure 
C88) δ 3.25-3.18 (ddd, J = 13.2, 8.8, 4.4 Hz, 1H), 3.07-2.98 (m, 2H), 2.97-2.93 (m, 1H), 2.91-
2.83 (m, 1H), 2.81 (dd, J = 16.8, 4.4 Hz, 1H), 2.40-2.27 (m, 2H), 2.32 (s, 3H), 2.23 (q, J = 9.2 
Hz, 1H), 2.16-2.06 (m, 2H), 2.02-1.90 (m, 2H), 1.82-1.72 (m, 2H), 1.67 (ddd, J = 14.4, 9.6, 
5.2 Hz, 1H), 1.63-1.44 (m, 2H), 1.10 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure 
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C89) δ 167.7, 165.0, 157.1, 131.1, 125.0, 112.7, 65.5, 57.2, 40.4, 33.4, 33.3, 30.5, 30.4, 29.0, 
27.8, 25.8, 21.9, 21.2; LRMS m/z calcd for C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure 
C3D); Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 
24.85 min (95% pure, Figure C90). 
 
Preparation of compound 5d. Compound 5d was prepared using 
general procedure E. Compound 37 (0.10g, 0.75 mmol), Cs2CO3 
(0.25 g, 0.75 mmol), TBAI (0.28 g, 0.75 mmol), and 2-(2-
chloroethyl)-1-methylpyrrolidine hydrochloride (0.11 g, 0.83 mmol) in anhydrous DMF (8 
mL were added to afford compound 5d (6 mg, 2%, Rf 0.27 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by recrystallization from 
Hexanes:EtOAc: 1H NMR (400 MHz, CD3OD, Figure C91) δ 3.28-3.24 (m, 2H), 3.02-2.94 
(m, 1H), 2.90-2.80 (m, 2H), 2.69-2.65 (m, 2H), 2.54 (very br t, 4H), 2.40-2.33 (m, 1H), 2.10-
2.02 (m, 1H), 1.78-1.68 (m, 1H), 1.64 (p, J = 5.6 Hz, 4H), 1.54-1.41 (m, 5H), 1.01 (t, J = 7.6 
Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure C92) δ 166.8, 163.9, 157.9, 130.3, 126.4, 
112.4, 67.8, 55.8, 38.2, 35.7, 30.9, 30.7, 29.0, 28.2, 28.1, 26.5, 25.2, 21.0, 10.4; LRMS m/z 
calcd for C19H28N4S2: 376.2; found 377.2 [M+H]+ (Figure C3E); Purity of the compound was 
further confirmed by RP-HPLC by using method 2: Rt = 22.53 min (96% pure, Figure C93). 
 
Preparation of compound 6d. Compound 6d was prepared using 
general procedure E. Compound 38 (0.10 g, 0.42 mmol), Cs2CO3 
(0.14 g, 0.42 mmol), TBAI (0.16 g, 0.42 mmol), and 2-(2-
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chloroethyl)-1-methylpyrrolidine hydrochloride (0.11 g, 0.62 mmol) in anhydrous DMF (8 
mL) were used to afford compound 6d (29 mg, 17%, Rf 0.41 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by recrystallization from 
Hexanes:EtOAc: 1H NMR (400 MHz, CDCl3, Figure C94) δ 5.22 (br s, 2H), 3.24 (ddd, J = 
13.2, 8.6, 5.2 Hz, 1H), 3.12-3.06 (m, 1H), 3.06-3.02 (m, 1H), 3.00-2.94 (m, 1H), 2.84-2.74 (m, 
2H), 2.56-2.46 (m, 1H), 2.33 (s, 3H), 2.28-2.20 (m, 1H), 2.20-2.13 (m, 1H), 2.12-2.05 (m, 2H), 
2.04-1.98 (m, 1H), 1.86-1.66 (m, 3H), 1.69-1.50 (m, 2H), 1.43 (qd, J = 12.0, 5.6 Hz, 1H), 0.94 
(s, 9H); 13C NMR (100 MHz, CDCl3, Figure C95) δ 168.1, 165.2, 157.3, 132.5, 125.6, 112.8, 
65.8, 57.4, 44.9, 40.6, 33.5, 32.7, 30.6, 28.0, 27.5, 27.3, 27.1, 24.3, 22.1; LRMS m/z calcd for 
C21H32N4S2: 404.2; found 405.1 [M+H]+ (Figure C3F); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 15.56 min (97% pure, Figure C96). 
 
Preparation of compound 7d. Compound 7d was prepared using 
procedure D. Compound 39 (0.20 g, 0.64 mmol), K2CO3 (0.20 g, 
1.41 mmol), and 2-(2-chloroethyl)-1-methylpyrrolidine 
hydrochloride (0.10 g, 0.65 mmol) in anhydrous DMF (4 mL) were used to afford compound 
7d (116 mg, 43%, Rf 0.39 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, 
CDCl3, Figure C97) δ 7.35-3.31 (m, 2H), 7.26-7.22 (m, 3H), 5.24 (br s, 2H),  3.25 (ddd, J = 
13.8, 9.8, 5.3 Hz, 1H), 3.12-2.85 (m, 7H), 2.34 (s, 3H), 2.37-1.95 (m, 6H), 1.85-1.68 (m, 3H), 
1.68-1.56 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure C98) δ 168.1, 165.4, 157.4, 145.2, 
131.2, 128.9, 127.0, 126.9, 125.4, 112.8, 66.0, 57.3, 40.5, 40.4, 33.3, 33.1, 30.5, 29.9, 28.0, 
26.5, 22.1; LRMS m/z calcd for C23H28N4S2: 424.2; found 425.0 [M+H]+ (Figure C3G); Purity 
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of the compound was further confirmed by RP-HPLC by using method 1: Rt = 14.85 min 
(95% pure, Figure C99). 
 
Preparation of compound 8d. Compound 8d was prepared using 
procedure D. Compound 40 (0.21 g, 0.82 mmol), K2CO3 (0.25 g, 1.82 
mmol), and 2-(2-chloroethyl)-1-methylpyrrolidine hydrochloride (0.15 
g, 1.01 mmol) in anhydrous DMF (4 mL) were used to afford compound 8d (153 mg, 52%, Rf 
0.43 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a brown solid after purification by 
column chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CDCl3, Figure 
C100) δ 5.45 (s, 2H), 3.20 (ddd, J = 13.3, 9.4, 5.2 Hz, 1H), 3.11-3.07 (m, 1H), 3.01 (ddd, J = 
13.3, 9.2, 6.7 Hz, 1H), 2.92-2.89 (m, 2H), 2.80-2.77 (m, 2H), 2.32 (s, 3H), 2.25 (qd, J = 8.4, 
3.4 Hz, 1H), 2.18 (q, J = 9.3 Hz, 1H), 2.12-1.96 (m, 2H), 1.87-1.80 (m, 2H), 1.75-1.70 (m, 
6H), 1.69-1.63 (m, 1H), 1.62-1.54 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure C101) δ 
166.3, 164.2, 157.3, 135.1, 130.4, 114.1, 65.5, 57.2, 40.4, 33.3, 30.6, 30.3, 29.9, 28.9, 27.7, 
27.1, 26.4, 21.9; LRMS m/z calcd for C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure C3H); 
Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 22.80 
min (97% pure, Figure C102). 
 
Preparation of compound 1e. Compound 1e was prepared using 
procedure D. Compound 33 (0.20 g, 0.92 mmol), K2CO3 (0.27 g, 1.97 
mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride (0.17 g, 0.91 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 1e (50 mg, 16%, Rf 0.12 in 
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9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a brown solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, 
CD3OD, Figure C103) δ 3.16-3.08 (m, 3H), 3.06-3.01 (m, 2H), 2.97-2.90 (m, 3H), 2.50 (p, J = 
4.0 Hz, 2H), 2.35 (s, 3H), 2.12 (td, J = 12.0, 4.0 Hz, 1H), 2.06-1.91 (m, 3H), 1.81-1.71 (m, 
1H), 1.60 (qt, J = 12.4, 4.0 Hz, 1H), 1.09 (qd, J = 13.6, 4.0 Hz, 1H); 13C NMR (100 MHz, 
(CD3)2SO, Figure C104) δ 171.5, 164.1, 157.1, 135.9, 134.1, 109.2, 60.1, 55.2, 45.7, 35.5, 
33.6, 29.0, 28.8, 28.7, 27.2, 24.0; LRMS m/z calcd for C16H22N4S2: 334.1; found 335.1 
[M+H]+ (Figure C3I); Purity of the compound was further confirmed by RP-HPLC by using 
method 2: Rt = 20.80 min (97% pure, Figure C105). 
 
Preparation of compound 2e. Compound 2e was prepared using 
procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.24 g, 1.72 
mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride (0.15 g, 0.78 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 2e (95 mg, 35%, Rf 0.15 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a dark yellow solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, 
CDCl3, Figure C106) δ 5.28 (br s, 2H), 3.14-3.03 (m, 3H), 2.85-2.80 (m, 2H), 2.76-2.73 (m, 
2H), 2.33 (s, 3H), 2.19-2.15 (m, 2H), 2.04-2.02 (m, 3H), 1.94-1.84 (m, 6H), 1.72-1.66 (m, 2H); 
13C NMR (100 MHz, (CD3)2SO, Figure C107) δ 166.6, 164.5, 158.0, 129.4, 127.2, 112.6, 60.5, 
55.6, 46.1, 36.0, 34.0, 29.2, 25.8, 25.1, 24.4, 22.7, 22.4; LRMS m/z calcd for C17H24N4S2: 
348.1; found 349.1 [M+H]+ (Figure C3J); Purity of the compound was further confirmed by 
RP-HPLC by using method 2: Rt = 21.48 min (97% pure, Figure C108). 
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Preparation of compound 3e. Compound 3e was prepared using 
procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.29 g, 0.90 
mmol), TBAI (0.29 g, 0.78 mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride 
(0.18 g, 1.21 mmol) in anhydrous DMF (4 mL) were used to afford compound 3e (180 mg, 
62%, Rf 0.32 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid: 1H NMR (400 
MHz, CD3OD, Figure C109) δ 3.56-3.43 (m, 1H), 3.42-3.32 (m, 1H), 3.26-3.00 (m, 4H), 
2.82-2.64 (m, 2H), 2.61 (s, 3H), 2.50 (m, 2H), 2.40 (t, J = 11.6 Hz, 1H), 2.20-1.60 (m, 8H), 
1.27 (d, J = 7.2 Hz, 3H), 1.26-1.10 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure C110) δ 
168.1, 164.9, 156.6, 131.2, 131.1, 112.4, 61.5, 56.3, 46.8, 36.4, 35.0, 29.9, 29.8, 29.6, 25.5, 
25.3, 21.9, 17.9; LRMS m/z calcd for C18H26N4S2: 362.2; found 363.0 [M+H]+ (Figure C3K); 
Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 13.03 
min (95% pure, Figure C111). 
 
Preparation of compound 4e. Compound 4e was prepared using 
procedure D. Compound 36 (0.10 g, 0.39 mmol), K2CO3 (0.06 g, 0.43 
mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride (0.08 g, 0.39 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 4e (120 mg, 85%, Rf 0.21 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by column 
chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, (CD3)2SO, Figure C112) δ 
6.85 (br s, 2H), 3.06-2.65 (m, 7H), 2.34-2.26 (m, 1H), 2.19 (s, 3H), 1.96 (t, J = 10.8 Hz, 1H), 
1.88-1.74 (m, 5H), 1.62 (dt, J = 13.2, 3.6 Hz, 2H), 1.49-1.34 (m, 2H), 1.03 (d, J = 6.8 Hz, 
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3H); 13C NMR (100 MHz, (CD3)2SO, Figure C113) δ 166.3, 164.1, 157.5, 128.5, 126.4, 112.0, 
60.3, 55.3, 45.8, 35.6, 33.7, 32.7, 30.0, 28.9, 28.5, 25.1, 24.1, 21.1; LRMS m/z calcd for 
C18H26N4S2: 362.2; found 363.1 [M+H]+ (Figure C3L); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 11.84 min (97% pure, Figure C114). 
 
Preparation of compound 5e. Compound 5e was prepared using 
procedure D. Compound 37 (0.11 g, 0.37 mmol), K2CO3 (0.11 g, 
0.81 mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride (0.08 g, 0.37 mmol), and 
DMF (4 mL) were used to afford compound 5e (18 mg, 13%, Rf 0.37 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a white solid after purification by recrystallization from MeCN: 1H 
NMR (400 MHz, CDCl3, Figure C115) δ 5.25 (s, 2H), 3.06 (d, J = 6.4 Hz, 2H), 2.95-2.87 (m, 
2H), 2.83 (dd, J = 16.0, 5.2 Hz, 2H), 2.71 (d, J = 11.2 Hz, 1H), 2.36 (dd, J = 16.4, 10.0 Hz, 
1H), 2.22 (s, 3H), 2.06-1.92 (m, 2H), 1.86 (td, J = 10.4, 2.0 Hz, 2H), 1.73-1.63 (m, 3H), 160-
1.48 (m, 2H), 1.46-1.34 (m, 3H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure 
C116) δ 167.9, 165.2, 157.2, 131.5, 125.5, 112.9, 61.6, 56.4, 46.9, 36.4, 35.9, 35.1, 31.4, 30.0, 
28.8, 28.6, 26.1, 25.4, 11.7; LRMS m/z calcd for C19H28N4S2: 376.2; found 377.1 [M+H]+ 
(Figure C4A); Purity of the compound was further confirmed by RP-HPLC by using method 
1: Rt = 14.22 min (96% pure, Figure C117). 
 
Preparation of compound 6e. Compound 6e was prepared using 
procedure D. Compound 38 (0.20 g, 0.70 mmol), K2CO3 (0.16 g, 
1.08 mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride 
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(0.10 g, 0.49 mmol) in anhydrous DMF (4 mL) were used to afford compound 6e (63 mg, 
28%, Rf 0.42 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid after purification 
by recrystallization from MeCN: 1H NMR (400 MHz, CDCl3, Figure C118) δ 5.41 (br s, 2H), 
3.05 (d, J = 6.8 Hz, 2H), 2.94-2.88 (m, 2H), 2.75 (dd, J = 16.4, 4.8 Hz, 2H), 2.70-2.68 (m, 1H), 
2.52-2.42 (m, 1H), 2.21 (s, 3H), 2.05 (dd, J = 13.2, 3.6 Hz, 1H), 2.00-1.90 (m, 1H), 1.89-1.80 
(m, 2H), 1.71-1.62 (m, 2H), 1.58-1.48 (m, 2H), 1.39 (qd, J = 12.0, 5.2 Hz, 1H), 0.98 (qd, J = 
12.0, 4.0 Hz, 1H), 0.92 (s, 9H); 13C NMR (100 MHz, CDCl3, Figure C119) δ 167.8, 165.1, 
157.3, 132.2, 125.6, 112.7, 61.6, 56.3, 46.8, 44.7, 36.4, 35.1, 32.6, 30.0, 27.4, 27.2, 27.0, 25.4, 
24.2; LRMS m/z calcd for C21H32N4S2: 404.2; found 405.1 [M+H]+ (Figure C4B); Purity of 
the compound was further confirmed by RP-HPLC by using method 2: Rt = 26.67 min (97% 
pure, Figure C120). 
 
Preparation of compound 7e. Compound 7e was prepared using 
procedure D. Compound 39 (0.20 g, 0.64 mmol), K2CO3 (0.20 g, 
1.42 mmol), and 3-chloromethyl-1-methylpiperidine 
hydrochloride (0.10 g, 0.65 mmol) in anhydrous DMF (4 mL) were used to afford compound 
7e (149 mg, 55%, Rf 0.24 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after 
purification by column chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, 
CD3OD, Figure C121) δ 7.31 (d, J = 4.4 Hz, 4H), 7.25-7.18 (m, 1H), 3.14-2.98 (m, 7H), 2.96-
2.78 (m, 2H), 2.27 (s, 3H), 2.24-2.16 (m, 1H), 2.11-1.90 (m, 4H), 1.84-1.70 (m, 2H), 1.65-
1.52 (m, 1H), 1.11-0.90 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure C122) δ 168.0, 165.4, 
157.4, 145.2, 131.2, 128.9, 127.1, 126.9, 125.4, 112.8, 61.3, 56.2, 46.5, 40.4, 36.1, 35.0, 33.1, 
29.9, 29.7, 26.5, 25.1; LRMS m/z calcd for C23H28N4S2: 424.2; found 425.0 [M+H]+ (Figure 
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C4C); Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 
25.33 min (98% pure, Figure C123). 
 
Preparation of compound 8e. Compound 8e was prepared using 
procedure D. Compound 40 (0.20 g, 0.81 mmol), K2CO3 (0.25 g, 1.80 
mmol), and 3-chloromethyl-1-methylpiperidine hydrochloride (1.50 g, 1.02 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 8e (159 mg, 55%, Rf 0.48 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid after purification by column 
chromatography (SiO2, 19:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C124) δ 
3.07-3.00 (m, 5H), 2.87-2.84 (m, 2H), 2.82-2.78 (m, 1H), 2.28 (s, 3H), 2.02-1.89 (m, 5H), 
1.85-1.71 (m, 6H), 1.57 (qt, J = 12.4, 3.6 Hz, 1H), 1.06 (qd, J = 12.4, 3.6 Hz, 1H); 13C NMR 
(100 MHz, CDCl3, Figure C125) δ 166.7, 164.6, 157.4, 135.5, 130.5, 114.4, 61.3, 56.2, 46.6, 
36.2, 35.1, 30.9, 30.2, 29.7, 29.2, 27.4, 26.7, 25.1; LRMS m/z calcd for C18H26N4S2: 362.2; 
found 363.1 [M+H]+ (Figure C4D); Purity of the compound was further confirmed by RP-
HPLC by using method 2: Rt = 22.57 min (98% pure, Figure C126). 
 
Preparation of compound 1f. Compound 1f was prepared using 
procedure E. Compound 33 (0.10 g, 0.45 mmol), Cs2CO3 (0.14 g, 
0.42 mmol), TBAI (0.17 g, 0.45 mmol), and compound 41 (0.11 g, 
0.62 mmol) in anhydrous DMF (8 mL) were used to afford compound 1f (33 mg, 21%, Rf 
0.33 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as light brown needles after purification 
by recrystallization from Hexanes:EtOAc and washed with Hexanes: 1H NMR (400 MHz, 
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CDCl3, Figure C127) δ 8.07 (br s, 1H), 5.50 (s, 2H), 3.73 (s, 2H), 3.32 (q, J = 5.6 Hz, 2H), 
3.01-2.95 (m, 4H), 2.52 (p, J = 7.2 Hz, 2H), 2.36 (t, J = 5.6 Hz, 2H), 2.13 (s, 6H); 13C NMR 
(100 MHz, CDCl3, Figure C128) δ 172.8, 170.2, 164.1, 157.2, 137.7, 134.6, 110.4, 58.1, 45.3, 
37.3, 35.0, 29.7, 29.2, 28.0; LRMS m/z calcd for C15H21N5OS2: 351.1; found 352.0 [M+H]+ 
(Figure C4E); Purity of the compound was further confirmed by RP-HPLC by using method 
1: Rt = 11.12 min (96% pure, Figure C129). 
 
Preparation of compound 2f. Compound 2f was prepared using 
procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.25 g, 
1.72 mmol), and compound 41 (0.19 g, 0.78 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 2f (159 mg, 59%, Rf 0.35 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, (CD3)2SO, Figure C130) δ 
7.97 (t, J = 4.8 Hz, 1H), 6.93 (br s, 2H), 3.75 (s, 2H), 3.15 (q, J = 6.0 Hz, 2H), 2.85 (m, 2H), 
2.70 (m, 2H), 2.67 (t, J = 6.8 Hz, 2H), 2.099 (s, 3H), 2.096 (s, 3H), 1.79 (m, 4H); 13C NMR 
(100 MHz, (CD3)2SO, Figure C131) δ 167.9, 166.0, 163.5, 157.6, 129.3, 126.8, 112.3, 57.9, 
45.0, 37.0, 34.1, 25.3, 24.7, 22.2, 21.9; LRMS m/z calcd for C16H23N5OS2: 365.1; found 366.0 
[M+H]+ (Figure C4F); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 11.59 min (96% pure, Figure C132). 
 
Preparation of compound 3f. Compound 3f was prepared using 
procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.29 g, 
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0.90 mmol), TBAI (0.29 g, 0.78 mmol), and compound 41 (0.30 g, 1.21 mmol), and DMF (4 
mL) were used to afford compound 3f (172 mg, 57%, Rf 0.40 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, CD3OD, Figure C133) δ 
3.88 (s, 2H), 3.59 (t, J = 6.0 Hz, 2H), 3.21 (t, J = 6.0 Hz, 2H), 3.22-3.14 (m, 1H), 2.85 (s, 6H), 
2.78-2.62 (m, 2H), 1.94-1.74 (m, 4H), 1.24 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD, 
Figure C134) δ 173.4, 168.6, 164.5, 158.7, 133.3, 131.9, 113.6, 58.4, 44.2, 36.5, 35.6, 30.7, 
30.3, 26.3, 22.4, 19.0; LRMS m/z calcd for C17H25N5OS2: 379.2; found 380.0 [M+H]+ (Figure 
C4G); Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 
22.49 min (95% pure, Figure C135). 
 
Preparation of compound 4f. Compound 4f was prepared using 
procedure D. Compound 36 (0.28 g, 0.78 mmol), K2CO3 (0.25 g, 
1.72 mmol), and compound 41 (0.19 g, 0.78 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 4f (132 mg, 44%, Rf 0.35 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, CD3OD, Figure C136) δ 
3.76 (s, 2H), 3.32 (t, J = 4.0 Hz, 2H), 3.01-2.93 (m, 1H), 2.91-2.83 (m, 1H), 2.81 (dd, J = 16.8, 
4.0 Hz, 1H) 2.39 (t, J = 6.4 Hz, 2H), 2.36-2.30 (m, 1H), 2.17 (s, 6H), 2.02-1.88 (m, 2H), 1.54-
1.44 (m, 1H), 1.10 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, (CD3)2SO, Figure C137) δ 167.9, 
166.2, 163.5, 157.6, 128.8, 126.4, 112.1, 57.9, 45.0, 37.0, 34.1, 32.6, 30.0, 28.4, 25.0, 21.0; 
LRMS m/z calcd for C17H25N5OS2: 379.2; found 380.0 [M+H]+ (Figure C4H); Purity of the 
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compound was further confirmed by RP-HPLC by using method 2: Rt = 17.70 min (98% pure, 
Figure C138). 
 
Preparation of compound 5f. Compound 5f was prepared using 
procedure D. Compound 37 (0.11 g, 0.37 mmol), K2CO3 (0.11 g, 
0.81 mmol), and compound 41 (0.09 g, 0.37 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 5f (5 mg, 4%, Rf 0.35 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a yellow solid after purification by recrystallization from MeCN: 1H 
NMR (400 MHz, CD3OD, Figure C139) δ 3.78 (s, 2H), 3.32 (t, J = 6.4 Hz, 2H), 3.03-2.95 (m, 
1H), 2.86 (dd, J = 16.0, 4.4 Hz, 1H), 2.91-2.79 (m, 1H), 2.42 (t, J = 6.4 Hz, 2H), 2.39-2.35 (m, 
1H), 2.20 (s, 6H), 2.10-2.02 (m, 1H), 1.80-1.66 (m, 1H), 1.55-1.41 (m, 3H), 1.01 (t, J = 7.6 Hz, 
3H); 13C NMR (100 MHz, CD3OD, Figure C140) δ 172.6, 168.3, 164.9, 159.6, 132.1, 128.0, 
114.1, 59.1, 45.5, 38.4, 37.3, 35.5, 32.3, 29.8, 29.7, 26.7, 11.9; LRMS m/z calcd for 
C18H27N5OS2: 393.2; found 394.1 [M+H]+ (Figure C4I); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 13.45 min (97% pure, Figure C141). 
 
Preparation of compound 6f. Compound 6f was prepared using 
procedure D. Compound 38 (0.20 g, 0.70 mmol, K2CO3 (0.15 g, 
1.08 mmol), and compound 41 (0.08 g, 0.39 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 6f (20 mg, 10%, Rf 0.32 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after purification by recrystallization from MeCN: 
1H NMR (400 MHz, CDCl3, Figure C142) δ 8.04 (br t, 1H), 5.71 (s, 2H), 3.74 (d, J = 14.8 Hz, 
S
N
N
H2N
S
HN
O
N
S
N
N
H2N
S
HN
O
N
 212 
1H), 3.69 (d, J = 14.8 Hz, 1H), 3.31 (q, J = 5.2 Hz, 2H), 2.97 (dd, J = 14.4, 4.8 Hz, 1H), 2.79 
(dd, J = 16.4, 4.8 Hz, 2H), 2.56-2.46 (m, 1H), 2.36 (t, J = 6.0 Hz, 2H), 2.13 (s, 6H), 2.10-2.07 
(m, 1H), 1.55 (td, J = 12.0, 4.0 Hz, 1H), 1.43 (qd, J = 12.0, 5.6 Hz, 1H), 0.94 (s, 9H); 13C 
NMR (100 MHz, CDCl3, Figure C143) δ 170.2, 167.7, 164.0, 157.7, 133.2, 125.6, 113.1, 58.1, 
45.3, 44.8, 37.2, 35.0, 32.7, 27.4, 27.3, 27.1, 24.3; LRMS m/z calcd for C20H31N5OS2: 421.2; 
found 422.2 [M+H]+ (Figure C4J); Purity of the compound was further confirmed by RP-
HPLC by using method 2: Rt = 22.69 min (98% pure, Figure C144). 
 
Preparation of compound 7f. Compound 7f was prepared 
using procedure D. Compound 39 (0.20 g, 0.64 mmol), K2CO3 
(0.20 g, 1.41 mmol), compound 41 (0.16 g, 0.65 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 7f (111 mg, 39%, Rf 0.27 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C145) δ 
7.33-7.28 (m, 4H), 7.23-7.19 (m, 1H), 3.80 (s, 2H), 3.32 (t, J = 6.4 Hz, 2H), 3.07-2.92 (m, 4H), 
2.92-2.81 (m, 1H), 2.42 (t, J = 6.4 Hz, 2H), 2.20 (s, 6H), 2.07-1.97 (m, 1H); 13C NMR (100 
MHz, CD3OD, Figure C146) δ 172.5, 168.4, 165.0, 159.6, 146.9, 131.9, 129.8, 128.1, 127.8, 
127.7, 114.0, 59.1, 45.5, 41.7, 38.4, 35.5, 34.0, 31.1, 27.2; LRMS m/z calcd for C22H27N5OS2: 
441.2; found 442.0 [M+H]+ (Figure C4K); Purity of the compound was further confirmed by 
RP-HPLC by using method 1: Rt = 12.14 min (98% pure, Figure C147). 
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Preparation of compound 8f. Compound 8f was prepared by using 
procedure D. Compound 39 (0.15 g, 0.59 mmol), K2CO3 (0.18 g, 
1.29 mmol), and compound 41 (0.14 g, 0.59 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 8f (122 mg, 55%, Rf 0.28 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a brown solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CDCl3, Figure C148) δ 8.05 (br t, 1H), 5.78 (s, 2H), 
3.71 (s, 2H), 3.32 (q, J = 6.0 Hz, 2H), 2.96-2.93 (m, 2H), 2.84-2.82 (m, 2H), 2.40 (t, J = 6.0 
Hz, 2H), 2.15 (s, 6H), 1.90-1.85 (m, 2H), 1.82-1.74 (m, 4H); 13C NMR (100 MHz, CDCl3, 
Figure C149) δ 170.1, 166.1, 163.2, 157.6, 136.0, 130.3, 114.4, 57.9, 45.0, 36.9, 34.7, 30.5, 
29.9, 28.9, 27.1, 26.4; LRMS m/z calcd for C17H25N5OS2: 379.2; found 380.1 [M+H]+ (Figure 
C4L); Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 
22.53 min (95% pure, Figure C150). 
 
Preparation of compound 1g. Compound 1g was prepared using 
procedure D. Compound 33 (0.20 g, 0.91 mmol), K2CO3 (0.27 g, 
1.98 mmol), and compound 42 (0.25 g, 0.90 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 1g (100 mg, 30%, Rf 0.23 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a brown solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, CD3OD, Figure C151) δ 
3.85 (s, 2H), 3.51 (t, J = 6.4 Hz, 2H), 3.02 (t, J = 6.4 Hz, 2H), 2.98 (q, J = 7.6 Hz, 4H), 2.95 (t, 
J = 7.6 Hz, 2H), 2.89 (t, J = 7.2 Hz, 2H), 2.45 (p, J = 3.2 Hz, 2H), 1.16 (t, J = 7.2 Hz, 6H); 13C 
NMR (100 MHz, CD3OD, Figure C152) δ 173.6 (2 carbons overlapping), 164.9, 159.3, 137.8, 
137.2, 111.5, 52.8, 49.2, 37.2, 35.9, 30.6, 30.2, 29.2, 10.5; LRMS m/z calcd for C17H25N5OS2: 
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379.2; found 380.1 [M+H]+ (Figure C5A); Purity of the compound was further confirmed by 
RP-HPLC by using method 2: Rt = 17.54 min (96% pure, Figure C153). 
 
Preparation of compound 2g. Compound 2g was prepared using 
procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.21 g, 
1.72 mmol), and compound 42 (0.21 g, 0.78 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 2g (165 mg, 54%, Rf 0.21 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a white solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, CDCl3, Figure C154) δ 7.65 
(t, J = 5.2 Hz, 1H), 5.92 (s, 2H), 3.68 (s, 2H), 3.21 (q, J = 5.2 Hz, 2H), 2.72 (m, 2H), 2.62 (m, 
2H), 2.43 (t, J = 5.2 Hz, 2H), 2.38 (q, J = 7.2 Hz, 4H), 1.76 (m, 4H), 0.82 (t, J = 7.2 Hz, 6H); 
13C NMR (100 MHz, CDCl3, Figure C155) δ 169.8, 166.9, 163.1, 157.5, 131.6, 125.7, 113.0, 
51.4, 46.7, 37.2, 34.5, 25.8, 25.2, 22.5, 22.3, 11.1; LRMS m/z calcd for C18H27N5OS2: 393.2; 
found 394.1 [M+H]+ (Figure C5B); Purity of the compound was further confirmed by RP-
HPLC by using method 2: Rt = 22.46 min (95% pure, Figure C156). 
 
Preparation of compound 3g. Compound 3g was prepared using 
procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.30 g, 
0.91 mmol), TBAI (0.29 g, 0.77 mmol), and compound 42 (0.33 g, 
1.20 mmol), and DMF (4 mL) were used to afford compound 3g (305 mg, 93%, Rf 0.33 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by flash column 
chromatography (9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C157) δ 3.80 (s, 
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2H), 3.33-3.31 (m, 2H), 3.28-3.20 (m, 1H), 2.84-2.68 (m, 2H), 2.55 (m, 6H), 2.02-1.78 (m, 
4H), 1.29 (d, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure 
C158) δ 169.2, 168.1, 163.5, 156.9, 131.9, 131.2, 112.8, 51.7, 47.1, 37.3, 34.8, 29.8, 29.6, 
25.5, 22.0, 17.9, 11.4; LRMS m/z calcd for C19H29N5OS2: 407.2; found 408.0 [M+H]+ (Figure 
C5C); Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
10.85 min (95% pure, Figure C159). 
 
Preparation of compound 4g. Compound 4g was prepared using 
procedure D. Compound 36 (0.28 g, 0.78 mmol), K2CO3 (0.25 g, 
1.72 mmol), and compound 42 (0.21 g, 0.78 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 4g (200 mg, 63%, Rf 0.42 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a yellow solid after purification by flash column chromatography 
(9:1/CH2Cl2:MeOH with NH4OH (7mL/L)): 1H NMR (400 MHz, CDCl3, Figure C160) δ 7.89 
(br t, 1H), 5.79 (s, 2H), 3.76 (s, 2H), 3.37 (q, J = 5.8 Hz, 2H), 2.93-2.77 (m, 3H), 2.67 (t, J = 
5.9 Hz, 2H), 2.62 (q, J = 7.2 Hz, 4H), 2.35 (ddt, J = 16.8, 9.3, 2.8 Hz, 1H), 1.99-1.92 (m, 2H), 
1.55-1.45 (m, 1H), 1.08 (d, J = 6.5 Hz, 3H), 1.01 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, 
CDCl3, Figure C161) δ 170.4, 167.6, 163.6, 157.7, 131.9, 125.3, 113.1, 51.9, 47.4, 37.0, 34.7, 
33.5, 30.7, 29.1, 25.9, 21.4, 10.8; LRMS m/z calcd for C19H29N5OS2: 407.2; found 408.0 
[M+H]+ (Figure C5D); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 11.42 min (95% pure, Figure C162). 
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Preparation of compound 5g. Compound 5g was prepared 
using procedure E. Compound 37 (0.1 g, 0.38 mmol), Cs2CO3 
(0.18 g, 0.57 mmol), TBAI (0.15 g, 0.38 mmol), and compound 
42 (0.11 g, 0.41 mmol) in anhydrous DMF (2 mL) were used to afford compound 5g (15 mg, 
10%, Rf 0.34 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification 
by recrystallization from Hexanes:EtOAc: 1H NMR (400 MHz, CD3OD, Figure C163) δ 3.79 
(s, 2H), 3.31 (t, J = 7.2 Hz, 2H), 3.01-2.92 (m, 1H), 2.84 (dd, J = 16.8, 4.0 Hz, 1H), 2.88-2.78 
(m, 1H), 2.57 (t, J = 7.2 Hz, 2H), 2.54 (q, J = 7.6 Hz, 4H), 2.40-2.31 (m, 1H), 2.09-2.01 (m, 
1H), 1.76-1.64 (m, 1H), 1.53-1.39 (m, 3H), 1.02 (t, J = 7.6 Hz, 6H), 0.97 (t, J = 7.6 Hz, 3H); 
13C NMR (100 MHz, CDCl3, Figure C164) δ 169.9, 167.7, 163.7, 157.6, 132.2, 125.6, 113.2, 
51.7, 47.1, 37.4, 35.9, 34.8, 31.4, 28.7, 28.6, 26.0, 11.7, 11.5; LRMS m/z calcd for 
C20H31N5OS2: 421.2; found 422.0 [M+H]+ (Figure C5E); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 12.01 min (98% pure, Figure C165). 
 
Preparation of compound 6g. Compound 6g was prepared 
using procedure E. Compound 38 (0.21, 0.68 mmol), Cs2CO3 
(0.34 g, 1.0 mmol), TBAI (0.26 g, 0.68 mmol), and compound 
42 (0.21 g, 0.75 mmol) in anhydrous DMF (4 mL) were used to afford compound 6g (68 mg, 
22%, Rf 0.50 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification 
by flash column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH) and then by 
recrystallization from Hexanes:EtOAc: 1H NMR (400 MHz, CD3OD, Figure C166) δ 3.80 (s, 
2H), 3.33 (t, J = 6.4 Hz, 2H), 3.08-3.02 (m, 1H), 2.84-2.76 (m, 2H), 2.60 (t, J = 6.8 Hz, 2H), 
2.57 (t, J = 7.6 Hz, 4H), 2.20-2.12 (m, 1H), 1.57 (td, J = 10.4, 3.6 Hz, 1H), 1.43 (qd, J = 11.6, 
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5.6 Hz, 1H), 0.99 (t, J = 8.4 Hz, 6H), 0.99 (s, 9H); 13C NMR (100 MHz, CDCl3, Figure C167) 
δ 171.8, 167.6, 163.5, 158.0, 132.4, 125.9, 112.9, 52.3, 48.2, 44.7, 35.8, 34.7, 32.6, 27.4, 27.1 
27.0, 24.2, 9.0; LRMS m/z calcd for C22H35N5OS2: 449.2; found 450.2 [M+H]+ (Figure C5F); 
Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 22.24 
min (96% pure, Figure C168). 
 
Preparation of compound 7g. Compound 7g was prepared 
using procedure D. Compound 39 (0.20 g, 0.64 mmol), 
K2CO3 (0.20 g, 1.44 mmol), compound 42 (0.18 g, 0.67 
mmol) in anhydrous DMF (4 mL) were used to afford compound 7g (77 mg, 26%, Rf 0.26 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by flash column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C169) δ 
7.31 (d, J = 4.8 Hz, 4H), 7.25-7.19 (m, 1H), 3.80 (s, 2H), 3.30 (t, J = 5.2 Hz, 2H), 3.14-2.98 
(m, 4H), 2.96-2.86 (m, 1H), 2.54 (t, J = 6.8 Hz, 2H), 2.51 (q, J = 6.8 Hz, 4H), 2.24-2.18 (m, 
1H), 2.12-2.01 (m, 1H), 0.96 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure C170) δ 
169.4, 167.5, 163.7, 157.4, 144.8, 131.5, 128.6, 126.8, 126.7, 125.3, 112.9, 51.4, 46.7, 40.0, 
37.3, 34.6, 32.8, 29.6, 26.2, 11.5; LRMS m/z calcd for C24H31N5OS2: 469.2; found 470.2 
[M+H]+ (Figure C5G); Purity of the compound was further confirmed by RP-HPLC by using 
method 2: Rt = 23.49 min (100% pure, Figure C171). 
 
Preparation of compound 8g. Compound 8g was prepared by 
using procedure D. Compound 40 (0.11 g, 0.43 mmol), K2CO3 
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(0.14 g, 0.948 mmol), and compound 42 0.12 g, 0.43 mmol) in anhydrous DMF (4 mL) were 
used to afford compound 8g (107 mg, 61%, Rf 0.28 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a tan solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH): 
1H NMR (400 MHz, CDCl3, Figure C172) δ 7.72 (br t, J = 5.4 Hz,1H), 5.78 (s, 2H), 3.73 (s, 
2H), 3.29 (q, J = 5.9 Hz, 2H), 2.92-2.90 (m, 2H), 2.80-2.78 (m, 2H), 2.53 (t, J = 6.0 Hz, 2H), 
2.47 (q, J = 7.2 Hz, 4H), 1.86-1.82 (m, 2H), 1.78-1.71 (m, 4H), 0.89 (t, J = 7.2 Hz, 6H); 13C 
NMR (100 MHz, CDCl3, Figure C173) δ 169.6, 166.1, 162.8, 157.5, 135.8, 130.4, 114.3, 51.4, 
46.7, 37.2, 34.5, 30.6, 29.9, 28.9, 27.1, 26.4, 11.3; LRMS m/z calcd for C19H29N5OS2: 407.2; 
found 408.1 [M+H]+ (Figure C5H); Purity of the compound was further confirmed by RP-
HPLC by using method 2: Rt = 24.35 min (96% pure, Figure C174). 
 
Preparation of compound 1h. Compound 1h was prepared using 
procedure D. Compound 33 (0.20 g, 0.91 mmol), K2CO3 (0.28 g, 
1.98 mmol), and compound 43 (0.27 g, 0.91 mmol) in anhydrous 
DMF (4.0 mL) were used to afford compound 1h (141 mg, 39%, Rf 0.35 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as an off-white solid after purification by flash 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 
MHz, CDCl3, Figure C175) δ 7.84 (br s, 1H), 5.63 (br s, 2H), 3.78 (s, 2H), 3.42 (q, J = 5.6 Hz, 
2H), 2.95 (m, 4H), 2.59 (m, 4H), 2.51 (p, J = 7.6 Hz, 4H), 1.55 (m, 4H), 1.40 (m, 2H); 13C 
NMR (100 MHz, CDCl3, Figure C176) δ 172.8, 169.7, 163.6, 157.0, 137.5, 134.6, 110.3, 57.4, 
54.4, 36.7, 34.8, 29.7, 29.2, 28.0, 25.8, 24.4; LRMS m/z calcd for C18H25N5OS2: 391.2; found 
392.0 [M+H]+ (Figure C5I); Purity of the compound was further confirmed by RP-HPLC by 
using method 2: Rt = 21.78 min (95% pure, Figure C177). 
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Preparation of compound 2h. Compound 2h was prepared using 
procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.25 g, 
1.72 mmol), and compound 43 (0.23 g, 0.78 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 2h (172 mg, 54%, Rf 0.31 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a brown solid after purification by flash column chromatography 
(SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 MHz, CD3OD, Figure C178) 
δ 3.79 (s, 2H), 3.33 (t, J = 6.4 Hz, 2H), 2.92-2.87 (m, 2H), 2.79-2.74 (m, 2H), 2.42 (t, J = 6.4 
Hz, 2H), 2.34 (m, 4H), 1.90 (m, 4H), 1.45 (p, J = 6.0 Hz, 4H) 1.37-1.36 (m, 2H); 13C NMR 
(100 MHz, CDCl3, Figure C179) δ 169.6, 167.3, 163.4, 157.3, 132.2, 125.4, 113.1, 57.2, 54.2, 
36.4, 34.5, 26.0, 25.6, 25.2, 24.2, 22.6, 22.4; LRMS m/z calcd for C19H27N5OS2: 405.2; found 
406.3 [M+H]+ (Figure C5J); Purity of the compound was further confirmed by RP-HPLC by 
using method 2: Rt = 18.53 min (97% pure, Figure C180). 
 
Preparation of compound 3h. Compound 3h was prepared using 
procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.29 g, 
0.90 mmol), TBAI (0.29 g, 0.78 mmol), and compound 43 (0.35 g, 
1.22 mmol) in anhydrous DMF (4 mL) were used to afford compound 3h (258 mg, 77%, Rf 
0.34 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by flash 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 
MHz, CD3OD, Figure C181) δ 3.76 (s, 2H), 3.31-3.28 (m, 2H), 3.26-3.18 (m, 1H), 2.80-2.62 
(m, 2H), 2.37 (t, J = 6.8 Hz, 2H), 2.32-2.22 (m, 4H), 2.0-1.74 (m, 4H), 1.39 (p, J = 5.2 Hz, 
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4H), 1.36-1.30 (m, 2H), 1.25 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CD3OD, Figure C182) 
δ 170.9, 167.1, 163.0, 157.3, 131.8, 130.4, 112.1, 57.1, 53.9, 36.3, 33.8, 29.2, 28.8, 25.1, 24.7, 
23.6, 20.9, 17.5; LRMS m/z calcd for C20H29N5OS2: 419.2; found 420.0 [M+H]+ (Figure 
C5K); Purity of the compound was further confirmed by RP-HPLC by using method 1: Rt = 
10.97 min (99% pure, Figure C183). 
 
Preparation of compound 4h. Compound 4h was prepared 
using procedure D. Compound 36 (0.29 g, 0.78 mmol), K2CO3 
(0.25 g, 1.72 mmol), compound 43 (0.24 g, 0.78 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 4h (222 mg, 68%, Rf 0.31 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid after purification by flash 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 
MHz, CDCl3, Figure C184) δ 7.74 (br s, 1H), 5.60 (br s, 2H), 3.77 (s, 2H), 3.36 (q, J = 5.6 Hz, 
2H), 2.93-2.78 (m, 3H), 2.49-2.34 (m, 7H), 1.99-1.95 (m, 2H), 1.56-1.46 (m, 5H), 1.36 (m, 
2H), 1.09 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C185) δ 169.5, 167.4, 
163.4, 157.3, 131.8, 125.1, 113.0, 57.2, 54.2, 36.5, 34.5, 33.2, 30.5, 28.9, 25.7, 25.6, 24.2, 
21.1; LRMS m/z calcd for C20H29N5OS2: 419.2; found 420.0 [M+H]+ (Figure C5L); Purity of 
the compound was further confirmed by RP-HPLC by using method 2: Rt = 20.03 min (100% 
pure, Figure C186). 
 
Preparation of compound 5h. Compound 5h was prepared 
using procedure E. Compound 37 (0.05 g, 0.19 mmol), Cs2CO3 
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(0.06 g, 0.19 mmol), TBAI (0.07 g, 0.19 mmol), and compound 43 (0.08 g, 0.28 mmol) in 
anhydrous DMF (8 mL) were used to afford compound 5h (56 mg, 68%, Rf 0.27 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by column 
chromatography (SiO2, CH2Cl2, 49:1/CH2Cl2:MeOH, 19:1/CH2Cl2:MeOH, 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L), then 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L)) and then 
recrystallization from Hexanes:EtOAc: 1H NMR (400 MHz, CD3OD, Figure C187) δ 3.78 (s, 
2H), 3.33 (t, J = 6.0 Hz, 2H), 3.03-2.95 (m, 1H), 2.87 (dd, J = 16.8, 4.0 Hz, 1H), 2.91-2.80 (m, 
1H), 2.40 (t, J = 6.4 Hz, 2H), 2.38-2.34 (m, 1H), 2.32 (m, 4H), 2.12-2.04 (m, 1H), 1.80-1.68 
(m, 1H), 1.56-1.42 (m, 3H), 1.44 (p, J = 4.8 Hz, 4H), 1.40-1.32 (m, 2H), 1.02 (t, J = 7.6 Hz, 
3H); 13C NMR (100 MHz, CD3OD, Figure C188) δ 172.5, 168.3, 164.7, 159.5, 132.1, 127.9, 
114.1, 58.7, 55.4, 37.8, 37.3, 35.4, 32.2, 29.71, 29.69, 26.7, 26.6, 25.1, 11.9; LRMS m/z calcd 
for C21H31N5OS2: 433.2; found 434.0 [M+H]+ (Figure C6A); Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 11.95 min (97% pure, Figure C189). 
 
Preparation of compound 6h. Compound 6h was prepared 
using procedure E. Compound 38 (0.10 g, 0.34 mmol), 
Cs2CO3 (0.11 g, 0.34 mmol), TBAI (0.13 g, 0.34 mmol), and 
compound 43 (0.15 g, 0.51 mmol) in anhydrous DMF (8 mL) were used to afford compound 
6h (88 mg, 56%, Rf 0.61 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, CH2Cl2, 49:1/CH2Cl2:MeOH, 
19:1/CH2Cl2:MeOH, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L), then 7:3/CH2Cl2:MeOH with 
NH4OH(7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C190) δ 3.84 (s, 2H), 3.54 (t, J = 6.0 
Hz, 2H), 3.10-2.94 (m, 3H), 3.03 (br t, 4H), 2.86-2.74 (m, 2H), 2.60-2.49 (m, 1H), 2.21-2.13 
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(m, 1H), 1.73 (p, J = 5.6 Hz, 4H), 1.62-1.52 (m, 3H), 1.43 (qd, J = 12.0, 5.2 Hz, 1H), 0.99 (s, 
9H); 13C NMR (100 MHz, CDCl3, Figure C191) δ 171.6, 167.8, 163.8, 158.0, 132.7, 125.8, 
112.9, 57.5, 54.6, 44.8, 35.2, 34.8, 32.7, 27.4, 27.2, 27.1, 24.3, 23.1, 22.3; LRMS m/z calcd 
for C23H35N5OS2: 461.2; found 462.1 [M+H]+ (Figure C6B); Purity of the compound was 
further confirmed by RP-HPLC by using method 1: Rt = 12.61 min (95% pure, Figure C192). 
 
Preparation of compound 7h. Compound 7h was prepared 
using procedure D. Compound 39 (0.20 g, 0.64 mmol), 
K2CO3 (0.20 g, 1.43 mmol), and compound 43 (0.19 g, 0.65 
mmol) in anhydrous DMF (4 mL) were used to afford compound 7h (151 mg, 49%, Rf 0.27 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C194) δ 
7.31 (m, 4H), 7.25-7.19 (m, 1H), 3.80 (s, 2H), 3.34 (t, J = 6.4 Hz, 2H), 3.21-2.99 (m, 4H), 
2.94-2.87 (m, 1H), 2.43 (t, J = 6.4 Hz, 2H), 2.35 (m, 4H), 2.22-2.16 (m, 1H), 2.11-2.00 (m, 
1H), 1.46 (app. p, J = 5.6 Hz, 4H), 1.40-1.35 (m, 2H); 13C NMR (100 MHz, CDCl3, Figure 
C194) δ 169.9, 167.7, 163.8, 157.7, 145.0, 131.7, 128.8, 127.0, 126.9, 125.5, 113.0, 57.4, 54.4, 
40.2, 36.6, 34.7, 33.0, 29.8, 26.4, 25.7, 24.4; LRMS m/z calcd for C25H31N5OS2: 481.2; found 
482.0 [M+H]+ (Figure C6C); Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 12.41 min (96% pure, Figure C195). 
 
Preparation of compound 8h. Compound 8h was prepared 
using procedure D. Compound 40 (0.08 g, 0.31 mmol), K2CO3 
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(0.10 g, 0.68 mmol), and compound 43 (0.09 g, 0.31 mmol) in anhydrous DMF (4 mL) were 
used to afford compound 8h (88 mg, 68%, Rf 0.31 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a brown solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CDCl3, Figure C196) δ 7.67 (br t, J = 5.2 Hz, 1H), 
5.71 (s, 2H), 3.75 (s, 2H), 3.33 (q, J = 5.6 Hz, 2H), 2.94-2.91 (m, 2H), 2.82-2.80 (m, 2H), 2.43 
(t, J = 6.0 Hz, 2H), 2.33-2.30 (m, 4H), 1.87-1.83 (m, 2H), 1.79-1.72 (m, 4H), 1.43-1.37 (m, 
4H), 1.34-1.30 (m, 2H); 13C NMR (100 MHz, CDCl3, Figure C197) δ 169.7, 166.1, 162.8, 
157.5, 135.8, 130.5, 114.3, 57.1, 54.1, 36.3, 34.4, 30.6, 29.9, 28.9, 27.1, 26.4, 25.4, 24.0; 
LRMS m/z calcd for C20H29N5OS2: 419.2; found 420.1 [M+H]+ (Figure C6D); Purity of the 
compound was further confirmed by RP-HPLC by using method 2: Rt = 23.50 min (95% pure, 
Figure C198). 
 
Preparation of compound 1i. Compound 1i was prepared using 
procedure D. Compound 33 (0.20 g, 0.91 mmol), K2CO3 (0.27 g, 
1.98 mmol), and compound 44 (0.26 g, 0.90 mmol) in anhydrous 
DMF (4.0 mL) were used to afford compound 1i (150 mg, 42%, Rf 0.51 in 9:1/CH2Cl2:MeOH 
with NH4OH (7mL/L)) as a white solid after purification by flash column chromatography 
(SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 MHz, CD3OD, Figure C199) 
δ 3.77 (s, 2H), 3.42 (t, J = 4.8 Hz, 4H), 3.30 (t, J = 6.0 Hz, 2H), 3.00 (tt, J = 7.6, 2.0 Hz, 2H), 
2.93 (tt, J = 7.6, 1.6 Hz, 2H), 2.48 (p, J = 7.6 Hz, 2H), 2.39 (t, J = 6.0 Hz, 2H), 2.28 (t, J = 4.4 
Hz, 4H); 13C NMR (100 MHz, CDCl3, Figure C200) δ 172.7, 169.8, 163.7, 156.9, 137.6, 
134.7, 110.3, 66.9, 57.1, 53.4, 36.3, 34.6, 29.7, 29.2, 28.0; LRMS m/z calcd for 
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C17H23N5O2S2: 393.1; found 394.1 [M+H]+ (Figure C6E); Purity of the compound was further 
confirmed by RP-HPLC by using method 2: Rt = 22.73 min (97% pure, Figure C201). 
 
Preparation of compound 2i. Compound 2i was prepared using 
procedure D. Compound 34 (0.20 g, 0.78 mmol), K2CO3 (0.25 g, 
1.72 mmol), and compound 44 (0.23 g, 0.78 mmol), and DMF 
(4.0 mL) were used to afford compound 2i (172 mg, 54%, Rf 0.40 in 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)) as a white solid after purification by flash column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 MHz, (CD3)2SO, Figure C202) δ 
7.91 (t, J = 5.5 Hz, 1H), 6.95 (br s, 2H), 3.74 (s, 2H), 3.45 (t, J = 4.7 Hz, 4H), 3.17 (q, J = 6.4 
Hz, 2H), 2.85 (m, 2H), 2.71 (m, 2H), 2.32-2.26 (m, 6H), 1.79 (m, 4H); 13C NMR (100 MHz, 
(CD3)2SO, Figure C203) δ 167.9, 166.0, 163.4, 157.6, 129.2, 126.8, 112.3, 66.0, 57.1, 53.1, 
36.1, 34.0, 25.3, 24.7, 22.2, 21.9; LRMS m/z calcd for C18H25N5O2S2: 407.1; found 408.2 
[M+H]+ (Figure C6F); Purity of the compound was further confirmed by RP-HPLC by using 
method 1: Rt = 10.64 min (99% pure, Figure C204). 
 
Preparation of compound 3i. Compound 3i was prepared using 
procedure E. Compound 35 (0.20 g, 0.80 mmol), Cs2CO3 (0.30 g, 
0.91 mmol), TBAI (0.29 g, 0.79 mmol), and compound 44 (0.34 g, 
1.19 mmol) in anhydrous DMF (4 mL) were used to afford compound 3i (177 mg, 53%, Rf 
0.30 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after purification by flash 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure 
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C205) δ 3.81 (d, J = 15.6 Hz, 1H), 3.77 (d, J = 15.6 Hz, 1H), 3.43 (t, J = 4.0 Hz, 4H), 3.33 (t, 
J = 6.0 Hz, 2H), 3.28-3.20 (m, 1H), 2.84-2.68 (m, 2H), 2.41 (t, J = 6.0 Hz, 2H), 2.31 (t, J = 
4.4 Hz, 4H), 2.04-1.76 (m, 4H), 1.29 (d, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure 
C206) δ 170.1, 168.0, 163.6, 156.9, 132.0, 131.3, 112.8, 66.5, 57.2, 53.4, 36.1, 34.6, 29.9, 
29.6, 25.5, 22.0, 17.9; LRMS m/z calcd for C19H27N5O2S2: 421.2; found 422.0 [M+H]+ 
(Figure C6G); Purity of the compound was further confirmed by RP-HPLC by using method 
2: Rt = 24.81 min (100% pure, Figure C207). 
 
Preparation of compound 4i. Compound 4i was prepared 
using procedure D. Compound 36 (0.28 g, 0.78 mmol), K2CO3 
(0.25 g, 1.72 mmol), and compound 44 (0.23 g, 0.78 mmol) in 
anhydrous DMF (4 mL) were used to afford compound 4i (196 mg, 60%, Rf 0.35 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a yellow solid after purification by flash 
column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 7 mL/L NH4OH)): 1H NMR (400 
MHz, CD3OD, Figure C208) δ 3.79 (s, 2H), 3.44 (t, J = 4.4 Hz, 4H), 3.32 (t, J = 6.0 Hz, 2H), 
3.01-2.96 (m, 1H), 2.92-2.86 (m, 1H), 2.83 (dd, J = 16.8, 5.2 Hz, 1H), 2.41 (t, J = 6.0 Hz, 2H), 
2.38-2.33 (m, 1H), 2.31 (t, J = 4.4 Hz, 4H), 2.04-1.90 (m, 2H), 1.57-1.46 (m, 1H), 1.12 (d, J = 
6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C209) δ 169.6, 167.3, 163.4, 157.2, 131.9, 
125.2, 112.9, 66.7, 56.9, 53.2, 36.1, 34.3, 33.2, 30.4, 28.9, 25.7, 21.1; LRMS m/z calcd for 
C19H27N5O2S2: 421.2; found 422.2 [M+H]+ (Figure C6H); Purity of the compound was further 
confirmed by RP-HPLC by using method 1: Rt = 11.16 min (96% pure, Figure C210). 
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Preparation of compound 5i. Compound 5i was prepared 
using procedure E. Compound 37 (0.05 g, 0.68 mmol), 
Cs2CO3 (0.06 g, 0.19 mmol), TBAI (0.07 g, 0.19 mmol), and 
compound 44 (0.08 g, 0.28 mmol) in anhydrous DMF (8 mL) were used to afford compound 
5i (10 mg, 12%, Rf 0.45 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, CH2Cl2, 49:1/CH2Cl2:MeOH, 
19:1/CH2Cl2:MeOH, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L), then 7:3/CH2Cl2:MeOH with 
NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C211) δ 3.79 (s, 2H), 3.46 (t, J = 4.8 
Hz, 4H), 3.31 (t, J = 6.0 Hz, 2H), 3.02-2.94 (m, 1H), 2.86 (dd, J = 16.8, 4.0 Hz, 1H), 2.90-
2.79 (m, 1H), 2.44 (t, J = 6.0 Hz, 2H), 2.40-2.36 (m, 1H), 2.34 (t, J = 4.4 Hz, 4H), 2.10-1.92 
(m, 1H), 1.78-1.68 (m, 1H), 1.55-1.39 (m, 3H), 1.01 (t, J = 7.2, 3H); 13C NMR (100 MHz, 
CDCl3, Figure C212) δ 169.9, 167.6, 163.7, 157.4, 132.3, 125.6, 113.2, 66.8, 57.1, 53.5, 36.3, 
35.9, 34.6, 31.4, 28.7, 28.6, 26.0, 11.7; LRMS m/z calcd for C20H29N5O2S2: 435.2; found 
436.0 [M+H]+ (Figure C6I) Purity of the compound was further confirmed by RP-HPLC by 
using method 1: Rt = 11.77 min (96% pure, Figure C213). 
 
Preparation of compound 6i. Compound 6i was prepared 
using procedure E. Compound 38 (0.21 g, 0.68 mmol), 
Cs2CO3 (0.33 g, 1.02 mmol), TBAI (0.25 g, 0.68 mmol), and 
compound 44 (0.22 g, 0.75 mmol) in anhydrous DMF (8 mL) were used to afford compound 
6i (126 mg, 40%, Rf 0.49 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a white solid after 
purification by column chromatography (SiO2, 49:1/CH2Cl2:MeOH, 19:1/CH2Cl2:MeOH, 
then 9:1/CH2Cl2:MeOH with  NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C214) 
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δ 3.76 (s, 2H), 3.43 (t, J = 4.4 Hz, 4H), 3.30 (t, J = 6.8 Hz, 2H), 3.06-2.99 (m, 1H), 2.83-2.72 
(m, 2H), 2.55-2.47 (m, 1H), 2.38 (t, J = 6.4 Hz, 2H), 2.28 (t, J = 4.4 Hz, 4H), 2.17-2.10 (m, 
1H), 1.59-1.50 (m, 1H), 1.41 (qd, J = 12.4, 5.2 Hz, 1H), 0.96 (s, 9H); 13C NMR (100 MHz, 
CD3OD, Figure C215) δ 172.4, 168.3, 164.7, 159.4, 133.0, 127.9, 114.0, 67.7, 58.3, 54.6, 46.1, 
37.5, 35.3, 33.4, 27.93, 27.90, 27.8, 25.4; LRMS m/z calcd for C22H33N5O2S2: 463.2; found 
464.1 [M+H]+ (Figure C6J); Purity of the compound was further confirmed by RP-HPLC by 
using method 2: Rt = 22.47 min (97% pure, Figure C216). 
 
Preparation of compound 7i. Compound 7i was prepared 
using procedure D. Compound 39 (0.20 g, 0.64 mmol), 
K2CO3 (0.20 g, 1.45 mmol), and compound 44 (0.19 g, 0.65 
mmol) in anhydrous DMF (4 mL) were used to afford compound 7i (119 mg, 38%, Rf 0.36 in 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a tan solid after purification by column 
chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L) then SiO2, 
19:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD, Figure C217) δ 
7.27 (d, J = 4.4 Hz, 4H), 7.24-7.16 (m, 1H), 3.78 (s, 2H), 3.45 (t, J = 4.4 Hz, 4H), 3.31 (t, J = 
6.4 Hz, 2H), 3.52-2.98 (m, 4H), 2.96-2.86 (m, 1H), 2.42 (t, J = 5.6 Hz, 2H), 2.32 (m, 4H), 
2.22-2.14 (m, 1H), 2.11-1.98 (m, 1H); 13C NMR (100 MHz, CDCl3, Figure C218) δ 169.5, 
167.4, 163.7, 157.4, 144.7, 131.6, 128.7, 126.8, 126.7, 125.4, 112.8, 66.7, 56.9, 53.2, 40.0, 
36.1, 34.3, 32.8, 29.6, 26.2; LRMS m/z calcd for C24H29N5O2S2: 483.2; found 484.0 [M+H]+ 
(Figure C6K); Purity of the compound was further confirmed by RP-HPLC by using method 
2: Rt = 20.96 min (95% pure, Figure C219). 
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Preparation of compound 8i. Compound 8i was prepared using 
procedure D. Compound 40 (0.20 g, 0.81 mmol), K2CO3 (0.25 g, 
1.79 mmol), and compound 44 (0.23 g, 0.82 mmol) in anhydrous 
DMF (4 mL) were used to afford compound 8i (191 mg, 56%, Rf 0.39 in 9:1/CH2Cl2:MeOH 
with NH4OH (7 mL/L)) as a pink solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH): 1H NMR (400 MHz, CD3OD, Figure C220) δ 3.80 (s, 2H), 3.49 (very br 
t, 4H), 3.36 (t, J = 6.4 Hz, 2H), 3.04-3.01 (m, 2H), 2.88-2.86 (m, 2H), 2.60-2.38 (m, 6H), 1.93 
(p, J = 6.4 Hz, 2H), 1.77 (p, J = 6.4 Hz, 4H); 13C NMR (100 MHz, CDCl3, Figure C221) δ 
169.7, 166.1, 162.9, 157.3, 136.0, 130.5, 114.3, 66.6, 56.9, 53.2, 36.0, 34.3, 30.6, 29.9, 28.9, 
27.1, 26.4; LRMS m/z calcd for C19H27N5O2S2: 421.2; found 422.1 [M+H]+ (Figure C6L); 
Purity of the compound was further confirmed by RP-HPLC by using method 2: Rt = 25.09 
min (97% pure, Figure C222). 
 
4.5.1.5. General procedure F for the preparation of compounds 41-44 
Amine (1.1 eq) was dissolved in anhydrous CH2Cl2 (6 mL). After this solution was cooled at -
10 °C for 20 min, bromoacetyl chloride (1 eq) was added. The reaction mixture was then 
removed from the ice bath and allowed to warm to rt. After reacting for about 19 h, the 
solvent was removed under reduced pressure to afford the desired products, which was used 
without any further purification. 
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Synthesis of compound 41. Compound 41 was synthesized using general 
procedure F. N,N-Diethylethylenediamine (0.42 mL, 2.96 mmol) and 
bromoacetyl chloride (0.47 g, 2.96 mmol) in anhydrous CH2Cl2 (6 mL) were used to afford 
compound 41 (805 mg, 99%) as a light pink solid, which was used without purification: 
LRMS m/z calcd for C6H14BrN2O+: 209.0; found 209.0 [M]+. 
 
Synthesis of compound 42. Compound 42 was synthesized using general 
procedure F. N,N-Dimethylethylenediamine (0.30 mL, 2.96 mmol) and 
bromoacetyl chloride (0.25 mL, 2.96 mmol) in anhydrous CH2Cl2 (6 mL) were used to afford 
compound 42 (641 mg, 91%) as a light pink solid, which was used without purification: 
LRMS m/z calcd for C8H18BrN2O+: 237.1; found 237.1 [M]+. 
 
Synthesis of compound 43. Compound 43 was synthesized using general 
procedure F. 1-(2-aminoethyl)piperidine (0.43 mL, 2.96 mmol) and 
bromoacetyl chloride (0.25 mL, 2.96 mmol) in anhydrous CH2Cl2 (6 mL) were used to afford 
compound 43 (845 mg, quant.) as a light pink solid, which was used without purification: 
LRMS m/z calcd for C9H18BrN2O+: 249.1; found 249.1 [M]+. 
 
Synthesis of compound 44. Compound 44 was synthesized using general 
procedure F. 4-(2-Aminoethyl)morpholine (0.42 g, 3.20 mmol) and 
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bromoacetyl chloride (0.25 mL, 3.00 mmol) in anhydrous CH2Cl2 (6 mL) were used to afford 
compound 44 (0.87 g, 99%) as a pale orange solid, which was used without any further 
purification: LRMS m/z calcd for C8H16BrN2O2+: 251.0; found 251.0 [M]+. 
 
4.5.2. Biochemical and biological methods 
4.5.2.1. High-throughput screening 
We expressed Eis protein from Mycobaterium tuberculosis (Eis_Mtb) using a previously 
described method.85 The following chemicals were required for biochemical/biological assays 
and acquired from Sigma-Aldrich (St. Louis, MO, USA): 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB), Tween® 80, kanamycin A (KAN), acetyl-CoA (AcCoA), and chlorhexidine. 
Albumin-dextrose-catalase (ADC) was acquired from BD Biosciences (San Jose, CA, USA). 
The high-throughput screening (HTS) was performed at the Center for Chemical Genomics 
(CCG, University of Michigan) and screened for putative inhibitors of purified Eis enzymes 
from three different libraries: (i) a ChemDiv library (20,000 compounds), (ii) the BioFocus 
NCC library (1,000 compounds), and (iii) the MicroSource MS2000 library (2,000 
compounds). The hit validation assay was done to confirm the inhibition of Eis_Mtb. We 
validated compound 2i by purchasing fresh powder from ChemDiv (San Diego, CA, USA). 
All small molecules synthesized (1a-i, 2a-i, 3a-i, 4a-i, 5a-i, 6a-i, 7a-i, 8a-i) in this study were 
dissolved in DMSO (10 mM stock) prior to testing. Please note that the concentrations listed 
below are the final concentrations in the assays. The pH of buffers was adjusted at rt. 
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4.5.2.2. Eis enzymatic assay 
As previously described,108 the Ellman’s reagent (DTNB) was used to monitor acetylation at 
412 nm. The reactions (40 µL) contained Tris-HCl (50 mM, pH 8.0), Eis (0.25 µM), NEO 
(100 µM), AcCoA (40 µM), DTNB (0.5 mM), and compounds 1a-i, 2a-i, 3a-i, 4a-i, 5a-i, 6a-i, 
7a-i, 8a-i (20 µM). Chlorhexidine (5 µM) and DMSO (0.5%) served as controls. Plates were 
incubated at rt and read on a PHERAstar plate reader 5 min after initiation of the reaction. The 
average Z' score for the HTS assay was 0.65. 
 
4.5.2.2. Antitubercular activity against Mtb cells 
The Mtb K204 cell line is a cell line that has been engineered to overexpress the eis gene and 
maintained at a BSL 3 facility at the CDC. The Mtb MC26020 cell line is BSL 2 and was a 
generous gift from Professor Bill Jacob’s laboratory. Sterile water (200 µL) was added to the 
outer wells of the plate. Middlebrook 7H9 (100 µL) supplemented with ADC (10%), Tween® 
80 (0.05%), and glycerol (0.4%) was added in columns 4-11. The same media (200 µL) was 
added to rows B-G. Compounds were added and serially diluted. The plate was then set aside 
while the bacteria culture was prepared. Media (5 mL) was added to a 15 mL screw-capped 
glass culture tubes. The culture tubes were placed in densitometer and the reference point was 
noted. The bacterial colonies were transferred to the culture tubes using a loop. The density of 
the culture tubes was aimed to be between 0.4 and 0.5 OD. The standard bacterial solution 
was diluted 100 fold using fresh media. The bacterial solution (100 µL) was then transferred 
to each well on the 96-well plate. The plate was incubated for 1-4 weeks and stained with 5 
µL of 2.5 mg/mL resazurin solution to track for growth rate. 
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Chapter 5 
 
Development of ebsulfur analogues as potent antibacterials against methicillin-resistant 
Staphylococcus aureus 
 
Note: 
These molecules were initially developed as antitubercular compounds. We were excited 
when we came across literature indicating that they are potential inhibitors of Ag85 enzymes, 
a group of mycolyltransferases that are essential for the biosynthesis of the Mtb cell wall. 
However, in our hand, these ebsulfur analogues only displayed low antitubercular activity. 
With these molecules already developed, we decided to screen them for other antimicrobial 
applications. In this chapter, we reported the activity of ebsulfur/ebselen scaffold against 
methicillin-resistant Staphylococcus aureus (MRSA), which was not well investigated in the 
literature. 
 
5.1. ABSTRACT 
Antibiotic resistance is a worldwide problem that needs to be addressed. MRSA is one of the 
dangerous “ESKAPE” pathogens that rapidly evolve and evade many current FDA-approved 
antibiotics. Thus, there is an urgent need for new anti-MRSA compounds. Ebselen (also 
known as 2-phenyl-1,2-benzisoselenazol-3(2H)-one) has shown promising activity in clinical 
trials for cerebral ischemia, bipolar disorder, and noise-induced hearing loss. Recently, there 
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has been a renewed interest in exploring the antibacterial properties of ebselen. In this study, 
we synthesized an ebselen-inspired library of 33 compounds where the selenium atom has 
been replaced by sulfur (ebsulfur derivatives) and evaluated them against a panel of drug 
sensitive and drug resistant S. aureus and non-S.aureus strains. Within our library, we 
identified three outstanding analogues with potent activity against all S. aureus strains tested 
(MIC values mostly ≤2 mg/mL), and numerous additional ones with overall very good to 
good antibacterial activity (1-7.8 mg/mL). We also characterized the time-kill analysis, anti-
biofilm ability, hemolytic activity, mammalian cytotoxicity, membrane-disruption ability, and 
reactive oxygen species (ROS) production of some of these analogues. 
 
5.2. INTRODUCTION 
Only two years after its introduction on the market in 1959, methicillin had experienced 
resistance by Staphylococcus aureus.159 Ever since, methicillin-resistant S. aureus (MRSA) 
strains have spread worldwide and have become resistant to many additional FDA approved 
antibiotics causing great harm to infected patients. In 2011, the Centers for Disease Control 
(CDC) estimated that the national incidence of invasive MRSA infections was 80,461 cases 
including 650 cases of death, which was the highest mortality rate among bacterial 
infections.160 S. aureus is a Gram-positive bacterium residing mostly on the skin and nasal 
lining of up to one-third of healthy individuals and can be transferred from one host to another 
by skin contact. Typically, the bacterium causes no symptoms. However, once the skin layer 
is broken due to scratches or cuts, S. aureus may lead to many problems varying from mild 
acne to life-threatening conditions such as bacteremia, pneumonia, endocarditis, and 
osteomyelitis.161 Furthermore, MRSA is one of the “ESKAPE” pathogens, which also include 
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Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Enterobacter species. The “ESKAPE” pathogens are termed that way 
because of their ability to escape the therapeutic effects of many known antibiotics and are 
responsible for the majority of hospital infections. In fact, the Infectious Diseases Society of 
America (IDSA) has expressed concerns about the empty pipeline for novel antibacterials that 
can target these pathogens.162 Thus, there is a need for new drug candidates to combat MRSA 
and the rest of the “ESKAPE” pathogens.  
 
In recent years, a number of novel scaffolds with promising activities and mechanism of 
actions against MRSA have been described. Among them, the compound 5-nitro-2-phenyl-
(1H)-indole was discovered as a NorA, efflux pump, inhibitor at IC50 values lower than 5.0 
µM.163 We also reported 6"-thioether tobramycin and kanamycin B analogues with long linear 
alkyl chains disrupting bacterial cell membranes and displaying good activity against S. 
aureus strains.164-166 Another compound, AFN-125, was found to selectively inhibit S. aureus 
enoyl-ACP reductase, and has even been tested in clinical trials.167 These recent advancements 
have certainly contributed towards our efforts of eradicating MRSA. However, the concerns 
about MRSA and “ESKAPE” pathogens have not been completely alleviated and novel 
scaffolds with potent antibacterial activities are still urgently needed. 
 
Ebselen (also known as 2-phenyl-1,2-benzisoselenazol-3(2H)-one) was developed by Daiichi 
Sankyo Pharmaceuticals in 1997 for cerebral ischemia in Japan, but failed during phase 3 
clinical trial due to insufficient efficacy.168-169 Since then, there has been a renewed interest in 
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this compound; in fact, ebselen is currently being evaluated in clinical trials for treatments of 
bipolar disorder170 and noise-induced hearing loss.171 Clinical applications of ebselen are 
hypothesized to be related to its ability to covalently bind to cysteine residues on targeted 
proteins or its antioxidant activity via mimicking glutathione peroxidase.172-173 In addition, 
ebselen was found to inhibit the growth of various Gram-positive and Gram-negative bacterial 
strains.174 In 2014, the crystal structure of antigen 85C, a putative drug target in 
Mycobacterium tuberculosis (Mtb), was solved and revealed that ebselen covalently inhibit 
the antigen 85 complex and hence, explained its activity against Mtb.175 From a high-
throughput screen, ebselen was discovered to target the cysteine protease domain within the 
major virulence factors A and B of Clostridium difficile.176 Futhermore, ebselen and ebsulfur 
(2a) were found to inhibit bacterial thioredoxin reductase, suggesting that they may be useful 
agents against bacteria lacking the glutathione redox system.177 Finally, ebselen especially 
caught our attention because it demonstrated potent bactericidal activity against many clinical 
isolates of drug-resistant S. aureus and was effective in a murine model of MRSA skin 
infection.178 These findings prompted us to investigate the antibacterial activity of our own 
library of ebselen-inspired compounds. 
 
Although no clear evidence has yet been established during clinical studies, there were initial 
concerns about selenium toxicity of ebselen as some systemic accumulation was observed.169 
In lieu of this potential adverse effect, we decided to study ebsulfur, in which the selenium of 
ebselen is replaced by a sulfur atom. Additionally, in terms of synthesis, the ebsulfur scaffold 
or 2-phenyl-1,2-benzisothiazol-3(2H)-one is readily accessible via a convenient 2-step 
synthesis, which allows for simple scale-up and derivatization. Herein, we synthesized and 
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evaluated ebsulfur (2a) and 32 of its analogues (2b-4n) against a panel of methicillin-sensitive 
S. aureus (MSSA), MRSA, and other bacterial strains. We also performed the time-kill 
analysis, established the anti-biofilm ability, hemolytic activity, membrane-disruption ability, 
and ROS production of some of these analogues. 
 
5.3. RESULTS AND DISCUSSION 
5.3.1. Chemistry 
To synthesize the desired ebsulfur (2a) and its derivatives 2b-3o, we first prepared the 
common intermediate compound 1 in 80% yield by refluxing 2,2'-dithio-dibenzoic acid with 
thionyl chloride (Figure 5.1). Compound 1 was then treated with a variety of aniline 
analogues and triethylamine in dichloromethane to afford compounds 2a-o in 9-51% yield, as 
shown in procedure A. We initially tried to use procedure A for the preparation of ebsulfur 
analogues with aliphatic amines, but were unsuccessful as the undesired 2,2'-dithio-
dibenzamide products were typically the major products observed. Thus, the undesired 2,2'-
dithio-dibenzamide products were converted to the desired products 3a-o in 14% to 
quantitative yield by subsequent addition of N-chlorosuccinimide to the reaction mixture, as 
shown in procedure B. During our synthesis, we also noticed that extra-long reaction time or 
poor-quality anhydrous dichloromethane led to the formation of the oxidized sulfoxide 
byproducts. On silica gel, the oxidized byproducts actually displayed retention times that were 
similar to the desired product and could be mistakenly isolated. Thus, we carefully monitored 
our reactions by TLC and verified their masses either by LRMS or HRMS. To test the effect 
of oxidation of the sulfur on the biological activity of our ebsulfur (2a) derivatives, we 
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randomly selected three compounds (3e, f, and n) for which we let the reaction go longer to 
isolate the corresponding oxidized derivatives 4e, f, and n. All new molecules were 
characterized by 1H and 13C NMR as well as by mass spectrometry and were confirmed to be 
≥95% purity. 
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Figure 5.1. Synthetic scheme for the preparation of compounds 2a-o, 3a-o, and 4e, 4f, and 4n 
following two different experimental procedures (A and B). 
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5.3.2. Biochemistry and Biology 
5.3.2.1. Evaluation of compounds 2a-4n as antibacterial agents 
The antibacterial activity of 2a-4n was evaluated against a panel of S. aureus strains 
comprised of three MSSA strains (A-C) and 25 MRSA strains (D-AB) (Table 5.1).179 We also 
tested the activity of all these analogues against non-S. aureus strains such as S. epidermidis, 
E. faecalis, E. faecium, VRE, L. monocytogenes, and M. smegmatis (AC-AI) (Table 5.2). 
Furthermore, the controls amikacin (AMK), ebselen, and ebsulfur (2a), along with our best 
compound, 2h, were tested against a panel of additional bacterial strains, which included A. 
baumannii, E. cloacae, E. coli, K. pneumoniae, P. aeruginosa, S. enterica, and S. epidermidis 
(Table 5.3). The strains tested ranged from completely resistant to the control AMK (≥125 
µg/mL, AD, AE, and AF) to very susceptible to AMK (≤0.50 µg/mL, B, T, and AI). 
Minimum inhibitory concentration (MIC) values were determined using the broth double 
dilution method. 
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Table 5.1. MIC valuesa (in µg/mL) determined for all compounds and for the control 
antibacterial agent (AMK) against various S. aureus strains. 
Cpd 
# A B C D E F G H I J K L M N 
Ebsel
en 2 3.9 2 0.5 
≤0.
25 2 7.8 2 1 0.5 2 3.9 1 2 
2a 7.8 3.9 3.9 0.5 2 7.8 7.8 3.9 2 2 7.8 3.9 2 3.9 
2b 3.9 2 3.9 1 3.9 2 3.9 2 3.9 1 3.9 3.9 2 2 
2c 3.9 2 2 1 1 1 3.9 2 1 1 3.9 3.9 1 2 
2d 2 2 2 0.5 3.9 2 3.9 2 2 1 3.9 3.9 2 2 
2e 2 2 ≤0.25 
≤0.
25 
≤0.
25 1 2 
≤0.
25 0.5 0.5 1 1 0.5 
≤0.
25 
2f 7.8 3.9 1 1 3.9 2 7.8 2 2 2 7.8 7.8 2 2 
2g 7.8 7.8 3.9 2 7.8 3.9 7.8 3.9 3.9 3.9 7.8 3.9 3.9 3.9 
2h 3.9 0.5 ≤0.25 
≤0.
25 
≤0.
25 
≤0.
25 1 
≤0.
25 
≤0.
25 
≤0.
25 0.5 
≤0.
25 
≤0.
25 
≤0.
25 
2j 7.8 7.8 3.9 1 7.8 7.8 7.8 3.9 3.9 3.9 15.6 7.8 7.8 7.8 
2k 1 0.5 ≤0.25 
≤0.
25 
≤0.
25 1 2 0.5 
≤0.
25 0.5 2 2 
≤0.
25 1 
2l >125 2 0.5 0.5 1 0.5 2 2 0.5 1 2 
15.
6 0.5 2 
2m 7.8 7.8 7.8 3.9 15.6 7.8 
15.
6 3.9 7.8 7.8 7.8 7.8 7.8 7.8 
3a 7.8 3.9 3.9 1 0.5 2 3.9 2 2 2 3.9 7.8 1 0.5 
3b 7.8 3.9 3.9 2 2 3.9 3.9 3.9 3.9 3.9 3.9 7.8 2 0.5 
3c 1 1 1 0.5 0.5 1 1 1 0.5 1 1 2 0.5 ≤0.25 
3d 62.5 3.9 3.9 2 
0.2
5 1 
15.
6 3.9 1 2 
15.
6 3.9 1 0.5 
3e 7.8 125 15.6 
>12
5 7.8 
15.
6 7.8 7.8 7.8 7.8 7.8 7.8 7.8 3.9 
3f 3.9 >125 3.9 
>12
5 3.9 7.8 3.9 3.9 3.9 3.9 3.9 7.8 3.9 2 
3g 15.6 
15.
6 
15.
6 3.9 7.8 
15.
6 
15.
6 7.8 7.8 
15.
6 
15.
6 
15.
6 7.8 7.8 
3h 2 3.9 1 1 0.5 2 2 3.9 1 1 2 3.9 1 1 
3i 3.9 1 2 1 1 1 2 2 2 2 2 3.9 1 0.5 
3j 3.9 2 2 1 0.5 2 3.9 2 2 2 3.9 3.9 2 0.5 
3k 7.8 3.9 2 3.9 2 3.9 3.9 3.9 3.9 3.9 3,9 3,9 3.9 2 
3l 7.8 3.9 3.8 2 2 3.9 7.8 2 3.9 3.9 2 3.9 3.9 2 
3m 7.8 3.9 3.9 1 2 3.9 2 2 2 3.9 2 3.9 1 0.5 
3n 2 >12 2 >12 3.9 3.9 3.9 3.9 3.9 3.9 2 3.9 2 1 
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4e >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>1
25 
>12
5 
>12
5 
>12
5 
4f >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>1
25 
>12
5 
>12
5 
>12
5 
4n >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>1
25 
>12
5 
>12
5 
>12
5 
AM
K 2 
≤0.
25 
62.
5 
31.
3 
31.
3 3.9 
62.
5 2 2 7.8 
31.
3 
31.
3 3.9 
31.
3 
Cpd 
# O P Q R S T U V W X Y Z AA AB 
Ebsel
en 1 1 1 7.8 1 3.9 
≤0.
25 1 1 0.5 2 2 3.9 3.9 
2a 3.9 3.9 2 7.8 3.9 3.9 ≤0.25 3.9 2 7.8 3.9 3.9 3.9 3.9 
2b 3.9 2 2 3.9 3.9 3.9 ≤0.25 3.9 2 2 2 3.9 2 2 
2c 2 2 1 3.9 3.9 3.9 ≤0.25 1 2 1 2 2 3.9 2 
2d 3.9 2 2 3.9 2 2 ≤0.25 3.9 2 2 7.8 3.9 3.9 3.9 
2e 0.5 1 1 2 0.5 1 ≤0.25 
≤0.
25 0.5 
≤0.
25 0.5 1 2 1 
2f 7.8 3.9 3.9 7.8 3.9 3.9 0.5 3.9 2 2 2 3.9 3.9 7.8 
2g 3.9 7.8 7.8 7.8 3.9 3.9 0.5 3.9 >125 3.9 3.9 7.8 3.9 7.8 
2h 0.5 0.5 0.5 1 ≤0.25 0.5 
≤0.
25 
≤0.
25 1 
≤0.
25 0.5 0.5 
≤0.
25 
≤0.
25 
2j 7.8 7.8 3.9 7.8 7.8 7.8 ≤0.25 3.9 3.9 7.8 3.9 7.8 7.8 7.8 
2k 1 0.5 ≤0.25 2 1 2 
≤0.
25 1 0.5 
≤0.
25 0.5 0.5 
≤0.
25 2 
2l 0.5 0.5 2 2 1 2 ≤0.25 1 1 0.5 0.5 2 2 2 
2m 7.8 7.8 7.8 15.6 7.8 
15.
6 2 7.8 7.8 7.8 7.8 7.8 7.8 
15.
6 
3a 2 2 2 2 3.9 2 ≤0.25 2 3.9 3.9 3.9 3.9 3.9 3.9 
3b 3.9 2 2 3.9 3.9 3.9 ≤0.25 3.9 3.9 3.9 7.8 7.8 3.9 7.8 
3c 1 1 1 1 1 1 ≤0.25 1 1 1 2 3.9 2 3.9 
3d 1 1 2 3.9 3.9 2 1 1 3.9 1 3.9 7.8 7.8 7.8 
3e 7.8 7.8 7.8 7.8 7.8 7.8 2 7.8 7.8 7.8 7.8 7.8 7.8 7.8 
3f 3.9 3.9 7.8 3.9 7.8 3.9 1 3.9 7.8 3.9 7.8 7.8 7.8 7.8 
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3g 15.6 
15.
6 
15.
6 
15.
6 7.8 
15.
6 2 
15.
6 
15.
6 
15.
6 
15.
6 
15.
6 
15.
6 
15.
6 
3h 2 1 1 1 2 1 ≤0.25 1 2 1 2 2 2 2 
3i 1 1 1 2 2 2 0.5 1 3.9 2 3.9 2 2 3.9 
3j 2 2 2 2 2 2 ≤0.25 2 3.9 2 2 3.9 2 3.9 
3k 3,9 3.9 3.9 3.9 3.9 3.9 0.5 3.9 7.8 3.9 3.9 3.9 3.9 7.8 
3l 3.9 3.9 3.9 3.9 3.9 3.9 0.5 7.8 7.8 3.9 7.8 7.8 7.8 7.8 
3m 2 2 3.9 2 3.9 2 0.5 1 3.9 3.9 3.9 7.8 15.6 7.8 
3n 2 2 3.9 0.5 2 2 1 2 7.8 3.9 7.8 7.8 7.8 7.8 
4e >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>1
25 
>12
5 
>12
5 
>12
5 
4f >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>1
25 
>12
5 
>12
5 
>12
5 
4n >125 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 
>12
5 125 
>1
25 
>12
5 
>12
5 
>12
5 
AM
K 
15.
6 
15.
6 
31.
3 
31.
3 
15.
6 0.5 7.8 
31.
3 7.8 
31.
3 
62.
5 
62.
5 
62.
5 
62.
5 
Bacterial strains: A = S. aureus ATCC 6538, B = S. aureus ATCC 25923, C = S. aureus 
ATCC 29213, D = S. aureus ATCC 33591, E = MRSA1, F = MRSA2, G = MRSA BRS3, H 
= MRSA C1, I = MRSA C2, J = MRSA C7, K = MRSA C14, L = MRSA C16, M = MRSA 
C19, N = MRSA G1, O = MRSA G6, P = MRSA G12, Q = MRSA G14, R = MRSA MRSA 
NRS4, S = MRSA NRS51, T = MRSA NRS77, U = MRSA S14, V = MRSA S17, W = 
MRSA S22, X = MRSA S24, Y = MRSA USA100, Z = MRSA USA200, AA = MRSA 
USA300, AB = MRSA USA600. 
 
Table 5.2. MIC valuesa (in µg/mL) determined for all compounds and for the control 
antibacterial agent (AMK) against various non-S. aureus bacterial strains. 
Cpd # AC AD AE AF AG AH AI 
Ebselen 0.25 0.5 ≤0.25 0.5 1 1 7.8 
2a 1 31.3 15.6 7.8 1 2 3.9 
2b 2 62.5 >125 31.3 2 2 1 
2c 1 62.5 >125 31.3 0.5 1 3.9 
2d 2 7.8 15.6 7.8 2 2 0.5 
2e 0.25 15.6 62.5 15.6 ≤0.25 0.5 0.5 
2f 2 7.8 <125 7.8 2 3.9 3.9 
2g 3.9 15.6 >125 15.6 7.8 3.9 3.9 
2h 0.25 >125 >125 3.9 ≤0.25 1 1 
2j 3.9 15.6 15.6 15.6 3.9 7.8 3.9 
2k 0.25 2 7.8 3.9 0.5 2 2 
2l 0.25 >125 >125 >125 0.5 2 1 
2m 3.9 >125 >125 >125 7.8 7.8 7.8 
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3a 3.9 7.8 >125 15.6 1 3.9 2 
3b 2 >125 >125 7.8 2 3.9 2 
3c 1 >125 >125 2 0.5 1 2 
3d 0.25 >125 >125 3.9 1 15.6 7.8 
3e 7.8 7.8 15.6 7.8 3.9 >125 3.9 
3f 3.9 7.8 15.6 7.8 2 >125 3.9 
3g 15.6 15.6 125 7.8 3.9 3.9 3.9 
3h 1 31.3 >125 2 1 1 2 
3i 2 >125 >125 >125 1 3.9 2 
3j 2 15.6 >125 15.6 0.5 2 3.9 
3k 2 >125 >125 >125 2 3.9 2 
3l 2 >125 >125 >125 2 3.9 2 
3m 2 >125 >125 7.8 2 3.9 7.8 
3n 3.9 15.6 15.6 15.6 1 >125 3.9 
4e >125 >125 >125 >125 >125 >125 >125 
4f >125 >125 >125 >125 >125 >125 >125 
4n >125 >125 >125 >125 >125 >125 >125 
AMK 15.6 125 >125 125 62.5 3.9 ≤0.25 
Bacterial strains: AC = S. epidermidis ATCC 35984, AD = E. faecalis ATCC 29212, AE = 
E. faecalis ATCC 49533, AF = E. faecium BM4105-RF, AG = VRE, AH = L. monocytogenes 
ATCC 19115, AI = M. smegmatis MC2-155. 
 
 
 
 
  
Table 5.3. MIC valuesa (in µg/mL) determined for all 
compounds 2a, 2h, and for the control antibacterial 
agent (AMK) against additional non-S. aureus 
bacterial strains. 
Strain Ebselen 2a 2h AMK 
A. baumannii ATCC 
19606 
15.6 15.6 31.3 7.8 
E. cloacae ATCC 
13047 
>125 125 >125 1 
E. coli MC1061 7.8 31.3 15.6 2 
K. pneumoniae 
ATCC 27736 
>125 62.5 >125 1 
P. aeruginosa ATCC 
27853 
>125 62.5 >125 31.3 
S. enterica ATCC 
14028 
>125 125 >125 7.8 
S. epidermidis 
ATCC 12228 
>125 125 >125 31.3 
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5.3.2.1a. Evaluation of compounds 2a-4n against various S. aureus strains 
We commenced our study by evaluating ebselen against a panel of 28 S. aureus strains (Table 
5.1). Ebselen displayed excellent (≤0.50 µg/mL), very good (1-2 µg/mL), and good (3.9-7.8 
µg/mL) activity against 5 (D, E, J, U, and X), 16 (A, C, F, H, I, K, M-Q, S, V, W, Y, and Z), 
and 7 (B, G, L, R, T, AA, and AB) of these S. aureus strains, respectively. We then 
investigated the replacement of the selenium atom by sulfur by synthesizing and testing 
ebsulfur (2a). Compound 2a was found to have similar MIC values to those of ebselen against 
all S. aureus strains tested. As replacement of the selenium atom by sulfur could result in 
decreased toxicity, we decided to use compound 2a as our model compound for further 
derivatization and evaluation. 
 
Previous literature on the antibacterial properties of ebselen suggested that the 1,2-
benzisothiazol-3(2H)-one core could be required for antibacterial activity.174, 177 We also 
thought of possibly removing the annulated benzene ring of the core to generate 1,2-
isothiazolin-3-one analogues. However, we shied away from these analogues once we realized 
that there were reports suggesting that these compounds could be allergenic and neurotoxic 
against humans.180-181 Thus, we decided to keep the 1,2-benzisothiazol-3(2H)-one core intact 
and hypothesized that the phenyl group adjacent to the core scaffold would be a good site for 
our investigation. In search of chemical modifications to increase the biological activity of 2a, 
we first replaced the phenyl ring by the following moieties: substituted phenyl and other 
aromatic rings (2b-o), alkyl chains (3a-g), alkyl chains with a terminal phenyl group (3h-j), 
and aliphatic rings (3k-o). In general, all of our analogues displayed moderate to excellent 
activity against S. aureus (15.6 to ≤0.25 µg/mL), except for compounds 4e, 4f, and 4n, which 
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were found to be completely inactive (>125 µg/mL) against all S. aureus strains tested. In 
addition, compounds 2i, 2n, 2o, and 3o were not evaluated due to solubility issues in liquid 
Mueller-Hinton medium. 
 
Most of the compounds with mono- (2b, 2c, 2d, 2f, and 2g) and disubstitutions (2i and 2j) at 
the 3- and 4-positions of the phenyl ring were found to display good to excellent activity (3.9 
to ≤0.25 µg/mL), but the activity was very similar to that of 2a. The three overall best 
compounds of this series of analogues (2e, 2h, and 2k) were found to have very good to 
excellent activity (≤2.0 µg/mL) across all S. aureus strains tested (Table 5.1). Among these 
three, the relatively bulkier 4-isopropylphenyl (2e) and 3-isopropylphenyl (2h) analogues 
were our two best compounds and displayed up to 16-fold improvement in MIC values when 
compared to the parent compound 2a. We also noticed that the substitution pattern (p- vs m-
isopropylphenyl (2e vs 2h) or p- vs m-bromophenyl (2d vs 2g)) did not have a substantial 
effect on the MIC values of these compounds (mostly within 2 fold dilutions). Intrigued by 
this result, we synthesized and tested more analogues with bulky substituents on the phenyl 
ring. Surprisingly, the 2,3-dimethoxyphenyl analogue (2k) also yielded very good to excellent 
MIC values (2 to ≤0.25 µg/mL). We decided to add even more bulkiness to the scaffold by 
synthesizing the naphthyl analogue (2l), which displayed very good to excellent MIC values 
(2 to ≤0.25 µg/mL). This result further suggested that adding different bulky groups to the 
phenyl ring is a favorable strategy to increase activity. 
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To further understand the structure-activity-relationship (SAR) of our ebsulfur scaffold, we 
decided to introduce a heteroatom into the benzene ring. Previously, the 3-chloropyridyl 
replacement of the phenyl ring in the ebselen scaffold was reported to greatly reduce toxicity 
in mammalian HEK293T cell line (IC50 >160 µM).182 We applied this knowledge to our 
ebsulfur scaffold and synthesized the pyridyl (2m), 3-chloropyridyl (2n), as well as the bulky 
quinolinyl (2o) analogues. However, only 2m was soluble enough for biological testing, but 
yielded inferior MIC values (15.6 to 2 µg/mL) relative to the parent compound 2a, suggesting 
that introduction of a nitrogen atom into the phenyl ring may not be the way to pursue. 
 
We next investigated the effect of replacing the phenyl ring by linear alkyl chains, which were 
previously shown to improve the antibacterial activity of another class of antibiotics, the 
aminoglycosides.164-166, 183-184 Compounds 3a-d were synthesized to contain n-pentyl, n-hexyl, 
n-octyl, and n-dodecyl side chains instead of the typical phenyl ring found in 2a. Among these 
compounds, the n-octyl analogue (3c) displayed the best MIC values (3.9 to ≤0.25 µg/mL). 
Compounds 3a, 3b, and 3d displayed MIC values (62.5 to 0.25 µg/mL) that were similar to 
that of the parent compound 2a. Inspired by our best compounds in series 2 containing an 
isopropyl moiety, compounds 2e and 2h, we decided to explore the effect of branched alkyl 
chains by synthesizing and testing compounds 3e-g. These compounds displayed mostly good 
to moderate activity (3.9 to 15.6 µg/mL). However, they were definitely inferior when 
comparing to compounds 2e and 2h. Additionally, we were also able to isolate the sulfoxide 
analogues of these compounds (4e and 4f) and evaluated them. We were surprised to find that 
these oxidized compounds completely lost their antibacterial activity against S. aureus. This 
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finding was consistent with previous reports that the S-N bond is essential for biological 
activity by covalently binding to cysteine residues of targeted enzymes.175, 177 
 
In an attempt to further understand the SAR of the phenyl ring, we explored whether having 
this ring directly attached to (compound 2a) or at a distance from the 1,2-benzisothiazol-
3(2H)-one core made any difference. We synthesized compounds 3h-j with 1-3 carbon linkers 
separating the phenyl ring and the core. These compounds displayed good to excellent activity 
(3.9 to ≤0.25 µg/mL). Lastly, to confirm that the aromaticity of the substituent is not required 
for antibacterial activity, we synthesized a series of compounds containing different-sized 
aliphatic rings (3k-o). We found that compound 3l with a cyclohexyl ring displayed very 
similar MIC values (7.8 to 0.5 µg/mL) to its aromatic counterpart 2a. We noted that all of 
these compounds retained good to excellent antibacterial activity against S. aureus, with the 
exception of the adamantyl derivative 3o, which could not be tested due to solubility issues. 
 
5.3.2.1b. Evaluation of compounds 2a-4n against various non-S. aureus strains 
To further examine the antibacterial spectrum of compounds 2a-4n, we also tested them 
against a panel of non-S. aureus strains. Overall, we found that many of our ebsulfur (2a) 
analogues were more specific towards S. aureus strains. We did observe that a few analogues 
actually displayed moderate to excellent activity (15.6 to ≤0.25 µg/mL) against certain non-S. 
aureus strains (Table 5.2). Interestingly, we found that ebselen still displayed good to 
excellent activity against many non-S. aureus strains (7.8 to ≤0.25 µg/mL), in contrary to 
what was previously observed when ebselen was tested against a different panel of bacterial 
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strains.174 We were especially enlightened to find that our best compounds, 2e and 2h, still 
retained their excellent activity (1 to ≤0.25 µg/mL) against selected strains such as S. 
epidermidis (AC), VRE (AG), L. monocytogenes (AH), and M. smegmatis (AI). 
 
To gain a better understanding of the antibacterial spectrum of our ebsulfur (2a) analogues, 
we decided to test them against a biofilm-forming S. epidermidis (AC), another Gram-positive 
bacterium of the genus Staphylococcus. As expected, other than the previously inactive 
oxidized compounds 4e, 4f, and 4n, we found that our entire library of analogues still retained 
moderate to excellent activity that was similarly observed during our evaluation of these 
compounds against the panel of S. aureus strains presented in Table 5.1.  
 
Next, we explored the activity of our analogues against examples of the genus Enterococcus. 
Against the E. faecalis strains (AD and AE) our ebsulfur analogues mostly showed moderate 
to poor activity (≥15.6 µg/mL), except in the case of compound 2k, which still displayed good 
to very good activity (7.8 to 2 µg/mL) (Table 5.2). When comparing the activity of our 
compounds against E. faecalis (strains AD and AE) and E. faecium (strain AF), we observed 
a slightly improved activity (lower MIC values) against E. faecium, with compounds 2a, 2d, 
2f, 2h, 2k, 3b-f, 3g, 3h, and 3m-n displaying good to very good activity (7.8 to 2 µg/mL). 
Surprisingly, against the vancomycin-resistant Enterococcus (VRE) strain (AG), all of our 
analogues (except for 4e, 4f, and 4n) displayed good to excellent activity (7.8 to ≤0.25 
µg/mL). 
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To continue our study, we explored the activity of our library against L. monocytogenes (AH) 
and M. smegmatis (AI). We found that most of our analogues (2a-h, 2k-m, 3a-f (except 3e,f 
against strain AH), and 3h-m) displayed good to excellent activity (7.8 to 0.5 µg/mL) against 
these strains.  
 
Intrigued by our results against the non-S. aureus panel, we further investigated the activity of 
our best compound, 2h, along with ebselen and ebsulfur (2a) against some additional non-S. 
aureus strains (A. baumannii, E. cloacae, E. coli, K. pneumoniae, P. aeruginosa, S. enterica, 
and an additional non-biofilm-forming S. epidermidis). However, we found that these 
compounds were mostly inactive against these strains (Table 5.3). 
 
5.3.2.2. Evaluation of time-kill curve of compounds 2a, 3b, and 3c 
To gain more insights into the antibacterial activity kinetics of our ebsulfur analogues, we 
performed time-kill assays185 of compounds 3b and 3c on MRSA S22 (strain W) over a period 
of 24 h and compared that to ebselen, ebsulfur (2a), and AMK (Figure 5.2). At sub-MIC 
concentration (0.5× MIC), as expected, we observed that strain W grew well in the presence 
of all these compounds. Unlike the control (untreated bacteria), we found that all of the 
compounds were bacteriostatic up until 3 to 6 h. At MIC concentration, we observed similar 
bacteriostatic profiles as described previously in our experiment at sub-MIC. We decided to 
conduct another study at 4× MIC, where we were surprised to find that ebselen was 
bactericidal and led to complete cell death at 24 h. Compounds 2a, 3b, and 3c reduced 
bacterial load by 1.5 orders of magnitude, but they still remained bacteriostatic. These results 
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are interesting and may suggest that the selenium atom has a role in promoting the bactericidal 
effect. However, it should be noted that the time-kill curve assays were conducted under 
different conditions than those used in the MIC broth double-dilution assays (inoculum size, 
air flow, and volumes of medium). These differences could lead to a change in the effective or 
therapeutic doses and thus, potentially explain why the 4× MIC dosages were required for 
strong efficacy. It is well established that increasing the inoculum size will require a different 
MIC to achieve therapeutic efficacy. To investigate whether the inoculum size affected our 
MIC values, we re-performed the MIC broth double-dilution assay on eight compounds 
(AMK, ebselen, 2a, 2g, 2h, and 3a-c) with the inoculum size used in time-kill assays (1×106 
CFU/mL) and found that the MIC values remained identical. Therefore, the selenium atom 
might indeed play a role in the bactericidal effect. 
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Figure 5.2. Representative time-kill studies of ebselen, AMK, 2a, 3c, and 3b against MRSA 
S22 (strain W). Bacterial cells were either treated with ebselen (white circle), AMK (white 
triangle), 2a (black inverted triangle), 3c (black square), and 3b (white square) at 0.5× MIC 
(top panel), 1× MIC (middle panel) and 4× MIC (bottom panel), respectively or no drug 
(black circle). 
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5.3.2.3. Activity against biofilms of S. aureus and S. epidermidis 
Having established that our compounds displayed activity against biofilm-forming S. aureus 
(strain A) and S. epidermidis (strain AC), we wanted to explore whether these compounds 
could also reduce the biofilm mass of these strains. Bacterial biofilm is a matrix of bacterial 
cells that are more tolerant to most antibacterial compounds and are highly associated with 
chronic persistent infections.186 Recently, ebselen was reported to display potent biofilm 
reduction properties against established biofilms of S. aureus and S. epidermidis. When 
compared to the biofilm reduction activity of conventional antibiotics (linezolid, mupirocin, 
vancomycin, and rifampicin), the activity of ebselen was found to be significantly superior.178 
We were interested in finding out whether our ebsulfur analogues also possess the same anti-
biofilm property, which would make them highly desirable in combating pathogenic bacteria 
associated with chronic infectious diseases. To evaluate the biofilm reduction activity,178 
ebselen, ebsulfur (2a), as well as some of our best compounds (2e, 2h, 2k, and 3c) were tested 
against the established biofilm of two biofilm-forming strains of S. aureus ATCC 6538 (strain 
A) and S. epidermidis ATCC 35984 (strain AC) at 125x, 62.5x, 31.3x, 15.6x, 7.8x, 3.9x, and 
1x MIC (Figure 5.3). Due to the observed ceiling effect (where the biofilm reduction 
plateaus), for each compound, we are reporting the lowest MIC folds at which the plateau 
begins. 
 
Against the established biofilm of strain A, we found that ebselen (at 15.6 µg/mL or 7.8x 
MIC) reduced approximately 20% of the biofilm when comparing to the biofilm of the control 
(untreated biofilm) (Figure 5.3A). This is different from previous finding about the biofilm 
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reduction of this MRSA strain by ebselen, which was reported to be approximately 60% at 2 
µg/mL.178 Ebsulfur (2a) (at 31.3 µg/mL or 3.9x MIC) displayed superior biofilm reduction, 
approximately 40%. Compound 2e also resulted in ~50% biofilm reduction at a much higher 
concentration of 125 µg/mL or 62.5x MIC. Meanwhile, compound 2h (at 62.5 µg/mL or 
15.6x MIC) only reduced the biofilm by ~10%. Compound 3c was also found to result in low 
to no biofilm reduction. However, we found that compound 2k displayed 40% biofilm 
reduction at 3.9 µg/mL or 3.9x MIC, which is the lowest concentration tested in our assay. 
 
Against the biofilm of strain AC, ebselen (at 31.3 µg/mL or 125x MIC) was found to result in 
~20% reduction of the biofilm (Figure 5.3B). Ebsulfur (2a) was found to be slightly more 
effective, reducing the biofilm by ~50%, but at a much higher concentration (125 µg/mL or 
125x MIC). Compounds 2e and 2h were found to have similar biofilm reduction activity 
(~60-50%) at 3.9 and 15.6 µg/mL (15.6x and 62.5x MIC), respectively. Compound 2k 
displayed about 50% biofilm reduction at 15.6 µg/mL or 62.5x MIC. Finally, we found that 
compound 3c displayed about 40% biofilm reduction at 31.3 µg/mL or 31.3x MIC. 
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Figure 5.3. Bar graphs showing the ability of selected compounds to reduce the amount of 
biofilm observed for A. S. aureus ATCC 6538 (strain A) and B. S. epidermidis ATCC 35984 
(strain AC). The fold MIC for the optimal reduction for each compound is shown into 
parenthesis beside the compound name/number. 
 
Overall, when compared to ebselen, we found that ebsulfur (2a) and compound 2e displayed 
more potent biofilm reduction, but at higher concentrations. Compounds 2h and 3c were 
found to be active against the biofilm of strain AC, but not against the biofilm of strain A. 
Finally, compound 2k displayed good biofilm disruption (40-50%) against both biofilm-
forming strains at relatively low concentrations (3.9 and 15.6 µg/mL). 
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5.3.2.4. Evaluation of the hemolytic potential of compounds 2a, 2h, and 3c 
As red blood cells are some of the more fragile mammalian cells, we were interested in 
assessing our analogues for their general mammalian cell cytotoxicity and establishing 
whether these compounds would be suitable for any applications in humans. Hemolytic 
assays187-188 were performed by testing ebselen, compounds 2a, 2h, and 3c, as well as AMK 
(as a negative control) at various concentrations against murine red blood cells (mRBCs) 
(Figure 5.4). We observed that our compounds tested did not show any significant hemolytic 
activity (≤20% hemolysis) up to 7.8 µg/mL. This result is relatively encouraging knowing that 
against S. aureus strains, compound 2h was found mostly to display MIC values ranging from 
≤0.25 to 1 µg/mL, while compound 3c mostly displayed MIC values ranging from ≤0.25 to 2 
µg/mL. Another interesting observation was that 2a and its analogues 2h and 3c were less 
hemolytic when compared to ebselen (100% hemolytic at 15.6 µg/mL). Amongst the ebsulfur 
analogues tested, compound 2h was found to be the least hemolytic. 
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Figure 5.4. Hemolytic activity of ebselen (black circle), 2a (white circle), AMK (black 
inverted triangle), 3c (white triangle), and 2h (black square) on mouse red blood cells. The 
positive control (untreated) was found to display no hemolysis while the negative control (1% 
Triton X) was found to display 100% hemolysis (not shown on the graph). 
 
5.3.2.5. Evaluation of mammalian toxicity potential of ebselen and compounds 2e, 2h, 2k, 
2l, 3c, 3i, and 3k 
Although the hemolysis data was encouraging, we realized that a more extensive in vitro 
cytotoxicity study would still be needed to further understand the mammalian toxicity 
potential of our compounds.30 Given that many current antibiotics are nephrotoxic, we 
selected the human embryonic kidney cell line HEK-293 as the model mammalian cell line 
for our cytotoxicity evaluation (Figure 5.5). Ebselen was used as the control because it was 
shown to be safe for human use.13 Compounds 2e, 2h, and 2l all did not display any 
significant cytotoxicity (>20% cell death) up until 10 µg/mL, which was very similar to what 
was found with ebselen. On the other hand, compounds 2k, 3c, 3i, and 3k were slightly more 
toxic against HEK-293 with >20% cell death observed at 1.25 µg/mL. Collectively, it was 
intriguing and encouraging that our best analogues 2e and 2h displayed stronger selectivity for 
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bacterial cells. Depending on the MRSA strains, there could be up to 40-fold difference when 
compared to their MIC values. 
 
 
Figure 5.5. Mammalian cytotoxicity of ebselen (orange bars), 2e (green bars), 2h (teal bars), 
2k (blue bars), 2l (yellow bars), 3c (purple bars), 3i (light green bars), and 3k (pink bars). 
Untreated cells were used as positive control and cells treated with 1% Triton X were used as 
negative control (not shown on graph). 
 
5.3.2.6. Evaluation of ebselen and compounds 2a and 3b,c as bacterial membrane 
disruptors 
Based on previous literature on membrane-disrupting cationic amphiphilic 
aminoglycosides,164-166 we suspected that our linear alkyl ebsulfur analogues (3b,c) could 
potentially exert their antibacterial activity by their ability to disrupt bacterial cell membranes. 
Thus, we tested compounds 3b,c along with 2a and ebselen against S. epidermidis ATCC 
35984 (strain AC) at their 1x and 4x MIC values and evaluated them for membrane 
disruption. We also used a tobramycin derivative with a linear alkyl chain of 14 carbons in 
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length attached in a thioether linkage to the 6"-position (C14-TOB) and AMK as positive and 
negative controls, respectively. We used propidium iodide (PI) staining to visualize any 
damage to the bacterial cell membrane. If the bacterial cell membrane was compromised, the 
PI would penetrate and stain the cells red. Based on our results, we saw no sign of membrane 
disruption from any of our compounds (Figure 5.6). Thus, membrane disruption is likely not a 
viable antibacterial mechanism of action for these analogues. We then decided to switch our 
attention to study another possible mechanism of action for these compounds, the production 
of ROS. 
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Figure 5.6. Effect of ebsulfur (2a) and its analogues 3b and 3c on cell membrane integrity of 
S. epidermidis ATCC 35984 (strain AC). Bacterial cells were treated with no drug or AMK 
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(negative controls), C14-TOB (positive control), or ebselen, 2a, 3b, and 3c, at their 1× and 4× 
respective MIC values. Propidium iodine (PI) dye was used to monitor the uptake by bacterial 
cells. 
 
5.3.2.7. Detection of reactive oxygen species (ROS) production 
 In bacteria lacking glutathione and glutaredoxin such as S. aureus and others, the thioredoxin 
system is crucial for ROS regulation and thus, bacterial survival and proliferation.189-191 
Ebselen was identified previously to inhibit bacterial thioredoxin reductase.177 To test the 
hypothesis that our analogues also inhibit thioredoxin reductase, we treated S. epidermidis 
ATCC 35984 (strain AC) with ebselen, compounds 2a and 3b,c at various concentrations (1x 
and 4x their respective MIC values). 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA)192 
was then used to detect and visualize ROS production (Figure 5.7). We found that ebselen and 
all of our analogues led to production of ROS and that inhibition of thioredoxin reductase is 
possibly the target responsible for antibacterial activity, which will be the subject of future 
studies. 
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Figure 5.7. Effect of ebsulfur (2a) and its analogues 3b and 3c on intracellular ROS 
production by S. epidermidis ATCC 35984 (strain AC). Bacterial cells were treated with no 
drug (negative control), 1 mM of H2O2 (positive control), or ebselen, 2a, 3b, and 3c, at their 
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1× and 4× respective MIC values for 1 h at 37 °C. After staining with DCFH-DA (40 µg/mL), 
the samples were analyzed using a Zeiss Axovert 200M fluorescence microscope. 
 
5.4. CONCLUSION 
We synthesized an ebselen-inspired (ebsulfur) library comprised of 33 molecules based on 
previous reports of the antibacterial activity of ebselen against drug-resistant S. aureus clinical 
isolates. Our SAR analysis suggested that replacing the selenium atom with the sulfur atom in 
the 1,2-benzisoselenazol-3(2H)-one core did not significantly alter antibacterial activity. 
However, oxidizing the sulfur atom of the 1,2-benzisothiazol-3(2H)-one core, as in 
compounds 4e, 4f, and 4n, completely obliterated antibacterial activity. This finding 
demonstrated that the stereoelectronic nature of the S-N bond is indeed important for 
biological activity, which is consistent with previous reports.175, 177 During our search for 
analogues with improved antibacterial activity, we identified three compounds (2e, 2h, and 
2k) with remarkably potent activity (MIC values mostly ≤2 µg/mL) against S. aureus clinical 
isolates. We then evaluated our compounds for their antibacterial spectrum by testing them 
against non-S. aureus strains. Our analogues were generally more selective towards 
Staphylococcus strains, but some of them also displayed good activities against VRE, L. 
monocytogenes, and M. smegmatis. Compounds with biofilm reduction are currently in high 
demand. Our evaluation showed that albeit at high concentrations, our analogues were able to 
reduce Staphylococcal established biofilms. We showed that the antibacterial activity of our 
compounds was highly correlated with ROS production. Lastly, we assessed our compounds 
for general mammalian toxicity by testing them against murine RBCs and HEK293. The 
mammalian toxicities of our most potent compounds were found to be acceptable. With 
 263 
further optimizations, these ebsulfur analogues could potentially have clinical utilities in our 
fight against bacterial resistance. 
 
5.5. MATERIALS AND INSTRUMENTATION 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and AK Scientific (Union 
City, CA) and used without further purification. Deuterated solvents were purchased from 
Cambridge Isotope Laboratories Inc. (Tewksbury, MA). Chemical reactions were monitored 
by TLC (Merck, Silica gel 60 F250). Flash column chromatography was performed on silica 
gel (Dynamic Adsorbents Inc., Flash silica gel 32-63u). Visualization was achieved using UV 
light and a cerium-molybdate stain ((NH4)2Ce(NO3)6 (5g), (NH4)6Mo7O24•4H4O (120 g), 
H2SO4 (80 mL), and H2O (720 mL)). NMR spectra were measured in δ (ppm) using the 1H 
NMR CDCl3 (δ 7.24 ppm) and 13C NMR CDCl3 (δ 77.23 ppm) as internal standards: where J 
= coupling constants in Hz. Abbreviations used: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of 
doublets, tt = triplet of triplets, qt = quartet of triplets, pd = pentet of doublets. NMR spectra 
were recorded on a Varian Unity Inova 400 MHz instrument (Palo Alto, CA). High-resolution 
electrospray mass spectra (HRMS) were recorded on a Q-TOF Tandem Mass Spectrometer 
and low-resolution electrospray mass spectra (LRMS) were recorded on a liquid 
chromatography-mass spectrometry using an Agilent 1200 series Quaternary LC system 
equipped with a diode array detector, and Eclipse XDB-C18 column (250 mm × 4.6 mm, 5 
µm), and an Agilent 6120 Quadrupole MSD mass spectrometer. All compounds were found to 
be ≥95% pure. Bacterial experiments utilized untreated 96-well plates (Corning), biofilm 
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measurements were performed using a SpectraMax M5 spectrometer (Molecular Devices, 
Sunnyvale, CA). 
 
5.6. METHODS 
5.6.1. Chemical methods 
5.6.1.1. Preparation of compound 1 
 
The known compound 1 was prepared using a published protocol.182 A 
mixture of 2,2'-dithio-dibenzoic acid (3.0 g, 9.8 mmol) and SOCl2 (25 mL) 
was heated under reflux for 48 h, and the solvent was removed by distillation followed by 
evaporation in vacuo. The residue was triturated with hexanes, quickly filtered, and washed 
with hexanes and dried under vacuum to afford compound 1 (2.69 g, 80%) as a yellow solid: 
1H NMR (400 MHz, CDCl3, Figure C1, which matches the lit.182) δ 8.37 (d, J = 7.6 Hz, 2H), 
7.75 (d, J = 8.4 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H). 
 
5.6.1.2. Preparation of compounds 2a-o following procedure A  
Compounds 2a-o were synthesized using a one-step strategy that employed Et3N and various 
aniline derivatives in CH2Cl2. 
 
Preparation of compound 2a. The known compound 2a was prepared using 
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a published protocol.182 To a stirred and ice-cooled mixture of aniline (0.13 mL, 1.0 mmol) 
and Et3N (0.45 mL, 3.2 mmol) in anhydrous CH2Cl2 (40 mL), 2,2'-dithiobenzoyl chloride (1, 
0.50 g, 1.5 mmol) in anhydrous CH2Cl2 (20 mL) was added dropwise over 20 min. The 
reaction mixture was warmed-up to rt, stirred for 12 h, and washed with aq. sat. NaHCO3 (30 
mL) and H2O (30 mL). The organic layer was dried over MgSO4, concentrated in vacuo, and 
the residue was purified by flash column chromatography (SiO2, 100% hexanes, 
1:9/EtOAc:hexanes, 3:17/EtOAc:hexanes, 1:4/EtOAc:hexanes, 1:3/EtOAc:hexanes, 
3:7/EtOAc:hexanes, then 100% EtOAc) and recrystallized in EtOH to afford compound 2a 
(30 mg, 9%, Rf 0.21 in 49:1/CH2Cl2:MeOH) as off-white needle crystals: 1H NMR (400 MHz, 
CDCl3, Figure C2, which matches the lit.193) δ 8.09 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 
2H), 7.65 (t, J = 8.0 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.48-7.42 (m, 3H), 7.31 (t, J = 7.6 Hz, 
1H). 
 
Preparation of compound 2b. Compound 2b was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 4-fluoroaniline (0.08 mL, 0.87 mmol) and Et3N (0.12 mL, 0.87 mmol) in 
anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.30 g, 0.87 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at 
rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer 
was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by 
flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 2b (102 mg, 
48%, Rf 0.33 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C3, 
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which matches the lit.194) δ 8.09 (d, J = 8.0 Hz, 1H), 7.68-7.65 (m, 3H), 7.57 (d, J = 8.4 Hz, 
1H), 7.48-7.40 (m, 3H). 
 
Preparation of compound 2c. Compound 2c was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 4-chloroaniline (0.11 g, 0.87 mmol) and Et3N (0.12 mL, 0.87 mmol) in anhydrous 
CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.30 g, 0.87 mmol) in anhydrous CH2Cl2 (20 
mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at rt, and 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 2c (89 mg, 39%, Rf 0.26 in 
1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C4, which matches 
the lit.195) δ 8.09 (d, J = 7.6 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.64 (dd, J = 8.8, 4.8 Hz, 2H), 
7.57 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.15 (t, J = 8.8 Hz, 2H). 
 
Preparation of compound 2d. The known compound 2d was synthesized 
following a procedure published for the preparation of similar 
compounds.182 To a mixture of 4-bromoaniline (0.34 g, 2.00 mmol) and Et3N (0.28 mL, 1.00 
mmol) in anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.68 g, 2.00 mmol) in 
anhydrous CH2Cl2 (20 mL) was added dropwise over 15 min. The reaction mixture was 
stirred for 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The 
organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was 
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purified by flash column chromatography (SiO2, 100% hexanes, 0.5:9.5/EtOAc:hexanes, 
1:9/EtOAc:hexanes, 3:17/EtOAc:hexanes, 1:4/EtOAc:hexanes, 1:3/EtOAc:hexanes, then 
100% EtOAc) and recrystallized in EtOH to afford compound 2d (199 mg, 33%, Rf 0.25 in 
1:3/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C5, which matches 
the lit.196) δ 8.08 (d, J = 8.0 Hz, 1H), 7.68-7.64 (m, 1H), 7.62-7.56 (m, 5H), 7.46-7.42 (m, 1H). 
 
Preparation of compound 2e. The known compound 2e was synthesized 
following a procedure published for the preparation of similar 
compounds.182 To a mixture of 4-isopropylaniline (0.12 mL, 0.87 mmol) and Et3N (0.12 mL, 
0.87 mmol) in anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.30 g, 0.87 mmol) 
in anhydrous CH2Cl2 (20 mL) was added dropwise over 15 min at rt. The reaction mixture 
was stirred for an additional 3 h at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), 
and brine (50 mL). The organic layer was dried over anhydrous MgSO4, concentrated in 
vacuo, and the residue was purified by flash column chromatography (SiO2, 
1:4/EtOAc:hexanes) and recrystallized from MeOH to afford compound 2e (30 mg, 13%, Rf 
0.25 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C6, which 
matches the lit.194) δ 8.09 (d, J = 7.6 Hz, 1H), 7.64 (td, J = 7.6, 0.8 Hz, 1H), 7.58 (d, J = 8.4 
Hz, 2H), 7.56 (d, J = 7.6 Hz, 1H), 7.43 (t, J = 7.6, 0.8 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 2.94 
(septet, J = 6.8 Hz, 1H), 1.26 (d, J = 6.8 Hz, 6H). 
 
Preparation of compound 2f. Compound 2f was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
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mixture of 4-ethinylaniline (0.14 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in anhydrous 
CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 
mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at rt, and 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:5/acetone:hexanes) to afford compound 2f (56 mg, 22%, Rf 0.18 in 
1:5/acetone:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C7) δ 8.08 (d, J = 
8.0 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.65 (m, 1H), 7.56 (d, J = 8.8 Hz, 3H), 7.43 (m, 1H), 
3.10 (s, 1H); 13C NMR (100 MHz, CDCl3, Figure C8) δ 164.3, 139.8, 138.0, 133.3, 132.8, 
127.5, 126.2, 125.0, 123.9, 120.6, 120.3, 83.0, 78.2; HRMS m/z calcd for C15H9NOS: 
251.0405; found 252.0476 [M+H]+. 
 
Preparation of compound 2g. The known compound 2g194 was synthesized 
following a procedure published for the preparation of similar compounds.182 
To a mixture of 3-bromoaniline (0.11 mL, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min at -15 °C. The reaction mixture was stirred 
for an additional 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 
mL). The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the 
residue was purified by flash column chromatography (SiO2, 1:3/EtOAc:hexanes) to afford 
compound 2g (107 mg, 35%, Rf 0.39 in 1:3/EtOAc:hexanes) as a white solid: 1H NMR (400 
MHz, CDCl3, Figure C9) δ 8.08 (d, J = 8.0 Hz, 1H), 7.92 (s, 1H), 7.65 (d, J = 7.6 Hz, 2H), 
7.57 (d, J = 8.4 Hz, 1H), 7.44 (t, J = 8.0 Hz, 2H), 7.31 (t, J = 8.0 Hz, 1H); 13C NMR (100 
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MHz, CDCl3, Figure C10) δ 164.3, 139.8, 138.7, 132.8, 132.9, 130.8, 130.1, 127.5, 127.4, 
126.2, 124.8, 123.0, 120.3; HRMS m/z calcd for C13H8BrNOS: 304.9510; found 305.9580 
[M+H]+. 
 
Preparation of compound 2h. Compound 2h was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 3-isopropylaniline (0.04 mL, 0.29 mmol) and Et3N (0.04 mL, 0.29 mmol) in 
anhydrous CH2Cl2 (5 mL), 2,2'-dithiobenzoyl chloride (1, 0.10 g, 0.29 mmol) in anhydrous 
CH2Cl2 (10 mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at 
rt, and washed with 1 M HCl (30 mL), H2O (30 mL), and brine (30 mL). The organic layer 
was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by 
flash column chromatography (SiO2, 1:4/EtOAc:hexanes) and recrystallized in EtOH to afford 
compound 2h (35 mg, 45%, Rf 0.39 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 
MHz, CDCl3, Figure C11) δ 8.09 (d, J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.57-7.55 (m, 
2H), 7.49-7.46 (m, 1H), 7.42 (t, J = 7.2 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.18 (d, J = 7.2 Hz, 
1H), 2.95 (sep, J = 7.2 Hz, 1H), 1.27 (d, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure 
C12) δ 164.3, 150.6, 140.2, 137.3, 132.5, 129.4, 127.3, 126.0, 125.5, 125.1, 123.1, 122.4, 
120.3, 34.3, 24.1; HRMS m/z calcd for C16H15NOS: 269.0874; found 270.0937 [M+H]+. 
 
Preparation of compound 2i. Compound 2i was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 3,5-dibromoaniline (0.22 g, 0.87 mmol) and Et3N (0.12 mL, 0.87 mmol) in 
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anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.30 g, 0.87 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at 
rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer 
was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by 
flash column chromatography (SiO2, 1:4/EtOAc:hexanes) and recrystallized in EtOH to afford 
compound 2i (135 mg, 33%, Rf 0.31 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 
MHz, CDCl3, Figure C13) δ 8.08 (d, J = 8.0 Hz, 1H), 7.89 (s, 2H), 7.68 (t, J = 6.8 Hz, 1H), 
7.58 (s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3, 
Figure C14) δ 164.3, 139.7, 139.6, 133.2, 132.5, 127.6, 126.4, 125.8, 124.5, 123.5, 120.4; 
LRMS m/z calcd for C13H7Br2NOS: 385.1; found 386.1 [M+H]+. 
 
Preparation of compound 2j. Compound 2j was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 3.5-dimethylaniline (0.12 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (5 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (10 mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at 
rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer 
was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by 
flash column chromatography (SiO2, 100% hexanes, 0.5:9.5/EtOAc:hexanes, 
1:9/EtOAc:hexanes, 3:17/EtOAc:hexanes, 1:4/EtOAc:hexanes, 1:3/EtOAc:hexanes, then 
100% EtOAc) and by preparative TLC (1:3/acetone:hexanes) to afford compound 2j (88 mg, 
35%, Rf 0.25 in 1:3/acetone:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure 
C15) δ 8.08 (d, J = 8.0 Hz, 1H), 7.63 (ddd, J = 7.6, 7.2, 1.2 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 
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7.41 (ddd, J = 8.0, 7.2, 1.2 Hz, 1H), 7.29 (s, 2H), 6.94 (s, 1H), 2.35 (s, 6H); 13C NMR (100 
MHz, CDCl3, Figure C16) δ 164.3, 140.2, 139.4, 137.1, 132.4, 129.2, 127.3, 125.9, 125.1, 
122.7, 120.2, 21.5; LRMS m/z calcd for C15H13NOS: 255.1; found 256.1 [M+H]+. 
 
Preparation of compound 2k. Compound 2k was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 3.5-dimethoxylaniline (0.15 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min. The reaction mixture was stirred for 3 h at 
rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer 
was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by 
flash column chromatography (SiO2, 1:4/acetone:hexanes) to afford compound 2k (96 mg, 
33%, Rf 0.18 in 1:4/acetone:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure 
C17) δ 8.07 (dd, J = 8.0 Hz, 1H), 7.63 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 
7.42 (ddd, J = 8.0, 7.2, 1.2 Hz, 1H), 6.92 (d, J = 2.4 Hz, 2H), 6.40 (t, J = 2.0 Hz, 1H), 3.81 (s, 
6H); 13C NMR (100 MHz, CDCl3, Figure C18) δ 164.3, 161.3, 140.0, 139.1, 132.6, 127.3, 
126.0, 125.2, 120.2, 102.9, 99.6, 55.8; HRMS m/z calcd for C15H13NO3S: 287.0616; found 
288.0682 [M+H]+. 
 
Preparation of compound 2l. The known compound 2l was synthesized 
following a procedure published for the preparation of similar compounds.182 
To a stirred and ice-cooled mixture of 1-naphthylamine (0.080 g, 0.50 mmol) and Et3N (0.04 
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mL, 0.50 mmol) in anhydrous CH2Cl2 (5 mL), 2,2'-dithiobenzoyl chloride (1, 0.15 g, 0.50 
mmol) in anhydrous CH2Cl2 (10 mL) was added dropwise over 20 min. The reaction mixture 
was warmed-up to rt, stirred for 12 h, and washed with aq. sat. NaHCO3 (15 mL) and H2O (15 
mL). The organic layer was dried over MgSO4, concentrated in vacuo, and the residue was 
purified by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) and recrystallized in 
MeOH to afford compound 2l (26 mg, 25%, Rf 0.31 in 1:4/EtOAc:hexanes) as white needle 
crystals: 1H NMR (400 MHz, CDCl3, Figure C19, which matches the lit., but our spectrum 
has better resolution197) δ 8.14-8.12 (m, 2H), 7.92 (d, J = 9.2 Hz, 1H), 7.88-7.84 (m, 3H), 7.67 
(ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.51 (m, 2H), 7.46 (ddd, J = 8.4, 7.2, 
1.2 Hz, 1H). 
 
Preparation of compound 2m. The known compound 2m was synthesized 
following a procedure published for the preparation of similar compounds.182 
To a mixture of 2-aminopyridine (0.10 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min at rt. The reaction mixture was stirred for 
an additional 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). 
The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue 
was purified by flash column chromatography (SiO2, 1:3/EtOAc:hexanes) to afford compound 
2m (55 mg, 24%, Rf 0.43 in 1:3/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, 
Figure C20, which matches the lit.182) δ 8.73 (d, J = 8.4 Hz, 1H), 8.40 (d, J = 4.4 Hz, 1H), 
8.05 (d, J = 7.6 Hz, 1H), 7.79 (t, J = 8.0 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.57 (d, J = 8.4 Hz, 
1H), 7.39 (t, J = 7.6 Hz, 1H), 7.13 (t, J = 6.4 Hz, 1H). 
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Preparation of compound 2n. The known compound 2n was synthesized 
following a procedure published for the preparation of similar 
compounds.182 To a mixture of 5-chloro-2-aminopyridine (0.06 g, 0.50 mmol) and Et3N (0.07 
mL, 0.05 mmol) in anhydrous CH2Cl2 (5 mL), 2,2'-dithiobenzoyl chloride (1, 0.15 g, 0.05 
mmol) in anhydrous CH2Cl2 (10 mL) was added dropwise over 15 min at rt. The reaction 
mixture was stirred for an additional 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 
mL), and brine (50 mL). The organic layer was dried over anhydrous MgSO4, concentrated in 
vacuo, and the residue was purified by flash column chromatography (SiO2, 
1:3/EtOAc:hexanes) to afford compound 2n (69 mg, 51%, Rf 0.56 in 1:3/EtOAc:hexanes) as a 
white solid: 1H NMR (400 MHz, CDCl3, Figure C21, which matches the lit.182) δ 8.73 (d, J = 
9.2 Hz, 1H), 8.35 (d, J = 2.4 Hz, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.76 (dd, J = 9.2, 2.4 Hz, 1H), 
7.65 (t, J = 8.4 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H). 
 
Preparation of compound 2o. Compound 2o was synthesized following a 
procedure published for the preparation of similar compounds.182 To a 
mixture of 2-aminoquinoline (0.14 g, 0.50 mmol) and Et3N (0.07 mL, 0.50 mmol) in 
anhydrous CH2Cl2 (5 mL), 2,2'-dithiobenzoyl chloride (1, 0.15 g, 0.44 mmol) in anhydrous 
CH2Cl2 (10 mL) was added dropwise over 15 min at rt. The reaction mixture was stirred for 
an additional 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). 
The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue 
was purified by flash column chromatography (SiO2, 1:3/EtOAc:hexanes) to afford compound 
2o (29 mg, 21%, Rf 0.50 in 1:3/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, 
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Figure C22) δ 8.91 (d, J = 9.2 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.81 
(d, J = 7.6 Hz, 1H), 7.71 (t, J = 7.6 Hz, 1H), 7.66 (t, J = 8.4 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 
7.49 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, CDCl3, Figure C23) δ 
164.6, 149.9, 146.5, 141.6, 138.8, 133.3, 130.5, 127.9, 127.8, 127.2, 127.00, 126.97, 126.0, 
125.8, 120.5, 114.1; HRMS m/z calcd for C16H10N2OS: 278.0514; found 279.0514 [M+H]+. 
 
5.6.1.3. Preparation of compounds 3a-4n following procedure B  
Compounds 3a-4n were synthesized using a two-step strategy that employed Et3N and various 
alkylamine derivatives in CH2Cl2 followed by use of N-chlorosuccinimide. 
 
Preparation of compound 3a. Compound 3a was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To a 
mixture of amylamine (0.10 mL, 0.87 mmol) and Et3N (0.12 mL, 0.86 mmol) in anhydrous 
CH2Cl2 (10 mL), compound 1 (0.27 g, 1.31 mmol) in anhydrous CH2Cl2 (20 mL) was added 
dropwise over 15 min at rt. A slurry solution was formed after another 5 min of stirring at rt. 
N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C 
for an additional 1 h. The reaction mixture was stirred for an additional 3 h at rt, and then 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 3a (65 mg, 34%, Rf 0.36 in 
1:4/EtOAc:hexanes) as a yellow oil: 1H NMR (400 MHz, CDCl3, Figure C24) δ 8.00 (d, J = 
7.6 Hz, 1H), 7.56 (td, J = 8.0, 0.8 Hz, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.36 (td, J = 8.0, 1.2 Hz, 
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1H), 3.86 (t, J = 7.2 Hz, 2H), 1.73 (p, J = 7.2 Hz, 2H), 1.35-1.29 (m, 4H), 0.87 (t, J = 7.2 Hz, 
3H); 13C NMR (100 MHz, CDCl3, Figure C25) δ 165.5, 140.3, 131.8, 126.8, 125.6, 125.0, 
120.5, 44.1, 29.4, 28.8, 22.4, 14.1; LRMS m/z calcd for C12H13NOS: 221.1; found 222.1 
[M+H]+. 
 
Preparation of compound 3b. Compound 3b was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To a 
mixture of hexylamine (0.11 mL, 0.87 mmol) and Et3N (0.12 mL, 0.87 mmol) in anhydrous 
CH2Cl2 (10 mL), compound 1 (0.27 g, 1.50 mmol) in anhydrous CH2Cl2 (20 mL) was added 
dropwise over 15 min. A slurry solution was formed after another 5 min of stirring at rt. N-
Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C for 
an additional 1 h. The reaction mixture was stirred for 3 h at rt, and washed with 1 M HCl (50 
mL), H2O (50 mL), and brine (50 mL). The organic layer was dried over anhydrous MgSO4, 
concentrated in vacuo, and the residue was purified by flash column chromatography (SiO2, 
1:4/EtOAc:hexanes) and recrystallized in EtOH to afford compound 3b (62 mg, 20%, Rf 0.35 
in 1:4/EtOAc:hexanes) as a yellow oil: 1H NMR (400 MHz, CDCl3, Figure C26) δ 7.99 (d, J = 
8.0 Hz, 1H), 7.54 (td, J = 8.0, 1.2 Hz, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.34 (td, J = 8.0, 1.2 Hz, 
1H), 3.84 (t, J = 7.6 Hz, 2H), 1.71 (p, J = 7.2 Hz, 2H), 1.37-1.21 (m, 6H), 0.84 (t, J = 7.6 Hz, 
3H); 13C NMR (100 MHz, CDCl3, Figure C27) δ 165.4, 140.3, 131.7, 126.7, 125.5 125.0, 
120.4, 44.1, 31.5, 29.6, 26.4, 22.6, 14.1; HRMS m/z calcd for C13H17NOS: 235.1031; found 
236.1103 [M+H]+. 
 
N 5S
O
 276 
Preparation of compound 3c. Compound 3c was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To a 
mixture of octylamine (0.17 mL, 1.50 mmol) and Et3N (0.14 mL, 1.00 mmol) in anhydrous 
CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) was added 
dropwise over 15 min at rt. A slurry solution was formed after another 5 min of stirring at rt. 
N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C 
for an additional 1 h. The reaction mixture was stirred for an additional 3 h at rt, and then 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, CH2Cl2) to afford compound 3c (64 mg, 24%, Rf 0.43 in CH2Cl2) as a 
white solid: 1H NMR (400 MHz, CDCl3, Figure C28) δ 8.00 (d, J = 7.6 Hz, 1H), 7.56 (ddd, J 
= 8.4, 7.2, 1.2 Hz, 1H), 7.53 (t, J = 8.4 Hz, 1H), 7.36 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 3.86 (t, J 
= 7.2 Hz, 2H), 1.73 (p, J = 7.2 Hz, 2H), 1.37-1.20 (m, 10H), 0.84 (t, J = 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3, Figure C29) δ 165.5, 140.3, 131.8, 126.8, 125.6, 125.1, 120.5, 44.2, 
31.9, 29.7, 29.35, 29.30, 26.8, 22.8, 14.3; HRMS m/z calcd for C15H21NOS: 263.1344; found 
264.1415 [M+H]+. 
 
Preparation of compound 3d. The known compound 3d was synthesized 
following a modified procedure published for the synthesis of similar 
compounds.198 To a mixture of dodecylamine (0.46 mL, 2.00 mmol) and Et3N (0.28 mL, 2.00 
mmol) in anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 
(20 mL) was added dropwise over 15 min at rt. A slurry solution was formed after another 5 
min of stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was 
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refluxed at 60 °C for an additional 1 h. The reaction mixture was stirred for an additional 3 h 
at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic 
layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified 
by flash column chromatography (SiO2, CH2Cl2) to afford compound 3d (130 mg, 41%, Rf 
0.30 in CH2Cl2) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C30, which matches the 
lit.199) δ 8.01 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.37 (t, J = 
7.6 Hz, 1H), 3.86 (t, J = 7.2 Hz, 2H), 1.73 (p, J = 7.2 Hz, 2H), 1.35-1.22 (m, 18H), 0.85 (t, J = 
6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C31) δ 165.5, 140.3, 131.8, 126.9, 125.6, 
125.1, 120.5, 44.2, 32.1, 29.81, 29.76, 29.7, 29.5, 29.4, 26.8, 22.9, 14.3. 
 
Preparation of compound 3e. Compound 3e was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of isobutylamine (0.20 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. The mixture was stirred for 1 h at rt to form a slurry 
solution. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed 
at 60 °C for an additional 1 h until the reaction mixture was clear. The reaction mixture was 
stirred for an additional 3 h at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and 
brine (50 mL). The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, 
and the residue was purified by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to 
afford compound 3e (180 mg, 87%, Rf 0.29 in 1:4/EtOAc:hexanes) as a yellow oil: 1H NMR 
(400 MHz, CDCl3, Figure C32) δ 8.02 (d, J = 8.4 Hz, 1H), 7.58 (td, J = 8.0, 0.8 Hz, 1H), 7.52 
(d, J = 8.4 Hz, 1H), 7.38 (td, J = 8.0, 0.8 Hz, 1H), 3.69 (d, J = 7.2 Hz, 2H), 2.12 (nonet, J = 
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6.4 Hz, 1H), 0.97 (d, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure C33) δ 165.8, 
140.4, 131.9, 127.0, 125.6, 124.9, 120.4, 51.4, 29.3, 20.1; LRMS m/z calcd for C11H13NOS: 
207.1; found 208.1 [M+H]+. 
 
Preparation of compound 3f. Compound 3f was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of isoamylamine (0.23 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. A slurry solution was formed after another 5 min of 
stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was stirred 
for an additional 4 h at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine 
(50 mL). The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the 
residue was purified by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford 
compound 3f (221 mg, quantitative yield, Rf 0.28 in 1:4/EtOAc:hexanes) as a yellow oil: 1H 
NMR (400 MHz, CDCl3, Figure C34) δ 8.00 (d, J = 8.0 Hz, 1H), 7.57 (td, J = 8.0, 1.2 Hz, 1H), 
7.52 (d, J = 8.4 Hz, 1H), 7.37 (td, J = 8.0, 0.8 Hz, 1H), 3.90 (t, J = 6.8 Hz, 2H), 1.67-1.60 (m, 
3H), 0.96 (d, J = 6.4 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure C35) δ 165.1, 140.0, 131.5, 
126.5, 125.3, 124.8, 120.2, 42.2, 38.2, 25.5, 22.3; LRMS m/z calcd for C12H15NOS: 221.1; 
found 222.1 [M+H]+. 
 
Preparation of compound 3g. The known compound 3g was synthesized 
following a modified procedure published for the preparation of similar 
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compounds.198 To a mixture of tert-butylamine (0.16 mL, 1.50 mmol) and Et3N (0.14 mL, 
1.00 mmol) in anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min at rt. A slurry solution was formed after 
another 5 min of stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the 
mixture was refluxed at 60 °C for an additional 1 h. The reaction mixture was stirred for an 
additional 3 h at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). 
The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue 
was purified by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 
3g (87 mg, 56%, Rf 0.25 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, 
Figure C36, which matches the lit.200) δ 7.90 (d, J = 7.2 Hz, 1H), 7.80 (d, J = 7.2 Hz, 1H), 
7.74 (td, J = 7.6, 1.2 Hz, 1H), 7.69 (td, J = 7.2, 1.2 Hz, 1H), 1.73 (s, 9H). 
 
Preparation of compound 3h. The known compound 3h was synthesized 
following a procedure published for the preparation of similar compounds.198 
To a mixture of benzylamine hydrochloride (0.14 g, 1.00 mmol) and Et3N (0.42 mL, 3.00 
mmol) in anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in 
anhydrous CH2Cl2 (20 mL) was added dropwise over 15 min. The reaction mixture was 
stirred for 3 h at rt, and washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The 
organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was 
purified by flash column chromatography (SiO2, CH2Cl2, 49:1/CH2Cl2:MeOH, then 
19:1/CH2Cl2:MeOH) to afford compound 3h (120 mg, 50%, Rf 0.23 in CH2Cl2) as a white 
solid: 1H NMR (400 MHz, CDCl3, Figure C37, which matches the lit.197) δ 8.05 (d, J = 7.6 Hz, 
1H), 7.59-7.55 (m, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.40-7.36 (m, 1H), 7.35-7.30 (m, 5H), 5.04 
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(s, 2H); 13C NMR (100 MHz, CDCl3, Figure C38) δ 165.5, 140.6, 136.4, 132.0, 129.0, 128.7, 
128.5, 127.0, 125.7, 124.7, 120.6, 47.8. 
 
Preparation of compound 3i. The known compound 3i200 was synthesized 
following a procedure published for the preparation of similar compounds.198 
To a mixture of phenethylamine (0.11 mL, 0.87 mmol) and Et3N (0.12 mL, 0.87 mmol) in 
anhydrous CH2Cl2 (30 mL), 2,2'-dithiobenzoyl chloride (1, 0.30 g, 0.87 mmol) was added in 
portions over 5 min at rt. A slurry solution is formed after another 5 min of stirring at rt. N-
chlorosuccinimide (0.10 g, 0.87 mmol) was added and the mixture was refluxed at 60 °C for 
an additional 1 h. The reaction mixture was cooled to rt and washed with 1 M HCl (50 mL), 
H2O (50 mL), and brine (50 mL). The organic layer was dried over anhydrous MgSO4, 
concentrated in vacuo, and the residue was purified by flash column chromatography (SiO2, 
1:4/EtOAc:hexanes) and recrystallized from MeOH to afford compound 3i (61 mg, 27%, Rf 
0.25 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C39, which 
matches the lit.200) δ 8.02 (d, J = 8.0 Hz, 1H), 7.58 (td, J = 7.6, 1.2 Hz, 1H), 7.49 (d, J = 8.0 
Hz, 1H), 7.37 (td, J = 8.0, 0.8 Hz, 1H), 7.32-7.20 (m, 5H), 4.11 (t, J = 7.6 Hz, 2H), 3.05 (t, J = 
7.6 Hz, 2H). 
 
Preparation of compound 3j. Compound 3j was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of phenylpropylamine (0.14 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
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was added dropwise over 15 min at rt. A slurry solution was formed after another 5 min of 
stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was 
refluxed at 60 °C for an additional 1 h. The reaction mixture was stirred for an additional 3 h 
at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic 
layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified 
by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 3j (142 mg, 
71%, Rf 0.30 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C40) 
δ 7.98 (d, J = 7.2 Hz, 1H), 7.88 (d, J = 7.2 Hz, 1H), 7.85 (td, J = 7.6, 0.8 Hz, 1H), 7.76 (td, J = 
7.2, 1.2 Hz, 1H), 7.28-7.24 (m, 2H), 7.20-7.14 (m, 3H), 4.00-3.92 (m, 1H), 3.86-3.79 (m, 1H), 
2.73 (t, J = 7.6 Hz, 2H), 2.14 (pd, J = 7.6, 2.4 Hz, 2H); 13C NMR (100 MHz, CDCl3, Figure 
C41) δ 165.6, 145.8, 141.0, 134.3, 133.4, 128.7, 128.6, 126.4, 126.3, 125.3, 41.3, 33.3, 31.0; 
LRMS m/z calcd for C16H15NOS: 269.1; found 270.1 [M+H]+. 
 
Preparation of compound 3k. Compound 3k was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of cyclopentylamine (0.10 mL, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (30 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) was added in 
portions over 5 min at rt. A slurry solution was formed after another 5 min of stirring at rt. N-
chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C for 
an additional 1 h. The reaction mixture was cooled to rt and washed with 1 M HCl (50 mL), 
H2O (50 mL), and brine (50 mL). The organic layer was dried over anhydrous MgSO4, 
concentrated in vacuo, and the residue was purified by flash column chromatography (SiO2, 
1:4/EtOAc:hexanes) to afford compound 3k (30 mg, 14%, Rf 0.30 in 1:4/EtOAc:hexanes) as a 
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white solid: 1H NMR (400 MHz, CDCl3, Figure C42) δ 8.00 (d, J = 7.6 Hz, 1H), 7.53 (td, J = 
8.4, 1.2 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.36 (td, J = 8.0, 1.2 Hz, 1H), 5.07 (p, J = 7.2 Hz, 
1H), 2.20-2.08 (m, 2H), 1.90-1.81 (m, 2H), 1.80-1.64 (m, 4H); 13C NMR (100 MHz, CDCl3, 
Figure C43) δ 165.6, 140.2, 131.7, 126.7, 125.63, 125.56, 120.5, 55.2, 32.4, 24.5; HRMS m/z 
calcd for C12H13NOS: 219.0718; found 220.0792 [M+H]+. 
 
Preparation of compound 3l. The known compound 3l was synthesized 
following a modified procedure published for the preparation of similar 
compounds.198 To a mixture of cyclohexylamine (0.11 mL, 1.00 mmol) and Et3N (0.14 mL, 
1.00 mmol) in anhydrous CH2Cl2 (30 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) 
was added in portions over 5 min at rt. A slurry solution was formed after another 5 min of 
stirring at rt. N-chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was 
refluxed at 60 °C for an additional 1 h. The reaction mixture was cooled to rt and washed with 
1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried over 
anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 3l (156 mg, 66%, Rf 0.30 in 
1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C44, which matches 
the lit.201) δ 8.03 (d, J = 8.0 Hz, 1H), 7.56 (td, J = 8.0, 1.2 Hz, 1H) 7.56-7.52 (m, 1H), 7.37 (td, 
J = 8.4, 1.6 Hz, 1H), 4.58 (tt, J = 11.2, 4.0 Hz, 1H), 2.08-2.00 (m, 2H), 1.89-1.80 (m, 3H), 
1.74-1.68 (m, 1H), 1.55 (td, J = 12.8, 3.2 Hz, 2H), 1.45 (qt, J = 12.8, 3.6 Hz, 1H), 1.19 (qt, J = 
12.8, 3.6 Hz, 1H); 13C NMR (100 MHz, CDCl3, Figure C45) δ 165.0, 140.5, 131.6, 126.7, 
125.7, 125.5, 120.5, 53.4, 33.1, 25.8, 25.5; HRMS m/z calcd for C13H15NOS: 233.0874; found 
234.0935 [M+H]+. 
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Preparation of compound 3m. Compound 3m was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of cycloheptylamine (0.25 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. A slurry solution was formed after another 1 h of 
stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was 
refluxed at 60 °C for an additional 1 h. The reaction mixture was stirred for an additional 3 h 
at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic 
layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified 
by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 3m (255 mg, 
51%, Rf 0.30 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C46) 
δ 8.01 (d, J = 8.0 Hz, 1H), 7.56 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.55-7.50 (m, 1H), 7.36 (ddd, 
J = 8.4, 6.8, 1.6 Hz, 1H), 4.79 (septet, J = 4.4 Hz, 1H), 2.30-2.02 (m, 2H), 1.84-1.52 (m, 
10H); 13C NMR (100 MHz, CDCl3, Figure C47) δ 164.7, 140.4, 131.6, 126.7, 125.5 (2 
carbons), 120.5, 55.4, 35.1, 28.1, 24.8; HRMS m/z calcd for C14H17NOS: 247.1031; found 
248.1104 [M+H]+. 
 
Preparation of compound 3n. Compound 3n was synthesized following a 
modified procedure published for the preparation of similar compounds.198 
To a mixture of cyclooctylamine (0.27 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
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was added dropwise over 15 min at rt. The mixture was allowed to stir for 1 h at rt. N-
Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was stirred for an 
additional 4 h at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). 
The organic layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue 
was purified by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 
3n (81 mg, 31%, Rf 0.26 in 1:4/EtOAc:hexanes) as a yellow oil: 1H NMR (400 MHz, CDCl3, 
Figure C48) δ 8.00 (dt, J = 8.0, 1.2 Hz, 1H), 7.58-7.53 (m, 2H), 7.36 (ddd, J = 7.6, 6.4, 1.2 Hz, 
1H) 4.86 (app. septet, J = 4.4 Hz, 1H), 1.99-1.58 (m, 14H); 13C NMR (100 MHz, CDCl3, 
Figure C49) δ 164.7, 140.5, 131.6, 126.7, 125.51, 125.46, 120.5, 54.4, 33.1, 27.0, 26.0, 24.7; 
LRMS m/z calcd for C15H19NOS: 261.1; found 262.1 [M+H]+. 
 
Preparation of compound 3o. Compound 3o was synthesized following a 
procedure published for the preparation of similar compounds.198 To a 
mixture of amantadine hydrochloride (0.19 g, 1.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), 2,2'-dithiobenzoyl chloride (1, 0.34 g, 1.00 mmol) in anhydrous 
CH2Cl2 (20 mL) was added dropwise over 15 min at -15 °C. N-Chlorosuccinimide (0.13 g, 
1.00 mmol) was added and the reaction mixture was stirred for an addition 3 h at rt, and 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:3/EtOAc:hexanes) to afford compound 3o (39 mg, 14%, Rf 0.60 in 
1:3/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C50) δ 7.93 (d, J = 
7.6, 1H), 7.53 (t, J = 7.2 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 6.8 Hz, 1H), 2.43 (s, 
6H), 2.18 (s, 3H), 1.77 (q, J = 12.8 Hz, 6H); 13C NMR (100 MHz, CDCl3, Figure C51) δ 
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165.6, 140.1, 131.4, 127.4, 126.3, 125.2, 120.0, 60.0, 40.8, 36.3, 30.2; HRMS m/z calcd for 
C17H19NOS: 285.1187; found 286.1270 [M+H]+. 
 
Preparation of compound 4e. Compound 4e was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
a mixture of isobutylamine (0.20 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. The mixture was stirred for 1 h at rt. N-
Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C for 
an additional 1 h. The reaction mixture was stirred for an additional 36 h at rt, and then 
washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried 
over anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 4e (239 mg, 58%, Rf 0.19 in 
1:4/EtOAc:hexanes) as a yellow oil: 1H NMR (400 MHz, CDCl3, Figure C52) δ 8.00-7.97 (m, 
1H), 7.90-7.88 (m, 1H), 7.78 (td, J = 7.6, 1.6 Hz, 1H), 7.74 (td, J = 7.6, 1.2 Hz, 1H), 3.75 (dd, 
J = 14.4, 7.6 Hz, 1H), 3.57 (dd, J = 14.4, 7.6 Hz, 1H), 2.19 (nonet, J = 6.8 Hz, 1H) 1.01 (d, J 
= 6.8 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3, Figure C53) δ 165.9, 
145.9, 134.3, 133.4, 128.5, 126.4, 125.3, 48.6, 28.7, 20.4, 20.3; HRMS m/z calcd for 
C11H13NO2S: 223.0667; found 224.0736 [M+H]+. 
 
Preparation of compound 4f. Compound 4f was synthesized following a 
modified procedure published for the preparation of similar compounds.198 To 
S
N
O
O
N 2S
O
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a mixture of isoamylamine (0.23 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. A slurry solution was formed after another 5 min of 
stirring at rt. N-Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was 
refluxed at 60 °C for an additional 1 h. The reaction mixture was stirred for an additional 36 h 
at rt, and then washed with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic 
layer was dried over anhydrous MgSO4, concentrated in vacuo, and the residue was purified 
by flash column chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 4f (193 mg, 
87%, Rf 0.25 in 1:4/EtOAc:hexanes) as a white solid: 1H NMR (400 MHz, CDCl3, Figure C54) 
δ 7.97 (dd, J = 6.8, 0.8 Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.76 (td, J = 7.6, 1.6 Hz, 1H), 7.73 
(td, J = 7.6, 0.8 Hz, 1H), 3.98 (dt, J = 14.4, 7.6 Hz, 1H), 3.76 (dt, J = 14.4, 7.6 Hz, 1H), 1.74-
1.60 (m, 3H), 0.97 (d, J = 4.4 Hz, 3H), 0.95 (d, J = 4.4 Hz, 3H); 13C NMR (100 MHz, CDCl3, 
Figure C55) δ 165.5, 145.8, 134.3, 133.4, 128.7, 126.3, 125.2, 39.9, 38.2, 26.1, 22.6, 22.5; 
HRMS m/z calcd for C12H15NO2S: 237.0823; found 238.0895 [M+H]+. 
 
Preparation of compound 4n. Compound 4n was synthesized following a 
modified procedure published for the preparation of similar compounds.198 
To a mixture of cyclooctylamine (0.27 mL, 2.00 mmol) and Et3N (0.14 mL, 1.00 mmol) in 
anhydrous CH2Cl2 (10 mL), compound 1 (0.34 g, 1.00 mmol) in anhydrous CH2Cl2 (20 mL) 
was added dropwise over 15 min at rt. The mixture was allowed to stir for 1 h at rt. N-
Chlorosuccinimide (0.13 g, 1.00 mmol) was added and the mixture was refluxed at 60 °C for 
an additional 1 h. The reaction mixture was stirred for an additional 3 h at rt, and then washed 
with 1 M HCl (50 mL), H2O (50 mL), and brine (50 mL). The organic layer was dried over 
S
N
O
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anhydrous MgSO4, concentrated in vacuo, and the residue was purified by flash column 
chromatography (SiO2, 1:4/EtOAc:hexanes) to afford compound 4n (229 mg, 44%, Rf 0.25 in 
1:4/EtOAc:hexanes) as an off-white solid: 1H NMR (400 MHz, CDCl3, Figure C56) δ 7.95 
(dd, J = 6.8, 1.2 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.57 (td, J = 7.2, 1.6 Hz, 1H), 7.71 (td, J = 
7.2, 1.2 Hz, 1H), 4.54 (tt, J = 10.4, 4.0 Hz, 1H), 2.22-2.02 (m, 3H), 2.00-1.92 (m, 1H), 1.90-
1.76 (m, 2H), 1.72-1.58 (m, 8H); 13C NMR (100 MHz, CDCl3, Figure C57) δ 165.3, 145.9, 
134.1, 133.2, 129.0, 126.2, 125.0, 56.0, 33.0, 32.9, 26.9, 26.8, 25.9, 25.1, 24.9; HRMS m/z 
calcd for C15H19NO2S: 277.1136; found 278.1210 [M+H]+. 
 
5.6.2. Biochemical and biological methods 
5.6.2.1. Bacterial strains 
S. aureus ATCC 6538 (strain A) and S. epidermidis ATCC 35984 (strain AC) were purchased 
from American Type Tissue Collection (ATCC, Manassas, VA). S. aureus ATCC 25923 
(strain B), S. aureus ATCC 33591 (strain D), MRSA2 (strain F), P. aeruginosa ATCC 27853, 
E. cloacae ATCC 13407, and S. epidermidis ATCC 12228 were donated by Prof. Dev P. Arya 
(Clemson University). S. aureus ATCC 29213 (strain C), MRSA BRS3 (strain G), MRSA C1 
(strain H), MRSA C2 (strain I), MRSA C7 (strain J), MRSA C14 (strain K), MRSA C16 
(strain L), MRSA C19 (strain M), MRSA G1 (strain N), MRSA G6 (strain O), MRSA G12 
(strain P), MRSA G14 (strain Q), MRSA NRS4 (strain R), MRSA NRS51 (strain S), MRSA 
NRS77 (strain T), MRSA S14 (strain U), MRSA S17 (strain V), MRSA S22 (strain W), 
MRSA S24 (strain X), MRSA USA100 (strain Y), MRSA USA200 (strain Z), MRSA 
USA300 (strain AA), MRSA USA600 (strain AB), E. faecalis ATCC 29212 (strain AD), E. 
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faecalis ATCC 49533 (strain AE), E. faecium BM4105-RF (strain AF), L. monocytogenes 
ATCC 19115 (strain AH), A. baumannii ATCC 19606, E. coli MC1061, and K. pneumoniae 
ATCC 27736 were a generous gift from Prof. Paul J. Hergenrother (University of Illinois 
Urbana-Champaign). MRSA1 (strain E) and VRE (strain AG) were obtained from Prof. 
David H. Sherman (University of Michigan). Finally, M. smegmatis MC2-155 (strain AI) was 
provided by Prof. Sabine Erht (Cornell University). 
 
5.6.2.2. Determination of MIC values against bacterial strains 
The MIC values against bacterial strains were determined based on a previously published 
protocol.179 The double-dilution method was used to determine MIC values starting at 125 
µg/mL. The tested compounds were dissolved in Mueller-Hinton (MH) broth and a 1:1000 
dilution of bacterial cultures were added. Bacteria were allowed to grow at 37 °C overnight. 
MIC values were determined by sight or by staining with MTT (1 mg/mL, 50 µL) when 
needed. These data are presented in Tables 5.1-5.3. 
 
5.6.2.3. Time-kill curves  
The efficiency of the compounds to kill MRSA S22 (strain W) was monitored using a slightly 
modified previously published protocol.185 The initial inoculum used for this assay was 1-
5×106 CFU/mL in MH medium at 37 °C in 50 mL Falcon tubes (10 mL volume) with 
continuous agitation (200 rpm). Ebselen, ebsulfur (2a), ebsulfur derivatives 3b and 3c, and 
AMK were used at concentrations of 0.5×, 1×, and 4× their respective MIC values. At 0, 3, 6, 
9, and 24 h, 100 µL aliquots were removed from each solution and serially diluted in sterile 
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ddH2O. Each dilution was spread onto MH-agar plates and incubated at 37 °C. Colony counts 
were determined after 24 h of incubation. The experiments were performed in duplicate 
(Figure 5.2). In order to confirm that the MIC values reported from the experiments described 
above, remained the same in the time-kill assays when 1×106 CFU/mL was used as an 
inoculum, we determined the MIC values again for the compounds evaluated in time-kill 
assays (AMK, ebselen, 2a, 3b, and 3c) and additional ones (2g, 2h, and 3a) using the double-
dilution method starting with 1×106 CFU/mL. We found the MIC values determined by both 
methods (different starting inoculum) to be identical for the compounds tested. 
 
5.6.2.4. Biofilm disruption 
The ability of the compounds to disrupt biofilms was tested based on a previously published 
protocol.178 Briefly, S. aureus ATCC 6538 (strain A) and S. epidermidis ATCC 35984 (strain 
AC) were grown overnight in Trypticase soy broth (TSB) at 37 °C. The bacteria were then 
diluted 1:100 in TSB with 1% glucose and plated (100 µL) in 96-well plates. The cells were 
grown for 24 h at 37 °C before the medium and planktonic bacteria were removed with PBS 
washing (4×100 µL). At this point, antibacterial compounds, dissolved in TBS (100 µL), were 
added to the biofilms and incubated for an additional 24 h at 37 °C. The compounds and 
medium were removed by submerging the entire plate in tap H2O. The biofilms were then 
stained with a 0.1% crystal violet solution by incubating 100 µL of the solution in the wells 
for 30 min. The excess crystal violet was removed by washing with ddH2O (4×100 µL). The 
plates were allowed to dry for 1 h and the dye was solubilized with 95% EtOH. After 
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thorough mixing the absorbance at 595 nm was read on a SpectraMax M5 plate reader. All 
readings were normalized to the biofilm formation without compound (Figure 5.3). 
 
5.6.2.5. Determination of hemolytic activity 
Hemolytic activity was determined as previously described with minor modifications (Figure 
5.4).187-188 To obtain red blood cells (RBCs), mouse RBCs (1 mL) were suspended in 9 mL of 
PBS (10 mM, pH 7.2) and centrifuged (1,200rpm) for 10 min. RBCs were washed in PBS 
(4×) and resuspended in fresh PBS to achieve the final concentration (107 RBCs/mL). Serial 
dilutions of compounds were prepared in Eppendorf tubes containing H2O (100 µL) and 
RBCs suspension (100 µL) was added to achieve final concentrations of compounds ranging 
from (31.2 to 0.24 µg/mL) and of RBCs at 5×106 RBCs/mL. After that, the tubes were 
incubated at 37 °C for 1 h Tubes containing ddH2O (200 µL) and Triton X-100® (1% v/v, 2 
µL) served as negative (blank) and positive (100%) control, respectively. Percent hemolysis 
was calculated using the following equation: % hemolysis = [(absorbance of sample) – 
(absorbance of blank)]×100/(absorbance of positive control). Fifty percent hemolysis (HC50) 
values were defined as the concentrations of compounds required to lyse 50% of the RBCs. 
 
5.6.2.6. Determination of mammalian cytotoxicity 
Mammalian cytotoxicity assays were performed as previously described with slight 
modifications.188 HEK-293 cells (ATCC CRL-1573) were cultured in DMEM medium 
(ATCC, Manasas, VA) with 10% FBS (ATCC, Manasas, VA) and 1% pen/strep (ATCC, 
Manasas, VA) at 37 °C with 5% CO2. Cells were plated at 10,000 cells per well (100 µL well) 
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overnight in 96-well microtiter plates. The next day, ebselen as well as compounds 2e, 2h, 2k, 
2l, 3c, 3i, and 3k were serially diluted and stored at 1000× stocks (10,000, 5,000, 2,500, 1,250, 
630, 310, 160, 80, and 40 µg/mL) in DMSO. Then, 1 µL of 1000× compound stocks was 
added to 999 mL medium to achieve final compound concentrations of 10, 5, 2.5, 1.25, 0.63, 
0.31, 0.16, 0.08, and 0.04 µg/mL with 0.1% DMSO, which was determined to not be toxic in 
HEK-293 cell line. The medium was removed from the 96-well microtiter plates and an 
additional 200 µL of medium with ebselen, 2e, 2h, 2k, 2l, 3c, 3i, and 3k were added to each 
well. The positive control consisted of cells treated with 0.1% DMSO, while the negative 
control consisted cells treated with Triton X-100® (1% v/v, 2 µL). The cells were incubated 
with the compounds for 24 h at 37 °C with 5% CO2. After the incubation, each well was 
treated with 10 µL (25 mg/L) of resazurin sodium salt (Sigma-Aldrich) for 6 h. Live cells can 
convert the blue-fluorescent dye resazurin to the highly fluorescent pink dye resorufin, which 
can be detected at A560 excitation and A590 emission wavelengths using a SpectraMax M5 
plate reader. Percent cell survival was calculated as: (test value/control value) x 100. Control 
value represents cells + resazurin without compounds and test value represents cells + 
resazurin + compounds. We thank Dr. Matthew S. Gentry (University of Kentucky) for kindly 
providing the HEK-293 cell line. 
 
5.6.2.7. Cell membrane permeabilization assay using propidium iodide (PI) staining  
A colony of S. epidermidis ATCC 35984 (strain AC) was used to inoculate 5 mL of MH broth 
in a Falcon tube and grown overnight at 37 °C at 200 rpm. The overnight culture was diluted 
by adding 200 µL of bacterial cells to 800 µL of MH broth. Cell suspension (50 µL) was then 
 292 
added to the MH broth containing no drug (negative control) or ebselen, 2a, 3b, 3c, and AMK, 
at their 1× and 4× MIC values, respectively. C14-thioether tobramycin166 was used as the 
positive control. The cell suspensions were then treated for 1 h at 37 °C with continuous 
agitation (200 rpm). Afterwards, treated cells were centrifuged and resuspended in 500 µL of 
PBS buffer (pH 7.2). Propidium iodide (PI) (3 µM, final concentration) was added and the 
mixture was incubated for 10 min at rt in the dark (PI is light sensitive) and centrifuged to 
remove excess PI. Glass slides with 10-15 µL of each mixture were prepared and observed in 
bright field and fluorescence modes (Texas red filter set, excitation, and emission wavelengths 
of 535 and 617 nm, respectively) using a Zeiss Axovert 200M fluorescence microscope. Data 
were obtained from two independent experiments (Figure 5.6). 
 
5.6.2.8. Assay for ROS production 
We used 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) dye as a probe to measure the 
production of ROS in bacterial cells upon treatment with our compounds (ebselen, 2a, 3b, and 
3c). This DCFH-DA was used as it can easily cross the cell membranes and be hydrolyzed by 
cellular esterases to the non-fluorescent 2',7'-dichlorodihydrofluorescein (DCFH), which can 
further be oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF) by the 
intracellular ROS.192 A colony of S. epidermidis ATCC 35984 (strain AC) was used to 
inoculate 5 mL of MH broth in a Falcon tube and grown overnight at 37 °C at 200 rpm. The 
overnight culture was diluted by adding 200 µL of bacterial cells to 800 µL of MH broth. Cell 
suspension (50 µL) was then added to the MH broth containing no drug (negative control) or 
ebselen, 2a, 3b, and 3c, at their 1x and 4x MIC and treated for 1 h at 37 °C. Hydrogen 
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peroxide (H2O2) at 1 mM concentration was used as a positive control. Cells were centrifuged 
and washed twice with PBS buffer (pH 7.2). Cells were resuspended in the same buffer and 
incubated with DCFH-DA (40 µg/mL) for 30 min in the dark. Afterwards, cells were 
centrifuged, washed with PBS buffer to remove the excess DCFH-DA. Glass slides with 10-
15 µL of each mixture were prepared and observed in bright field and fluorescence modes 
(FITC filter set, excitation, and emission wavelengths of 488 and 512 nm, respectively) using 
a Zeiss Axovert 200M fluorescence microscope (Figure 5.7). 
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Chapter 6 
 
Introduction: fungal diseases, current antifungal agents, and resistance associated with 
fungal diseases 
 
6.1. INTRODUCTION TO FUNGAL DISEASES 
Fungal infections have become a major burden for society, especially with the current rise in 
the number of immunocompromised patients. Candida albicans is the major pathogen and is 
responsible for 50-70% cases of total fungal infections worldwide.202 Among the fungal 
infections, invasive candidiasis is one of the most common nosocomical fungal disease with 
an estimate of 250,000 cases and more than 50,000 deaths worldwide per year.202-203 
Additionally, Aspergillus strains are also the culprits of numerous disease states. For instance, 
approximately 2.5% of adults with asthma also suffer with allergic bronchopulmonary 
aspergillosis (ABPA).204 According to the Centers for Disease Control, out of these roughly 
4.8 million patients with ABPA, 400,000 end up with chronic pulmonary aspergillosis 
(CPA).204 As recently as 2012, in the USA, a multistate outbreak of fungal meningitis and 
associated diseases (749 reported cases) were discovered to be due to steroid injections 
contaminated with fungal pathogens prepared by a single compounding pharmacy.205 Based 
on some experts opinions, fungal diseases are expected to become even more prominent in the 
near future as a result of global warming and the rise of fungal strains that are capable of 
surviving and propagating at mammalian body temperature.206 
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The impact of fungi extends far beyond direct human infections. The main human food 
sources, comprised of livestock and plants, are also hosts for a variety of fungal pathogens. In 
fact, there are historical examples of food sources contaminated by fungi, which have 
presented and continue to present challenges to human civilization. A dark period in the 
history of the USA was the Salem witch-trials. A well-known scientific explanation for the 
reported afflictions was that the alleged victims unknowingly consumed mouldy bread 
contaminated with a fungus called Claviceps purpurea, more commonly known as ergot. This 
fungus, infecting the head of rye and other grains, produces psychotropic natural products.207 
In the nineteenth century, fungal diseases in crops were responsible for multiple famines. For 
example, the Irish Potato Famine resulted from a phytopathogenic fungus, Phytophthora 
infestans, which led to innumerable dead from starvation and triggered the emigration of an 
estimated half a million Irish citizens to the USA.208-210 Currently, the fungus Puccina 
graminis tritici Ug99, responsible for stem or black rust disease on wheat, is threatening to 
wipe out the world wheat production.211 Fungal diseases also affect livestock. Mastitis in dairy 
cattle is an inflammation of the udder often caused by infectious microorganisms. Recently, a 
group from Poland identified milk samples of mastitic cows to be contaminated with Candida 
parapsilosis, a pathogen capable of infecting humans.212-213 
 
It is therefore clear that fungal afflictions have arisen in various links of the food web 
throughout history (Figure 6.1A). Over the ages, fungi have come out of their hiding places 
and humans have sought new ways to overcome these pathogens. We are currently in an era 
where resistance to all the currently used antifungal agents is fast emerging. Thus, there is a 
need for new, safe, and effective antifungals to combat214 these pathogens. Unlike the case of 
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antibacterials, our repertoire of antifungals is limited, and the antifungal pharmaceutical 
pipeline is running dry. It is important to note that the most clinically useful antifungal classes 
(polyenes and azoles) were discovered at least 40 years ago and the azoles are used in 
livestock and plants as well. While also important, the literature on antifungal usage in 
livestock is limited and will not be directly addressed herein. On the contrary, since the 
introduction of the most commonly used antifungals, there has been an explosion in the 
number of manuscripts related to antifungals since the 1960s, as exemplified by the increase 
from ~443 and 39 to 4934 and 1088 manuscripts in PubMed and Scifinder, respectively, from 
1960 to 2015 (Figure 6.1B).  
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Figure 6.1. A. Schematic showing that fungi can infect not only humans, but affect humans at 
multiple points of the food web. Lines indicate connections through food sources. Examples 
of pathogenic fungi are written adjacent to each point or connection. B. Line graph showing 
the increase in the publication of antifungal papers. 
 
6.2. CURRENT ANTIFUNGAL AGENTS 
The antifungal drug pipeline has received contributions from many chemical classes: natural 
products, synthetic organic molecules, and inorganic compounds (Figure 6.2). Collectively, 
synthetic organic molecules have been the predominant class in terms of applications in both 
humans and crops.215-216 There is currently an alarmingly high number of molecules used in 
crops that are either structurally or pharmacologically the same as the FDA-approved drugs 
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utilized in medicine. This observed crossover could potentially contribute to widespread 
fungal resistance in the future. In the following sections we discuss the antifungal compounds 
currently used in both humans and agriculture. The most common antifungal targets include 
fungal ergosterol (e.g., the 14α-demethylases), β-1,3-D-glucan synthase, N-
myristoyltransferase, aminoacyl tRNA synthase, chitin synthase, elongation factor, and the 
secreted aspartic protease. Detailed information about each of these targets can be found in a 
recent review article.217 
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Figure 6.2. A. Timeline showing the introduction to market (year of introduction into 
parentheses) of the antifungals for human use (top) and for use on crops (bottom) discussed in 
this chapter. AmB = amphotericin B, 5-FC = 5-fluorocytosine, NYS = nystatin, MCZ = 
miconazole, NAF = naftifine, FLC = fluconazole, KTC = ketoconazole, ITC = itraconazole, 
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TER = terbinafine, CFG = caspofungin, VOR = voriconazole, MFG = micafungin, POS = 
posaconazole, AFG = anidulafungin, CBM = carbendazim, PCZ = propiconazole, TBC = 
tebuconazole, FPN = fenpropidin, DTM = dimethomorph, AXN = azoxystrobin, KS-M = 
kresoxim-methyl, ECZ = epoxiconazole, FLU = flumorph. B. Structures of antifungals 
currently used in the clinic and as fungicides. 
 
The first conjugated polyketide (PK) natural product, nystatin (NYS), discovered to display 
antifungal activity, was isolated from Streptomyces noursei (named for the dairy farmer 
William Nourse) in 1950.218 Although this discovery was a monumental achievement in the 
field of medical mycology, it was apparent that, due to its toxicity, NYS would not be an ideal 
drug for systemic fungal infections, a complication for healthcare providers at the time. 
Hence, new antifungal compounds capable of treating systemic fungal diseases were 
necessary. However, this discovery put the spotlight on antifungal natural product isolation, 
specifically the polyenes. Eventually, amphotericin B (AmB), a heptaene PK, was isolated in 
1953 from a soil sample from Venezuela.219 The discovery of AmB was essential considering 
that it was the first drug that could be used to treat deep-seated systemic fungal infections.208 
Both NYS and AmB act on fungal cells by binding to ergosterol and forming a 
transmembrane channel leading to monovalent ion leakage.220 Approximately 60 years after 
the isolation of AmB, this polyene compound still remains a major cornerstone of several 
treatment guidelines for invasive fungal infections.221 Despite its potent antifungal activity, 
AmB has severe off-target effects and is often reserved for life-threatening infections.222-224 
Patients treated with AmB frequently experience infusion-related adverse effects and/or dose-
limiting nephrotoxicity.225 The liposomal formulations of AmB have alleviated some of its 
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toxicity concerns, but not to a satisfactory extent.225 And in addition, AmB formulations are 
required to be administered parenterally. 
 
In fact, it took 30 years after the isolation of AmB for the first oral antifungal agent, 
fluconazole (FLC), to be introduced for clinical use. FLC is part of the azole class of 
antifungals that inhibit 14α-demethylase (ERG11 for Candida spp. or CYP51 for Aspergillus 
spp.), an enzyme essential in the biosynthesis of a major component of the fungal cell 
membrane, ergosterol via lanosterol.220 Inhibition of 14α-demethylase causes the 
accumulation of toxic methylated sterols, eventually leading to fungal cell death.226 Unlike 
AmB, FLC exhibits excellent oral bioavailability, predictable linear pharmacokinetics, 
broader scope of affected tissues, and fewer adverse effects.227-228 As a result, FLC quickly 
became one of the most prescribed antifungal agents in clinics worldwide. However, some 
fungal strains, such as Candida glabrata, Candida krusei, Aspergillus spp., Fusarium spp., 
and the Mucorales were found to exhibit intrinsic resistance to FLC.215 Consequently, to 
expand the clinical utilities of azoles, new FLC analogues with broader spectrum of activity, 
such as itraconazole (ITC), voriconazole (VOR), and posaconazole (POS), were developed 
and introduced in 1992, 2002, and 2006, respectively (Figure 6.2B).229-230 ITC and POS 
contain modified and extended hydrophobic side chains, which allow for additional 
interactions with the enzyme targets, leading to an enhanced spectrum of activity.231-232 These 
azole compounds have been essential in our fight against many types of fungal diseases. 
However, azoles have their own shortcomings. Despite their tremendous clinical utilities, they 
also inhibit the human cytochrome P450 (CYP) enzymes interfering with the metabolism of 
many other concomitant drugs. Indeed, to correct the problem of azole-related drug 
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interactions, many research groups have been designing novel azole analogues that selectively 
target the fungal 14α-demethylase enzyme (See the modification of current antifungals and 
other FDA-approved drugs section). 
 
An alternative strategy that has been used to overcome the problem of selectivity towards the 
fungal enzymes, is the development of another class of compounds, the allylamines, which 
inhibit a different target in the ergosterol biosynthetic pathway. The first FDA-approved 
allylamines included terbinafine (TER) and naftifine (NAF), which were put on the market in 
1996 and 1988, respectively (Figure 6.2).233 These compounds inhibit squalene epoxidase, the 
enzyme responsible for generating a sterol upstream of ergosterol.234 TER has been shown to 
accumulate more in the skin and nail beds relative to blood plasma, possibly due to its 
lipophilicity.235 Thus, TER and the other allylamines are highly effective against 
dermatophytes and employed for the treatment of onychomycosis and cutaneous fungal 
infections.236 
 
Despite the improvements brought by the allylamines, in order to further differentiate between 
mammalian and fungal cells, their distinct cell walls have been targeted by the echinocandins. 
This latest milestone in medical mycology provided us with caspofungin (CFG), micafungin 
(MFG), and anidulafungin (AFG), which were introduced in 2001, 2005, and 2006, 
respectively.237-238 More specifically, these compounds target glucan synthesis, which is the 
most notable aberration between fungal and mammalian cells, by inhibiting the β-1,3-D-
glucan synthase. The polymer β-glucan is an essential component of many fungal cell 
walls.239 As a result of this unique mechanism of action, the echinocandins addressed an 
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important scientific challenge in medical mycology, which is selective toxicity against the 
eukaryotic fungal cell.240 Indeed, when comparing the rate of treatment discontinuation due to 
adverse effects, the aforementioned echinocandins were found to be more tolerable than AmB 
in all formulations, ITC, and VOR. 241 The echinocandins are fungicidal against most Candida 
spp. and fungistatic against Aspergillus spp. Unfortunately, they are generally not active 
against Zygomycetes, Cryptococcus neoformans, or Fusarium spp.237 Recent work by Nett 
and Andes provides a full account of the antifungals currently approved and used in the 
medical field, their spectrum of activity, resistance, pharmacology, clinical indications of use, 
toxicities, and any drug-drug interactions.242 Although good antifungal agents exist, based on 
the number of affected individuals and the number of deaths from candidiasis, aspergillosis, 
and cryptococcal meningitis, among other diseases (Figure 6.3), it is clear that new and 
improved antifungals are urgently needed. 
 
 
Figure 6.3. Bar graphical representation of the number of individuals living with and deaths 
caused by fungal infections. Data for this graph were obtained from the Global Action Fund 
for Fungal Infections website (www.gaffi.org). 
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6.3. RESISTANCE ASSOCIATED WITH FUNGAL DISEASES 
Much like their bacterial counterparts,15, 44 the number of fungi resistant to the current 
antifungals and fungicides is rapidly increasing. Below, we briefly summarize the main 
mechanisms of resistance for human pathogens and some phytopathogens. Although 
phytopathogens are abundant, the literature examining their mechanisms of resistance to 
fungicides is sparse, at best. For full coverage of the resistance mechanisms found in human 
fungal pathogens, please refer to the recent review by Sanglard on resistant fungal 
pathogens.243 
 
There are two types of resistance found in fungi: (i) acquired resistance through exposure to 
antifungal agents and (ii) intrinsic resistance, a genetic predisposition that precludes the 
activity of a particular antimycotic agent. The former has been reported for nearly every major 
fungal pathogen.244 Molecularly, resistance occurs in one of three ways:243 (i) decrease in 
effective drug concentration, (ii) drug target alterations, and (iii) metabolic bypasses. A 
decrease in intracellular concentration can be achieved in several ways including active efflux, 
target overexpression, and compartmentalization through the formation of biofilms.243 One 
recent case reported in phytopathogens is the development of resistance in P. capsici due to a 
mutation in the CesA3 gene, involved in cellulose synthesis.245 Drug targets are altered 
primarily through mutation of the given enzyme (e.g., 14α-lanosterol demethylase and β-1,3-
glucan synthase) so that the antifungal agent no longer efficiently prevents the enzyme from 
performing its dedicated task.243 Metabolic bypasses can include alternative metabolic or 
shunt pathways that convert the toxic metabolites, created by antifungal treatment, into a 
secondary metabolic or excretion route.246 In the following sections, we discuss the new 
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antifungal compounds that either overcome these methods of resistance, or avoid the currently 
targeted metabolic pathways. 
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Chapter 7 
 
Identification of ebsulfur analogues with broad-spectrum antifungal activity 
 
7.1. ABSTRACT 
Invasive fungal infections are on the rise due to an increased population of critically ill 
patients as a result of HIV infections, chemotherapies, and organ transplantations. Current 
antifungal drugs are helpful, but insufficient in addressing the problem of drug-resistant 
fungal infections. Thus, there is a growing need for novel antimycotics that are safe and 
effective. The ebselen scaffold has been evaluated in clinical trials and has been shown to be 
safe in humans. This makes ebselen an attractive scaffold for facile translation from bench to 
bedside. We have recently reported a library of ebselen-inspired ebsulfur analogues with 
antibacterial properties, but their antifungal activity has not been characterized. Herein, we 
repurposed ebselen, ebsulfur, and 32 additional ebsulfur analogues as antifungal agents by 
evaluating their antifungal activity against a panel of 13 clinically relevant fungal strains. The 
effect of induction of reactive oxygen species (ROS) by three of these compounds was 
evaluated. Their hemolytic and cytotoxicity activities were also determined using mouse 
erythrocytes and mammalian cells. The MIC values of these compounds were in the ranges of 
0.02-12.5 µg/mL against the fungal strains tested. Notably, yeast cells treated with our 
compounds showed the accumulation of ROS, which may further contribute to the growth 
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inhibitory effect against fungi. This study provides new lead compounds for the development 
of antimycotic agents. 
7.2. INTRODUCTION 
Fungal infections have become an emerging public health threat mainly due to the increasing 
size of the immunocompromised patient population.202 This population includes patients with 
AIDS, primary immune deficiency, and those who are immunocompromised due to 
chemotherapy or organ and bone marrow transplantation. Globally, Candida species are the 
predominant causes of invasive systemic fungal infections with the prevalence reported at 6.9 
cases per 1000 patients.247 In the United States, Candida infections rank fourth among all 
hospital-acquired systemic infections in intensive care units.248 In most population-based 
studies, Candida infections represent the seventh to tenth most common bloodstream 
infections.203 Additionally, many patients are now infected with other fungal species including 
Aspergillus fumigatus,249 Aspergillus nidulans,250 and Cryptococcus neoformans.251 
 
Common therapeutic classes used to treat systemic fungal infections include azoles (e.g., 
fluconazole (FLC), itraconazole (ITC), posaconazole (POS), and voriconazole (VOR)), 
polyenes (e.g., amphotericin B (AmB), nystatin (NYS), and candicidin (CAN)), and 
echinocandins (e.g., micafungin, caspofungin, and anidulafungin).4 These drugs function by 
different mechanisms of action: (i) inhibition of the cytochrome P450 enzyme 14a-
demethylase (azoles),252 (ii) introduction of transmembrane channel leading to monovalent ion 
leakage (polyenes),253-254 and (iii) inhibition of synthesis of glucan in the fungal cell wall via 
the enzyme 1,3-β-glucan synthase (echinochandins).255 
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Due to improper usage of these antifungal agents, more drug-resistant fungal strains have 
evolved.256-257 Specifically, these improper usages include insufficient dosages and durations 
of treatment.258 Additionally, new evidence suggests that antibacterials also contribute to this 
development of fungal resistance.259 Overall, fungal resistance is still relatively uncommon, 
but this problem is on the rise and expected to become a major healthcare problem. Thus, we 
have a critical need for the development of novel antifungal compounds. 
 
Currently, three strategies to overcome antifungal drug resistance have been employed. The 
first strategy is the development of compounds with novel mechanisms of action distinct from 
previous antifungal agents. For instance, compound E1210 was discovered as a novel first-in-
class antifungal compound by the Tsukuba Research Laboratories of Eisai Co., Ltd. This 
compound was discovered to inhibit fungal glycosylphosphatidylinositol (GPI) biosynthesis 
and validated in murine models of candidiasis, aspergillosis, and fusariosis.260 The second 
strategy is the combination of two antifungal agents. In the literature, there have been plenty 
of examples using two compounds in conjunction to produce synergistic antifungal activity 
and reduce resistance as well as toxicity.261-262 Specifically, in patients diagnosed with 
cryptococcal meningitis, the combination therapy of flucytosine and AmB was shown to be 
essential for successful clinical outcomes.263 Recently, it was also found that a combination of 
azoles and analogues of the aminoglycoside antibiotics tobramycin and kanamycin B resulted 
in favorable synergistic effects against drug-resistant Candida albicans strains.165, 188 Lastly, 
the third strategy is the repurposing of existing compounds for new applications. For example, 
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the decongestant drug octodrine was identified as a broad-spectrum antifungal compound.264 
In this study, we employed a combination of the first and third strategy to address the problem 
of antifungal drug resistance. We originally attempted to utilize all three strategies, but found 
that our novel compounds did not display synergy with currently used antifungal agents. 
 
Ebselen (1, Figure 7.1) is an organoseleno compound, which has completed phase I clinical 
trial for general safety in human use. Ebselen (1) has very diverse therapeutic applications and 
has been studied in several clinical trials.265 During the phase I study, up to 1,600 mg of 
ebselen (1) was dosed orally and found to be very well tolerated compared to placebo in 32 
healthy male and female subjects.171 Ebselen (1) is currently in phase II clinical trials for the 
treatment of chemotherapy-induced hearing loss and Meniere’s disease 
(http://clinicaltrials.gov). Furthermore, ebselen (1) completed a 300-patient phase III clinical 
trial for cerebral ischemia in Japan.169 The ebsulfur or 1,2-benzisothiazol-3(2H)-one scaffold 
has been demonstrated to have a very narrow spectrum of antibacterial activity (only really 
being active against methicillin-resistant Staphylococcus aureus (MRSA)), in our previous 
work.266 We hypothesized that ebsulfur (2a, Figure 7.1) would have a similar safety profile 
compared to that of ebselen (1). This scaffold is interesting because it is structurally very 
similar to ebselen (1, Figure 7.1). Therefore, we hypothesized that ebsulfur (2a, Figure 7.1) 
and its analogues would have a safety profile comparable to that of ebselen (1). In the 
literature, the antifungal activity of the ebsulfur scaffold had not been well characterized. 
Herein, we explored the antifungal properties of ebselen (1) as well as ebsulfur (2a) and 32 of 
its analogues (2b-4n, Figure 7.1) by using a combination of minimum inhibitory 
concentration (MIC) study, time-kill study, and reactive oxygen species (ROS) assays. The 
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safety of these compounds was also assessed and compared to ebselen (1) via mammalian 
cytotoxicity and hemolytic assays. Our study provides us with a better understanding of the 
structure-activity-relationship (SAR) of ebselen (1) and the 1,2-benzisothiazol-3(2H)-one 
scaffold as well as their potential as a new class of antifungal agents. 
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Figure 7.1. Chemical structures of our library featuring ebselen (1), ebsulfur (2a), and 32 
ebsulfur analogues. 
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7.3. RESULTS AND DISCUSSION 
7.3.1. Antifungal activity  
Compounds 1-3a-o and 4e-n were evaluated for whole-cell activity against a panel of 
clinically relevant fungal strains (Table 7.1). Our library of compounds featured ebselen (1) 
and ebsulfur (2a) as the main scaffolds. From the ebsulfur scaffold, the library was further 
organized into three sub-series: analogues with aromatic substituents (2 series, 2a-o), 
analogues with aliphatic substituents (3 series, 3a-o), and oxidized sulfoxide analogues (4 
series, 4e, 4f, and 4n). Series 2 contained aromatic substituents such as mono- and 
disubstituted phenyl rings (2a-k), naphthyl (2l), and nitrogen-containing aromatic 
heterocycles (2m-o). Series 3 contained analogues with substituents such as linear alkyl 
chains (3a-d), branched alkyl chains (3e-g), alkyl with terminal phenyl ring (3h-j), aliphatic 
rings (3k-n), and adamantyl (3o). In our previous work, we have verified that all the 
compounds tested were at least 95% pure by NMR and HRMS.26 We used the commercially 
available AmB, FLC, ITC, POS, and VOR as positive controls. The MIC values listed for the 
controls were either tested herein or acquired from some of our previously published 
manuscripts on unrelated antifungal agents.166 For the controls, AmB, as expected, was the 
most active against both Candida and Aspergillus strains with MIC values ranging from 0.98-
15.6 mg/mL. Despite its potent antifungal activity, it should be noted that AmB, even with the 
liposomal formulations, has been well known for its severe and potentially lethal side effects 
such as nephrotoxicity and hypokalemia.224, 267 FLC, the most popular and well-tolerated FDA 
approved antifungal agent, was fairly inactive against our panel of fungal strains with MIC 
values mostly from >31.2->125 µg/mL (except against Candida parapsilosis ATCC 22019 
(strain J), MIC = 1.95 µg/mL). ITC, POS, and VOR displayed similar activity against our 
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strains with MIC values mostly ranging from <0.03-31.2 µg/mL. The azole compounds, 
however, are potent inhibitors of human cytochrome P450 enzymes, which somewhat limit 
their applications due to drug-drug interactions with co-administered drugs.268 ITC and VOR 
are also generally not as well tolerated as FLC.241 To effectively evaluate the activities of our 
compounds, we define poor, good, very good, and excellent activity as ≥12.5 µg/mL, 1.56-
6.25 µg/mL, 0.39-0.78 µg/mL, and ≤0.10 µg/mL, respectively. In our broth dilution assays, 
the concentration of DMSO used is less than 1%, which was previously experimentally 
determined to not cause any DMSO-related cytotoxicity effect. 
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Table 7.1. MIC valuesa,b (in µg/mL) (and µM in parentheses)c determined for compounds 1-4n 
and for five control antifungal agents (AmB, FLC, ITC, POS, and VOR) against various yeast 
strains and filamentous fungi. 
 Yeast strains Filamentous fungi 
Cpd 
# A B C D E F G H I J K L M 
1 
12.5 
(45.
6) 
12.5 
(45.
6) 
12.5 
(45.6) 
1.56 
(5.69) 
3.13 
(11.4) 
>12.5 
(45.6) 
12.5 
(45.6) 
1.56 
(45.6
) 
1.56 
(5.69
) 
6.25 
(22.8) 
6.25 
(22.8
) 
1.56 
(5.69) 
1.56 
(5.69) 
2a 
12.5 
(55.
0) 
>12.
5 
(55.
0) 
12.5 
(55.0) 
3.13 
(13.8) 
6.25 
(27.5) 
>12.5 
(55.0) 
>12.5 
(55.0) 
6.25 
(27.5
) 
3.13 
(13.8
) 
12.5 
(55.0) 
6.25 
(27.5
) 
6.25 
(27.5) 
6.25 
(27.5) 
2b 
3.13 
(12.
8) 
6.25 
(25.
5) 
3.13 
(12.8) 
3.13 
(12.8) 
3.13 
(12.8) 
6.25 
(25.5) 
1.56 
(6.36) 
6.25 
(25.5
) 
3.13 
(12.8
) 
12.5 
(12.8) 
6.25 
(25.5
) 
12.5 
(51.0) 
12.5 
(51.0) 
2c 
3.13 
(12.
0) 
>12.
5 
(47.
8) 
12.5 
(47.8) 
6.25 
(23.9) 
6.25 
(23.9) 
6.25 
(23.9) 
12.5 
(47.8) 
6.25 
(23.9
) 
3.13 
(12.0
) 
12.5 
(47.8) 
6.25 
(23.9
) 
6.25 
(23.9) 
6.25 
(23.9) 
2d 
3.13 
(10.
2) 
3.13 
(10.
2) 
1.56 
(5.10) 
3.13 
(10.2) 
0.78 
(2.55) 
1.56 
(5.10) 
3.13 
(10.2) 
6.25 
(20.4
) 
3.13 
(10.2
) 
6.25 
(20.4) 
12.5 
(40.8
) 
12.5 
(40.8) 
12.5 
(40.8) 
2e 
3.13 
(11.
6) 
3.13 
(11.
6) 
3.13 
(11.6) 
3.13 
(11.6) 
3.13 
(11.6) 
6.25 
(23.2) 
3.13 
(11.6) 
3.13 
(11.6
) 
3.13 
(11.6
) 
3.13 
(11.6) 
6.25 
(23.2
) 
6.25 
(23.2) 
6.25 
(23.2) 
2f 
12.5 
(49.
7) 
12.5 
(49.
7) 
>12.5 
(49.7) 
12.5 
(49.7) 
>12.5 
(49.7) 
12.5 
(49.7) 
12.5 
(49.7) 
6.25 
(49.7
) 
6.25 
(49.7
) 
12.5 
(49.7) 
12.5 
(49.7
) 
12.5 
(49.7) 
12.5 
(49.7) 
2g 
>12.
5 
(40.
8) 
12.5 
(40.
8) 
12.5 
(40.8) 
12.5 
(40.8) 
>12.5 
(40.8) 
12.5 
(40.8) 
12.5 
(40.8) 
12.5 
(40.8
) 
12.5 
(40.8
) 
12.5 
(40.8) 
12.5 
(40.8
) 
12.5 
(40.8) 
12.5 
(40.8) 
2h 
3.13 
(11.
6) 
3.13 
(11.
6) 
3.13 
(11.6) 
3.13 
(11.6) 
3.13 
(11.6) 
3.13 
(11.6) 
3.13 
(11.6) 
3.13 
(11.6
) 
3.13 
(11.6
) 
3.13 
(11.6) 
6.25 
(23.2
) 
12.5 
(46.4) 
12.5 
(46.4) 
2i 
3.13 
(8.1
3) 
6.25 
(16.
2) 
6.25 
(16.2) 
6.25 
(16.2) 
6.25 
(16.2) 
3.13 
(8.13) 
6.25 
(16.2) 
6.25 
(16.2
) 
6.25 
(16.2
) 
6.25 
(16.2) 
12.5 
(32.5
) 
3.13 
(8.13) 
12.5 
(32.5) 
2j 
3.13 
(12.
3) 
6.25 
(24.
5) 
1.56 
(6.11) 
12.5 
(49.0) 
0.78 
(3.05) 
3.13 
(12.3) 
3.13 
(12.3) 
12.5 
(49.0
) 
12.5 
(49.0
) 
12.5 
(49.0) 
12.5 
(49.0
) 
12.5 
(49.0) 
12.5 
(49.0) 
2k 12.5 12.5 3.13 3.13 1.56 12.5 12.5 6.25 6.25 6.25 6.25 6.25 6.25 
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(43.
5) 
(43.
5) 
(10.9) (10.9) (5.43) (43.5) (43.5) (21.8
) 
(21.8
) 
(21.8) (21.8
) 
(21.8) (21.8) 
2l 
6.25 
(22.
5) 
12.5 
(45.
1) 
>12.5 
(45.1) 
3.13(1
1.3) 
>12.5 
(45.1) 
>12.5 
(45.1) 
6.25 
(22.5) 
12.5 
(45.1
) 
6.25 
(22.5
) 
12.5 
(45.1) 
12.5 
(45.1
) 
12.5 
(45.1) 
12.5 
(45.1) 
2m 
6.25 
(27.
4) 
6.25 
(27.
4) 
12.5 
(54.8) 
6.25 
(27.4) 
6.25 
(27.4) 
6.25 
(27.4) 
6.25 
(27.4) 
12.5 
(54.8
) 
6.25 
(27.4
) 
12.5 
(54.8) 
12.5 
(54.8
) 
12.5 
(54.8) 
12.5 
(54.8) 
2n 
12.5 
(47.
6) 
12.5 
(47.
6) 
12.5 
(47.6) 
>12.5 
(47.6) 
12.5 
(47.6) 
12.5 
(47.6) 
12.5 
(47.6) 
>12.5 
(47.6
) 
>12.5 
(47.6
) 
>12.5 
(47.6) 
>12.5 
(47.6
) 
>12.5 
(47.6) 
>12.5 
(47.6) 
2o ND ND ND ND ND ND ND ND ND ND ND ND ND 
3a 
1.56 
(7.0
5) 
0.39 
(1.7
6) 
0.78 
(3.52) 
1.56 
(7.05) 
0.39 
(1.76) 
0.78 
(3.52) 
0.78 
(3.52) 
1.56 
(7.05
) 
0.78 
(3.52
) 
0.78 
(3.52) 
≤0.02 
(0.09
) 
≤0.02 
(0.09) 
≤0.02 
(0.09) 
3b 
1.56 
(6.6
3) 
1.56 
(6.6
3) 
0.78 
(3.31) 
1.56 
(6.63) 
0.78 
(3.31) 
1.56 
(6.63) 
0.78 
(3.31) 
1.56 
(6.63
) 
0.78 
(3.31
) 
0.78 
(3.31) 
≤0.02 
(0.08
) 
≤0.02 
(0.08) 
≤0.02 
(0.08) 
3c 
6.25 
(23.
7) 
1.56 
(5.9
2) 
6.25 
(23.7) 
3.13 
(11.9) 
1.56 
(5.92) 
1.56 
(5.92) 
1.56 
(5.92) 
1.56 
(5.92
) 
1.56 
(5.92
) 
0.78 
(2.96) 
≤0.02 
(0.08
) 
≤0.02 
(0.08) 
≤0.02 
(0.08) 
3d 
>12.
5 
(39.
1) 
>12.
5 
(39.
1) 
>12.5 
(39.1) 
>12.5 
(39.1) 
>12.5 
(39.1) 
>12.5 
(39.1) 
>12.5 
(39.1) 
12.5 
(39.1
) 
>12.5 
(39.1
) 
>12.5 
(39.1) 
>12.5 
(39.1
) 
>12.5 
(39.1) 
>12.5 
(39.1) 
3e 
0.78 
(3.7
6) 
1.56 
(7.5
3) 
0.78 
(3.76) 
0.78 
(3.76) 
0.78 
(3.76) 
0.78 
(3.76) 
1.56 
(7.53) 
1.56 
(7.53
) 
0.39 
(1.88
) 
0.78 
(3.76) 
0.20 
(0.96
) 
0.02 
(0.10) 
0.10 
(0.48) 
3f 
1.56 
(7.0
5) 
0.78 
(3.5
2) 
1.56 
(7.05) 
0.78 
(3.52) 
0.78 
(3.52) 
0.78 
(3.52) 
1.56 
(7.05) 
1.56 
(7.05
) 
0.39 
(1.76
) 
1.56 
(7.05) 
0.20 
(0.90
) 
0.02 
(0.09) 
0.10 
(0.45) 
3g 
0.78 
(3.7
6) 
1.56 
(7.5
3) 
3.13 
(15.1) 
1.56 
(7.53) 
1.56 
(7.53) 
1.56 
(7.53) 
1.56 
(7.53) 
1.56 
(7.53
) 
0.78 
(3.76
) 
1.56 
(7.53) 
0.10 
(0.48
) 
0.10 
(0.48) 
0.10 
(0.48) 
3h 
0.39 
(1.6
2) 
1.56 
(6.4
6) 
1.56 
(6.46) 
1.56 
(6.46) 
1.56 
(6.46) 
1.56 
(6.46) 
0.78 
(3.23) 
1.56 
(6.46
) 
0.39 
(1.62
) 
0.78 
(3.23) 
0.78 
(3.23
) 
0.39 
(1.62) 
0.39 
(1.62) 
3i 
1.56 
(6.1
1) 
1.56 
(6.1
1) 
1.56 
(6.11) 
1.56 
(6.11) 
1.56 
(6.11) 
1.56 
(6.11) 
1.56 
(6.11) 
1.56 
(6.11
) 
1.56 
(6.11
) 
1.56 
(6.11) 
0.78 
(3.05
) 
0.20 
(0.78) 
0.20 
(0.78) 
3j 
6.25 
(23.
2) 
3.13 
(11.
6) 
6.25 
(23.2) 
3.13 
(11.6) 
6.25 
(23.2) 
6.25 
(23.2) 
6.25 
(23.2) 
1.56 
(5.79
) 
1.56 
(5.79
) 
6.25 
(23.2) 
0.78 
(2.90
) 
0.20 
(0.74) 
0.20 
(0.74) 
3k 
0.39 
(1.7
8) 
1.56 
(7.1
1) 
0.78 
(3.56) 
0.39 
(1.78) 
0.39 
(1.78) 
0.39 
(1.78) 
0.78 
(3.56) 
0.78 
(3.56
) 
0.39 
(1.78
) 
1.56 
(7.11) 
0.20 
(0.91
) 
0.10 
(0.46) 
0.10 
(0.46) 
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3l 
0.78 
(3.3
4) 
1.56 
(6.6
9) 
3.13 
(13.41
) 
0.78 
(3.34) 
1.56 
(6.69) 
0.78 
(3.34) 
1.56 
(6.69) 
1.56 
(6.69
) 
0.78 
(3.34
) 
1.56 
(6.69) 
0.20 
(0.86
) 
0.20 
(0.86) 
0.20 
(0.86) 
3m 
1.56 
(6.3
1) 
1.56 
(6.3
1) 
3.13 
(12.7) 
1.56 
(6.31) 
3.13 
(12.7) 
1.56 
(6.31) 
3.13 
(12.7) 
3.13 
(12.7
) 
0.39 
(1.58
) 
3.13 
(12.7) 
0.10 
(0.40
) 
0.20 
(0.81) 
0.20 
(0.81) 
3n 
3.13 
(11.
2) 
3.13 
(11.
2) 
6.25 
(23.9) 
6.25 
(23.9) 
6.25 
(23.9) 
6.25 
(23.9) 
6.25 
(23.9) 
3.13 
(11.2
) 
0.39 
(1.49
) 
3.13 
(11.2) 
≤0.02 
(0.08
) 
0.05 
(0.19) 
≤0.02 
(0.08) 
3o ND ND ND ND ND ND ND ND ND ND ND ND ND 
4e 
>12.
5 
(56.
0) 
>12.
5 
(56.
0) 
>12.5 
(56.0) 
>12.5 
(56.0) 
>12.5 
(56.0) 
>12.5 
(56.0) 
>12.5 
(56.0) 
>12.5 
(56.0
) 
>12.5 
(56.0
) 
>12.5 
(56.0) 
>12.5 
(56.0
) 
>12.5 
(56.0) 
>12.5 
(56.0) 
4f 
>12.
5 
(52.
7) 
>12.
5 
(52.
7) 
>12.5 
(52.7) 
>12.5 
(52.7) 
>12.5 
(52.7) 
>12.5 
(52.7) 
>12.5 
(52.7) 
>12.5 
(52.7
) 
>12.5 
(52.7
) 
>12.5 
(52.7) 
>12.5 
(52.7
) 
>12.5 
(52.7) 
>12.5 
(52.7) 
4n 
>12.
5 
(45.
1) 
>12.
5 
(45.
1) 
>12.5 
(45.1) 
>12.5 
(45.1) 
>12.5 
(45.1) 
>12.5 
(45.1) 
>12.5 
(45.1) 
>12.5 
(45.1
) 
>12.5 
(45.1
) 
>12.5 
(45.1) 
>12.5 
(45.1
) 
>12.5 
(45.1) 
>12.5 
(45.1) 
Am
B 
3.9 
(4.2
2) 
3.9 
(4.2
2) 
1.95 
(2.11) 
0.98 
(1.06) 
1.95 
(2.11) 
3.9 
(4.22) 
3.9 
(4.22) 
1.95 
(2.11
) 
3.9 
(4.22
) 
1.95 
(2.11) 
15.6 
(16.9
) 
15.6 
(16.9) 3.9 (4.22) 
FL
C 
62.5 
(204
)a  
>12
5 
(408
)a 
15.6 
(51.0)a 
>125 
(408)a 
>125 
(408)a 
62.5 
(204)a 
62.5 
(204)a 
>31.2 
(102) 
>31.2 
(102) 
1.95 
(6.37) 
62.5 
(204) 62.5 
(204)a 
62.5 (204) 
ITC 
0.5 
(0.7
1)a 
>62.
5 
(88.
6)a 
7.8 
(11.1)a 
31.2 
(44.2)a 
31.2 
(44.2)a 
31.2 
(44.2)a  
31.2 
(44.2)
a 
7.8 
(11.1
) 
0.48 
(0.68
) 
0.12 
(0.17) 
0.48 
(0.68
) 
0.195 
(0.28)a 
0.975 
(1.38) 
PO
S 
0.5 
(0.7
1)a 
>62.
5 
(89.
3)a 
7.8 
(11.1)a 
31.2 
(44.5)a 
31.2 
(44.5)a 
15.6 
(22.3)a 
15.6 
(22.3)
a 
0.12 
(0.17
) 
0.06 
(0.09
) 
<0.03 
(0.04) 
0.24 
(0.34
) 
0.195 
(0.28)a 
0.48 
(0.68) 
VO
R 
7.8 
(22.
3) 
>31.
2 
(89.
3) 
0.975 
(2.79) 
1.95 
(5.58) 
1.95 
(5.58) 
0.975 
(2.79) 
7.8 
(22.3) 
0.06 
(0.17
) 
0.12 
(0.34
) 
<0.03 
(0.09) 
0.24 
(0.69
) 
0.03 
(0.09) 
0.12 
(0.34) 
Yeast strains: A = Candida albicans ATCC 10231, B = C. albicans ATCC 64124, C = C. 
albicans ATCC MYA-2876(S), D = C. albicans ATCC 90819(R), E = C. albicans ATCC MYA-
2310(S), F = C. albicans ATCC MYA-1237(R), G = C. albicans ATCC MYA-1003(R), H = 
Candida glabrata ATCC 2001, I = Candida krusei ATCC 6258, J = Candida parapsilosis ATCC 
22019. NOTE: Here, the (S) and (R) indicate that ATCC reports these strains to be susceptible (S) 
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and resistant (R) to ITC and FLC. 
Filamentous fungi: K = Aspergillus flavus ATCC MYA-3631, L = Aspergillus nidulans ATCC 
38163, M = Aspergillus terreus ATCC MYA- 3633. 
Known antifungal agents: AmB = amphotericin B, FLC = fluconazole, ITC = itraconazole, POS = 
posaconazole, and VOR = voriconazole. 
a These values were previously reported in ref #166. 
b For yeast strains: MIC-0 values are reported for compounds 1-4n and AmB, whereas MIC-2 
values are reported for azoles. For filamentous fungi, MIC-0 values are reported for all 
compounds. 
c Values in µM are presented so that the reader can visualize the potential impact of the varied 
molecular weights of the compounds. 
ND indicates that MIC values were not determined due to solubility issues with the compound. 
 
We first tested ebselen (1) against our panel of Candida strains (A-J). Ebselen (1) displayed 
good activity against C. albicans ATCC 90819(R) (strain D), C. albicans ATCC MYA-
2310(S) (strain E), C. glabrata ATCC 2001 (strain H), C. krusei (strain I), and C. parapsilosis 
ATCC 22019 (strain J) (1.56-6.25 mg/mL) and poor activity against strains C. albicans 
ATCC 10231 (strain A), C. albicans ATCC 64124 (strain B), C. albicans ATCC MYA-
2876(S) (strain C), C. albicans ATCC MYA-1237(R) (strain F), and C. albicans ATCC 
MYA-1003(R) (strain G) (≥12.5 µg/mL). When compared to the controls, these MIC values 
were generally better than the MIC values of the azoles (except against strains A and H-J), 
but were worse than those of AmB. Next, we evaluated ebsulfur (2a) to gain insight into the 
importance of the sulfur atom for antifungal activity. Ebsulfur (2a) displayed a very similar 
anti-Candida profile to that of ebselen (1). In fact, we noticed that in general, they displayed 
good and poor activity against the same Candida strains. With the exception of strain J, 2a 
was active against strains D, E, H, and I (1.56-6.25 µg/mL) and poorly active against strains 
A, B, C, F, G, and J (≥12.5 µg/mL). This finding demonstrates that replacing the Se atom 
with the S atom does not compromise antifungal activity. 
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In search for a chemical modification that would increase the activity of the parent scaffolds, 
we first decided to assess our analogues with substituents at the para- and meta-positions of 
the phenyl ring adjacent to the 1,2-benzisothiazol-3(2H)-one (ebsulfur) core. Compounds 2b-
d were systematically prepared to contain p-substituted halogen atoms that increased in 
bulkiness with F < Cl < Br. The SAR comparison for these compounds, however, was flat 
with all three compounds generally displaying MIC values from 1.56-6.25 µg/mL. We then 
tested the p-substituted isopropyl analogue (2e), which was previously found to be among the 
best ebsulfur antibacterial analogues.266 Compound 2e displayed good MIC values (3.13-6.25 
µg/mL) similarly to those of 2b-d. Lastly, we tested the p-ethinyl analogue (2f) and found that 
2f displayed mostly poor activity against Candida strains (≥12.5 µg/mL). We speculated that 
substitution at the para-position was not well tolerated due to steric hindrance with the 
putative target(s) and that a meta-substitution might show a different pattern of activities. 
 
Based on this assumption, we next examined the m-monosubstituted analogues (2g,h) and the 
3,5-disubstituted analogues (2i-k). While the m-Br substitution in 2g was not beneficial at all 
(≥12.5 µg/mL) against Candida strains, the m-iPr (2h), m,m-di-Br (2i), m,m-di-Me (2j), and 
m,m-di-OMe (2k) analogues were overall better tolerated with good to moderate MIC values 
(3.13->12.5 µg/mL). By comparing the p-substituted analogues 2d,e and their m-substituted 
counterparts 2g,h, we noticed that switching from p-Br (2d) to m-Br (2g) led to loss of 
activity, whereas switching from p-iPr (2e) and m-iPr (2h) led to compounds which displayed 
very similar MIC values. Overall, the activity of these compounds appeared to weakly 
correlate with the number or the positions of the substituents on the phenyl ring. 
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Moving away from the substituted phenyl strategy, we next explored the analogues with more 
complex aromatic rings such as the naphthyl (2l), pyridyl (2m,n), and quinolinyl (2o). We 
found that these relatively bulkier rings were not as well tolerated. Compounds 2l,m displayed 
good to poor activity (6.25-≥12.5 µg/mL), while compound 2n was poorly active (≥12.5 
µg/mL) and 2o could not be evaluated due to solubility issues in our RPMI 1640 medium. In 
conclusion, the chemical strategy of installing flat aromatic moieties to the core scaffold of the 
2 series was able to generate many analogues with mostly good MIC values that are 
comparable to the parent ebsulfur (2a). We identified compounds 2d, 2e, 2h, and 2i that 
displayed incrementally improved MIC values when compared to those of ebsulfur (2a), but 
these improvements were still insufficient. Next, we pondered whether modifications with 
substituents possessing more geometric freedom and flexibility would be able to generate 
more substantially potent analogues. 
 
Inspired by the observation that coupling linear alkyl chains to aminoglycoside antibiotics 
resulted in a significant improvement of their antifungal activity,165-166, 269-271 we 
systematically generated and examined the antifungal activities of ebsulfur analogues with 
linear alkyl chains of 5-12 carbons (C5, C6, C8, and C12, 3a-d). Based on our previous work 
with aminoglycosides where tobramycin and kanamycin analogues with C12 and C14 alkyl 
chains displayed the best antifungal activity, we hypothesized that our longer C12 ebsulfur 
analogue (3d) would be the most active. Surprisingly, we observed an opposite trend than that 
displayed by the aminoglycosides; we found that our shorter C5 (3a) and C6 (3b) analogues 
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were remarkably effective with very good to good MIC values against all Candida strains 
(0.39-1.56 µg/mL). The C8 analogue (3c) was slightly worse when compared to the C5 (3a) 
and C6 (3b) analogues (specifically against strains A and C), and our C12 analogue (3d) 
displayed poor MIC values (>12.5 µg/mL), which was the worst amongst the analogues. 
 
We were intrigued to identify the C5 (3a) and C6 (3b) linear alkyl analogues as the best anti-
Candida agents in our library, thus far. Compared to FLC, 3a was 20- to 320-fold more potent 
in MIC values (except against strain J). When compared to AmB, 3a was 1.25- to 10-fold 
more active. Since the C5 and C6 alkyl chains were extremely well tolerated, we speculated 
whether our putative target(s) could also tolerate branched alkyl chains with similar chain 
lengths. We went ahead and evaluated the iso-butyl (3e) and iso-amyl (3f) analogues. 
Interestingly, both 3e and 3f were equally as effective as 3a and 3b (0.39-1.56 µg/mL). We 
then examined the final branched analogue in our library, the tert-butyl compound 3g. 
Compound 3g was also as effective as 3a-f (within 2-fold dilution, 0.78-3.13 µg/mL). Against 
Candida strains, analogues with aliphatic alkyl chains (linear or branched) were found to be 
very beneficial, which could possibly be attributed to the added rotational flexibility.  
 
As we found that additional methylene groups were highly favorable, we hypothesized that 
adding methylene linkers (C1 (3h), C2 (3i), and C3 (3j)) in between the 1,2-benzisothiazol-
3(2H)-one core and the phenyl ring could provide the added rotational flexibility needed to 
generate analogues with improved MIC values when compared to the parent compound (2a), 
which was flat and rigid. The C1 and C2-linker analogues (3h,i) indeed had better MIC values 
 321 
comparing to 2a (0.39-1.56 µg/mL). However, the C3-linker analogue (3j) was not as potent 
(1.56-62.5 µg/mL). From these observations, we noticed that addition of flexible methylene 
linkers were well tolerated up to two carbons. 
 
To further understand the correlation between the flexibility of the R group and activity, we 
tested our non-aromatic analogues (3k-o) as non-aromatic rings are considerably more 
flexible than their aromatic counterparts. We first tested the cyclopentyl analogue (3k) and 
found it to be just as active (0.39-1.56 µg/mL) as some of our best analogues 3a-c described 
above. On the other hand, the cyclohexyl analogue (3l) still displayed very good to good 
activity (0.78-3.13 µg/mL), but overall was slightly worse relative to 3k. The cycloheptyl (3m) 
and cyclooctyl (3n) analogues were also not as good as 3k,l. We also attempted to test 
whether an ultra-bulky ring such as the adamantane could still be accommodated, but our 
adamantyl analogue (3o) was not soluble in the RPMI 1640 medium that we used for 
determination of MIC values. Collectively, the SAR showed a modest preference for smaller 
size ring, as systematically expanding the ring size resulted in a gradual loss in activity. 
 
Lastly, we tested the oxidized analogues 4e, 4f, and 4n. Oxidizing the sulfur atom to sulfoxide 
completely abolish antifungal activity. This finding was in accord with our previous report of 
these compounds as antibacterials and with other r eports in the literature that the biological 
activity of ebselen (1) and ebsulfur (2a) was highly dependent on the Se-N or S-N bonds.182, 
266 Ebselen (1) has been reported to utilize the electrophilic Se-N bond to covalently bind to 
cysteine residues of multiple enzyme targets.265 
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Invasive aspergillosis is highly correlated with fulminant development and poor prognosis.272 
Compounds with potent anti-Aspergillus activity are considered to be of great valuable. To 
evaluate the antifungal spectrum of our compounds, we tested them against freshly harvested 
spores of three Aspergillus strains: A. flavus ATCC MYA-3631 (strain K), A. nidulans ATCC 
38163 (strain L), and A. terreus ATCC MYA-3633 (strain M). Overall, our compounds were 
mostly active against Aspergillus strains and the SAR trends observed from our study with 
Candida strains were highly translatable to Aspergillus strains. Aromatic analogues (2a-o) 
remained to have either good to poor activity against strains K-M (1.56-12.5 µg/mL). We 
were especially intrigued to observe that our linear-chain C5, C6, and C8 analogues (3a-c) 
displayed excellent activity at ng/mL concentrations (≤0.02-0.20 µg/mL). These results were 
equivalent or slightly better when comparing them to VOR (0.03-0.24 µg/mL), the gold 
standard for the treatment of invasive aspergillosis.273 Other analogues (3e-m) displayed very 
good activity (0.10-0.78 µg/mL), but they were not as effective as 3a-c. We were also 
surprised to find that our cyclooctyl analogue (3n) displayed excellent activity against 
Aspergillus strains (≤0.02-0.05 µg/mL). These values were equivalent to our best anti-
Aspergillus analogues 3a-c. We realized that many of our potent analogues were lipophilic. 
Thus, we investigated the log P values of all the compounds by two log P calculators 
(ChemDraw and molinspiration) (Table 7.2). In general, we observed that compounds with 
extremely high or very low lipophilicity did not display good antifungal activity. However, we 
found that increasing lipophilicity, to a certain extent, generally correlated with increase in 
antifungal activity. 
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Table 7.2. log Pa values for all compounds 
studied. 
Cpd 
# 
log P Cpd # log P 
1 2.84 
(2.92) 
3b N/Ab (4.33) 
2a 3.46 
(3.16) 
3c N/Ab (5.34) 
2b 3.62 
(3.32) 
3d N/Ab (7.37) 
2c 4.02 
(3.84) 
3e N/Ab (3.01) 
2d 4.29 
(3.97) 
3f N/Ab (3.54) 
2e 4.70 
(4.67) 
3g N/Ab (3.07) 
2f 3.62 
(2.92) 
3h 3.53 (3.48) 
2g 
4.29 
(4.16) 3i 
N/Ab (3.69) 
2h 4.70 
(4.86) 
3j N/Ab (4.21) 
2i 5.12 
(5.13) 
3k N/Ab (3.29) 
2j 4.44 
(4.41) 
3l N/Ab (3.79) 
2k 3.21 
(3.62) 
3m N/Ab (4.30) 
2l 4.46 
(4.53) 
3n N/Ab (4.80) 
2m 2.84 
(2.68) 
3o N/Ab (4.80) 
2n 3.40 
(3.53) 
4e N/Ab (2.16) 
2o 4.26 
(3.93) 
4f N/Ab (2.69) 
3a N/Ab 
(3.83) 
4n N/Ab (3.95) 
a Calculated from ChemDraw and from 
Molinspiration (in parenthesis). b Indicates 
that ChemDraw did not provide a log P 
value. 
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7.3.2. Time-kill curves 
To gain insight for the rate of fungicidal activity of our compounds, we performed time-kill 
assays with ebsulfur (2a) and our most potent analogue 3a (Figure 7.2). We then compared 
the results of our compounds to ebselen (1) and the clinically potent and widely used 
antifungal agent AmB, which also served as our positive control. We selected ebsulfur (2a) 
because we previously observed that this compound was bacteriostatic and we pondered 
whether a similar fungistatic effect would be observed.266 We commenced our study by dosing 
all of our tested compounds (ebselen (1), ebsulfur (2a), 3a, and AmB) at 1× their respective 
MIC values (Figure 7.2A). For ebsulfur (2a), although the MIC value for ebsulfur (2a) against 
strain B was greater than 12.5 µg/mL, we decided to test this compound at 12.5 µg/mL 
because we were concerned that higher concentration may lead to precipitation of the 
compounds. We observed that ebselen (1) (at 12.5 µg/mL) displayed potent fungicidal activity 
leading to complete fungal cell death at the 6-h mark, which was even quicker than AmB (at 
3.9 µg/mL). Our ebsulfur (2a) (at 12.5 µg/mL) and 3a (at 0.39 µg/mL) displayed fungistatic 
effects. However, at their 1× MIC, ebsulfur (2a) and 3a were not able to completely inhibit 
fungal re-growth even after 24 h incubation. Hence, we decided to double the doses of our 
compounds for our additional time-kill analysis experiments.  
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Figure 7.2. Time-kill analysis of ebselen (1) (black inverted triangles), ebsulfur (2a) (white 
triangle), compound 3a (black squares) at 0, 3, 6, 9, 12, and 24 h. A. Cultures were exposed to 
compounds at 1× their respective MIC values. B. Cultures were exposed to compounds at 2× 
their respective MIC values. C. Cultures were exposed to compounds at 4× their respective 
MIC values. Untreated culture (black circles) was used as the negative control and AmB 
(white circles) was used the positive control. Data was combined from two independent 
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experiments. The first experiment was conducted with the standard 1× and 2× respective MIC 
values. The second experiment was needed to supplement the analysis and was performed at 
4× their respective MIC values. Each data points were collected in duplicates. The error bars 
were reported as ± standard deviations. 
 
At 2× MIC (Figure 2B), Ebselen (1) (at 25 µg/mL) and AmB (at 7.8 µg/mL) were completely 
fungicidal from 3 and 6 h, respectively. At the higher concentration, ebsulfur (2a) (25 µg/mL) 
interestingly became fungicidal. Conversely, compound 3a (at 0.78 µg/mL) remained 
fungistatic with a 4-log reduction of fungal cells at approximately the 24-h mark. We were 
very intrigued by this result and pondered whether fungicidal and fungistatic effects could be 
concentration dependent. Thus, we further increase the concentration of compound 3a to 4× 
its MIC value with the hope that 3a would also switch to the fungicidal mode. We performed 
the assay and actually found that 3a at 4× MIC (at 1.56 µg/mL) still remained fungistatic 
(Figure 2C). These findings suggested that in order for ebsulfur (2a) and compound 3a to be 
effective antifungal agents, they would have to be dosed at ≥2× their respective MIC values 
while albeit at high concentration, ebselen (1) could still be effective at 1× MIC. 
 
Based on the time-kill curves, we observed that ebselen (1) and ebsulur (2a) were fungicidal 
at high concentrations (12.5 and 25 µg/mL or 45.6 and 110 µM, respectively) and our best 
compound from the MIC determination assays, 3a was fungistatic at 0.78 and 1.56 µg/mL 
(3.5 and 7.0 µM), which were much lower than the fungicidal concentrations of the other 
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compounds. Fungistatic property does not necessarily mean that compound 3a is not as good 
as ebselen (1) and ebsulfur (2a) as an antifungal agent because the most popular antifungal 
compound (FLC) is also fungistatic. This data, however, gave us hints that compound 3a may 
potentially not be suitable for some specific fungal infections that absolutely require 
fungicidal effect for clinical efficacy such as cryptococcal meningitis. Additionally, the fact 
that these benzisothiazolinone compounds exhibit fungicidal effect at high concentrations may 
mean that they target a different fungal enzymatic pathway when the concentrations are high. 
 
7.3.3. Hemolytic assay 
Although we were excited to discover new analogues with improved antifungal activity 
relatively to ebselen (1), we pondered whether this cytotoxic property could be more selective 
towards fungal cells than mammalian cells. We were cautiously optimistic that our analogues 
would still retain some of the good tolerability properties that were highly desirable in the 
original ebselen (1) scaffold. Previously, our lab studied aminoglycoside analogues with linear 
alkyl chains and reported that aminoglycoside analogues with linear alkyl chains could 
potentially be toxic to red blood cells (RBCs) as these RBCs have ultra thin cell membrane 
and thus, are prone to hemolysis.165 Therefore, we decided to evaluate some of our compounds 
with linear alkyl chains, the C5 analogue 3a and the C8 analogue 3c against murine red blood 
cells (mRBCs) and compare their results to ebselen (1) (Figure 7.3). Although the C6 analogue 
3b was also one of our top analogues, we did not test this analogue because its chain length 
(C6) was extremely similar structurally to the C5 compound 3a. We also excluded the C12 
analogue 3d because it was completely inactive against fungal strains. Ebsulfur (2a) was 
chosen because we were interested to verify that the linear alkyl chain would be a required 
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feature for hemolysis. Most of the compounds (ebselen (1), ebsulfur (2a), and compound 3c) 
tested did not show any significant hemolytic activity until 15.6 µg/mL (56.9 µM for ebselen 
(1), 68.6 µM for ebsulfur (2a), and 59.2 µM for 3c). At first glance, compound 3a appeared to 
be very hemolytic at approximately 3.9 µg/mL (17.6 µM). However, it should be noted that 
this compound showed remarkable potency against fungal cells. The MIC values of 
compound 3a were at least 5- to 195-fold lower than the hemolytic concentrations for 
Candida and Aspergillus strains, respectively. Thus, we could observe that there was still 
some cytocidal selectivity towards fungal cells. Initially, we expected the C8 analogue 3c to be 
more hemolytic because analogues with longer linear alkyl chains tend to perforate cell 
membranes easily. Thus, it was unexpected to find the C5 analogue 3a to be hemolytic. This 
observation led us to speculate that the hemolytic activity was not due to disruption of the cell 
membrane of the mRBCs, but was simply an artifact of general mammalian cytotoxicity. This 
prompted us to evaluate our three best compounds 3a, 3b, and 3g (in terms of their overall 
antifungal activity against both Candida and Aspergillus strains) against two different 
mammalian cell lines, which have normal cell membranes and are not susceptible to 
membrane-lytic compounds. 
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Figure 7.3. Hemolytic assays of ebselen (1), ebsulfur (2a), compound 3a, and compound 3c 
against murine red blood cells (mRBCs). Ebselen (1), ebsulfur (2a), compound 3a, and 
compound 3c are represented as black circles, white circles, inverted orange triangle, and 
upright white triangle, respectively. The data points of ebselen (1), ebsulfur (2a), and 
compound 3c were previously present in one of our publications and are used here for 
comparison.266 Each data point was collected in duplicates. The error bars were reported as ± 
standard deviations. 
 
7.3.4 Mammalian cytotoxicity assay 
Compounds 3a, 3b, and 3g were evaluated for their cytotoxicity against HEK293 and J774 
cell lines using a resazurin assay.20 The concentration of DMSO used in the cytotoxicty assay 
is 0.1%, which was ensured to not demonstrate any DMSO-related toxicity to the cells. We 
compared the percentage of surviving cells treated with our analogues versus the percentage 
of surviving cells treated with ebselen (1) (Figure 7.4). Against the HEK293 cell line (Figure 
7.4A), we noticed that all of our analogues (3a, 3b, and 3g) were slightly more toxic but 
overall, quite comparable to ebselen (1) at all concentrations tested. Overall, for all the tested 
compounds (ebselen (1), 3a, 3b, and 3g) the IC50 values were greater than10 µg/mL (Figure 
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7.4A). This corresponds to IC50 values of 36.5 µM for ebselen (1), 45.2 µM for 3a, 42.5 µM 
for 3b, and 48.2 µM for 3g. We verified that the cytotoxicity data of ebselen (1) found in our 
study was fairly consistent with other reported in vitro mammalian cytotoxicity studies of 
ebselen (1).274-275 Given the good tolerability of ebselen (1) during clinical trials, it was 
perplexing to us ebselen (1) displayed some in vitro cytotoxicity. The HEK293 cell line was 
chosen because we were interested to determine whether our compounds could potentially 
cause kidney injury. The kidney is a highly perfused organ and comes in contact with many 
compounds due to renal excretion. Thus, many compounds such as AmB are highly 
nephrotoxic and cause great burden to patients with compromised renal function.  
 
Next, we evaluated our compounds against J774 (Figure 7.4B), a murine macrophage cell 
line. This cell line was selected because macrophages are the first-line of defense against 
fungal infection and we were hopeful that our compounds would not interfere with the 
survival of host macrophages. Against the J774 cell line, we observed a trend similar to the 
HEK293 cell line and found that our analogues (3a and 3b) were slightly more toxic but still 
comparable to ebselen (1) with IC50 values approximately at 10 µg/mL. It was interesting that 
compounds 3g actually did not show any toxicity at all up to 5 µg/mL (24.1 µM). Typically, 
the difference between the toxic dose in mammalian cells and the fungal MIC value should be 
at least 10-fold. The fact that this was the case for our most potent antifungal compounds is 
highly encouraging. 
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We acknowledge that there are concerns in the literature regarding the highly reactive 
benzisothiazolinone moiety of the ebsulfur (2a) scaffold, which possibly explains the toxicity 
effects observed against mammalian cell lines.276 This concern is valid considering that the 
parent compound ebselen (1) has also been found to target different proteins.265 However, we 
argue that this scaffold still merits further consideration as a potential antifungal candidate 
based on two particular reasons. First, since many potent antifungal compounds are only 
available intravenously, there is currently a dire clinical need for orally active antifungals to 
assist the azoles as an alternative option for step-down therapy.221 These azoles often 
complicate drug dosing due to interactions with the metabolism of many drugs and have 
experienced an increased rate of resistance.277-278, 279 The ebsulfur analogues would most likely 
be orally active due to its similarity to ebselen (1), which was successfully administered 
orally.168, 171 Secondly, while we are also concerned about the high reactivity of the 
benzisothiazolinone moiety towards non-specific cysteine residues, ebselen (1) with the 
benzisoselenazolinone moiety has been shown to be well-tolerated during clinical trials. There 
are also examples of other clinically successful small-molecule drugs with highly reactive 
pharmacophores within the FDA-approved chemical space. Some of these compounds are 
penicillin, fosfomycin, or bendamustine.280 Compounds 3a and 3b displayed MIC values 
against Candida strains at 780 ng/mL and Aspergillus strains at ≤20 ng/mL, which are much 
lower than their IC50 values against mammalian cells. This could potentially be due to the fact 
that 3a and 3b may have a fungal-specific mechanism of action at lower concentrations. To 
gain insights on the mechanism of action, we decided to first look at ROS induction of these 
compounds. 
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Figure 7.4. Mammalian cell cytotoxicity of ebselen (1) (yellow bars), and compounds 3a 
(orange bars), 3b (turquoise bars), and 3g (purple bars) against A. HEK 293 cell line and B. 
J774 cell line,.Triton-X 100® (1%, v/v) was used as the positive control (data not shown). 
Each data point was collected in quadruplicates. The error bars were reported as ± standard 
deviations. 
 
7.3.5. ROS production 
Recently, we showed that ebselen (1) and our ebsulfur analogues with antibacterial activity 
were highly correlated with ROS production in MRSA bacterial cells.266 Another group 
independently reported that ebselen (1) induced ROS-mediated cytotoxicity in Saccharomyces 
cerevisiae via inhibition of glutamate dehydrogenase.281 Thus, we sought to determine 
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whether our analogues would also induce ROS against C. albicans via inhibition of the C. 
albicans glutamate dehydrogenase. Ebselen (1), ebsulfur (2a), and compound 3a were tested 
against C. albicans ATCC 10231 cells (strain A) at 1× and 2× their respective MIC values. 
2',7'-dichlorodihydrofluorescin diacetate (DCFH-DA) was then used to detect and visualize 
ROS production (Figure 7.5). As a positive control, we treated cells with H2O2, which is an 
inducer of hydroxyl radical formation. After 1-h treatment, we found that all the compounds 
tested and the positive control were highly fluorescent, which indicated ROS induction. We 
also compared the samples that were treated with different doses of compounds (1× and 2× 
their respective MIC values) and observed that the amount ROS induction could potentially be 
concentration dependent. It is certainly possible that this ROS induction in C. albicans spp. is 
due to inhibition of C. albicans glutamate dehydrogenase as we hypothesized. However, this 
finding still does not rule out other potential drug targets such as fungal enzymes responsible 
for ROS regulation or it is simply a downstream secondary effect as the ebselen (1) and 
ebsulfur (2a) scaffolds inhibit enzymes that are unrelated to ROS generation. Assays to 
determine the specific molecular target(s) of our best compound, 3a, are ongoing and will be 
the subject of future reports. 
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Figure 7.5. ROS induction assay of ebselen (1), ebsulfur (2a), and compound 3a against C. 
albicans ATCC 10231 (strain A). Candida cells were treated with no drug (negative control), 
1 mM of H2O2 (positive control), or ebselen, 2a, and 3a at their 1× and 2× respective MIC 
values for 1 h at 37 °C. DCFH-DA (40 µg/mL) was added to detect ROS and the samples 
were analyzed using a Zeiss Axovert 200M fluorescence microscope. 
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7.4. CONCLUSION  
In summary, we expanded our knowledge of this scaffold in terms of the antifungal activity 
against a panel of clinically relevant Candida and Aspergillus strains. In light of our SAR 
analysis, we identified that the addition of flexible chemical moieties to the 1,2-
benzisothiazol-3(2H)-one scaffold is a viable strategy to generate analogues with potent 
antifungal activities. Interestingly, the majority of our compounds displayed comparable or, in 
most cases, enhanced antifungal activities against all fungal strains when compared to ebselen 
(1) and the reference drugs used in this study. Although, our best compound (3a) exhibited 
some hemolytic activity, its effect on nucleated mammalian cells was found to be in the 
acceptable range considering their antifungal efficacies. Finally, our preliminary study on 
mechanism of action indicated that the growth inhibitory effect of fungi by these compounds 
might be due to the elevating concentration of ROS in the yeast cells. However, the biological 
activities of the ebselen (1) and ebsulfur (2a) scaffolds are complex due to their general 
electrophilicity. An extensive study is required to identify the specific mode of action against 
fungal strains. Once the mechanism of action is established, we feel that this scaffold would 
have merit for further evaluation in a fungal infected murine model. 
 
7.5. MATERIALS AND INSTRUMENTATION 
7.5.1. Antifungals and equipment 
The antifungal agents amphotericin B (AmB), fluconazole (FLC), itraconazole (ITC), 
posaconazole (POS), and voriconazole (VOR) were obtained from AK Scientific (Union City, 
CA, USA) and used without further purification. AmB, FLC, ITC, POS, and VOR were 
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dissolved in DMSO at a final concentration of 5 mg/mL. All these antifungal agent stocks 
were stored at -20 °C. Fungal MIC determination experiments were performed using untreated 
96-well plates (Corning). Cells were counted either by using a hemocytometer (Hausser 
Scientific, Horsham, PA, USA) or by measuring optical density at attenuance of 600 nm 
(OD600) by using a Genesys 20 spectrophotometer (Thermo Scientific, Waltham, MA, USA). 
Spectrophotometric and colorimetric measurements in 96-well plates were performed using a 
SpectraMax M5 spectrometer (Molecular Devices, Sunnyvale, CA, USA). 
 
7.5.2. Fungal strains 
The yeast strains Candida albicans ATCC 10231 (strain A), C. albicans ATCC 64124 (strain 
B), and C. albicans ATCC MYA-2876(S) (strain C) were kindly provided by Dr. Jon Y. 
Takemoto (Utah State University, Logan, UT, USA). C. albicans ATCC MYA-90819(R) 
(strain D), C. albicans ATCC MYA-2310(S) (strain E), C. albicans ATCC 1237(R) (strain F), 
C. albicans ATCC MYA-1003(R) (strain G), Candida glabrata ATCC 2001 (strain H), 
Candida krusei ATCC 6258 (strain I), and Candida parapsilosis ATCC 22019 (strain J) were 
obtained from the American Type Culture Collection (ATCC, Manasas, VA, USA). The (S) 
and (R) indicate that ATCC reports these strains to be susceptible (S) and resistant (R) to ITC 
and FLC. The filamentous fungal strains Aspergillus flavus ATCC MYA-3631 (strain K), and 
Aspergillus terreus ATCC MYA-3633 (strain M) were also obtained from the American Type 
Culture Collection (ATCC, Manasas, VA, USA). Aspergillus nidulans ATCC 38163 (strain L) 
was kindly provided by Dr. Jon S. Thorson (University of Kentucky, Lexington, KY, USA), 
respectively. Yeast strains were cultured at 35 °C. Filamentous fungal strains were cultured at 
25 °C and the spores were harvested. All fungal strains were cultured in RPMI 1640 medium 
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(catalog # R6504, Sigma-Aldrich Chemical Co., St. Louis, Mo.) buffered to pH 7.0 with 0.165 
M morpholinepropanesulfonic acid (MOPS) buffer (Sigma-Aldrich Chemical Co.).  
 
7.5.3. Mammalian cells 
The human embryonic kidney cell line HEK-293 (ATCC CRL-1573) and the murine 
macrophage cell line J774A.1 (ATCC TIB-67) were kindly provided by Dr. Matthew S. 
Gentry and Dr. David J. Feola (University of Kentucky, Lexington, KY, USA), respectively. 
The HEK-293 cell line was grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (ATCC, 
Manasas, VA, USA) with 10% fetal bovine serum (FBS) (ATCC, Manasas, VA, USA) and 1% 
Pen/Strep (ATCC, Manasas, VA, USA). The J774A.1 cell line was grown under the same 
conditions, except that the medium used was a different type of DMEM (catalog# 30-2002, 
ATCC, Manasas, VA, USA). The HEK-293 cell line was passaged by trypsinization with 
0.05%-trypsin-0.53 mM EDTA (ATCC, Manasas, VA, USA). The J774A.1 cell line was 
passaged mechanically by cell scrapers (ATCC, Manasas, VA, USA). Cell confluency was 
observed by using a Nikon Eclipse TS100 microscope (Minato, Tokyo, Japan). 
 
7.6. METHODS 
7.6.1. Determination of MIC values against fungal strains 
The MIC values against fungal strains were determined based on a previously published 
protocol.188 MIC values for ebsulfur (2a) analogues against fungal cells were evaluated in 96-
well plates as described in the CLSI document M27-A3 with minor modifications.282 Some of 
the fungal strains, such as C. albicans ATCC 64124 (strain B) tend to produce pseudohyphae 
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(filaments) in RPMI 1640 medium, which was found to hinder cell counting when using a 
hemocytometer. Therefore, potato dextrose broth (PDB) was used to grow the yeast inocula of 
all strains tested, which were later diluted in RPMI 1640 medium to perform determination of 
MIC values. Minor modifications included growing yeast cells in PDB for 24-48 h at 35 °C at 
200 rpm, diluting in RPMI 1640 medium to a concentration of 1 × 106 cells/mL (as 
determined by using a hemocytometer or an OD600 of 0.12) and using a final inoculum size of 
5 × 103 CFU/mL for all the assays. The tested compounds (10 mg/mL) were diluted to the 
working stocks (500 µg/mL) by addition of DMSO. Two-fold serial dilution of the working 
stocks was prepared by addition of RPMI 1640 medium (100 µL) and cell suspension (100 µL) 
to 96-well microtiter plate to achieve final drug and inoculum concentrations ranging from 
12.5-0.02 µg/mL and 5 × 103 CFU/mL, respectively. Plates were incubated for 48 h at 35 °C. 
The MIC values for all tested compounds studied were defined as the lowest drug 
concentration that inhibits the visible growth of fungal strains after a 48-h incubation period. 
MIC assays for the spore-forming filamentous fungi, such as strain A. flavus ATCC MYA-
3631 (strain K), were performed in a similar fashion. The filamentous fungal strains were first 
cultured at 25 °C on potato dextrose agar (PDA) plates for 3-5 days or until confluent. We 
collected the spores by washing the surface of the agar plates with ddH2O (5 mL) and then 
isolated the spores by gravity filtration (the spores are H2O soluble). The spores were then 
counted by using a hemocytometer and added to the MIC assays to achieve a final 
concentration of 5 × 103 cells/mL. Researchers working with spores should wear a facemask 
to prevent spore inhalation. These MIC data are presented in Table 7.1. 
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7.6.2. Mammalian cytotoxicity assays 
Mammalian cytotoxicity assays were performed as previously described with minor 
modifications (Figure 7.4).188 The HEK-293 and J774A.1 cell lines were grown in various 
Dulbecco’s Modified Eagle’s Medium (DMEM) (see mammalian cell lines section above) 
with 10% fetal bovine serum (FBS) and 1% Pen/Strep at 37 °C with 5% CO2. The confluent 
cells were either trypsinized with 0.05%-trypsin-0.53 mM EDTA (HEK-293 cell line) or 
mechanically removed by cell scrapers (J774A.1 cell line). The cells were transferred into 96-
well microtiter plates at a density of 1 × 104 cells/mL (HEK-293 cell line) or 2 × 104 cells/mL 
(J774A.1 cell line) and were grown for 16 h overnight. The following day, the media were 
replaced by fresh media (100 µL) containing no compound (negative control), triton-X 100® 
(positive control) (1%, v/v), and serially diluted ebselen (1), 3a, 3b, and 3g at final 
concentrations of 10-0.02 µg/mL. Every well contained 0.1% DMSO, which is not toxic 
against these mammalian cell lines. The cells were incubated with tested compounds for 
another 24 h at 37 °C with 5% CO2. Cell survival was assessed by resazurin assay. Each well 
was treated with resazurin (10 µL of a 25 mg/L solution) for 6 h. Live cells produced the 
highly fluorescent pink dye resorufin, which was detected at λ560 absorption and λ590 emission 
by a SpectraMax M5 plate reader. Dead cells remain purple/blue. The percentage of survival 
rate was calculated by using the following formula: [(test value)/(control value) × 100]. The 
control value is obtained from the wells, which have cells and resazurin, but no tested 
compounds. 
 
 340 
7.6.3. Assay for reactive oxygen species (ROS) production 
ROS production assay was performed as previously described with minor modifications.192, 266 
The 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) probe was used to measure the 
production of ROS in fungal cells after treatment of cells with ebselen, ebsulfur (2a), and 3a. 
Once entering the cells, the DCFH-DA probe is first hydrolyzed to the non-fluorescent 2',7'-
dichlorodihydrofluorescein (DCFH) by cellular esterases. After that, DCFH is oxidized to the 
highly fluorescent 2',7'-dichlorofluorescein (DCF) by intracellular ROS. A colony of C. 
albicans ATCC 10231 (strain A) was used to inoculate 5 mL of PDB in a Falcon tube and 
grown overnight at 35 °C at 200 rpm. In the morning, we diluted the culture by addition of 
fungal cells (200 µL) to RPMI 1640 medium (800 µL). After that, we added the newly diluted 
cell suspension (100 µL) to the RPMI 1640 medium (900 µL) containing no drug (negative 
control) or ebselen, 2a, and 3a, at their 1x and 2x MIC values and incubated for 1 h at 37 °C. 
Glass slides (with 10-15 of each mixture) were prepared and observed in bright field and 
fluorescence modes (FITC filter set, λex = 488 nm and λem = 512 nm excitation) using a Zeiss 
Axovert 200M fluorescence microscope (Figure 7.5). 
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Chapter 8 
 
Ongoing research 
 
8.1. EXPANSION OF THE THIENO[2,3-D]PYRIMIDINE LIBRARY 
Chapter 4 introduced the thieno[2,3-d]pyrimidine library. We were able to further expand this 
library of compounds and generated a series of analogues. The 4-aminopyrimidine adjacent to 
the thiophene ring was replaced by a pyrimidone. The following molecules were prepared and 
added to our library using the protocol that we previously established in Chapter 4 (Figure 
8.1). These compounds will help us further understand the SAR of this scaffold against Eis as 
well as their unique toxicity activity against Mtb cells. 
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Figure 8.1. Synthetic scheme to expand the thieno[2,3-d]pyrimidine library.  
 
8.1.1. Preparation of compounds 3-4 
Synthesis of compounds 3-4 was done following a modified published protocol.155 Ethyl 
cyanoacetate (1 eq) and sulfur (1 eq) were added to a solution of a cycloalkyl ketone (1 eq) in 
EtOH (30 mL). Morpholine (5 mL) was added to the mixture. After stirring at rt for 1-15 h, 
the reaction was quenched by the addition of ddH2O. The product was filtered, washed with 
ddH2O, and dried to afford the desired product. 
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Preparation of compound 3. The known compound 3 was prepared as 
described above. Ethyl cyanoacetate (4.74 mL, 44.6 mmol), sulfur (1.43 g, 
59.5 mmol), 4-methyl cyclohexanone (compound 1) (5.47 mL, 44.6 mmol), and morpholine 
(5 mL) in EtOH (30 mL) were used to afford compound 3 (10.6 g, quant.) as a yellow solid 
after reacting for 15 h. This product was without any further purification: 1H NMR (400 MHz, 
(CDCl3) δ 5.90 (br s, 2H), 4.25 (q, J = 7.2 Hz, 2H), 2.88-2.81 (m, 1H), 2.62-2.49 (m, 2H), 
2.15-2.07 (m, 1H), 1.88-1.77 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H), 1.02 (d, J = 4.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 166.3, 162.0, 132.3, 117.4, 105.9, 59.6, 32.9, 31.3, 29.7, 26.9, 
21.7, 14.7. 
 
Preparation of compound 4. The known compound 4 was prepared as 
described above. Ethyl cyanoacetate (4.20 mL, 39.6 mmol), sulfur (1.27 g, 
39.6 mmol), 4-ethyl cyclohexanone (compound 2)  (5.60 mL, 39.6 mmol), and morpholine (5 
mL) in EtOH (30 mL) were used to afford compound 4 (8.0 g, 80%) as a yellow solid after 
reacting for 15 h. This product was purified via recrystallization in i-OH: 1H NMR (400 MHz, 
CDCl3) δ 5.89 (br s, 2H), 4.24 (q, J = 7.2 Hz, 2H), 2.89-2.82 (m, 1H), 2.60-2.50 (m, 2H), 
2.16-2.08 (m, 1H), 1.90-1.83 (m, 1H), 1.65-1.58 (m, 1H), 1.42-1.26 (m, 3H), 1.31 (t, J = 7.2 
HZ, 3H), 0.93 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.1, 161.7, 132.4, 117.3, 
105.6, 59.3, 36.3, 30.5, 28.9, 28.7, 26.8, 14.4, 11.5. 
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8.1.2. Preparation of compounds 7-8 
Synthesis of compounds 5-6 was done following a published protocol.155 Benzoyl 
isothiocyanate (1 eq) was added to a solution of a thiophene derivative (1 eq) in anhydrous 
1,4-dioxane (20 mL). After stirring at rt for 1-3 h, the product was filtered and washed with a 
4:1/Hexanes:EtOAc mixture to afford the desired product, which was used in the next step 
without any further purification. 
Synthesis of compounds 7-8 was done following a published protocol.155 2 N NaOH (50 mL) 
was added to a mixture of benzamides (38.3 mmol) in EtOH (70 mL). After refluxing at 
100 °C for 30 min to 2 h, the solution was cooled to rt and then neutralized in an ice bath by 
adding 10% AcOH until the pH reached 7. The resultant precipitate was filtered and washed 
with a 4:1/H2O:EtOH mixture to afford the desired product. 
 
Preparation of compound 7. Compound 7 was prepared as described 
above. 2 N NaOH (50 mL) and compound 5 (5.14 g, 12.8 mmol) in EtOH 
(50 mL) were used to afford compound 7 (2.64 g, 82%) as a yellow solid after refluxing for 2 
h: 1H NMR (400 MHz, (CD3)2SO) δ 13.29 (s, 1H), 12.27 (s, 1H), 2.97-2.90 (m, 1H), 2.78-
2.70 (m, 1H), 2.67-2.55 (m, 1H), 2.28-2.20 (m, 1H), 1.91-1.77 (m, 2H), 1.40-1.25 (m, 1H), 
1.02 (d, J = 6.8 Hz, 3H). 
 
Preparation of compound 8. Compound 8 was prepared as described 
above. 2 N NaOH (50 mL) and compound 5 (5.00 g, 12.0 mmol) in EtOH 
(50 mL) were used to afford compound 7 (1.61 g, 50%) as a yellow solid after refluxing for 2 
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h: 1H NMR (400 MHz, (CD3)2SO) δ 3.07-2.97 (m, 1H), 2.83-2.75 (m, 1H), 2.73-2.60 (m, 1H), 
2.35-2.23 (m, 1H), 2.00-1.90 (m, 1H), 1.75-1.63 (m, 1H), 1.50-1.30 (m, 3H), 0.98 (t, J = 7.2 
Hz, 3H). 
 
8.1.3. Preparation of compounds 9-13 
The synthesis of these compounds was done following a published thiol alkylation protocol.158 
Cs2CO3 (1.1 eq) and TBAI (1 eq) were added to a solution of thieno[2,3-d]pyrimidin-4amines 
(1 eq) in anhydrous DMF and stirred at 80 °C for 30 min. Alkyl halide (1.5 eq) was added, 
and the mixture was heated at 80 °C for an additional 1-4 h. The reaction was cooled to rt and 
quenched by addition of aq. NaHCO3, extracted with EtOAc three times, and washed with 
brine three times. The organic layer was then dried over MgSO4 and evaporated to dryness 
under reduced pressure to give a residue, which was purified by column chromatography to 
afford the desire product. 
 
Preparation of compound 9. Compound 9 was prepared as 
described above. Compound 7 (0.10 g, 0.40 mmol), Cs2CO3 (0.13 g, 
0.40 mmol), TBAI (0.15 g, 0.40 mmol), and 1-(3-
chloropropyl)piperidine monohydrochloride (0.12 g, 0.59 mmol) in anhydrous DMF (8 mL) 
were used to afford compound 9 (103 mg, 69%, Rf 0.48 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a white solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD) δ 3.70-3.45 (m, 
2H), 3.43-3.35 (m, 1H), 3.31 (t, J = 6.8 Hz, 2H), 3.20-3.10 (m, 2H), 2.87-2.75 (m, 3H), 2.40-
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2.25 (m, 4H), 2.15-1.85 (m, 6H), 1.70-1.50 (m, 2H), 1.47-1.35 (m, 2H), 1.07 (d, J = 6.4 Hz, 
3H); 13C NMR (100 MHz, (CD3)2SO) δ 162.7, 158.2, 155.5, 130.2, 129.8, 118.9, 55.1, 52.3, 
32.3, 30.0, 28.8, 27.2, 24.9, 23.9, 23.0, 22.0, 21.2. 
 
Preparation of compound 10. Compound 10 was prepared as 
described above. Compound 7 (0.10 g, 0.40 mmol), Cs2CO3 (0.13 g, 
0.40 mmol), TBAI (0.15 g, 0.40 mmol), and 2-bromo-N-(2-
dimethylaminoethyl)acetamide (0.13 g, 0.53 mmol) in anhydrous DMF (8 mL) were used to 
afford compound 10 (57 mg, 38%, Rf 0.26 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a 
white solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD) δ 4.01 (s, 2H), 3.64 (t, J = 6.0 Hz, 2H), 3.30 
(t, J = 6.0 Hz, 2H), 3.10-3.00 (m, 1H), 2.92 (s, 6H), 2.82-2.66 (m, 2H), 2.34-2.24 (m, 1H), 
1.94-1.84 (m, 2H), 1.44-1.32 (m, 1H), 1.08 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CD3OD) 
δ 171.6, 165.0, 160.4, 155.7, 132.6, 131.7, 120.5, 58.2, 44.0, 36.3, 34.9, 33.8, 31.6, 30.6, 26.3, 
21.8. 
 
Preparation of compound 11. Compound 11 was prepared as 
described above. Compound 7 (0.10 g, 0.40 mmol), Cs2CO3 (0.13 
g, 0.40 mmol), TBAI (0.15 g, 0.40 mmol), and 2-bromo-N-(2-
diethylaminoethyl)acetamide (0.16 g, 0.58 mmol) in anhydrous DMF (8 mL) were used to 
afford compound 11 (42 mg, 26%, Rf 0.51 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as a 
white solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 
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NH4OH (7 mL/L)): 1H NMR (400 MHz, (CD3)2SO) δ 8.40 (br t, 1H), 3.91 (s, 2H), 3.32 (q, J 
= 6.4 Hz, 2H), 3.06-2.96 (m, 1H), 2.90-2.80 (m, 6H), 2.75-2.60 (m, 2H), 2.40-2.20 (m, 1H), 
2.00-1.80 (m, 2H), 1.50-1.30 (m, 1H), 1.07 (t, J = 7.2 Hz, 6H), 1.04 (t, J = 6.4 Hz, 3H); 13C 
NMR (100 MHz, (CD3)2SO) δ 167.7, 163.0, 158.6, 155.7, 130.6, 130.3, 119.4, 50.6, 46.9, 
34.4, 32.7, 30.4, 29.2, 25.3, 21.6, 10.1. 
 
Preparation of compound 12. Compound 12 was prepared as 
described above. Compound 7 (0.10 g, 0.40 mmol), Cs2CO3 
(0.13 g, 0.40 mmol), TBAI (0.15 g, 0.40 mmol), and 2-bromo-N-
[2-(piperidin-1-yl)ethyl]acetamide (0.17 g, 0.59 mmol) in anhydrous DMF (8 mL) were used 
to afford compound 12 (55 mg, 36%, Rf 0.30 in 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)) as 
a white solid after purification by column chromatography (SiO2, 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD) δ 3.90 (s, 2H), 3.49 (t, J = 6.4 Hz, 2H), 
3.12-3.00 (m, 1H), 2.82 (t, J = 6.4 Hz, 2H), 2.80-2.67 (m, 6H), 2.34-2.23 (m, 1H), 1.96-1.82 
(m, 2H), 1.66 (p, J = 5.6 Hz, 4H), 1.50 (p, J = 5.6 Hz, 2H), 1.45-1.30 (m, 1H), 1.07 (d, J = 6.8 
Hz, 3H); 13C NMR (100 MHz, CD3OD) δ 170.0, 163.9, 160.8, 155.8, 130.5, 130.1, 119.0, 
56.7, 53.6, 35.5, 33.5, 32.5, 30.3, 29.2, 25.0, 24.0, 22.5, 20.4. 
 
 Preparation of compound 13. Compound 13 was prepared as 
described above. Compound 8 (0.10 g, 0.38 mmol), Cs2CO3 (0.12 
g, 0.38 mmol), TBAI (0.14 g, 0.38 mmol), and 1-(3-
chloropropyl)piperidine monohydrochloride (0.11 g, 0.56 mmol) in anhydrous DMF (8 mL) 
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were used to afford compound 13 (24 mg, 16%, Rf 0.30 in 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L)) as a white solid after purification by column chromatography (SiO2, 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L)): 1H NMR (400 MHz, CD3OD) δ 3.87 (s, 2H), 
3.41 (t, J = 6.4 Hz, 2H), 3.20-3.05 (m, 1H), 2.90-2.80 (m, 1H), 2.80-2.70 (m, 1H), 2.62 (t, J = 
6.4 Hz, 2H), 2.60-2.50 (m, 4H), 2.40-2.30 (m, 1H), 2.05-1.95 (m, 1H), 1.80-1.65 (m, 1H), 
1.57 (p, J = 5.6 Hz, 4H), 1.53-1.35 (m, 5H), 1.00 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, 
CD3OD) δ 171.8, 166.1, 163.3, 158.1, 132.4, 132.3, 121.0, 58.9, 55.7, 38.0, 37.8, 35.4, 32.4, 
30.3, 30.0, 27.0, 26.4, 25.0. 
 
8.2. EBSELEN ANALOGUES 
Previously, an ebsulfur analogue library was generated in Chapter 5. However, we were also 
interested in comparing those to their selenium counterparts. To complement our previous 
ebsulfur studies, a series of ebselen analogues were generated and biological evaluations of 
these molecules are ongoing (Figure 8.2).  
 
 
Figure 8.2. Synthetic scheme to generate ebselen analogues.  
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a) amines, Et3N, CH2Cl2, 25%-quant. yield; b) CuI, 1,10-phenanthroline, Cs2CO3, KSeCN, 
DMF, 6-13% yield.
15-19 20-23
b 15,20: R = phenyl
16,21: R = benzyl
17,22: R = phenethyl
18,23: R = i-pentyl
19: R = cyclohexyl14
 350 
8.2.1. Preparation of 2-Iodobenzamides (compounds 15-19) 
Preparation of compound 15. To a solution of aniline (0.40 mL, 4.50 mmol) 
and Et3N (0.90 mL, 9 mmol) in anhydrous CH2Cl2 (20 mL), 2-iodobenzoyl 
chloride (0.5 mL, 3.75 mmol) was added dropwise. The product was washed with 1 N HCl 
(50 mL) and a saturated solution of sodium bicarbonate (50 mL) and dried with MgSO4. The 
organic layer was removed in vacuo and the crude product was purified via recrystallization in 
i-PrOH to afford the known compound 15283 (299 mg, 25%) as a pink solid: 1H NMR (400 
MHz, CDCl3) δ 7.89 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 6.8 Hz, 1H), 
7.48-7.30 (m, 4H), 7.20-7.10 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 167.4, 142.3, 140.2, 
137.7, 131.7, 129.3, 128.7, 128.5, 125.1, 120.3, 92.6. 
 
Preparation of compound 16. To a solution of benzylamine hydrochloride 
(0.65 g, 4.50 mmol) and Et3N (0.90 mL, 9 mmol) in anhydrous CH2Cl2 (20 
mL), 2-iodobenzoyl chloride (0.5 mL, 3.75 mmol) was added dropwise. The product was 
washed with 1 N HCl (50 mL) and a saturated solution of sodium bicarbonate (50 mL) and 
dried with MgSO4. The organic layer was removed in vacuo and the crude product was 
purified via recrystallization in i-PrOH to afford the known compound 16283 (639 mg, 51%) as 
a white solid: 1H NMR (400 MHz, CD3OD) δ 7.88 (d, J = 8.0 Hz, 1H), 7.46-7.40 (m, 3H), 
7.30-7.37 (m, 3H), 7.24-7.28 (m, 1H), 7.14 (app. tt, J = 7.6, 2.0 Hz, 1H), 4.53 (s, 2H); 13C 
NMR (100 MHz, CDCl3) δ 169.4, 142.3, 140.1, 137.7, 131.4, 129.0, 128.5, 128.4 (2 carbons), 
127.9, 92.6, 44.4. 
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Preparation of compound 17. To a solution of phenethylamine (1.1 mL, 
9.0 mmol) and Et3N (2.0 mL, 15.0 mmol) in anhydrous CH2Cl2 (20 mL), 
2-iodobenzoyl chloride (1.0 mL mL, 3.75 mmol) was added dropwise. The product was 
washed with 1 N HCl (50 mL) and a saturated solution of sodium bicarbonate (50 mL) and 
dried with MgSO4. The organic layer was removed in vacuo to afford the known compound 
17 (2.6 g, quantitative yield) as a yellow solid: 1H NMR (400 MHz, CD3OD) δ 7.86 (d, J = 
8.0 Hz, 1H), 7.38 (app. tt, J = 8.0, 1.2 Hz, 1H), 7.32-7.24 (m, 4H), 7.24-7.16 (m, 2H), 7.20-
6.80 (m, 1H), 3.56 (t, J = 8.0 Hz, 2H), 2.92 (t, J = 7.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
169.6, 142.4, 140.0, 138.8, 131.2, 129.1, 129.0, 128.9, 128.3, 126.8, 92.6, 41.3, 35.6. 
 
Preparation of compound 18. To a solution of isoamylamine (1.0 mL, 9.0 
mmol) and Et3N (2.0 mL, 15.0 mmol) in anhydrous CH2Cl2 (20 mL), 2-
iodobenzoyl chloride (1.0 mL mL, 3.75 mmol) was added dropwise. The product was washed 
with 1 N HCl (50 mL) and a saturated solution of sodium bicarbonate (50 mL) and dried with 
MgSO4. The organic layer was removed in vacuo to afford the known compound 18 (2.4 g, 
quantitative yield) as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.0 Hz, 1H), 
7.33 (d, J = 3.6 Hz, 2H), 7.10-7.00 (m, 1H), 5.78 (s, 1H), 3.43 (q, J = 7.6 Hz, 2H), 1.69 (nonet, 
J = 6.4 Hz, 1H), 1.49 (q, J = 7.6 Hz, 2H), 0.93 (d, J = 6.4 Hz, 6H); 13C NMR (100 MHz, 
CDCl3) δ 169.5, 142.7, 140.0, 131.1, 128.4, 128.3, 92.6, 38.6, 38.4, 26.1, 22.6. 
 
Preparation of compound 19. To a solution of cyclohexylamine (1.0 mL, 
9.0 mmol) and Et3N (2.0 mL, 15.0 mmol) in anhydrous CH2Cl2 (20 mL), 2-
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iodobenzoyl chloride (1.0 mL mL, 3.75 mmol) was added dropwise. The product was washed 
with 1 N HCl (50 mL) and a saturated solution of sodium bicarbonate (50 mL) and dried with 
MgSO4. The organic layer was removed in vacuo to afford the known compound 19 (836 mg, 
34%) as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.0 Hz, 1H), 7.40-7.28 (m, 
2H), 7.28-7.20 (m, 1H), 5.65 (br s, 1H), 4.02-3.90 (m, 1H), 2.10-2.00 (m, 2H), 1.73 (dp, J = 
13.2, 3.6 Hz, 2H), 1.62 (dp, J = 12.8, 3.6 Hz, 1H), 1.40 (m, 2H), 1.30-1.10 (m, 3H); 13C NMR 
(100 MHz, CDCl3) δ 168.7, 142.8, 139.9, 131.1, 128.4, 128.3, 92.7, 49.1, 33.1, 25.7, 25.0. 
 
8.2.2. Preparation of isoselenazolone compounds (compounds 20-23) 
Preparation of compound 20. The known compound 15 was prepared using 
a previously published protocol.284 Compound 1 (0.299 g, 1 mmol), copper(I) 
iodide (0.18 g, 1 mmol), 1,10-phenanthroline (0.17 g, 1 mmol), cesium carbonate (0.81 g, 2.5 
mmol), and potassium selenocyanate (0.16 g, 1.2 mmol) were suspended in DMF (5 mL). The 
mixture turned red and was heated to 100 °C for 12 h. The reaction mixture was cooled to 
room temperature, diluted with EtOAc (40 mL), and filtered through Celite®. The filtrate was 
washed with cold H2O (2×20 mL) and brine (2×20 mL), and dried with MgSO4. The organic 
layer was removed in vacuo and the crude product was purified via recrystallization from 
EtOH and flash column chromatography (SiO2, 49:1/CH2Cl2:MeOH) to afford the known 
compound 20284 (14 mg, 6%) as colorless needles: 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 
7.6 Hz, 1H), 7.68-7.56 (m, 4H), 7.48-7.43 (m, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.26 (t, J = 7.6 Hz, 
1H). 
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Preparation of compound 21. The known compound 16 was prepared using 
a previously published protocol.284 Compound 2 (0.34 g, 1 mmol), copper (I) 
iodide (0.19 g, 1 mmol), 1,10-phenanthroline (0.18 g, 1 mmol), cesium carbonate (0.70 g, 2 
mmol), and potassium selenocyanate (0.16 g, 1.2 mmol) were suspended in DMF (5 mL). The 
mixture turned red and was heated to 100 °C for 12 h. The reaction mixture was cooled to 
room temperature, diluted with EtOAc (40 mL), and filtered through Celite®. The filtrate was 
washed with cold H2O (2×20 mL) and brine (2×20 mL), and dried with MgSO4. The organic 
layer was removed in vacuo and the crude product was purified via recrystallization from i-
PrOH and flash column chromatography (SiO2, 49:1/CH2Cl2:MeOH then 19:1/CH2Cl2:MeOH) 
to afford the known compound 21284 (38 mg, 13%) as white solid: 1H NMR (400 MHz, CDCl3) 
δ 8.04 (d, J = 7.6 Hz, 1H), 7.91 (d, J = 6.4 Hz, 1H), 7.76-7.64 (m, 2H), 7.39 (d, J = 7.2 Hz, 
2H), 7.36-7.24 (m, 3H), 5.36 (d, J = 14.8 Hz, 1H), 4.60 (d, J = 14.8 Hz, 1H); 13C NMR (100 
MHz, CDCl3, which matches the literature284) δ 168.2, 145.1, 136.7, 134.5, 133.3, 130.8, 
129.3, 129.0, 128.7, 128.6, 126.6, 45.5. 
 
Preparation of compound 22. Compound 17 (0.35 g, 1 mmol), copper (I) 
iodide (0.19 g, 1 mmol), 1,10-phenanthroline (0.18 g, 1 mmol), cesium 
carbonate (0.70 g, 2 mmol), and potassium selenocyanate (0.16 g, 1.2 mmol) were suspended 
in DMF (5 mL). The mixture turned red and was heated to 100 °C for 3 h. The reaction 
mixture was cooled to room temperature, diluted with EtOAc (40 mL), and filtered through 
Celite®. The filtrate was washed with cold H2O (2×20 mL) and brine (2×20 mL), and dried 
with MgSO4. The organic layer was removed in vacuo and the crude product was purified via 
recrystallization from i-PrOH and twice via flash column chromatography (SiO2, 
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49:1/CH2Cl2:MeOH then 19:1/CH2Cl2:MeOH) to afford the known compound 22 (12 mg, 4%) 
as white solid: 1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 3.6 Hz, 
2H), 7.42-7.36 (m, 1H), 7.32-7.20 (m, 6H), 4.09 (t, J = 6.8 Hz, 2H), 3.02 (t, J = 7.2 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 167.1, 148.3, 138.0, 137.9, 131.9, 129.02, 128.96, 128.8, 
128.6, 127.1, 126.7, 126.1, 123.9, 46.2, 36.4. 
 
 
Preparation of compound 23. Compound 18 (0.32 g, 1 mmol), copper (I) 
iodide (0.19 g, 1 mmol), 1,10-phenanthroline (0.18 g, 1 mmol), cesium 
carbonate (0.70 g, 2 mmol), and potassium selenocyanate (0.16 g, 1.2 mmol) were suspended 
in DMF (5 mL). The mixture turned red and was heated to 100 °C for 3 h. The reaction 
mixture was cooled to room temperature, diluted with EtOAc (40 mL), and filtered through 
Celite®. The filtrate was washed with cold H2O (2×20 mL) and brine (2×20 mL), and dried 
with MgSO4. The organic layer was removed in vacuo and the crude product was purified via 
recrystallization from EtOAc and twice via flash column chromatography (SiO2, 
49:1/CH2Cl2:MeOH then 19:1/CH2Cl2:MeOH) to afford the known compound 23 (26 mg, 
10%) as white solid: 1H NMR (400 MHz, CDCl3, which matches the literature285) δ 8.01 (d, J 
= 7.6 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 3.86 
(t, J = 6.8 Hz, 2H), 1.67 (nonet, J = 6.4 Hz, 1H), 1.59 (q, J = 6.4 Hz, 2H), 0.95 (d, J = 6.8 Hz, 
6H); 13C NMR (100 MHz, CDCl3, which matches the literature285) δ 167.3, 137.8, 132.0, 
129.0, 127.9, 126.4, 124.1, 43.4, 39.6, 25.9, 22.7. 
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Chapter 9 
Conclusion and future directions 
9.1. EIS INHIBITORS
 
It has been shown that Eis from Mtb can be successfully inhibited by a variety of small-
molecule scaffolds. During my time working on Eis inhibitors in the Garneau-Tsodikova 
laboratory, we were able to optimize the potency of the following classes of Eis inhibitors 
(Chapters 2, 3, and 4): (1) pyrrolo[1,5-a]pyrazine, (2) 1,2,4-triazino[5,6b]indole-3-thioether, 
and (3) thieno[2,3-d]pyrimidine. Additionally, we found that these inhibitors occupies part of 
the Eis active site and compete for the AG-binding pocket. Uniquely, the 1,2,4-
triazino[5,6b]indole-3-thioether-based inhibitors were found to interact with an additional 
region of the Eis active site that was not previously seen in other Eis inhibitors. In all the 
classes of inhibitors, we found that Eis inhbitors were able to fully or partially recover the 
activity of KAN against an Eis-mediated-KAN-resistant cell line, Mtb K204.  
However, it is still unclear why, in many instances, in vitro Eis inhibition does not perfectly 
correlate with recovery of KAN activity in Mtb K204 cells. Further studies are needed to 
clarify this observation. Additionally, the biology of Eis has not fully been elucidated. First, 
since Eis is expressed and purified as highly stable hexamers, it is unclear whether inhibiting 
one monomer of Eis would be sufficient to shut down the activity of the hexameric enzyme. 
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Further biochemical optimization to separate the hexameric and monomeric forms of Eis 
would be exciting future research topics. Second, various research groups have hypothesized 
that Eis can play an important role in enabling Mtb cells to survive within human 
macrophages. It would be interesting to investigate whether the Eis inhibitors in this 
dissertation can disrupt the ability of Mtb cells to survive in macrophages.  
In order to further investigate the clinical relevance of these inhibitors, we need to understand 
more about the absorption, disposition, metabolism, and excretion (ADME) properties of 
these compounds and their in vivo efficacies. Ongoing collaboration with the laboratory of 
Professor Tanya Parish at the Infectious Diseases Research Institute at University of 
Washington is aimed to explore the PK properties of these molecules. To develop clinically 
relevant AG adjuvants, we must ensure that the PK properties of the adjuvants and KAN are 
completely compatible. Patients must be able to concurrently experience exposures of both 
agents. Thus, future results from this collaboration would be crucial for ADME optimization 
of these inhibitors to compatibly co-administer with KAN or other AGs. Additionally, once 
we successfully identify inhibitors with compatible PK properties, these inhibitors and KAN 
should be evaluated for in vivo efficacies in a MDR-TB mouse model. Since mice exhibit a 
different physiological form of TB granuloma from human granuloma, further in vivo efficacy 
studies in larger animals such as pigs or monkeys will also be necessary before a first-in-
human Phase I trial. 
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9.2. EBSULFUR/EBSELEN ANALOGUES 
In Chapter 5 and 7, we successfully generated and repurposed the ebsulfur scaffold as potent 
MRSA and antifungal agents. The ebsulfur/ebselen scaffold is valuable because ebselen has 
successfully overcome many safety hurdles during clinical trials. However, the mechanism of 
action responsible for their antibacterial and antifungal activities remains to be elucidated. Our 
preliminary results showed that the mechanism might be associated with ROS generation. 
Ongoing research efforts are to generate biotin tagged ebsulfur and ebselen analogues to 
perform pull down experiments with streptavidin to identify the protein targets. Additionally, 
we are hoping to start evaluating these compounds against bacterial and fungal mouse models.  
We are also actively looking for other applications of this scaffold. Recent collaborations with 
Professor Vincent Lee at the University of Maryland revealed that these compounds are active 
against Pseudomonas aeruginosa, an important pathogen in patients with cystic fibrosis, 
through inhibition of alginate production. We are working closely with the Lee laboratory to 
further understand the action of ebsulfur/ebselen analogues on the specific protein target 
within the alginate biosynthesis. 
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APPENDIX A 
Spectroscopic spectra A1-A156 (1H, 13C NMR, and HPLC) for Chapter 2 
Figure A1: 1H NMR spectrum for compound 4 in CDCl3 (400 MHz). 
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Figure A2: 1H NMR spectrum for compound 5 in CDCl3 (400 MHz). 
 
 
Figure A3: 1H NMR spectrum for compound 6 in CDCl3 (400 MHz). 
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Figure A4: 13C NMR spectrum for compound 6 in CDCl3 (100 MHz). 
Figure A5: 1H NMR spectrum for compound 7 in CDCl3 (400 MHz). 
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Figure A6: 13C NMR spectrum for compound 7 in CDCl3 (100 MHz). 
 
 
Figure A7: 1H NMR spectrum for compound 8 in CDCl3 (400 MHz). 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
N
HN
O
F
F
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
N N
 362 
 
Figure A8: 1H NMR spectrum for compound 9 in CDCl3 (400 MHz). 
 
 
Figure A9: 1H NMR spectrum for compound 10 in CDCl3 (400 MHz). 
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Figure A10: 13C NMR spectrum for compound 10 in CDCl3 (100 MHz). 
 
 
Figure A11: 1H NMR spectrum for compound 1a in CDCl3 (400 MHz). 
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Figure A12: 13C NMR spectrum for compound 1a in CDCl3 (100 MHz). 
 
Figure A13: HPLC trace for compound 1a. Rt = 9.94 min. 
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Figure A14: 1H NMR spectrum for compound 1b in (CD3)2SO (500 MHz). 
 
 
Figure A15: 13C NMR spectrum for compound 1b in (CD3)2SO (125 MHz). 
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Figure A16: HPLC trace for compound 1b. Rt = 8.75 min. 
 
 
Figure A17: 1H NMR spectrum for compound 1c in CDCl3 (400 MHz). 
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Figure A18: 13C NMR spectrum for compound 1c in CDCl3 (100 MHz). 
 
 
Figure A19: HPLC trace for compound 1c. Rt = 8.49 min. 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
N N
OBr
F
0
20
40
60
80
100
120
140
160
180
200
0 5 10 15 20 25 30
Time (min)
8.49
m
A
U
 368 
 
Figure A20: 1H NMR spectrum for compound 1d in CDCl3 (400 MHz). 
 
 
Figure A21: 13C NMR spectrum for compound 1d in CDCl3 (100 MHz). 
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Figure A22: HPLC trace for compound 1d. Rt = 8.23 min. 
 
 
Figure A23: 1H NMR spectrum for compound 1e in (CD3)2SO (500 MHz). 
 
 
Figure A23: 13C NMR spectrum for compound 1e in (CD3)2SO (125 MHz). 
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Figure A25: HPLC trace for compound 1e. Rt = 9.66 min. 
 
 
Figure A26: 1H NMR spectrum for compound 1f in (CD3)2SO (500 MHz). 
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Figure A27: 13C NMR spectrum for compound 1f in (CD3)2SO (125 MHz). 
 
 
Figure A28: HPLC trace for compound 1f. Rt = 9.25 min. 
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Figure A29: 1H NMR spectrum for compound 1g in (CD3)2SO (500 MHz). 
 
 
Figure A30: 13C NMR spectrum for compound 1g in (CD3)2SO (125 MHz). 
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Figure A31: HPLC trace for compound 1g. Rt = 8.87 min. 
 
 
Figure A32: 1H NMR spectrum for compound 1h in (CD3)2SO (500 MHz). 
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Figure A33: 13C NMR spectrum for compound 1h in (CD3)2SO (125 MHz). 
 
 
Figure A34: HPLC trace for compound 1h. Rt = 8.66 min. 
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Figure A35: 1H NMR spectrum for compound 1i in (CD3)2SO (500 MHz). 
 
 
Figure A36: 13C NMR spectrum for compound 1i in (CD3)2SO (125 MHz). 
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Figure A37: HPLC trace for compound 1i. Rt = 8.99 min. 
 
0
m
A
U
50
100
150
200
250
300
350
400
0 5 10 15 20 25 30
Time (min)
8.99
 377 
 
Figure A38: 1H NMR spectrum for compound 1j in (CD3)2SO (500 MHz). 
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Figure A39: 13C NMR spectrum for compound 1j in CDCl3 (100 MHz). 
 
 
Figure A40: HPLC trace for compound 1j. Rt = 8.96 min. 
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Figure A41: 1H NMR spectrum for compound 1k in CDCl3 (400 MHz). 
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Figure A42: 13C NMR spectrum for compound 1k in CDCl3 (100 MHz). 
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Figure A43: HPLC trace for compound 1k. Rt = 10.52 min. 
 
 
Figure A44: 1H NMR spectrum for compound 2a in CDCl3 (400 MHz). 
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Figure A45: 13C NMR spectrum for compound 2a in CDCl3 (100 MHz). 
 
 
Figure A46: HPLC trace for compound 2a. Rt = 9.85 min. 
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Figure A47: 1H NMR spectrum for compound 2b in CDCl3 (400 MHz). 
 
 
Figure A48: 13C NMR spectrum for compound 2b in CDCl3 (100 MHz). 
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Figure A49: HPLC trace for compound 2b. Rt = 9.22 min. 
 
 
Figure A50: 1H NMR spectrum for compound 2c in (CD3)2SO (400 MHz). 
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Figure A51: 13C NMR spectrum for compound 2c in (CD3)2SO (100 MHz). 
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Figure A52: HPLC trace for compound 2c. Rt = 9.07 min. 
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Figure A53: 1H NMR spectrum for compound 2d in (CD3)2SO (400 MHz). 
 
 
Figure A54: 13C NMR spectrum for compound 2d in (CD3)2SO (100 MHz). 
 
 
Figure A55: HPLC trace for compound 2d. Rt = 8.39 min. 
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Figure A56: 1H NMR spectrum for compound 2e in (CD3)2SO (400 MHz). 
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Figure A57: 13C NMR spectrum for compound 2e in CDCl3 (100 MHz). 
Figure A58: HPLC trace for compound 2e. Rt = 9.44 min. 
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Figure A59: 1H NMR spectrum for compound 2f in (CD3)2SO (400 MHz). 
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Figure A60: 13C NMR spectrum for compound 2f in (CD3)2SO (100 MHz). 
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Figure A61: HPLC trace for compound 2f. Rt = 8.25 min. 
 
 
Figure A62: 1H NMR spectrum for compound 2g in (CD3)2SO (400 MHz). 
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Figure A63: 13C NMR spectrum for compound 2g in CDCl3 (100 MHz). 
 
 
Figure A64: HPLC trace for compound 2g. Rt = 8.89 min. 
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Figure A65: 1H NMR spectrum for compound 2h in CDCl3 (400 MHz). 
 
 
Figure A66: 13C NMR spectrum for compound 2h in CDCl3 (100 MHz). 
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Figure A67: HPLC trace for compound 2h. Rt = 8.97 min. 
 
 
Figure A68: 1H NMR spectrum for compound 2i in (CD3)2SO (400 MHz). 
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Figure A69: 13C NMR spectrum for compound 2i in CDCl3 (100 MHz). 
 
 
Figure A70: HPLC trace for compound 2i. Rt = 9.52 min. 
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Figure A71: 1H NMR spectrum for compound 2j in (CD3)2SO (400 MHz). 
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Figure A72: 13C NMR spectrum for compound 2j in CDCl3 (100 MHz). 
 
 
Figure A73: HPLC trace for compound 2j. Rt = 9.53 min. 
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Figure A74: 1H NMR spectrum for compound 2k in CDCl3 (400 MHz). 
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Figure A75: 13C NMR spectrum for compound 2k in CDCl3 (100 MHz). 
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Figure A76: HPLC trace for compound 2k. Rt = 9.98 min. 
 
 
Figure A77: 1H NMR spectrum for compound 3a in CDCl3 (400 MHz). 
 
 
Figure A78: 13C NMR spectrum for compound 3a in CDCl3 (100 MHz). 
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Figure A79: HPLC trace for compound 3a. Rt = 8.79 min. 
 
 
Figure A80: 1H NMR spectrum for compound 3d in CDCl3 (400 MHz). 
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Figure A81: 13C NMR spectrum for compound 3d in CDCl3 (100 MHz). 
 
 
Figure A82: HPLC trace for compound 3d. Rt = 9.94 min. 
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Figure A83: 1H NMR spectrum for compound 3h in CDCl3 (400 MHz). 
 
 
Figure A84: 13C NMR spectrum for compound 3h in CDCl3 (100 MHz). 
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Figure A85: HPLC trace for compound 3h. Rt = 9.02 min. 
 
 
Figure A86: 1H NMR spectrum for compound 3k in CDCl3 (400 MHz). 
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Figure A87: 13C NMR spectrum for compound 3k in CDCl3 (100 MHz). 
 
 
Figure A88: HPLC trace for compound 3k. Rt = 9.58 min. 
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Figure A89: 1H NMR spectrum for compound 11 in CDCl3 (400 MHz). 
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Figure A90: 1H NMR spectrum for compound 12 in CDCl3 (400 MHz). 
 
 
Figure A91: 1H NMR spectrum for compound 1a* in CDCl3 (400 MHz). 
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Figure A92: 13C NMR spectrum for compound 1a* in CDCl3 (100 MHz). 
 
 
Figure A93: HPLC trace for compound 1a*. Rt = 8.99 min. 
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Figure A94: 1H NMR spectrum for compound 1b* in CDCl3 (400 MHz). 
 
 
Figure A95: 13C NMR spectrum for compound 1b* in CDCl3 (100 MHz). 
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Figure A96: HPLC trace for compound 1b*. Rt = 8.69 min. 
 
 
Figure A97: 1H NMR spectrum for compound 1c* in CDCl3 (400 MHz). 
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Figure A98: 13C NMR spectrum for compound 1c* in CDCl3 (100 MHz). 
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Figure A99: HPLC trace for compound 1c*. Rt = 9.14 min. 
 
 
Figure A100: 1H NMR spectrum for compound 1d* in CDCl3 (400 MHz). 
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Figure A101: 13C NMR spectrum for compound 1d* in CDCl3 (100 MHz). 
 
 
Figure A102: HPLC trace for compound 1d*. Rt = 8.95 min. 
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Figure A103: 1H NMR spectrum for compound 1e* in CDCl3 (400 MHz). 
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Figure A104: 13C NMR spectrum for compound 1e* in CDCl3 (100 MHz). 
 
 
Figure A105: HPLC trace for compound 1e*. Rt = 9.24 min. 
 
 
Figure A106: 1H NMR spectrum for compound 1f* in CDCl3 (400 MHz). 
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Figure A107: 13C NMR spectrum for compound 1f* in CDCl3 (100 MHz). 
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Figure A108: HPLC trace for compound 1f*. Rt = 8.00 min. 
 
 
Figure A109: 1H NMR spectrum for compound 1g* in CDCl3 (400 MHz). 
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Figure A110: 13C NMR spectrum for compound 1g* in CDCl3 (100 MHz). 
 
 
Figure A111: HPLC trace for compound 1g*. Rt = 8.86 min. 
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Figure A112: 1H NMR spectrum for compound 1h* in CDCl3 (400 MHz). 
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Figure A113: 13C NMR spectrum for compound 1h* in CDCl3 (100 MHz). 
 
 
Figure A114: HPLC trace for compound 1h*. Rt = 8.67 min. 
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Figure A115: 1H NMR spectrum for compound 1i* in CDCl3 (400 MHz). 
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Figure A116: 13C NMR spectrum for compound 1i* in CDCl3 (100 MHz). 
 
 
Figure A117: HPLC trace for compound 1i*. Rt = 9.25 min. 
 
 
Figure A118: 1H NMR spectrum for compound 1j* in CDCl3 (400 MHz). 
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Figure A119: 13C NMR spectrum for compound 1j* in CDCl3 (100 MHz). 
 
 
Figure A120: HPLC trace for compound 1j*. Rt = 9.25 min. 
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Figure A121: 1H NMR spectrum for compound 1k* in CDCl3 (400 MHz). 
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Figure A122: 13C NMR spectrum for compound 1k* in CDCl3 (100 MHz). 
 
 
Figure A123: HPLC trace for compound 1k*. Rt = 9.25 min. 
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Figure A124: 1H NMR spectrum for compound 2a* in CDCl3 (400 MHz). 
 
 
Figure A125: 13C NMR spectrum for compound 2a* in CDCl3 (100 MHz). 
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
N N
OBr
F
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
N N
OBr
F
 428 
 
 
Figure A126: HPLC trace for compound 2a*. Rt = 9.43 min. 
 
 
Figure A127: 1H NMR spectrum for compound 2b* in CDCl3 (400 MHz). 
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Figure A128: 13C NMR spectrum for compound 2b* in CDCl3 (100 MHz). 
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Figure A129: HPLC trace for compound 2b*. Rt = 8.48 min. 
 
 
Figure A130: 1H NMR spectrum for compound 2c* in CDCl3 (400 MHz). 
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Figure A131: 13C NMR spectrum for compound 2c* in (CD3)2SO (100 MHz). 
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Figure A132: HPLC trace for compound 2c*. Rt = 8.59 min. 
 
 
Figure A133: 1H NMR spectrum for compound 2d* in CDCl3 (400 MHz). 
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Figure A134: 13C NMR spectrum for compound 2d* in (CD3)2SO (100 MHz). 
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Figure A135: HPLC trace for compound 2d*. Rt = 9.26 min. 
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Figure A136: 1H NMR spectrum for compound 2e* in CDCl3 (400 MHz). 
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Figure A137: 13C NMR spectrum for compound 2e* in (CD3)2SO (100 MHz). 
 
220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
N N
OBr
Br
F
 437 
 
Figure A138: HPLC trace for compound 2e*. Rt = 8.89 min. 
 
 
Figure A139: 1H NMR spectrum for compound 2f* in CDCl3 (400 MHz). 
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Figure A140: 13C NMR spectrum for compound 2f* in (CD3)2SO (100 MHz). 
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Figure A141: HPLC trace for compound 2f*. Rt = 7.66 min. 
 
 
Figure A142: 1H NMR spectrum for compound 2g* in CDCl3 (400 MHz). 
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Figure A143: 13C NMR spectrum for compound 2g* in CDCl3 (100 MHz). 
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Figure A144: HPLC trace for compound 2g*. Rt = 9.45 min. 
 
 
Figure A145: 1H NMR spectrum for compound 2h* in CDCl3 (400 MHz). 
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Figure A146: 13C NMR spectrum for compound 2h* in CDCl3 (100 MHz). 
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Figure A147: HPLC trace for compound 2h*. Rt = 8.31 min. 
 
 
Figure A148: 1H NMR spectrum for compound 2i* in CDCl3 (400 MHz). 
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Figure A149: 13C NMR spectrum for compound 2i* in CDCl3 (100 MHz). 
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Figure A150: HPLC trace for compound 2i*. Rt = 9.13 min. 
 
 
Figure A151: 1H NMR spectrum for compound 2j* in CDCl3 (400 MHz). 
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Figure A152: 13C NMR spectrum for compound 2j* in CDCl3 (100 MHz). 
 
 
Figure A153: HPLC trace for compound 2j*. Rt = 9.30 min. 
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Figure A154: 1H NMR spectrum for compound 2k* in CDCl3 (400 MHz). 
 
 
Figure A155: 13C NMR spectrum for compound 2k* in CDCl3 (100 MHz). 
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Figure A156: HPLC trace for compound 2k*. Rt = 9.62 min. 
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APPENDIX B 
Spectroscopic spectra B1-B78 (1H, 13C NMR, and HPLC) for Chapter 3 
Figure B1: 1H NMR spectrum for compound 32b in (CD3)2SO. 
Figure B2: 13C NMR spectrum for compound 32b in (CD3)2SO. 
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Figure B3: HPLC trace for compound 32b. Rt = 5.02 min. 
 
 
Figure B4: 1H NMR spectrum for compound 34b in CDCl3. 
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Figure B5: 13C NMR spectrum for compound 34b in CDCl3. 
 
 
Figure B6: HPLC trace for compound 34b. Rt = 7.90 min. 
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Figure B7: 1H NMR spectrum for compound 35b in CDCl3. 
 
 
Figure B8: 13C NMR spectrum for compound 35b in CDCl3. 
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Figure B9: HPLC trace for compound 35b. Rt = 7.38 min. 
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Figure B10: 1H NMR spectrum for compound 36b in CDCl3. 
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Figure B11: 13C NMR spectrum for compound 36b in CDCl3. 
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Figure B12: HPLC trace for compound 36b. Rt = 7.02 min. 
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Figure B13: 1H NMR spectrum for compound 37b in CDCl3. 
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Figure B14: 13C NMR spectrum for compound 37b in CDCl3. 
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Figure B15: HPLC trace for compound 37b. Rt = 7.71 min. 
 
 
Figure B16: 1H NMR spectrum for compound 37h in CDCl3. 
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Figure B17: 13C NMR spectrum for compound 37h in CDCl3. 
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Figure B18: HPLC trace for compound 37h. Rt = 9.49 min. 
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Figure B19: 1H NMR spectrum for compound 38b in CDCl3. 
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Figure B20: 13C NMR spectrum for compound 38b in CDCl3. 
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Figure B21: HPLC trace for compound 38b. Rt = 7.73 min. 
 
0
20
40
60
80
100
120
140
160
180
200
0 5 10 15 20 25 30
Time (min)
7.73
m
A
U
 465 
 
Figure B22: 1H NMR spectrum for compound 39b in CDCl3. 
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Figure B23: 13C NMR spectrum for compound 39b in CDCl3. 
 
 
Figure B24: HPLC trace for compound 39b. Rt = 8.18 min. 
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Figure B25: 1H NMR spectrum for compound 42b in CDCl3. 
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Figure B26: 13C NMR spectrum for compound 42b in CDCl3. 
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Figure B27: HPLC trace for compound 42b. Rt = 10.36 min. 
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Figure B28: 1H NMR spectrum for compound 43b in CDCl3. 
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Figure B29: 13C NMR spectrum for compound 43b in CDCl3. 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
 472 
 
Figure B30: HPLC trace for compound 43b. Rt = 7.41 min. 
 
 
Figure B31: 1H NMR spectrum for compound 43d in CDCl3. 
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Figure B32: 13C NMR spectrum for compound 43d in CDCl3. 
 
 
Figure B33: HPLC trace for compound 43d. Rt = 6.29 min. 
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Figure B34: 1H NMR spectrum for compound 44b in CDCl3. 
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Figure B35: 13C NMR spectrum for compound 44b in CDCl3. 
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Figure B36: HPLC trace for compound 44b. Rt = 8.58 min. 
 
 
Figure B37: 1H NMR spectrum for compound 45b in CDCl3. 
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Figure B38: 13C NMR spectrum for compound 45b in CDCl3. 
 
 
Figure B39: HPLC trace for compound 45b. Rt = 8.11 min. 
 
 
Figure B40: 1H NMR spectrum for compound 46b in CDCl3. 
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Figure B41: 13C NMR spectrum for compound 46b in CDCl3. 
 
 
Figure B42: HPLC trace for compound 46b. Rt = 8.84 min. 
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Figure B43: 1H NMR spectrum for compound 48b in CDCl3. 
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Figure B44: 13C NMR spectrum for compound 48b in CDCl3. 
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Figure B45: HPLC trace for compound 48b. Rt = 8.26 min. 
 
 
Figure B46: 1H NMR spectrum for compound 48c in CDCl3. 
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Figure B47: 13C NMR spectrum for compound 48c in CDCl3. 
 
 
Figure B48: HPLC trace for compound 48c. Rt = 8.55 min. 
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Figure B49: 1H NMR spectrum for compound 48d in CDCl3. 
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Figure B50: 13C NMR spectrum for compound 48d in CDCl3. 
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Figure B51: HPLC trace for compound 48d. Rt = 8.96 min. 
 
 
Figure B52: 1H NMR spectrum for compound 48f in CDCl3. 
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Figure B53: 13C NMR spectrum for compound 48f in CDCl3. 
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Figure B54: HPLC trace for compound 48f. Rt = 9.13 min. 
 
 
Figure B55: 1H NMR spectrum for compound 48h in CDCl3. 
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Figure B56: 13C NMR spectrum for compound 48h in CDCl3. 
 
 
Figure B57: HPLC trace for compound 48h. Rt = 9.35 min. 
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Figure B58: 1H NMR spectrum for compound 49b in CDCl3. 
 
 
Figure B59: 13C NMR spectrum for compound 49b in CDCl3. 
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Figure B60: HPLC trace for compound 49b. Rt = 8.13 min. 
 
 
Figure B61: 1H NMR spectrum for compound 33b in CDCl3. 
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Figure B62: 13C NMR spectrum for compound 33b in CDCl3. 
 
 
Figure B63: HPLC trace for compound 33b. Rt = 8.05 min. 
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Figure B64: 1H NMR spectrum for compound 47b in CDCl3. 
 
 
Figure B65: 13C NMR spectrum for compound 47b in CDCl3. 
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Figure B66: HPLC trace for compound 47b. Rt = 7.92 min. 
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Figure B67: 1H NMR spectrum for compound 60b in CDCl3. 
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Figure B68: 13C NMR spectrum for compound 60b in CDCl3. 
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Figure B69: HPLC trace for compound 60b. Rt = 7.92 min. 
 
0
20
40
60
80
100
120
140
160
180
200
0 5 10 15 20 25 30
Time (min)
7.92
m
A
U
 497 
 
Figure B70: 1H NMR spectrum for compound 61b in CDCl3. 
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Figure B71: 13C NMR spectrum for compound 61b in CDCl3. 
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Figure B72: HPLC trace for compound 61b. Rt = 5.99 min. 
 
 
Figure B73: 1H NMR spectrum for compound 52 in CDCl3. 
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Figure B74: 13C NMR spectrum for compound 52 in CDCl3. 
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Figure B75: HPLC trace for compound 52. Rt = 3.30 min. 
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Figure B76: 1H NMR spectrum for compound 53 in CDCl3. 
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Figure B77: 13C NMR spectrum for compound 53 in CDCl3. 
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Figure B78: HPLC trace for compound 53. Rt = 4.97 min. 
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APPENDIX C 
Spectroscopic spectra C1-C222 (1H, 13C NMR, and HPLC) for Chapter 4 
 
 
Figure C1: Mass spectra for compounds 1a-4b. 
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Figure C2: Mass spectra for compounds 5b-8c. 
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Figure C3: Mass spectra for compounds 1d-4e. 
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Figure C4: Mass spectra for compounds 5e-8f. 
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Figure C5: Mass spectra for compounds 1g-4h. 
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Figure C6: Mass spectra for compounds 5h-8i. 
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Figure C7: 1H NMR spectrum for compound 1a in CD3OD. 
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Figure C8: 13C NMR spectrum for compound 1a in (CD3)2SO. 
 
 
Figure C9: HPLC trace for compound 1a. Rt = 19.29 min. 
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Figure C10: 1H NMR spectrum for compound 2a in (CD3)2SO. 
 
 
Figure C11: 13C NMR spectrum for compound 2a in (CD3)2SO. 
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Figure C12: HPLC trace for compound 2a. Rt = 19.96 min. 
 
 
Figure C13: 1H NMR spectrum for compound 3a in CD3OD. 
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Figure C14: 13C NMR spectrum for compound 3a in CDCl3. 
 
 
Figure C15: HPLC trace for compound 3a. Rt = 20.82 min. 
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Figure C16: 1H NMR spectrum for compound 4a in CD3OD. 
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Figure C17: 13C NMR spectrum for compound 4a in CD3OD. 
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Figure C18: HPLC trace for compound 4a. Rt = 11.72 min. 
 
 
Figure C19: 1H NMR spectrum for compound 5a in CD3OD. 
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Figure C20: 13C NMR spectrum for compound 5a in (CD3)2SO. 
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Figure C21: HPLC trace for compound 5a. Rt = 22.41 min. 
 
 
Figure C22: 1H NMR spectrum for compound 6a in CDCl3. 
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Figure C23: 13C NMR spectrum for compound 6a in CDCl3. 
 
 
Figure C24: HPLC trace for compound 6a. Rt = 15.69 min. 
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Figure C25: 1H NMR spectrum for compound 7a in CDCl3. 
 
 
Figure C26: 13C NMR spectrum for compound 7a in CDCl3. 
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Figure C27: HPLC trace for compound 7a. Rt = 14.85 min. 
 
 
Figure C28: 1H NMR spectrum for compound 8a in (CD3)2SO. 
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Figure C29: 13C NMR spectrum for compound 8a in CDCl3. 
 
 
Figure C30: HPLC trace for compound 8a. Rt = 13.24 min. 
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Figure C31: 1H NMR spectrum for compound 1b in CDCl3. 
 
 
Figure C32: 13C NMR spectrum for compound 1b in (CD3)2SO. 
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Figure C33: HPLC trace for compound 1b. Rt = 20.59 min. 
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Figure C34: 1H NMR spectrum for compound 2b in CDCl3. 
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Figure C35: 13C NMR spectrum for compound 2b in (CD3)2SO. 
 
 
Figure C36: HPLC trace for compound 2b. Rt = 20.21 min. 
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Figure C37: 1H NMR spectrum for compound 3b in CD3OD. 
 
 
Figure C38: 13C NMR spectrum for compound 3b in CDCl3. 
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Figure C39: HPLC trace for compound 3b. Rt = 13.68 min. 
 
 
Figure C40: 1H NMR spectrum for compound 4b in (CD3)2SO. 
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Figure C41: 13C NMR spectrum for compoundd4b in (CD3)2SO. 
 
 
Figure C42: HPLC trace for compound 4b. Rt = 20.74 min. 
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Figure C43: 1H NMR spectrum for compound 5b in CD3OD. 
 
 
Figure C44: 13C NMR spectrum for compound 5b in CDCl3. 
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Figure C45: HPLC trace for compound 5b. Rt = 14.82 min. 
 
 
Figure C46: 1H NMR spectrum for compound 6b in CDCl3. 
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Figure C47: 13C NMR spectrum for compound 6b in CDCl3. 
 
 
Figure C48: HPLC trace for compound 6b. Rt = 16.03 min. 
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Figure C49: 1H NMR spectrum for compound 7b in CDCl3. 
 
 
Figure C50: 13C NMR spectrum for compound 7b in CDCl3. 
 
 
Figure C51: HPLC trace for compound 7b. Rt = 22.54 min. 
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Figure C52: 1H NMR spectrum for compound 8b in CDCl3. 
 
 
Figure C53: 13C NMR spectrum for compound 8b in CDCl3. 
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Figure C54: HPLC trace for compound 8b. Rt = 23.15 min. 
 
 
Figure C55: 1H NMR spectrum for compound 1c in (CD3)2SO. 
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Figure C56: 13C NMR spectrum for compound 1c in (CD3)2SO. 
 
 
Figure C57: HPLC trace for compound 1c. Rt = 24.10 min. 
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Figure C58: 1H NMR spectrum for compound 2c in CD3OD. 
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Figure C59: 13C NMR spectrum for compound 2c in (CD3)2SO. 
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Figure C60: HPLC trace for compound 2c. Rt = 18.58 min. 
 
 
Figure C61: 1H NMR spectrum for compound 3c in CD3OD. 
 
Time (min)
m
A
U
0 5 10 15 20 25
18.58
0
200
400
600
800
1000
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
 542 
 
Figure C62: 13C NMR spectrum for compound 3c in CDCl3. 
 
 
Figure C63: HPLC trace for compound 3c. Rt = 11.81 min. 
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Figure C64: 1H NMR spectrum for compound 4c in CD3OD. 
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Figure C65: 13C NMR spectrum for compound 4c in CDCl3. 
 
 
Figure C66: HPLC trace for compound 4c. Rt = 13.58 min. 
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Figure C67: 1H NMR spectrum for compound 5c in CD3OD. 
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Figure C68: 13C NMR spectrum for compound 5c in CD3OD. 
 
 
Figure C69: HPLC trace for compound 5c. Rt = 14.47 min. 
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Figure C70: 1H NMR spectrum for compound 6c in CD3OD. 
 
 
Figure C71: 13C NMR spectrum for compound 6c in CDCl3. 
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Figure C72: HPLC trace for compound 6c. Rt = 15.83 min. 
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Figure C73: 1H NMR spectrum for compound 7c in CD3OD. 
 
 
Figure C74: 13C NMR spectrum for compound 7c in CDCl3. 
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Figure C75: HPLC trace for compound 7c. Rt = 15.61 min. 
 
 
Figure C76: 1H NMR spectrum for compound 8c in CDCl3. 
 
15.61
Time (min)
0 5 10 15 20 25
m
A
U
0
200
400
600
800
1000
1200
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
 551 
 
Figure C77: 13C NMR spectrum for compound 8c in CDCl3. 
 
 
Figure C78: HPLC trace for compound 8c. Rt = 20.59 min. 
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Figure C79: 1H NMR spectrum for compound 1d in CD3OD. 
 
 
Figure C80: 13C NMR spectrum for compound 1d in (CD3)2SO. 
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Figure C81: HPLC trace for compound 1d. Rt = 23.38 min. 
 
 
Figure C82: 1H NMR spectrum for compound 2d in CD3OD. 
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Figure C83: 13C NMR spectrum for compound 2d in CD3OD. 
 
 
Figure C84: HPLC trace for compound 2d. Rt = 12.45 min. 
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Figure C85: 1H NMR spectrum for compound 3d in CD3OD. 
 
 
Figure C86: 13C NMR spectrum for compound 3d in CDCl3. 
 
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
 556 
 
Figure C87: HPLC trace for compound 3d. Rt = 20.18 min. 
 
 
Figure C88: 1H NMR spectrum for compound 4d in CD3OD. 
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Figure C89: 13C NMR spectrum for compound 4d in CDCl3. 
 
 
Figure C90: HPLC trace for compound 4d. Rt = 24.85 min. 
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Figure C91: 1H NMR spectrum for compound 5d in CD3OD. 
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Figure C92: 13C NMR spectrum for compound 5d in CD3OD. 
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Figure C93: HPLC trace for compound 5d. Rt = 22.53 min. 
 
 
Figure C94: 1H NMR spectrum for compound 6d in CDCl3. 
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Figure C95: 13C NMR spectrum for compound 6d in CDCl3. 
 
 
Figure C96: HPLC trace for compound 6d. Rt = 15.56 min. 
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Figure C97: 1H NMR spectrum for compound 7d in CDCl3. 
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Figure C98: 13C NMR spectrum for compound 7d in CDCl3. 
 
 
Figure C99: HPLC trace for compound 7d. Rt = 14.85 min. 
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Figure C100: 1H NMR spectrum for compound 8d in CDCl3. 
 
 
Figure C101: 13C NMR spectrum for compound 8d in CDCl3. 
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Figure C102: HPLC trace for compound 8d. Rt = 22.80 min. 
 
Time (min)
0 5 10 15 20 25
m
A
U
0
200
400
600
800
1000
8d_HXN-1-89
22.80
 566 
 
Figure C103: 1H NMR spectrum for compound 1e in CD3OD. 
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Figure C104: 13C NMR spectrum for compound 1e in (CD3)2SO. 
 
 
Figure C105: HPLC trace for compound 1e. Rt = 20.80 min. 
 
 
Figure C106: 1H NMR spectrum for compound 2e in CDCl3. 
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Figure C107: 13C NMR spectrum for compound 2e in (CD3)2SO. 
 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
Time (min)
0 5 10 15 20 25
m
A
U
0
200
400
600
800
1000
21.48
2e_HXN-1-97
 569 
Figure C108: HPLC trace for compound 2e. Rt = 21.48 min. 
 
 
Figure C109: 1H NMR spectrum for compound 3e in CD3OD. 
 
 
Figure C110: 13C NMR spectrum for compound 3e in CDCl3. 
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Figure C111: HPLC trace for compound 3e. Rt = 13.03 min. 
 
 
Figure C112: 1H NMR spectrum for compound 4e in (CD3)2SO. 
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Figure C113: 13C NMR spectrum for compound 4e in (CD3)2SO. 
 
 
Figure C114: HPLC trace for compound 4e. Rt = 11.84 min. 
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Figure C115: 1H NMR spectrum for compound 5e in CDCl3. 
 
 
Figure C116: 13C NMR spectrum for compound 5e in CDCl3. 
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Figure C117: HPLC trace for compound 5e. Rt = 14.22 min. 
 
 
Figure C118: 1H NMR spectrum for compound 6e in CDCl3. 
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Figure C119: 13C NMR spectrum for compound 6e in CDCl3. 
 
 
Figure C120: HPLC trace for compound 6e. Rt = 26.67 min. 
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Figure C121: 1H NMR spectrum for compound 7e in CD3OD. 
 
 
Figure C122: 13C NMR spectrum for compound 7e in CDCl3. 
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Figure C123: HPLC trace for compound 7e. Rt = 25.33 min. 
 
 
Figure C124: 1H NMR spectrum for compound 8e in CD3OD. 
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Figure C125: 13C NMR spectrum for compound 8e in CDCl3. 
 
 
Figure C126: HPLC trace for compound 8e. Rt = 22.57 min. 
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Figure C127: 1H NMR spectrum for compound 1f in CDCl3. 
 
 
Figure C128: 13C NMR spectrum for compound 1f in CDCl3. 
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Figure C128: HPLC trace for compound 1f. Rt = 11.12 min. 
 
11.12
Time (min)
0 5 10 15 20 25
m
A
U
0
200
400
600
800
1000
1200
1400
 580 
 
Figure C130: 1H NMR spectrum for compound 2f in (CD3)2SO. 
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Figure C131: 13C NMR spectrum for compound 2f in (CD3)2SO. 
 
 
Figure C132: HPLC trace for compound 2f. Rt = 11.59 min. 
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Figure C133: 1H NMR spectrum for compound 3f in CD3OD. 
 
 
Figure C134: 13C NMR spectrum for compound 3f in CD3OD. 
 
 
Figure C135: HPLC trace for compound 3f. Rt = 22.49 min. 
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Figure C136: 1H NMR spectrum for compound 4f in CD3OD. 
 
 
Figure C137: 13C NMR spectrum for compound 4f in (CD3)2SO. 
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Figure C138: HPLC trace for compound 4f. Rt = 17.70 min. 
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Figure C139: 1H NMR spectrum for compound 5f in CD3OD. 
 
 
Figure C140: 13C NMR spectrum for compound 5f in CD3OD. 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
 586 
 
Figure C141: HPLC trace for compound 5f. Rt = 13.45 min. 
 
 
Figure C142: 1H NMR spectrum for compound 6f in CDCl3. 
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Figure C143: 13C NMR spectrum for compound 6f in CDCl3. 
 
 
Figure C144: HPLC trace for compound 6f. Rt = 22.69 min. 
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Figure C145: 1H NMR spectrum for compound 7f in CD3OD. 
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Figure C146: 13C NMR spectrum for compound 7f in CD3OD. 
 
 
Figure C147: HPLC trace for compound 7f. Rt = 12.14 min. 
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Figure C148: 1H NMR spectrum for compound 8f in CDCl3. 
 
 
Figure C149: 13C NMR spectrum for compound 8f in CDCl3. 
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Figure C150: HPLC trace for compound 8f. Rt = 22.53 min. 
 
 
Figure C151: 1H NMR spectrum for compound 1g in CD3OD. 
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Figure C152: 13C NMR spectrum for compound 1g in CD3OD. 
 
 
Figure C153: HPLC trace for compound 1g. Rt = 17.54 min. 
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Figure C154: 1H NMR spectrum for compound 2g in CDCl3. 
 
14 13 12 11 10 9 8 7 6 5 4 23 1 0 -1
(ppm)
 594 
 
Figure C155: 13C NMR spectrum for compound 2g in CDCl3. 
 
 
Figure C156: HPLC trace for compound 2g. Rt = 22.46 min. 
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Figure C157: 1H NMR spectrum for compound 3g in CD3OD. 
 
 
Figure C158: 13C NMR spectrum for compound 3g in CDCl3. 
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Figure C159: HPLC trace for compound 3g. Rt = 10.85 min. 
 
 
Figure C160: 1H NMR spectrum for compound 4g in CDCl3. 
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Figure C161: 13C NMR spectrum for compound 4g in CDCl3. 
 
 
Figure C162: HPLC trace for compound 4g. Rt = 11.42 min. 
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Figure C163: 1H NMR spectrum for compound 5g in CD3OD. 
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Figure C164: 13C NMR spectrum for compound 5g in CDCl3. 
 
 
Figure C165: HPLC trace for compound 5g. Rt = 12.01 min. 
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Figure C166: 1H NMR spectrum for compound 6g in CD3OD. 
 
 
Figure C167: 13C NMR spectrum for compound 6g in CDCl3. 
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Figure C168: HPLC trace for compound 6g. Rt = 22.24 min. 
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Figure C169: 1H NMR spectrum for compound 7g in CD3OD. 
 
 
Figure C170: 13C NMR spectrum for compound 7g in CDCl3. 
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Figure C171: HPLC trace for compound 7g. Rt = 23.49 min. 
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Figure C172: 1H NMR spectrum for compound 8g in CDCl3. 
 
 
Figure C173: 13C NMR spectrum for compound 8g in CDCl3. 
 
 
Figure C174: HPLC trace for compound 8g. Rt = 24.35 min. 
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Figure C175: 1H NMR spectrum for compound 1h in CDCl3. 
 
 
Figure C176: 13C NMR spectrum for compound 1h in CDCl3. 
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Figure C177: HPLC trace for compound 1h. Rt = 21.78 min. 
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Figure C178: 1H NMR spectrum for compound 2h in CD3OD. 
 
 
Figure C179: 13C NMR spectrum for compound 2h in CDCl3. 
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Figure C180: HPLC trace for compound 2h. Rt = 18.53 min. 
 
 
Figure C181: 1H NMR spectrum for compound 3h in CD3OD. 
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Figure C182: 13C NMR spectrum for compound 3h in CD3OD. 
 
 
Figure C183: HPLC trace for compound 3h. Rt = 10.97 min. 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
Time (min)
0 5 10 15 20 25
m
A
U
0
1000
2000
3000
4000 10.97
 610 
 
Figure C184: 1H NMR spectrum for compound 4h in CDCl3. 
 
 
Figure C185: 13C NMR spectrum for compound 4h in CDCl3. 
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Figure C186: HPLC trace for compound 4h. Rt = 20.03 min. 
 
 
Figure C187: 1H NMR spectrum for compound 5h in CD3OD. 
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Figure C188: 13C NMR spectrum for compound 5h in CD3OD. 
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Figure C189: HPLC trace for compound 5h. Rt = 11.95 min. 
 
 
Figure C190: 1H NMR spectrum for compound 6h in CD3OD. 
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Figure C191: 13C NMR spectrum for compounds 6h in CDCl3. 
 
 
Figure C192: HPLC trace for compound 6h. Rt = 12.61 min. 
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Figure C193: 1H NMR spectrum for compound 7h in CD3OD. 
 
 
Figure C194: 13C NMR spectrum for compound 7h in CDCl3. 
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Figure C195: HPLC trace for compound 7h. Rt = 12.41 min. 
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Figure C196: 1H NMR spectrum for compound 8h in CDCl3. 
 
 
Figure C197: 13C NMR spectrum for compound 8h in CDCl3. 
 
 
Figure C198: HPLC trace for compound 8h. Rt = 23.50 min. 
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Figure C199: 1H NMR spectrum for compound 1i in CD3OD. 
 
 
Figure C200: 13C NMR spectrum for compound 1i in CDCl3. 
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Figure C201: HPLC trace for compound 1i. Rt = 22.73 min. 
 
 
Figure C202: 1H NMR spectrum for compound 2i in (CD3)2SO. 
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Figure C203: 13C NMR spectrum for compound 2i in (CD3)2SO. 
 
 
Figure C204: HPLC trace for compound 2i. Rt = 10.64 min. 
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Figure C205: 1H NMR spectrum for compound 3i in CD3OD. 
 
 
Figure C206: 13C NMR spectrum for compound 3i in CDCl3. 
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Figure C207: HPLC trace for compound 3i. Rt = 24.81 min. 
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Figure C208: 1H NMR spectrum for compound 4i in CD3OD. 
 
 
Figure C209: 13C NMR spectrum for compound 4i in CDCl3. 
 
 
Figure C210: HPLC trace for compound 4i. Rt = 11.16 min. 
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Figure C211: 1H NMR spectrum for compound 5i in CD3OD. 
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Figure C212: 13C NMR spectrum for compound 5i in CDCl3. 
 
 
Figure C213: HPLC trace for compound 5i. Rt = 11.77 min. 
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Figure C214: 1H NMR spectrum for compound 6i in CD3OD. 
 
 
Figure C215: 13C NMR spectrum for compound 6i in CD3OD. 
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Figure C216: HPLC trace for compound 6i. Rt = 22.47 min. 
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Figure C217: 1H NMR spectrum for compound 7i in CD3OD. 
 
 
Figure C218: 13C NMR spectrum for compound 7i in CDCl3. 
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Figure C219: HPLC trace for compound 7i. Rt = 20.96 min. 
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Figure C220: 1H NMR spectrum for compound 8i in CD3OD. 
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Figure C221: 13C NMR spectrum for compound 8i in CDCl3. 
 
 
Figure C222: HPLC trace for compound 8i. R t = 25.09 min. 
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APPENDIX D 
Spectroscopic spectra D1-D57 (1H, 13C NMR, and HPLC) for Chapter 5 
 
 
Figure D1: 1H NMR spectrum for compound 1 in CDCl3 (400 MHz). 
 
 
Figure D2: 1H NMR spectrum for compound 2a in CDCl3 (400 MHz). 
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Figure D3: 1H NMR spectrum for compound 2b in CDCl3 (400 MHz). 
 
 
Figure D4: 1H NMR spectrum for compound 2c in CDCl3 (400 MHz). 
 
 
Figure D5: 1H NMR spectrum for compound 2d in CDCl3 (400 MHz). 
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Figure D6: 1H NMR spectrum for compound 2e in CDCl3 (400 MHz). 
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Figure D7: 1H NMR spectrum for compound 2f in CDCl3 (400 MHz). 
 
 
Figure D8: 13C NMR spectrum for compound 2f in CDCl3 (100 MHz). 
 
 
Figure D9: 1H NMR spectrum for compound 2g in CDCl3 (400 MHz). 
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Figure D10: 13C NMR spectrum for compound 2g in CDCl3 (100 MHz). 
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Figure D11: 1H NMR spectrum for compound 2h in CDCl3 (400 MHz). 
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Figure D12: 13C NMR spectrum for compound 2h in CDCl3 (100 MHz). 
 
Figure D13: 1H NMR spectrum for compound 2i in CDCl3 (400 MHz). 
 
 
Figure D14: 13C NMR spectrum for compound 2i in CDCl3 (100 MHz). 
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Figure D15: 1H NMR spectrum for compound 2j in CDCl3 (400 MHz). 
 
 
Figure D16: 13C NMR spectrum for compound 2j in CDCl3 (100 MHz). 
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Figure D17: 1H NMR spectrum for compound 2k in CDCl3 (400 MHz). 
 
 
Figure D18: 13C NMR spectrum for compound 2k in CDCl3 (100 MHz). 
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Figure D19: 1H NMR spectrum for compound 2l in CDCl3 (400 MHz). 
 
 
Figure D20: 1H NMR spectrum for compound 2m in CDCl3 (400 MHz). 
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Figure D21: 1H NMR spectrum for compound 2n in CDCl3 (400 MHz). 
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Figure D22: 1H NMR spectrum for compound 2o in CDCl3 (400 MHz). 
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Figure D23: 13C NMR spectrum for compound 2o in CDCl3 (100 MHz). 
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Figure D24: 1H NMR spectrum for compound 3a in CDCl3 (400 MHz). 
 
 
Figure D25: 13C NMR spectrum for compound 3a in CDCl3 (100 MHz). 
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Figure D26: 1H NMR spectrum for compound 3b in CDCl3 (400 MHz). 
 
 
Figure D27: 13C NMR spectrum for compound 3b in CDCl3 (100 MHz). 
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Figure D28: 1H NMR spectrum for compound 3c in CDCl3 (400 MHz). 
 
 
Figure D29: 13C NMR spectrum for compound 3c in CDCl3 (100 MHz). 
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Figure D30: 1H NMR spectrum for compound 3d in CDCl3 (400 MHz). 
 
 
Figure D31: 13C NMR spectrum for compound 3d in CDCl3 (100 MHz). 
 
 
Figure D32: 1H NMR spectrum for compound 3e in CDCl3 (400 MHz). 
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Figure D33: 13C NMR spectrum for compound 3e in CDCl3 (100 MHz). 
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Figure D34: 1H NMR spectrum for compound 3f in CDCl3 (400 MHz). 
 
 
Figure D35: 13C NMR spectrum for compound 3f in CDCl3 (100 MHz). 
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Figure D36: 1H NMR spectrum for compound 3g in CDCl3 (400 MHz). 
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Figure D37: 1H NMR spectrum for compound 3h in CDCl3 (400 MHz). 
 
 
Figure D38: 13C NMR spectrum for compound 3h in CDCl3 (100 MHz). 
 
 
Figure D39: 1H NMR spectrum for compound 3i in CDCl3 (400 MHz). 
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Figure D40: 1H NMR spectrum for compound 3j in CDCl3 (400 MHz). 
 
 
Figure D41: 13C NMR spectrum for compound 3j in CDCl3 (100 MHz). 
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Figure D42: 1H NMR spectrum for compound 3k in CDCl3 (400 MHz). 
 
 
Figure D43: 13C NMR spectrum for compound 3k in CDCl3 (100 MHz). 
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Figure D44: 1H NMR spectrum for compound 3l in CDCl3 (400 MHz). 
 
 
Figure D45: 13C NMR spectrum for compound 3l in CDCl3 (100 MHz). 
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Figure D46: 1H NMR spectrum for compound 3m in CDCl3 (400 MHz). 
 
 
Figure D47: 13C NMR spectrum for compound 3m in CDCl3 (100 MHz). 
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Figure D48: 1H NMR spectrum for compound 3n in CDCl3 (400 MHz). 
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Figure D49: 13C NMR spectrum for compound 3n in CDCl3 (100 MHz). 
 
 
Figure D50: 1H NMR spectrum for compound 3o in CDCl3 (400 MHz). 
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Figure D51: 13C NMR spectrum for compound 3o in CDCl3 (100 MHz). 
 
230 220
(ppm)
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 -100
N
S
O
 660 
 
Figure D52: 1H NMR spectrum for compound 4e in CDCl3 (400 MHz). 
 
 
Figure D53: 13C NMR spectrum for compound 4e in CDCl3 (100 MHz). 
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Figure D54: 1H NMR spectrum for compound 4f in CDCl3 (400 MHz). 
 
 
Figure D55: 13C NMR spectrum for compound 4f in CDCl3 (100 MHz). 
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Figure D56: 1H NMR spectrum for compound 4n in CDCl3 (400 MHz). 
 
 
Figure D57: 13C NMR spectrum for compound 4n in CDCl3 (100 MHz). 
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